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Summary 
The complement system has crucial functions in host defence. Novel data revealed 
a role for complement components in the pathology of osteoarthritis (OA). CD59a is 
a regulator of the terminal complement pathway in mice; the purpose of the study 
was to determine if CD59a-/- mice have an osteoarthritic bone phenotype.  
Osteoblast (OB) mineralisation, colony forming unit (CFU) and OCG assays 
were performed in vitro from bone marrow preparations of 8-20 week old mice. 
Decreased CFU differentiating towards osteoblasts and adipocytes (n=1 only), as 
well as an increased OCG, was revealed in male CD59a deficient (-/-) over wildtype 
(WT) mice. OCG in females were comparable. A human CD59 knockdown system 
utilising short hairpin (sh) ribonucleic acid (RNA) delivered by adenoviruses was 
established but did not differentiate into osteoclasts (OC).  
In vivo the bone phenotype of CD59a-/- mice was established for femora and 
vertebra L6 via X-ray, microcomputed tomography and histology. In male mice 
femoral length was increased in CD59a-/- versus WT mice at 8-10, 20 and 50 weeks. 
Cortical bone volume was increased whilst bone mineral density (BMD) was 
reduced in CD59a-/- versus WT mice at 8-10 and 20 weeks. Trabecular bone 
analysis of the distal femur (and spine) showed increased trabecular bone ratio, 
number, thickness, connectivity and total BMD in CD59a-/- over WT at 8-10 (and 20) 
weeks of age. In female mice there was no difference in femoral length and 
trabecular bone, but cortical BMD was raised at 50 weeks (CD59a-/- versus WT). 
Finally, histology revealed enhanced mineral apposition rate and OC surface as well 
as reduced osteoid surface in male CD59a-/- over WT mice at 8-10 weeks of age.   
Increased bone growth and turnover related to CD59a gene deletion were 
gender specific. These studies highlight CD59a as a potential target for OA 
treatment. 
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1.1 Summary 
CD59 is a regulator of the membrane attack complex (MAC) of the complement 
system. Additionally, it regulates functions that are independent of the complement 
system e.g. lymphocyte expansion (Kimberley et al. 2007). The level of CD59 
expression on surfaces has implications for haematological and auto-immune 
diseases such as Paroxysmal nocturnal hemoglobinuria (PNH), diabetes and 
Alzheimer’s in which CD59 is deficient (Yamashina et al. 1990; Yang et al. 2000; 
Qin et al. 2004). To identify the functional role in these diseases a number of in vivo 
and in vitro experimental models have been utilised. The murine analogue of human 
CD59 is CD59a, a genetically modified CD59a-/- strain (Holt et al. 2001), was 
created in mice to uncover CD59a’s role in age-related macular degeneration (Bora 
et al. 2007), renal thrombotic microangiopahty (Nangaku et al. 1998), acute 
experimental autoimmune encephalomyelitis (Mead et al. 2003) as well as 
experimental models of rheumatoid arthritis (RA) (Williams et al. 2004) and 
osteoarthritis (OA) (Wang et al. 2011).  
This project specifically concentrates on a role of CD59a in regulating bone 
homeostasis. Little is known about its actions in bone, but clues are derived from 
experimental models of arthritis. When CD59a is blocked with monoclonal 
antibodies joints are more susceptible to damage in arthritis models. Furthermore, 
CD59a-/- mice exhibit more severe arthritis than wild type (WT) mice (Williams et al. 
2004). Experimental models of OA also point towards similar modulation of disease. 
CD59a-/- mice showed worse disease than WT, whereas C3 deficient (C3-/-) mice did 
not show an effect in osteoarthritis progression. C5 deficient (C5-/-) and C6 deficient 
(C6-/-) mice showed less osteophyte formation than WT animals (Wang et al. 2011). 
These data demonstrate the relative importance of terminal pathway regulation over 
the alternative or classical pathway in bone. 
Human research is somewhat limited. A study in multiple myeloma patients 
uncovered a correlation with CD59 and CD55 deficiency and elevation of osteoclast 
numbers (Terpos et al. 2003). In a different study, expression of CD59 in human 
osteoclasts and osteoblasts was shown (Ignatius et al. 2011).  These are indicators 
of CD59’s involvement in bone homeostasis, but functional significance of human 
CD59 or murine CD59a was not established. My study therefore focuses on 
investigating the role of CD59a in bone remodelling, and its implications in health 
and disease. 
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1.2 The Complement System and Historical Perspective 
In the 19th century, researchers strove to establish the mechanism of bacterial lysis. 
Two theories arose to explain the process. The first one suggested that cells in the 
blood were responsible for bacterial elimination, whereas the second one stated that 
serum components performed this action. The second theory was proven by an 
experiment in which animal serum lost its lytic ability when heated, but the activity 
was restored by adding fresh serum. These investigations led to the discovery of 
complement proteins that were characteristically heat-labile (Morley and Walport 
2000; Walport 2001; Janeway et al. 2005). Complement was shown to agglutinate in 
antibody sensitised ox, human and sheep cells (Gorrill and Hobson 1952), this led to 
the discovery of the first 4 complement components (C1-4) (Talmage 1957) in the 
1950s, followed by C5 (Nilsson and Müller-Eberhard 1965) to C8 (Manni and Müller-
Eberhard 1969) characterisation in the 1960s.  New components have been 
identified readily since, and additional players are still discovered today such as 
β2GPI, a brand new complement regulator (Gropp et al. 2011), whose involvement 
in the complement system was revealed in 2011. This is discussed later in section 
1.2.3. Currently, the complement system consists of more than 30 proteins found in 
plasma and expressed on cell membranes. Soluble complement components are 
mainly synthesised in the liver, and membrane anchored proteins are present on all 
circulating and many tissue cells (Walport 2001). 
Functionally, the complement system serves to protect the host from 
pathogens. It is an integral component of the innate immune system and links innate 
with adaptive immunity. When the complement system works properly it is beneficial 
for health, but complement dys-regulation can result in tissue damage, pathology 
and disease (Müller-Eberhard 1988; Morgan and Harris 1999; Walport 2001). 
The complement system is subdivided into 3 main activation pathways: classical, 
alternative and the mannan-binding lectin (MBL) pathway. More recently it has been 
discovered that different proteases of the coagulation pathway, as well as 
phagocytic cells, can activate complement components (Ehrnthaller et al. 2011). 
Consequently, all activation pathways result in the amplification pathway 
followed by the MAC/lytic pathway. All these will be described in turn in the sections 
below.  
 
1.2.1 Activation Pathways  
Classical Pathway 
The classical pathway is activated by complement unit C1 binding to an immune 
complex made of an antibody attached to an antigen (Janeway et al. 2005). C1 is 
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also able to bind antigens alone on apoptotic cells, viral proteins, gram-negative 
bacteria (polyanions), β-amyloid, mitochondrial fragments and C-reactive proteins 
associated with a ligand. Fig. 1.1 provides a pictorial representation of the classical 
pathway which involves C1, C2 and C4 as well as its negative regulators on host 
cells: C1 inhibitor (C1-INH), C4 binding protein (C4bp) and complement receptor 1 
(CR1) (Müller-Eberhard 1988). At the surface of a pathogen these regulators are 
missing, and the classical pathway will lead to the generation of the C3 convertase 
consisting of C4b2a (Kinoshita 1991; Walport 2001; Ehrnthaller et al. 2011). 
Individual complements are tabulated in Tab 1.1.  
 
Figure 1.1 Classical Complement Activation Pathway. C1q bound to the immune 
complex is recognised by C1r and two molecules bind. These activate homeodimers 
of C1s to form the C1 complex. C1-INH induces C1 complex’s irreversible 
dissociation by removing C1s and C1r subunits, therefore operating as a 
complement regulator early in the cascade. C4 is cleaved by the C1s subunit to 
generate C4b which attaches to the surface and releases C4a. Subsequently C1s 
cleaves C2 and C2a binds to C4b to form the C3 convertase whereas C2b is 
liberated. C4bp and CR1 can stimulate C4b inactivation by factor I cleavage (Reid 
and Porter 1981; Müller-Eberhard 1988; Janeway et al. 2005; Ehrnthaller et al. 
2011). 
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Part of 
System 
ID Structure Serum 
[conc.] 
Subunits Function 
Activation  C1 750kD, metallo-
protein complex of 
C1q and C1r2s2 
35μg/ml C1q, 
C1r, C1s 
C1r auto-activates when it recognises C1q binding and activates C1s, 
which then cleaves C4 to C4a and C4b. 
  C4 200kD, zymogen, 3 
polypeptide chain 
(βαγ) - internal 
thioester bond in α-
chain 
450-750 
μg/ml 
C4a, 
C4b 
C4a attaches to cell surfaces to act as weak mediator of inflammation. 
C4b attaches to cell surfaces with its internal thioester and binds C2a. 
  C2 102kD, zymogen 20μg/ml C2a, 
C2b 
C2b is a precursor of vasoactive C2 kinin and C2a cleaves C3 and C5 as 
part of the C4b2a convertase. 
Regulation C1-
INH 
100kD, single-chain 
glycoprotein with 
40% carbohydrate 
content  
240 
μg/ml 
- Binds rapidly to active C1s and more slowly to active C1r. It attaches very 
tightly and therefore causes dissociation. 
 C4bp 540-590kD, 
glycoprotein, 
contains 2 different 
polypeptide chains 
(7α1β) 
300 
μg/ml 
- Binds up to 4 C4b molecules strongly with α-chain and β-chain 
associates with anti-coagulant Vitamin K-dependent protein. Can present 
C3b and C4b to factor I cleavage. 
Table 1.1 Classical Pathway Components (Reid and Porter 1981; Sanchez-Corral et al. 1995; Caliezi et al. 2000; Morley and Walport 2000; 
Martin et al. 2009). 
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Alternative Pathway 
In the alternative pathway C3 from blood plasma activates spontaneously by 
hydrolysis. This liberates the cell surface binding site, a thioester bond of C3b. 
Covalent binding to the hydroxyl or amino group of proteins and carbohydrates can 
now follow at the surface of many bacteria, fungi, viruses and tumour cells. 
Components of this cascade are called factors and are described in Fig. 1.2 and 
Tab. 1.2. Properdin can elongate C3bBb’s half-life whereas factor H, factor H like 
protein 1, factor I and β2GPI contribute to the regulation of the pathway which 
results in the C3 convertase C3bBb (Müller-Eberhard 1988; Zipfel and Skerka 1999; 
Ehrnthaller et al. 2011; Gropp et al. 2011).  
 
Figure 1.2 Alternative Complement Activation Pathway. In this pathway 
spontaneously formed C3b inactivates unless factor B (equivalent to C2) binds. 
Factor D cleaves the complex to create the convertase, C3bBb (Müller-Eberhard 
1988; Walport 2001). Factor H competes with factor B for the C3b binding site and 
inhibits C3 convertase formation. Furthermore bound factor H (and factor H like 
protein 1) induces C3b inactivation to C3bi by factor I (Müller-Eberhard 1988; Zipfel 
and Skerka 1999; Ehrnthaller et al. 2011). Another complement regulator of C3 is 
β2GPI, which was recently discovered to control apoptotic cells by binding C3/C3b 
and can be inactivated by factor I (same mechanism as for factor H) (Gropp et al. 
2011).  
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Part of 
System 
ID Structure Serum 
[conc.] 
Subunits Function 
Activation C3 190kD, 
zymogen, β- 
and α-chain - 
internal 
thioester bond 
in α-chain 
1000-
1600μg/ml 
C3a, C3b, 
C3bi and 
C3dg are the 
major 
subunits 
C3a triggers local inflammatory response via anaphylatoxin 
activity. C3b recognises antigens, is subunit of C5 
convertases, ligand for CR1 and induces opsonisation. 
C3bi interacts with CR3 and induces opsonisation whereas 
C3dg binds to complement receptor 2 (CR2) on B-cells and 
influences their activation. 
 Factor B 90kDa, 
zymogen 
200μg/ml Ba, Bb Binds to C3b with Bb. 
 Factor D 24kDa, single 
chain 
zymogen 
1μg/ml - Binding specificity to Arg-Lys bond of factor B. Cleaves 
factor B into its subunits. 
Regulation Factor H 160kD, single 
chain 
zymogen 
360-550 
μg/ml 
- Binds C3b to block convertase formation and acts as factor 
I co-factor. 
 Factor I 88kDa, 
2 chain 
zymogen 
35μg/ml - Cleaves C3b and C4b in presence of co-factor factor H, 
CR1, C4bp, MCP and β2GPI. 
    Table 1.2 Alternative Pathway Components (Müller-Eberhard 1988; Gropp et al. 2011). 
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MBL Pathway 
In this pathway MBLs bind to glycans and phospholipids with mannose, glucose, 
fucose or N-acetylglucosamine as the terminal carbohydrate (Hoffmann et al. 1999; 
Walport 2001; Janeway et al. 2005). Additionally the molecule ficolin contains a 
lectin domain and is able to recognise different carbohydrates (Gadjeva et al. 2001). 
MBL associated proteases 1 and 2 (MASP-1 and MASP-2) and the non-protease 
small MBL-associated protein (sMAP) are part of the cascade. C1-INH, C4bp and 
CR1 can also interfere with the MBL pathway. When the cascade forms successfully 
it results in the formation of the C3 convertase composed of the C4b2a complex as 
shown in Fig. 1.3 (Ehrnthaller et al. 2011).  
 
Figure 1.3 MBL Activation Pathway. MBL forms a complex with MASP-1, MASP-2 
and sMAP. MASP-2 has the same function as C1s but both, MASP-1 and MASP-2, 
can activate C2. It is thought that MASP-1 might be able to cleave C3 directly 
without formation of the convertase (Walport 2001). C1-INH can interfere with the 
pathway formation by MASP-1 and MASP-2 inactivation. C4bp and CR1 can also 
inhibit C4b as in the classical pathway. 
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1.2.2 Amplification Pathway 
The classical, alternative and MBL pathway converge at the point of C3 convertase 
generation, consisting of either C4b2a or C3bBb.  These convertases are able to 
cleave C3 molecules, which attach covalently to the membrane close to the 
activation site for the accumulation of C3b (Tab. 1.2) (Müller-Eberhard 1988; 
Janeway et al. 2005). Each newly generated C3b molecule can bind to factor B and 
form another convertase by factor D cleavage. Additionally, C3b can bind to the C3b 
or C4b of a C3 convertase. This complex acts as C5 convertase as illustrated in Fig. 
1.4. 
 Membrane co-factor protein (MCP) and decay accelerating factor (DAF) 
are main regulators of the C3 and C5 convertase, but complement receptor of the 
immunoglobulin superfamily (CRIg), Factor H–related protein 1 (CFHR1) and 
previously mentioned C3 and C4 regulators are also influencing this pathway.  
 
Figure 1.4 Amplification Pathway. Once C3b and convertases are deposited, DAF 
speeds up the separation of the convertases by attaching to bound C4b, C2a, C3b, 
Bb. MCP associates with surface bound C3b, C4b and C3bi with 50 times more 
efficiency than factor H and acts as co-factor for C3b cleavage by factor I (Müller-
Eberhard 1988). Furthermore CRIg, found on macrophages, binds to C3b in C3 and 
C5 convertase and CFHR1 attaches to C3b and C3d (degradation product) to 
prevent substrate adherence (He et al. 2008; Heinen et al. 2009).  
 
1.2.3 Terminal Pathway 
The C5 convertase generation leads to cleavage of C5. C5b triggers MAC 
composed of C5b to C9 (Tab. 1.3). This complex creates a transmembrane pore 
which leads to cell lysis (Davies et al. 1989). Its assembly is pictorially illustrated in 
Fig. 1.5 (Müller-Eberhard 1988; Walport 2001; Janeway et al. 2005). MAC is 
controlled by CFHR1, serumprotein S, clusterin and CD59 (Ehrnthaller et al. 2011). 
CD59 is the final regulator which arrests unwanted complement activation that has 
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not been controlled at earlier stages (Ruiz-Argüelles and Llorente 2007). It interacts 
with the α-chain of C8 and binds tightly to the C5-8 complement complex inserted 
into the cell membrane. It inhibits polymerisation of C9 (Meri et al. 1990) and it was 
shown that one C9 molecule can bind to the C5-8-CD59 complex. CD59 binds to the 
C9b-fragment and consequently limits C9 unfolding (Meri and Jarva 1998). 
Therefore the attachment site for further C9 molecules is inaccessible and cell lysis 
by MAC is prevented (Farkas et al. 2002).  
 
 
Figure 1.5 Terminal Pathway. When C5 encounters the C5 convertase, it binds to 
the extra C3b. This changes C5’s conformation so it can be readily cleaved into C5a 
and C5b by Bb/C2a. C6 binds to C5b and C7, C8 and multiple molecules of the C9 
bind sequentially to the complex to form the cell lysing MAC. The assembly can be 
regulated at various steps. CFHR1 can attach to C5, when attached to C3b, and 
C5b6 therefore inhibiting the C5 convertase generation as well as the MAC 
assembly (Heinen et al. 2009). Additionally serumprotein S and clusterin bind to a 
lipophilic group of C7 hindering the MAC formation (Ehrnthaller et al. 2011). CD59, 
the final regulator, binds tightly to the C5b-8 or C5b-9 complement complex to inhibit 
polymerisation of C9 (Farkas et al. 2002). 
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ID Structure Serum [conc.] Subunits Function 
C5 191kD, zymogen, β- and 
α-chain - linked by 
disulphide bond 
80-340 μg/ml C5a, C5b C5a is a peptide mediator of inflammation. C5b is an initiator of 
MAC, it is meta-stable and attracts C6. 
C6 MW 104,800-128,000, 
single chain glycoproteins 
50-70μg/ml   C6 binds to C5b, the complex is still connected to C3b and forms 
the acceptor for C7. 
C7 MW 92,400-121,000, 
single chain glycoproteins 
50-70μg/ml   C7 binds to C5b6. C5b67 induces conformational change of C7 to 
expose a hydrophobic patch which allows dissociation from the 
convertase and binds to the membrane layer. 
C8 151kD, 3 chain protein, α 
and γ-chain are linked via 
a disulphide bond which 
complex is covalently 
linked to the β-chain 
55μg/ml   The β-chain of C8 has a recognition site for C5b and binding 
causes structural changes within the complement molecule. This 
allows the α-chain of C8 to anchor deeper into the lipid bilayer.  
C9 71kD, single-chain 
glycoprotein 
50-60μg/ml   C9 binds to C5b678 complex. The first molecule attaches quickly 
and then undergoes conformational changes which slow down the 
polymerisation. Between 10 and 16 C9 units are required to create 
a channel through the membrane which induces cell lysis. 
    Table 1.3 Membrane Attack Complex formation (Morley and Walport 2000; Gressner et al. 2007). 
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Invading microorganisms do not express complement regulators and are therefore 
not protected. The way the complement components join to protect host and 
evading pathogens is demonstrated below in Fig. 1.6. The bioactivity of the 
complement system is mediated by a series of receptors and inflammatory 
mediators called anaphylatoxin, C3a and C5a as summarised in Tab. 1.4. The data 
presented thus far demonstrates that the complement system is tightly regulated. 
This thesis focuses on CD59 as a major regulator of the terminal pathway. Its 
function in host defence, health and disease is described in the following sections.  
 
 
Figure 1.6 The Complement System. 
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Receptor Cell expression Ligand Pathway Function 
CR1 Monocytes, macrophages, 
neutrophils, erythrocytes, B-cells, 
polymorphonuclear leukocytes, 
follicular dendritic cells (FDC) 
C4b, C3b, 
iC3b 
Co-factor for factor I inactivation, mediation of 
phagocytosis, transport of immune complexes to 
macrophages in the liver for removal from the body. 
CR2 B-cells, FDC C3d, iC3b, 
C3dg, Epstein-
Barr virus 
Co-receptor for B-cell component and viral 
receptor. 
Complement receptor 3 (CR3) Antibody-dependent cytotoxic 
lymphocytes, neutrophils and 
macrophages, FDC 
iC3b Binds to C3bi to induce phagocytic removal of 
foreign fragments. 
Complement receptor 4 (CR4) Macrophages, monocytes, 
antibody-dependent cytotoxic 
lymphocytes, dendritic cells 
iC3b Binds to C3bi to induce phagocytic removal of 
foreign fragments. 
C1q receptor (C1qR) Monocytes, B-cells C1q Induces phagocytosis and cell adhesion. 
Dendritic cell-specific ICAM3-
grabbing non-integrin 
homologue SIGN-related 1 
(SIGNR1) 
Dendritic cells, microglial cells C1q Induces phagocytosis as well as signalling and 
inflammation. 
C3a receptor (C3aR) Endothelial cells, mast cells, 
phagocytes 
C3a Induces migration of phagocytes by activating G 
protein, regulated by carboxypeptidase N that 
targets ligand degradation. 
C5a receptor (C5aR) Endothelial cells, mast cells, 
phagocytes 
C5a Induces migration of phagocytes by activating G 
protein, regulated by carboxypeptidase N that 
targets ligand degradation. 
C5a receptor-like 2 (C5L2) Macrophages, neutrophils C5a Inhibits phagocyte migration by uncoupling G 
protein. 
Table 1.4 Complement receptors (Müller-Eberhard 1988; Morgan 1990; Morley and Walport 2000; Janeway et al. 2005; Zipfel and Skerka 
2009). 
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1.3 CD59 and Historical Perspective 
CD59 was discovered as a 20kDa protein by monoclonal antibodies YTH53.1 and 
MEM43 raised against leukocyte antigens. It obtained its name in the 4th Leukocyte 
Workshop in 1989. Davies et al. showed that YTH53.1 bound to CD59 causing 
enhanced cell lysis on erythrocytes and lymphocytes when activated C56 (purified 
from acute-phase serum) and normal human serum (source of C7-9) were 
incubated with the cells (Davies et al. 1989). 
 CD59 is ubiquitously expressed on all circulating cells, including 
erythrocytes and granulocytes as well as lymphocytes, and numerous tissue cells, 
such as epidermis and endothelia of the skin, vascular endothelia of the liver and 
glomerular epithelia cells (Davies et al. 1989; Meri et al. 1991). CD59 is a globular 
cellular protein consisting of a single polypeptide chain attached to the cell surface 
via a glycosylphosphatidylinisotol (GPI) anchor. A soluble form of CD59 (sCD59) is 
also found in urine (MW 13kDa). sCD59 is 200 fold less efficient at protecting cells 
from MAC lysis but its ability to bind the MAC complex is preserved (Lehto et al. 
1995). Complement dependent function of CD59 has been discussed in section 
1.2.3. However some alternative roles of CD59 have been discovered.  
 
1.3.1 Proposed Complement Independent Roles of CD59 
CD59 cross-linking was shown to induce intracellular signalling but a potential ligand 
to induce cross-linking has not been identified. These functions have been termed 
complement independent functions as they were observed away from the active site 
of MAC within the protein structure of CD59a. Proposed ligands for CD59 have been 
described according to their binding capacity and influence on cell regulation but a 
mechanism for these alternative roles has not been established yet. Complement 
independent functions have been demonstrated on a variety of cells such as T-cells, 
B-cells and Natural Killer (NK) cells. (Kimberley et al. 2007).  
 
1.3.1.1 Complement Independent Roles of CD59 in T-Cells 
Within cell membranes CD59 is one of multiple GPI anchored proteins located in 
lipid rafts. GPI-anchors are connected to cytoplasmic protein tyrosine kinase which 
were thought to alter T-cell activation in humans (Longhi et al. 2005). CD59’s 
involvement was tested by generating Fab fragments of 2 anti-CD59 antibodies with 
different antigen specificity. One of the antibodies blocked complement regulation 
(MEM-43) whereas the other one did not (HC-1). When incubating CD4+ T-cells with 
the antigen-specific Fab fragments of antiCD59 antibodies, HC-1 binding resulted in 
a dose dependent up-regulation of CD4+ T-cell proliferation and interferon (IFN) γ 
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production, whereas no effect was seen with MEM-43 suggesting CD59 reduces T-
cell expansion in a complement independent manner (Sivasankar et al. 2009). The 
effect was confirmed in vivo in a mouse model. CD4+ T-cells from CD59a-/- mice 
proliferated and produced more cytokines than WT mice after in vivo infection with a 
recombinant vaccine virus, confirming down-regulation by CD59a (Longhi et al. 
2005). 
 
1.3.1.2 Complement Independent Roles of CD59 on B-Cells 
CD59 was also suggested to function on CD4+ T-cells in order to stimulate B-cell 
proliferation. CD59 is only expressed on B-cells in the splenic marginal zone.  
CD59a-/- mice have a defective humoral response, but their B-cells appeared normal 
during experiments. It was discovered that when CD59+CD4+ T-cells interact with B-
cells CD59 operated as co-factor to an unknown ligand, resulting in B-cell 
expansion. This function was identified as complement independent when 
lymphocytes were cultured ex vivo in presence and absence of CD59a (Kimberley et 
al. 2007). As these cultures are performed in heat inactivated serum, no MAC 
activation should have occurred. 
 
1.3.1.3 Complement Independent Roles of CD59 on NK Cells 
Additionally, subpopulations of NK cells expressing CD59 were found to be more 
active at cell killing than CD59- NK cells. The mechanism was thought to involve 
CD59 acting via natural cytotoxicity receptors NKp46 and NKp30. These receptors 
signal through a tyrosine kinase phosphorylation. CD59 was cross-linked by 
antibodies which induced tyrosine phosphorylation through the GPI-anchor 
(Marcenaro et al. 2003). This mechanism was also seen in T-cell expansion (section 
1.3.1.1) and was confirmed as complement independent in T-cells. Therefore it was 
proposed that CD59 signalling in NK cells was utilising an alternative mechanism to 
MAC activation (Kimberley et al. 2007).  
CD59 is not only important on NK cells but also on NK target cells. U937, a 
CD59- cell line, was transfected with CD59 expressing plasmids with different 
membrane anchors. Cells, expressing GPI-anchored CD59, were more susceptible 
to NK cytotoxicity probably due to interactions with the NK receptor. To determine if 
the effect was complement independent, antibodies targeting the C8/C9 binding site 
and antibodies against a different isotope were tested. Only antibodies against the 
alternative epitope affected cytotoxicity (Omidvar et al. 2006; Kimberley et al. 2007).  
CD59 is also involved in a number of other functions. These are described in 
the Tab. 1.5. 
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Function Interaction Mechanism 
Lipopolysaccharide 
(LPS) receptor 
CD59 blocking antibody and anti-sense 
oligonucleotides caused reduced LPS signalling 
and cytokine generation on CD14- keratinocytes. 
Utilising GPI-anchor for nuclear factor (NF)-κB signalling, 
interleukin (IL)-6, Granulocyte macrophage-colony stimulating 
factor and tumour necrosis factor (TNF) α secretion. 
Apoptosis Cross-linking of CD59 induced apoptosis of 
Jurkat cells and T-cell-blasts which could be 
blocked by anti-TNF-related apoptosis-inducing 
ligand (TRAIL) antibodies. 
Activation induced cell death (AICD) regulates lymphocyte 
maturation and is stimulated by cross-linked CD59 to signal 
via TRAIL instead of Fas ligand. 
Cell surface 
interactions 
CD59 was found to weakly bind CD2 on T-cells 
and NK cells. Anti-CD59 antibodies were 
identified to inhibit erythrocyte interaction with T-
cells.  
CD2 is an adhesion and signalling protein that binds mainly 
CD58 on target cells as co-stimulatory signal to activate T-
cells and induce NK- and cytotoxic T-cell lysis. CD59 
interaction was proposed to be indirect maybe via a protein 
complex.   
 CD59 has a receptor function for intermedilysin 
(ILY), a pore-forming bacterial toxin of 
Streptococcus intermedius. Its attachment site is 
the same as for C8α and C9. 
Once ILY is bound to CD59 it will form a lytic pore. 
 Binding of CD59 to calreticulin (CRT) was 
shown. PNH patients showed decreased binding 
of CRT. 
CRT, a calcium binding receptor on neutrophils, does not 
have a transmembrane domain and uses GPI-anchored 
proteins, including CD59, to signal. 
Reproduction CD59 is present in large quantities on cells of 
the reproductive system and in seminal plasma.  
CD59 prevents complement lysis via the transit into the 
female tract. It adds to immune tolerance to ensure 
fertilisation and pregnancy. CD59 might also support cell 
adhesion when egg and sperm interact. 
Development A GPI-anchored homologous of CD59 was 
identified as Prod 1 in newt.  
Prod 1 is required in limb generation during development. 
Location of free Prod 1 at the proximal end helps cell 
identification. 
    Table 1.5 Alternative Roles of CD59 (Monleon et al. 2000; Kimberley et al. 2007). 
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1.3.2 Human Diseases Correlated with CD59 Deficiency 
CD59 is involved in numerous processes throughout the body but the regulation of 
MAC is most pronounced. The main disease linked to CD59 deficiency is PNH. It is 
a rare, acquired disorder in which blood cells are subjected to complement lysis. In 
PNH patients’ erythrocyte and platelet lysis causes haemolytic anaemia and 
thrombosis that can result in strokes (Holguin et al. 1989; Yamashina et al. 1990). 
PNH develops due to somatic mutations of the PIG-A gene in dividing bone marrow 
cells. The mutations result in a loss of GPI-anchored proteins including DAF and 
CD59. It was shown that DAF is not responsible for the increased susceptibility to 
complement lysis in PNH because in add-back experiments DAF could only partly 
reduce the haemolysis (Medof et al. 1987).  
 Reduced CD59 expression has also been linked with other 
haematological disorders as well as autoimmune diseases such as diabetes, 
Alzheimer’s and inflammatory arthritis (Alegretti et al. 2009). Diabetes patients suffer 
from vascular damage and this pathology was linked to CD59. Patients’ CD59 can 
be inactivated by glycation in the vascular endothelia. In this process glucose binds 
the active domain of CD59 resulting in an increased MAC deposition (Qin et al. 
2004). 
 In Alzheimer’s’ disease MAC assembly and subsequent neuritic losses 
were revealed. During the disease CD59 was found to be reduced in the frontal 
cortex and hippocampus. CD59 was discovered to be down-regulated by amyloid β-
peptide at the mRNA level causing increased susceptibility to cell lysis (Yang et al. 
2000).  
 Furthermore, in RA, increased MAC assembly was identified to 
contribute to synovitis. This was probably due to the reduced expression of CD59 
discovered in synovial membrane of patients (Konttinen et al. 1996). Similarly in OA 
increased MAC expression in synovium and around chondrocytes was revealed 
(Wang et al. 2011). In Psoriatic Arthritis (PsA) increased MAC deposition was found 
on erythrocytes which might have contributed to synovitis and inflammation. Again, 
impaired CD59 expression on erythrocytes was identified as a possible cause of 
disease (Triolo et al. 2003). 
 Inflammatory arthritic disorders have distinct patterns of bone pathology, 
in which too much bone is produced or eroded, affecting joint function. The 
significance of CD59’s effect on bone is not known but clues can be derived from 
inflammatory studies in rodents, which have been well characterised. 
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1.3.3 CD59 in Experimental Disease Models 
Experiments with mice revealed gene duplication - CD59a and CD59b. These 
proteins were found to share 63% sequence homology. CD59b is only expressed in 
the testis, whereas CD59a is more widely expressed and proven to be the main 
regulator of the terminal pathway. The CD59a gene was characterised, cloned and 4 
exons were identified, of which the major coding region is located in the third exon. 
CD59a-/- mice were created by homologous recombination, replacing the third exon 
with a neomycin resistance gene in mouse embryonic stem cells (Holt et al. 2001).  
CD59a-/- mice only show a mild PNH phenotype, which is probably due to 
protection by the additional murine complement regulator complement receptor-1 
related gene/protein Y. The spontaneous intravascular haemolysis was shown to be 
higher in male over female mice. Interestingly, male mice also presented an 
increased complement activity which might explain the enhanced susceptibility.  
CD59 has been studied in various disease models, and the CD59a-/- mouse model 
was utilised frequently (Holt et al. 2001; Baalasubramanian et al. 2004). 
 
1.3.3.1 Inflammatory Arthritis Models 
A number of inflammatory arthritis studies have demonstrated the terminal pathway 
to be a major player in pathology and regulation of CD59. During these studies 
effects on joint swelling as well as the synovium, cartilage and bone were 
investigated, which will be described in detail below. 
 
1.3.3.1.1 Swelling and Synovitis 
Clinical features of inflammation manifest as joint swelling and erythema, which can 
be scored according to severity. In murine models, paw diameters and volume are 
also measures for quantitative analysis. Goodfellow et al. established a rat collagen 
induced arthritis (CIA) model, and proved that the onset of inflammation was 
delayed when complement was depleted with cobra venom factor (CVF). This 
highlighted the importance of complement in arthritis development. Treatment of CIA 
with C3 inhibitor soluble CR1 (sCR1) showed a stronger suppression of disease 
onset than CVF (Goodfellow et al. 2000).  
To uncover if CR1 was blocking C3 and C4, Solomon et al. studied joint 
swelling in the K/BxN serum-induced RA model. When using C4 deficient (C4-/-) 
mice, it was discovered that arthritis progression was not affected. This took the 
classical and MBL activation pathways out of the equation for complement 
involvement in arthritis development (Solomon et al. 2002). 
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On the other hand C3-/- mice, studied by Wang et al., showed that a single hit 
of bovine type II collagen (BCII) did not cause arthritis in comparison to WT mice. 
Multiple hits resulted in mild joint swelling in C3-/- mice but less severe than in WT 
mice (Hietala et al. 2002). 
The role of C5 in arthritis has been studied in various papers and the most 
recent on using C5-/- DBA/1 mice in a CIA model showed resistance to inflammation 
onset in single and multiple hit experiments (Wang et al. 2000). 
 To further investigate the involvement of MAC Mizuno et al. used the Fab 
fraction of a monoclonal CD59 blocking antibody (6D1) to study complement in the 
synovium. Rats were injected with 6D1 and presented acute, transient arthritis 
characterised by joint swelling at day 1 which ceased by day 3, suggesting 
uncontrolled MAC deposition (Mizuno et al. 1997). 
In antigen induced arthritis (AIA) Williams et al. revealed that knee swelling 
was increased in CD59a-/- mice over age-matched WT mice 1 day after disease 
initiation, which stayed increased until day 7. This effect was reversible by addition 
of recombinant membrane targeted CD59 (sCD59-APT542), confirming a CD59a 
deficiency effect and the importance of MAC activation in arthritic inflammation  
(Williams et al. 2004).  
When looking closer at the synovium by histological analysis, Hietala 
identified pannus formation and synovial thickening with a single dose of BCII in WT 
animals, which resulted in vast infiltration of inflammatory cells during boosting. This 
inflammation was not seen in C3-/-  animals (Hietala et al. 2002). 
 Wang et al. showed that C5-/- mice were also resistant to synovial cell 
proliferation, infiltration by neutrophils, lymphocytes, and plasma cells as well as 
pannus development. This was despite IgG and C3 binding to collagen and cartilage 
as well as specific TNFα secreting T-cells within the nearby lymph nodes (Wang et 
al. 2000).  
When looking at the terminal pathway, histological processing of 6D1 treated 
rat joints uncovered that 6D1 was bound to CD59 at the synovial lining, surrounding 
tissue and blood vessels. It caused synovial infiltrate and thickening which 
exacerbated between 6 and 24h after injection. MAC deposition was identified at the 
synovial surface in 6D1 treated rats (Mizuno et al. 1997).  
To confirm this data, AIA histological sections were stained for MAC 
deposition. CD59a-/- mice showed exacerbated cellular infiltrate and larger MAC 
deposition at the synovial lining, whereas only patches were stained in the WT 
control group (Williams et al. 2004). 
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OA is another disease which has recently been found to be inflammatory 
with up-regulated complement activation in synovial fluid of patients. Wang et al. 
induced murine OA models by medial meniscectomy, meniscal tearing and aging. 
He identified that C3-/- mice showed synovitis development similar to WT animals 
but C5-/- and C6-/- mice were protected. CD59a-/- mice showed worse disease 
highlighting CD59’s role in MAC regulation (Wang et al. 2011). All these are 
evidence for the terminal pathway contribution in development of synovitis.  
 
1.3.3.1.2 Cartilage Pathology 
Other components of the joint, such as cartilage, are also affected in the above 
described models. During BCII boosting WT animals showed cartilage destruction, 
an effect not seen in C3-/-  or C5-/- mice (Wang et al. 2000; Hietala et al. 2002).  
 Additionally, joint erosion was visible earlier in CD59a-/- compared to WT 
animals in the AIA model. This was caused by MAC deposition, as MAC staining 
was discovered in the connective tissue adjacent to the synovial lining in CD59a-/- 
mice only (Williams et al. 2004).  
CD59a-/- mice also showed enhanced proteoglycan loss and cartilage 
degradation in comparison to WT and C3-/- mice in OA models. C5-/- and C6-/- mice 
were protected from any cartilage degradation (Wang et al. 2011). Very often when 
joint destruction is described, cartilage and bone changes are reported together. 
 
1.3.3.1.3 Bone Pathology 
Bone destruction was identified in BCII boosted WT animals but not in C3-/-  or C5-/- 
mice (Wang et al. 2000; Hietala et al. 2002).  This was comparable to the OA model 
in which C5-/- and C6-/- mice were protected from bone erosion and osteophyte 
development over WT animals. C3-/- mice did not show alteration to the bone 
phenotype in comparison to WT mice, but CD59a-/- mice showed enhanced 
osteophyte formation and bone erosion in  these models (Wang et al. 2011).  
These data demonstrate the relative importance of terminal pathway 
regulation over activation pathways in bone. CD59 expression has been shown on 
normal human mesenchymal stem cells (MSCs), OCs and OBs (Ignatius et al. 
2011). In a clinical study of 43 newly diagnosed multiple myeloma patients, 56% of 
patients showed CD55 and/or CD59 deficiency on their erythrocytes and the 
deficiency correlated to elevated resorption markers. This association suggests that 
CD55 and CD59 regulate osteoclast activity (Terpos et al. 2003). This has not been 
intensively studied and was therefore chosen for this project.  
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CD59 has been investigated in further disease models of which some are 
described in Tab. 1.6. 
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Disease Model Experiments Mechanism 
Renal allograft 
transplantation 
in miniature pigs 
Rejected kidneys showed MAC and C3 presence at the time of rejection. In 
accommodated kidneys CD59 level was increased which was not seen in rejected 
organs. Accommodated kidneys were re-transplanted and low MAC deposition was 
found on these organs supporting a CD59 effect. 
Increased CD59 expression 
protects from allografts rejection 
by blocking MAC mediated cell 
lysis (Griesemer et al. 2009). 
Age-related 
macular 
degeneration 
(AMD) 
During this eye disease new blood vessels are formed by chorodial 
neovascularisation (CNV). In the animal model a membrane of the choroid is 
disrupted with laser photocoagulation resulting in MAC deposition. CD59a was 
found to be down-regulated during CNV. CD59a-/- mice developed CNV early, more 
severe and showed increased MAC deposition in comparison to WT mice. CNV 
was prevented when sCD59a, fused to the Fc region of an antibody, was added.  
Decreased CD59 expression 
leads to increased MAC mediated 
cell lysis and angiogenic growth 
factor secretion to form CNV. 
sCD59-Fc can reverse AMD 
development (Bora et al. 2007). 
Experimental 
renal thromboitic 
microangiopahty 
(TMA). 
Auto-antibodies against glomerular endothelial cells (GEN) are generated. Fab 
fragment of anti-CD59 and anti-GEN antibodies were introduced into rats via renal 
artery perfusion. In TMA treated with anti-CD59 increased MAC deposition and 
endothelial injury developed in comparison to TMA without anti-CD59. 
CD59 protects from MAC 
dependent lysis in glomerular 
endothelium (Nangaku et al. 
1998). 
Acute 
experimental 
autoimmune 
encephalomyeli-
tis (EAE) 
This mouse model of multiple sclerosis resembles demyelination and axonal injury 
of neurons. Disease was induced with recombinant MOG, a glycoprotein important 
for myelination. CD59a-/- mice exhibited more severe pathology and cellular 
infiltrate than WT mice. MAC deposition overlaid with the sites of inflammation and 
injury.  
In the brain CD59 is expressed at 
low level and might either be 
depleted after chronic 
complement activation or auto-
antibodies block its activity (Mead 
et al. 2003) . 
Myasthenia 
gravis (MG) 
During MG auto-antibodies against the acetylcholine receptor (AChR) cause loss of 
neuromuscular transmission. Complement was activated at AchR, CD59a-/- and 
DAF deficient (DAF-/-) showed a mild MG whereas CD59a-/-DAF-/- mice presented 
severe disease. Anti-C5 blocking antibodies administrated to CD59a-/-DAF-/- mice 
revealed that disease progression was arrested. 
MAC formation plays a major role 
in MG development (Morgan et al. 
2006). 
Wallerian 
degeneration 
Neurons were exposed surgically and crushed with forceps. CD59a-/- mice showed 
increased MAC deposition and damage to the nerve axon as well as increased 
macrophage infiltration over WT mice early after surgery. 
CD59 is thought to protect from 
early MAC dependent axon 
destruction after lesion (Ramaglia 
et al. 2009). 
Table 1.6 Role of CD59 in experimental disease models. 
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The role of CD59 in age related joint degeneration and bone pathology has not been 
described. To appreciate the effect, the structure and function of bone, as well as its 
homeostasis, has to be outlined. 
 
1.4 Structure and Function of Bone in the Human Skeleton 
The skeleton consists of different types of bone: the skull, exoskeleton and long 
bones. Each type has a distinct structure and function, and develops in different 
ways. The skull and exoskeleton provide organ protection whereas long bones 
provide strength and allow for motility. The majority of this project deals with the long 
bones and these will be covered in further detail below. 
 
1.4.1 Embryonic Development of Long Bones 
Long bones develop via endochondral ossification. Here chondrocytes are formed 
which proliferate to form a cartilage model of the developing bone. Chondrocytes 
become hypertrophic, which means they stop proliferating but enlarge in size and 
produce a different matrix which allows calcification and invasion by blood vessels. 
Chondrocytes eventually undergo apoptosis to make space for the bone marrow 
cavity and OBs which secrete bone matrix (Fig. 1.7) (Ham and Cormack 1979; 
Gilbert 2000a; Rosen 2008).  
Not all cartilage has turned into bone at birth. Bones continue to grow from 
ossification fronts (growth plates) in which chondrocytes proliferated throughout 
childhood and turn into mineralised bone gradually (Gilbert 2000b). 
 
 
 
24 
 
 
Figure 1.7 Endochondral cartilage. Blood vessels enter cartilage to deliver 
chondrocytes, which degrade cartilage, and MSCs that differentiate into OBs to 
synthesise bone (Andrades et al. 1996; Abad et al. 2002). 
 
1.4.2 Bone Structure 
The bone matrix of an adult has a much larger connective tissue mass than any 
other organ. It consists of 50-70% of calcium and phosphate minerals called 
hydroxyapatite crystals and 20-40% of protein. The main protein component is type I 
collagen (Col1), but small amounts of other collagens and non-collagenous proteins 
reside in bone as shown in Tab. 1.7 (Favus 2006). 
Mineralised matrix can be divided into 2 types, woven and lamellar. Woven 
bone is the immature form found in bone development and fracture repair. It has a 
high turnover rate and shows a random pattern of collagen fibres and mineralisation; 
hence it is more flexible. Lamellar mature bone consists of tightly packed collagen 
fibres. Neighbouring lamellae run in different directions, interconnect and give 
strength to the bone (Buckwalter and Cooper 1987). 
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Protein Function 
Aggrecan Arranges matrix, stores water and ions for 
mechanical integrity. 
Albumin Blocks hydroxyapatite expansion. 
Alkaline phosphatase (ALP) Transports Ca2+, hydrolysis pyrophosphates 
and other mineralization inhibitors as 
phosphate source. 
Asporin Modulates collagen arrangement. 
Biglycan Associates with collagen and growth factor, 
present at peak of bone mass. 
Bone sialoprotein (BSP) Associates with cells, may induce 
mineralisation. 
Decorin Associates with collagen (for modulating 
fibre thickness), transforming growth factor 
(TGF) β (to control function) and blocks cell 
binding to fibronectin. 
Fibrillin 1 and 2 May modulate elastic fibre assembly. 
Fibromodulin Associates with collagen and TGFβ, may 
control fibril assembly. 
Fibronectin Associates with cells, fibrin heparin, gelatin 
and collagen. 
Glypican Modulates bone morphogenic protein 
(BMP)-SMAD (intracellular transcription 
factors) signalling and cell differentiation. 
Lumican Associates with collagen, may control fibril 
assembly. 
Matrix Gla protein Inhibitor of mineralisation. 
MEPE Modulates mineralisation and hormone 
function. 
Osteoadherin May induce cell binding. 
Osteocalcin (OCL) May modulate OC precursor and OC 
function, may induce reversal of 
remodelling, and blocks mineralisation. 
Osteoglycin/Mimecan Associates with TGFβ and controls collagen 
fibre formation. 
Osteonectin (ON) Controls collagen assembly and maybe 
hydroxyapatite storage, associates with 
growth factors and favours bone formation 
signalling. 
Osteopontin (OPN) Associates with cells, may modulate 
mineralisation and proliferation, blocks nitric 
oxide synthase. 
Perlecan Modulates cell communication in 
conjunction with other matrix proteins. 
Protein S May be produced by OB lineage cells. 
Secreted phosphoprotein 24 May modulate thiol proteases. 
Tenascin-C Inhibits cell-fibronectin binding. 
Tenascin-X Controls cell-matrix associations. 
Tetranectin May modulate mineralisation. 
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Protein Function 
Thrombospondin Associates cells to matrix, binds collagen, 
histidine rich glycoproteins and coagulation 
cascade proteins. 
Type III and V collagen Small amounts in bone to regulate collagen 
fibre width. 
Vitronectin Associates cells to matrix, binds coagulation 
cascade proteins. 
α2HS glycoprotein Blocks calcification and stimulates 
endocytosis, acts as opsonin/chemokine. 
Table 1.7 Bone matrix proteins (Rosen 2008). 
 
Once long bones have reached maturity they consist of 3 sections: epiphysis, 
metaphysis and the shaft. Each of these is further divided into cortical and 
trabecular bone (Fig. 1.9) (Buckwalter and Cooper 1987; Favus 2006).    
 
1.4.2.1 Structure and Function of Cortical Bone 
Cortical bone is dense, solid and builds the outer layer of each bone with a 
thickness of approximately (approx.) 1-5mm (Wehrli 2007). It makes up 80% of adult 
bone and is composed of osteons or Haversian system, which is the basic structural 
element of mineralised bone (Fig. 1.8) (Hall 2005). The human osteon is 2,000 μm 
in length, up to 200 μm wide and forms at a speed of 20-40 μm/day (Raisz 1999). 
Cortical bone is covered by an outer fibrous connective tissue layer, the periosteum. 
The inside of cortical bone is coated by the endosteum (Fig. 1.9). The periosteum 
contains nerve endings, and both layers possess blood vessels and bone cells 
(Favus 2006). Cortical bone is essential for mechanical functions as it is much more 
tightly packed than trabecular bone. Its tubular and stiff structure in the shaft allows 
for efficient counteracting to torsion and bending (Buckwalter and Cooper 1987; 
Favus 2006).  
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Figure 1.8 Osteon. The Haversian canal is surrounded by lamella of extracellular 
matrix (ECM) and osteocytes. Canaliculi connect osteocytes (OT) and osteon 
surfaces. Bone remodelling takes place in the Haversian canal (Enlow 1962; 
Buckwalter and Cooper 1987; Favus 2006). 
 
1.4.2.2 The Structure and Function of Trabecular Bone 
Trabecular bone is a spacious network of thin bone plates and bars of approx. 0.1-
0.15mm thickness (Wehrli 2007). Its structure is orientated to support mechanical 
resistance (Keaveny et al. 2001) but its low density also allows for some degree of 
elasticity. When load is applied to a long bone the metaphysis, which is 
predominately made of trabecular bone, allows for deformation. Trabecular bone is 
composed similarly to cortical bone but bone marrow runs through its interconnected 
structure (Fig. 1.9). Its osteons are only half the size of the Haversian channel. It 
forms a thinner saucer-shaped channel called Howship lacunae (Fig. 1.8) (Raisz 
1999; Hadjidakis and Androulakis 2006). Trabecular bone has a large surface 
covered by bone cells which allows for fast resorption or apposition according to the 
body’s requirements. Trabecular bone therefore regulates acid-base levels as well 
as calcium and phosphate haemostasis. Extra-cellular fluids contain constant 
calcium (8.5-10.5 mg/decilitre (dl)), phosphorus (2.5-4.5 mg/dl) and pH (7.4) levels 
which are regulated by a variety of hormones controlling bone turnover, further 
described in Tab. 1.10 (Buckwalter and Cooper 1987; Levi and Popovtzer 1999; 
Yarbro et al. 2004; de Baat et al. 2005). 
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Figure 1.9 Architecture of a long bone. 
 
1.4.3 The Biology of Bone Cells 
Mature bones are remodelled by OCs, OBs and OT. The individual cell types are 
discussed in detail below. 
 
1.4.3.1 The Biology of Osteoclasts 
The OC originates from myeloid lineage of the bone marrow or blood. Human 
peripheral blood OC precursor cells express a variety of markers such as CD14 
(monocyte marker), CD33 (myeloid marker) and CD45 (leukocyte marker) as well as 
some markers shared with murine precursor cells listed in Tab. 1.8 (Filgueira 2009). 
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Marker 
(human/mouse) 
Description Human blood Mouse primary cells 
CX3CR1 chemokine receptor 
for adhesion of 
leukocytes 
Low + 
CR3 Macrophage 
differentiation marker 
+ 
negative  
to dull 
RANK Receptor activator of 
NFκB 
+ Low (Muto et al. 2011) 
c-Fms Macrophage colony 
stimulating factor (M-
CSF) receptor 
+ + 
OSCAR Osteoclast associated 
receptor (IgG-like 
receptor) 
+ - (Kim et al. 2002) 
Table 1.8 Osteoclast precursor marker expression (Lorenzo et al. 2010). 
 
OC differentiation requires two cytokines: RANK ligand (RANKL) and M-CSF. Both 
are produced in membrane bound and soluble form by bone lining cells and stromal 
cells. This allows cell-to-cell and paracrine communication between haematopoietic 
and non-haematopoietic cells. Both mediators are essential for all stages of OC 
differentiation as depicted in Fig. 1.10.  
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Figure 1.10 Osteoclastogenesis (OCG). OC precursors become c-Fms positive 
after activation of transcription factor PU.1. This enables M-CSF stimulation that 
initiates RANK expression. RANKL binding activates different pathways, including 
NFκB and, with OSCAR as co-activator, nuclear factor of activated T cells 
(NFATc1). The latter modulates expression of Cathepsin K (Cat K), tartrate-resistant 
acid phosphatase (TRAP), calcitonin receptor (CTR) and dendritic cell specific 
transmembrane protein (DC-STAMP) (Athanasou 2011). Microphthalmia 
transcription factor (MITF), DC-STAMP and CD47 are essential for cell fusion. Once 
vitronectin receptor αvβ3 (VNR) is expressed additional survival and differentiation 
signals are induced and functional proteins such as Cat K and matrix 
metalloproteinase 9 (MMP-9) are produced (Favus 2006; Filgueira 2009; Knowles 
and Athanasou 2009; Athanasou 2011).  
 
 
Mature OCs are terminally differentiated, multinucleated cells (≥2 nuclei) attached to 
calcified bone lining (Morriss-Kay et al. 2001; Amoui et al. 2004; Teitelbaum 2004; 
Favus 2006). They are bone ‘breaker’ cells and are essential for bone remodelling 
as is portrayed in detail in section 1.5. 
 
1.4.3.2 The Biology of Osteoblasts 
OBs originate from MSCs which can be isolated from bone marrow, explants, fat 
tissue, blood and Wharton’s Jelly (a fluid within the umbilical cord). MSCs develop 
colonies of stromal bone marrow cells. Stroma defines non-haematopoietic 
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connective tissue milieu that is essential for haematopoiesis. Stromal colonies 
develop from a single precursor cell and are called colony forming unit fibroblasts 
(CFU-F) which have been identified in many species. Human and mouse CFU-F can 
be identified in bone marrow as myeloid lineage marker negative. Mouse CFU-F are 
stem cell antigen-1 (Sca-1) positive whereas human CFU-F are stem cell factor 
(CD34) and STRO-1 positive. They can also express vascular cell adhesion 
molecule -1 (CD106), receptor for TGF-beta superfamily ligands (CD105) and other 
markers (Short et al. 2003; De Schauwer et al. 2011).  
Runx2 is a transcription factor and the main regulator of bone formation as 
shown in Fig. 1.11 (Bianco 2011). Once matured, OBs look like round to polygonal 
cells sandwiched between an osteoid and the bone surface. They do not proliferate 
(Ham and Cormack 1979; Buckwalter and Cooper 1987; Favus 2006; Lorenzo et al. 
2010). OBs are bone ‘makers’ and are also required for bone remodelling as 
explained in section 1.5. 
 
Figure 1.11 Bone formation.  Runx2 acts through osterix and FOXO1 to initiate 
MSC differentiation which results in a common progenitor with chondrocytes. This 
early process is also supported by BMPs. Next β-catenin, part of the Wnt signalling 
pathway, is the transcription factor that guarantees differentiation of 
osteochondrogenic precursors towards osteoprogenitors. Indian hedgehog (Ihh) 
also induces Runx2 expression in favour for bone formation.  Resulting 
ostoeprogenitor populations proliferate due to PTH stimulation. Further 
differentiation is achieved by fibroblast growth factors (FGFs) and insulin-like growth 
factor 1 (IGF-1) signalling via protein kinase C (PKC) pathway-dependent Runx2. 
BMPs and TGFβ support this action by signalling through SMADs. They associate 
with Runx2 to induce further BMP, Runx2 and osterix expression and cells turn into 
pre-osteoblasts. Runx2 then regulates expression of Col1, ALP, OPN, BSP, OCL) 
and ON (Rosen 2008; Lorenzo et al. 2010). These matrix proteins can be used as 
markers for different stages of bone formation. Whereas ALP is expressed early in 
differentiation; Col1, BSP, OPN appear later on and OCL is a marker of mineralising 
OBs (Buckwalter and Cooper 1987; Favus 2006; Rosen 2008; Bianco 2011). 
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1.4.3.3 The Biology of Osteocytes 
About 30-50% of all OBs terminally differentiate into OTs. They are buried within the 
osteon but keep secreting matrix proteins such as OCL and dentin matrix protein. 
OTs are oval shaped cells with spikes that lose cell volume and organelles upon 
aging. They are mechanosensor cells that initiate and control bone remodelling as 
explained in section 1.5 (Buckwalter and Cooper 1987; Favus 2006; Hadjidakis and 
Androulakis 2006; Rosen 2008; Lorenzo et al. 2010). 
 
1.5 Bone Modelling and Remodelling 
In bone all 3 cells work in harmony to maintain healthy and strong bones. There are 
2 mechanisms of renewal: bone modelling and remodelling. Bone utilises the 
mechanism of modelling when structural changes are required, for example, during 
growth and increased load. In this process bone resorption by OCs and bone 
formation by OBs are uncoupled (Favus 2006). Bone remodelling, on the other 
hand, is a coupled process of constant replacement of old and fractured bone by 
newly synthesised one. It is performed by the bone remodelling unit (BRU), in which 
a variety of cell types interact with each other and work sequentially in four stages: 
activation, resorption, reversal and bone formation (Fig. 1.8). These will be covered 
in detail below. 
 
1.5.1 Activation of Bone Remodelling 
OCs are implicitly involved in the activation phase of remodelling which consists of 2 
phases. Firstly the identification of a remodelling surface is covered followed by 
osteoclast recruitment. 
 
Identification of Remodelling Surface 
The process starts with the activation of a resting bone surface into a remodelling 
one. The selection of a new remodelling surface is mainly non-specific and not fully 
understood but it has been shown to be activated in fractured areas. OTs are 
thought to be involved in the initiation. OTs have long microfilaments creating a 
system of processes encapsulated in canaliculi that extend throughout the whole 
bone matrix connecting each other and the bone surface via gap junctions 
consisting of connexion 43 (Fig. 1.8). Alterations in biomechanics might trigger 
signalling to bone lining and stromal cells (Buckwalter and Cooper 1987; Hadjidakis 
and Androulakis 2006; Rosen 2008; Lorenzo et al. 2010).  
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Osteoclast Recruitment 
Stromal cell signalling is essential for differentiation and survival of haematopoietic 
stem cells (HSCs). The bone marrow consists of numerous niches of stem cells. 
The HSC niche contains bone lining cells that keep HSCs in a resting 
undifferentiated stage. When stromal or bone lining cells are activated, their 
morphology changes and this causes HSC recruitment by Notch and stromal cell-
derived factor (SDF)-1, as well as by mediators they release. This includes secretion 
of the chemokine (C-C motif) ligand 9 (CCL9/MIP-1γ) and RANKL. OC precursor 
cells express RANK as well as CCR1 (receptor for CCL9/MIP-1γ), and are attracted 
not only from the niche but the circulation to the bone surface where they enter the 
bone lining. Here they adhere via N-cadherin, β-catenin and vascular cell adhesion 
molecule (VCAM) and differentiate into mature OCs, which is described in section 
1.4.3.1 (Raisz 1999; Favus 2006; Hadjidakis and Androulakis 2006; Filgueira 2009; 
Lorenzo et al. 2010).  
 
1.5.2 Bone Resorption 
Mature OCs adhere tightly to the bone surface to allow for resorption to occur and 
for removal of degradation products (explained below). 
 
Generation of Resorption Pit 
Mature OCs polarise towards their basal membrane and obtain physical contact with 
bone matrix. To strengthen the attachment, VNR triggers adherence to the bone by 
connecting to the Arginine-Glycine-Aspartic acid motive of OPN and other matrix 
proteins. VNR also activates ontogenic protein-tyrosine Src kinase which causes 
establishment of the actin ring. This is a sub-membrane, circular shaped 
cytoskeleton organisation which results in a tight sealing zone that produces a 
separate compartment called the resorption pit (Xu and Lindquist 1993; Favus 
2006). 
 
Vesicle Transport and Resorption 
The basal membrane within the resorption pit is a dynamic ruffled border in which 
secretion and phagocytosis are taking place simultaneously. Vesicles of 
continuously produced enzymes and vacuolar proton pumps (H+-ATPase) move 
towards the pit. Protons are produced by carbonic anhydrase II (Ca II) within the cell 
and when released generate an acidic pH of 4.5 within the compartment to decalcify 
hydroxyapatite (see section 1.5.4) underneath. At the same time lysosomal proteins 
such as MMP-9, Cat K and TRAP work efficiently at low pH to digest organic parts 
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of the matrix (Filgueira 2009; Lorenzo et al. 2010). Additionally, digested products 
and some freed OTs are phagocytosed from the pit and transported inside the OC 
via phagolysomal vesicles. Acidic intracellular compartments contain enzymes such 
as TRAP to further degrade collagen. Digests and enzymes such as Cat K are 
transcytosed towards the apical membrane and secreted into the blood stream, from 
which they are further excreted into the urine. End-products of resorption, such as 
Col1 cross-linked N-telopeptide, are detectable in urine and blood fluids (Favus 
2006; Hadjidakis and Androulakis 2006; Filgueira 2009; Proff and Römer 2009). 
OCs are terminated by osteoprotegerin (OPG), a soluble decoy receptor of RANKL, 
and undergo apoptosis. At the same time mononucleated cells finish off the 
resorption process (Favus 2006; Hadjidakis and Androulakis 2006). 
 
1.5.3 Reversal of Bone Remodelling 
Resorption is succeeded by the reversal stage of the BRU. The cavities created by 
OCs are filled with monocytes and freed OTs. These attract pre-OB which provide 
signals for OB migration and differentiation. The process of recruitment is unknown 
but some evidence has shown that coupling factors produced by OCs, or freed 
during resorption, may be involved. For example, TGF-β, released from the matrix, 
was found to induce bone formation. Furthermore ephrinB2, secreted by OCs, has 
been identified to modulate OB differentiation (Favus 2006; Okamoto et al. 2011). 
 
1.5.4 Bone Formation 
The final stage of remodelling is formation. Once OBs have differentiated they 
secrete the organic matrix, which is then followed by mineralisation. The osteoid is 
secreted first and mainly consists of Col1 organised in long thick fibres to arrange 
matrix which then determines flexibility. Consequently, non-collagenous proteins 
bind to the collagen. Microfibrils made of fibrillin sit between the collagen fibres and 
bind growth factors such as TGF-β and BMPs to regulate cell signalling.  
Once the osteoid has matured it undergoes mineralisation. For this OBs 
liberate small, membrane-bound vesicles with calcium and phosphate ions as well 
as degrading inhibitors of mineralisation (pyrophosphate and proteoglycans). The 
secreted hydroxyapatite (Ca10(PO4)6(OH)2) is very small and contains impurities 
such as carbonate, magnesium and acid phosphate. Impurities make the structure 
weaker, which allows readily resorption when needed. Minerals are deposited at 
various collagen sites, starting off small but growing with matrix maturation and as 
they do so contain fewer impurities. Minerals then start accumulating to fill the 
spaces between collagen bundles to finish the process (Favus 2006; Hadjidakis and 
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Androulakis 2006; Rosen 2008). The surface is then covered by bone lining cells 
and seen as a resting surface whilst other osteons are remodelled. Bone 
remodelling is controlled by a range of factors – biochemical, mechanical and 
environmental as described in Tab. 1.9 (Favus 2006; Hadjidakis and Androulakis 
2006).  
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 Factor Produced by Causal Effect 
Break 
down 
Peroxisome 
proliferators-activated 
receptor (PPAR)γ 
Haematopoietic 
lineage cells 
including OCs 
Inhibits MSC differentiation via transcriptional modulation of positive (eg. 
BMP4) and negative (eg. Transducer of ErbB-2 (Tob) 1) regulators 
(Shockley et al. 2009).  
 Sclerostin OT Inhibits Wnt signalling resulting in reduced OB differentiation. 
 OF45 OT Inhibitor of bone formation, modulates phosphate metabolism (Marie 2009). 
 Pro-inflammatory 
cytokines (eg. TNFα, 
IL-6)  
Stromal cells Induces RANKL expression or gives co-stimulatory effects to OCs (Take et 
al. 2005; Favus 2006; Hadjidakis and Androulakis 2006; Filgueira 2009; 
Proff and Römer 2009; Athanasou 2011). 
 Prostaglandin E2 OB Enhances RANKL expression. 
 Glucocorticoids OC Inhibits BMP and Wnt signalling and enhance parathyroid hormone (PTH) 
signalling resulting in reduced bone formation. 
Formation OPG Stromal cells/OBs Soluble decoy receptor for RANKL, inhibits OCG and resorption. 
 Calcitonin (CT) Thyroidal C-cells Calcium sensor that blocks OC fusion and resorption by removing the ruffled 
border, blocking OC movement and proteins secretion (Favus 2006; 
Hadjidakis and Androulakis 2006; Filgueira 2009; Proff and Römer 2009).  
 TGFβ Stromal cells Inhibits OC differentiation. 
 Dentin matrix protein 
(DMP)-1 
OT Regulates phosphate metabolism and mineralisation. 
 Phex and Fimbrin OT Controls phosphate metabolism. 
 PTH-related protein 
(PTHrP) 
Many tissues Regulates chondrocyte proliferation during endochondral ossification. 
 Androgens Glands Induces periosteum and trabecular bone generation by increasing β-catenin 
and reducing Axin and Axin2. 
 Oestrogen Glands Induces OPG and diminished production of IL-6, TNFα and IL-1 by 
circulating macrophages and modulates RANKL and TNFα expression of T-
cells. Induces TGFβ by dendritic cells/macrophages to reduce resorption. 
 Growth factors (eg. 
IGF, BMPs) 
Hepatocytes, 
stromal cells  
Control mineralisation. IGF-1 supports PTH anabolic effect. Platelet-derived 
growth factor (PDGF) is required for migration and proliferation. 
 Toll-like receptor 
(TLR) 2 and 4 
Macrophages Inhibits resorption by down-regulating RANK expression in OCs (Ferrari-
Lacraz and Burger 2010). 
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 Factor Produced by Causal Effect 
Dual 
activities 
PTH Parathyroid cells 
(Suva 2006) 
Induces bone resorption (constant signal) and controls mineral homeostasis 
(anabolic intermittent signal). It promotes Runx2 expression via PKC 
pathway or inhibits Runx2 and osterix. Runx2 can be further regulated by its 
inhibitor Notch to determine when OB mineralisation is saturated (Rosen 
2008; Lorenzo et al. 2010).  
 1,25-dihydroxyvitamin 
D3 (Vit D) 
Not made in the 
body but converted 
by liver and kidney 
to its active form. 
Stimulates OCG and also favours bone formation by inhibiting PTH. Induces 
secreting of OPN, OCL and matrix Gla protein in favour of mineralisation  
(Sato et al. 1993). 
 Leptin Adipocytes Dose dependent: low dose favours bone formation over adipogenesis, 
induce OPG in OBs; high dose induces MSC and adipocyte apoptosis and 
blocks bone formation via neuropeptide in hypothalamus (Cirmanova et al. 
2008). 
Environ-
ment 
Diet  Different diets can influence bone health. High calcium diet, for example, 
supports bone health whereas a diet high in protein leads to loss of calcium 
from the body (Bowen et al. 2004). 
 Age  OBs and adipocytes originate from the same precursor (MSC), reciprocally 
regulated, adipocyte number increases with age where as OB number 
declines. 
 Sex  In women menopause causes oestrogen level drop resulting in low bone 
mineral density. 
 Weight  Increased weight also stimulates increased bone apposition but rapid weight 
loss in obese persons can result in drastic bone loss. 
 Physical activity  Exercise that leads to increased muscle mass also has an anabolic effect on 
bone. 
  Table 1.9 Mediators of bone remodelling (Rosen 2008). 
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When the dynamic is distorted the healthy bone becomes diseased. A variety of 
diseases characterised by too much or too little bone matrix are described in Tab. 
1.10. 
  
39 
 
 Disease Cells implicated/mechanism Treatment 
Reduced 
bone 
formation 
Osteoporosis In post menopausal women, oestrogen deficiency 
induces up-regulation of OC numbers and 
resorption. Osteoblasts can also be dysfunctional 
due to aberrant regulation of hormones such as 
IGF-1 and PTH (Raisz 1999; Rodan and Martin 
2000). 
Calcium and Vit D supplements, oestrogens and 
progestin, selective oestrogen receptor modulators 
(SERMs) (eg. Raloxifene), bisphosphonates (eg. 
Alendronate), teripartide (recombinant PTH), 
strontium ranelate, CT and Cathepsin K inhibitor 
(Rodan and Martin 2000; Rosen 2008).  
 Solid tumours and 
haematopoietic 
malignancies 
Enhancing OCG and resorption. Bone resorption 
releases TGFβ and with the help of pro-
inflammatory cytokines allows seeding of local 
bone metastases (Rodan and Martin 2000).  
Bisphosphonates (eg. Zoledronic acid). 
 Hyperparathyroidism PTH overproduction leads to up-regulation of OCs, 
bone remodelling and hypercalcaemia (Raisz 1999; 
Rosen 2008). 
Surgical removal of parathyroid glands, controlled 
calcium and Vit D intake. 
 Non-union fracture Caused by low numbers of osteoprogenitor cells 
and mal-regulation of OBs (Griffin et al. 2008; 
Hofmann et al. 2008). 
Surgical removal of scar tissue and placing metal 
plates, autogenous bone graft or tissue engineered 
bone into the wound (Yoshikawa et al. 2011). 
Increased 
bone 
formation 
Paget’s disease Viral infection or genetic mutation leads to atypical 
OCs. Irregular resorption by OCs leads to 
enhanced bone formation of woven bone 
weakening the skeleton (Raisz 1999; Rosen 2008; 
Saluja et al. 2009; Michou and Brown 2011).  
Bisphosphonates (eg. Etidronate), synthetic 
salmon CT as well as analgesics (eg. Aspirin), 
anti-inflammatory drugs, orthopaedic and 
neurosurgical treatments. 
 Osteopetrosis Rare genetic disease in which mutations in OC 
leads to increased bone formation resulting in 
thickening of bone (Raisz 1999; Rosen 2008; 
Saluja et al. 2009; Michou and Brown 2011). 
Bone marrow transplantation, calcium deficient 
diet, high glucocorticoid treatment. 
 
 
 
40 
 
 Disease Cells implicated/mechanism Treatment 
Inflammatory 
arthritis 
RA Chronic inflammation of synovial joints leads to local 
production of pro-inflammatory cytokines as well as 
RANKL production by synovial fibroblasts and T-
cells. These fuel the OC activity and cause cartilage 
and subchondral bone erosion (Rodan and Martin 
2000; Piccoli et al. 2011). 
TNF-blocker (eg. Infliximab), IL6-blocker (eg. 
Tocilizumab), CD20- (Retuximab) and CD22-
blockers (Epratuzumab), non-steroidal anti-
inflammatory drugs (NSAIDs) (eg. Ibuprofen), 
anti-rheumatic drugs (DMARD) (eg. 
Methotrexate), corticosteroids (Prednisolone) 
(NHS-Choices 2010a; Mizuno and Morgan 
2011). 
 OA Mechanical and osmotic stresses alter metabolism 
resulting in cytokine production, cartilage 
degradation. This causes blood vessel invasion and 
microfractures resulting in osteophytes and 
subchondral sclerosis due to up-regulated OC 
activity and changes of OB phenotype to produce 
more RANKL and MMPs (Karsdal et al. 2008; 
Abramson and Attur 2009).  
Exercise, weight loss, pain killers (paracetamol, 
NSAIDs, opioids, capsaicin cream), intra-
articular injection of corticosteroids (NHS-
Choices 2010b). 
 PsA Synovitis causes invasive OC precursor 
development and recruitment to the joint due to 
TNFα. High concentrations of RANKL and TNFα in 
the joint causes increased OCG and extensive bone 
erosion (Ritchlin et al. 2003). 
Physiotherapy, DMARD (eg. Methotrexate), 
NSAIDs (eg. Ibuprofen), TNF-blocker 
(eg.Etanercept), steroid injection (The-Psoriasis-
Association). 
 Ankylosing 
Spondylitis  
Inflammation triggers increased OC activity and 
extensive bone formation in the spine due to BMP 
signalling that leads to fusion of vertebrae (Braun 
and Sieper 2007). 
NSAIDs (eg. Indocin), DMARD (eg. 
Sulfasalazine) and TNF-blocker (eg. Infliximab) 
(Braun and Sieper 2007; Spondylitis-
Association-of-America 2011). 
Table 1.10 Bone diseases (Rosen 2008). 
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The interplay between the complement system and bone diseases such as RA and 
OA has been investigated, but each arthritic disease demonstrated variable bone 
phenotypes. Dynamics between complement components and bone homeostasis 
have also been established.  
 
1.6 The Role of Complement Regulating Bone in Health and 
 Disease 
The complement system’s involvement in OCG and bone formation has been 
investigated in a number of in vitro and in vivo studies which are described in detail 
below. 
 
1.6.1  Role of Complement on OCG 
OCG regulation has been discovered to depend on C3 when stimulated with Vit. D. 
This opened up research into C3 and C5 receptors. Findings from initial 
differentiation assays were supported by studies into different knockout models. 
 
1.6.1.1 In Vitro Role of Complement on OCG 
In the early 90s a Japanese group was the first to publish complement involvement 
in bone cells. Initially they discovered that cultured murine stromal cells and calvarial 
primary osteoblasts stimulated with Vit D produced a 190kDa protein which they 
identified as C3. Next the authors prepared co-cultures from bone marrow 
supplemented with Vit D which produced ALP+ colonies and TRAP+ multinucleated 
cells adjacent to each other. When C3 was blocked no colonies or TRAP+ cells 
appeared. In cultures with added C3 and no Vit D stimulation TRAP
+ cells were not 
detectable, suggesting that C3 is working together with other factors stimulated by 
Vit D to induce OCG (Sato et al. 1991).  
During OCG, Sato et al. (1993) identified that C3 was stimulating 
macrophage-like cells, mononuclear TRAP+ cells and small multinucleated (up to 5 
nuclei) TRAP+ cells. These cells were found to have multiple C3 receptors. Blocking 
antibodies against these receptors revealed that C3 produced by OBs and stromal 
cells binds mainly CR3, which disappears during OCs maturation. When blocking 
C3 at different time points of OCG, C3 was found to be most important during late 
proliferation and early differentiation (Sato et al. 1993).  
In 2 human studies OBs and OCs were shown to activate C5. C3a/C5a, in 
synergy with IL-1β, could induce IL-6, IL-8, RANKL and OPG release by OBs. 
Furthermore C3a and C5a were supposedly able to induce OCG in absence of 
RANKL and M-CSF (Pobanz et al. 2000; Ignatius et al. 2011). Recently, C1q 
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expression was also discovered in OC cultures derived from human peripheral blood 
monocytes. C1q expression was most pronounced in immature osteoclasts and C1q 
supplementation increased OCG, suggesting that the classical pathway is also 
playing a role (Boon et al. 2012). 
 
1.6.1.2 In Vivo Role of Complement on OCG 
To obtain an in vivo appreciation of complement on OCG, C3 production was 
studied in Vit D-deficient (Vit D-/-) animals. Calvarial levels of C3 were much lower in 
Vit D-/- animals than in controls. When Vit D was administered C3 production was 
stimulated in bone. C3+ cells were located in the peristeum and tibial metaphyses 
co-localised with OB precursor cells (Jin et al. 1992; Sato et al. 1993).  
 This data was confirmed by Mangham et al. who showed that C3 
deposited to the hydroxyapatite of trabecular surfaces of human foetuses. TRAP+ 
mononuclear cells expressing CR3 and CR4 were localised to the same area. When 
multinucleated cells were formed, expression of these receptors was lost, showing 
that complement was needed for the recruitment of OC precursor cells to the site of 
resorption (Mangham et al. 1993). 
Furthermore, C3-/- mice were found to express lower RANKL and OPG 
levels, which resulted in reduced production of M-CSF and IL-6 as well as fewer 
OCs being present (Tu et al. 2010).  
Recent research has also concentrated on the anaphylatoxins, C5a and 
C3a, and their receptors. In an abstract Ehrnthaller et al. described that C5aR was 
hardly detectable in MSC but readily expressed by OTs, OBs and OCs in trabecular 
bone (Ehrnthaller et al. 2009). It was identified that components of the alternative 
pathway were produced locally to activate C3, and released C3a/C5a where 
required for optimal OC generation by controlling IL-6 levels (Tu et al. 2010). 
 
1.6.2 Role of Complement on Bone Formation 
In order to characterise OB in more detail murine calvaria cultures were analysed 
via the Affymetrix Gene-Chip array. When looking at 27,000 genes prominent 
complement expression was discovered. All 3 chains of C1q were expressed the 
most, followed by C4, C3aR, properdin, C1 inhibitor and factor H (Roman-Roman et 
al. 2003).  
Around the same time another group performed an Affymetrix gene chip on 
adult human cell lines from different stages of the OB differentiation, starting with a 
pre-OB line to a pre-OT line. C1r, C1s and factor H were among the 47 genes that 
changed in a consistent down-regulation between all cell lines. The authors 
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suggested that this mechanism causes inhibition of OCG in the area of newly 
generated bone (Billiard et al. 2003).   
Most of the research has concentrated on the complement components and 
their cleavage products, however, the role of complement regulators in bone is 
unclear.  
 
1.7  Hypothesis and Aims of the Project 
Preliminary data by Dr Anwen Williams revealed a spontaneously induced bone 
disease when histologically examining joint tissue from 19 month old CD59a-/- mice 
compared to age matched WT mice. The pathology was featured by enhanced OC 
localisation and disorganised bone resorption in the epiphysis. Inflammation was not 
identified in synovium of either CD59a
-/-
 or WT mice. The articular cartilage of the joint 
was replaced by bone and aberrant endochondral ossification and osteophyte formation 
was observed. These features are characteristic for OA.  
 This evidence allowed constructing the hypothesis that CD59a-/- mice 
have an osteoarthritic bone phenotype. Currently no treatments are available to 
inhibit the development of osteoarthritis (Wang et al. 2011) therefore the following 
research question arose: Would CD59 be suitable for osteoarthritis treatment? In 
order to investigate the hypothesis 4 specific aims were derived which are 
investigated in the following chapters. 
 
Aim 1:  Determining the role in OB differentiation and maturation. 
Aim 2:  Assessing the impact of CD59a on OCG.  
Aim 3: Investigating the role of human CD59 in resorption assays. 
Aim 4:  Phenotypic analysis of bone structure in CD59a-/- mice. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 Materials 
Acids and solvents were obtained from Fisher Scientific. Other reagents were 
supplied by Sigma-Aldrich unless stated otherwise. A comprehensive, alphabetical 
list of suppliers is provided in Appendix 1. 
 
2.2 Solutions 
A number of solutions, stains and buffers were used throughout the thesis, they are 
listed alphabetically below:- 
 
(i) Acetate Solution - 3.5 ml Sodium acetate (1.64 mg/ml (w/v)), 1.5 ml glacial acetic 
acid (1.5% (v/v)) were added to distilled water (dH2O) to a final volume of 10 ml. 
 
(ii) Alkaline Phosphatase (ALP) stain – 3.34 μl BCIP solution (see (ix)) and 4.4 μl 
NBT solution (see (xxxvi)) were added to 2-Amino-2-hydroxymethyl-propane-1,3-diol 
buffered hydrogen chloride (Tris-HCl) solution (see (lii)) to a final volume of 1 ml.  
 
(iii) Alizarin red - The stain (10 g/l (w/v)) was prepared in dH2O at pH 4.2. The 
solution was filtered (Fisherbrand QT 260 filter paper (Fisher)) before use. 
 
(iv) Ammonium persulfate solution - A fresh solution (10%, w/v) was prepared every 
time by dissolving Ammonium persulfate in dH2O. 
 
(v) Ampicillin plate - Autoclaved lysogeny broth (see below) containing ampicillin 
(Fisher Scientific, 50 mg/ml (v/v)) and Ultrapure-agar (Invitrogen, 3.75 g) was 
poured into sterile Petri-dishes before surfaces were flamed to keep aseptic. 
 
(vi) Aniline blue acid – Aniline blue (0.3 mg/ml) and Phosphotungstic acid (10 mg/ml) 
were dissolved in dH2O. 
 
(vii) l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (ASP) stock solution 
– ASP (12.5 mg/ml (w/v)) was prepared in sterile phosphate buffered saline (PBS, 
Invitrogen) and stored at -20°C. 
 
(viii) Assay buffer – A solution of Bovine serum albumin (BSA, 1% (w/v)) was 
prepared by dissolving BSA in PBS (see (xliii), pH 7.3) containing Tween 20 (0.05% 
(v/v)). 
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(ix) 5-bromo-4-chloro-3 indolyphosphate (BCIP) solution - BCIP (75 µg) was diluted 
in 1 µl of dimethylformamide (DMF from Fisher, 70% (v/v)). 
 
(x) Buffer A - A solution of Tris-HCl (100 mM, pH 7.4) was prepared in dH2O that 
contained calcium chloride (CaCl2, 5 mM). 
 
(xi) Buffer B – A Sodium acetate (NaOAc, 50 mM) solution (pH 5.5) was prepared, 
ethylenediaminetetraacetic acid (EDTA, 2 mM), Dithiothreitol (DTT, 2 mM), NaCl 
(350 mM) and chondroitin 4-sulfate sodium salt (0.15% (w/v)) were then added. 
 
(xii) Buffered formalin - A stock solution (4% (v/v)) of tissue fixative was prepared by 
adding 100 ml Formaldehyde solution (37%) to 900 ml of PBS (see (xliii), pH7.3). 
 
(xiii) Blocking buffer – BSA (1% (w/v)) was dissolved in PBS (see (xliii), pH7.3). 
 
(xiv) Calcein solution – Calcein (1.75 mg/ml) was dissolved in sterile PBS containing 
sodium bicarbonate (NaHCO3, 2% (w/v)). 
 
(xv) Citrate buffer - Hydrogen peroxide (H2O2, 1 µl/ml (v/v)) was mixed with citric acid 
solution (42 g/l (w/v), pH 3.95) immediately before use. 
 
(xvi) Chloramphenicol plate – Bacto-tryptone (BD Biosciences, 10 g), Bacto-yeast 
extract (Merck, 5 g), Ultrapure-agar (15 g) were prepared in 1 l sucrose solution (see 
(xlviii), 5%). Solution was autoclaved, cooled and chloramphenicol (12.5 µg/ml), 5-
bromo-4-chloro-3-indolyl β-D-galactoside (X-gal, 80 µg/ml) and isopropyl-beta-D-
thiogalactopyranoside (IPTG, 200 µM) were added. Plates were poured into sterile 
Petri-dishes under aseptic conditions. 
 
(xvii) Col1 (calf skin) – A stock solution of Col1 (2.5 mg/ml (w/v)) was prepared in 
acetic acid solution (50 mM) with agitation over night. The solution was buffered with 
Tris (1.5 M) to pH 8.8 and a concentration of 2 mg/ml. 
 
(xviii) Collagenase (Clostridiopeptidase A) Type I - A stock solution of collagenase 
(1mg/ml (w/v)) was prepared in dH2O. 
 
(xix) Complete medium for HEK 293T cells – Heat-inactivated foetal calf serum 
(FCS from Lonza, 10% (v/v)), penicillin-streptomycin (Gibco, 50 units/ml - 50 µg/ml), 
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sodium pyruvate (1mM) and L-glutamine (Gibco, 2 mM) were added to Dulbecco’s 
modified eagle medium (Invitrogen). 
 
(xx) Complete medium for human cell cultures - Heat-inactivated FCS (Biosera, 10% 
(v/v)), penicillin-streptomycin (Gibco, 50 units/ml - 50 µg/ml) and L-glutamine (Gibco, 
2 mM) were added to Roswell Park Memorial Institute 1640 basal medium (RPMI, 
Invitrogen). 
 
(xxi) Complete medium for murine cell cultures – α-minimum essential medium 
(αMEM, Invitrogen, 100 g) and NaHCO3 (2.2 g) were dissolved in dH2O to a final 
volume of 10 l. The solution was sterile filtered (0.22 µm pore size) and autoclaved 
before use. Penicillin-streptomycin (Lonza) was added to the medium to achieve a 
final concentration of 50 units/ml/ 50 µg/ml (v/v), and heat-inactivated FCS (Lonza) 
was added to the medium for a final concentration of 10% (v/v) for OC cultures 
whereas the treatment for FCS in OB cultures varied. 
 
(xxii) Dexamethasone (DEX) stock solution – DEX (10 mM) was prepared in ethanol 
(100%). This was used as stock solution for CFU-AD medium. The solution was 
further diluted to 0.5 mM in sterile PBS as a stock solution for CFU and 
mineralisation medium. All stock solutions were aliquoted and stored at -20°C. 
 
(xxiii) Eosin solution - Eosin tetrabromo fluorescein 225 (Fisher Scientific, 1% (w/v)) 
was prepared in dH2O. 
 
(xxiv) FACS buffer - FCS (2% (v/v)) was dissolved in PBS (see (xlii), pH 7.3). 
 
(xxv) Giemsa stain – This commercially available stain was diluted (1:10) using PBS 
(see (xlii), pH 6.8) to a final concentration of 0.04% (v/v). 
 
(xxvi) Glacial acetic acid solution – Glacial acetic acid (2% (v/v)) was prepared in 
dH2O. 
 
(xxvii) Glutaraldehyde solution – A fresh solution (40% (v/v)) was prepared in dH2O. 
 
(xxviii) Glycerol buffer – Glycerol (65% (v/v), Mg SO4 (0.1 M) and Tris-HCl (0.025 M, 
pH 8) were prepared in dH2O. 
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(xxix) β-Glycerophosphate (βGP) stock solution - βGP (1 M) was dissolved in sterile 
PBS and stored at -20°C. 
 
(xxx) Indomethacin stock solution – Indomethacin (50 mM) was dissolved in ethanol 
(100%) and stored at -20°C. 
 
(xxxi) Insulin stock solution – Insulin (2 mg/ml (w/v)) was prepared in glacial acetic 
acid (1% (v/v)) and stored at -20°C. 
 
(xxxii) 3-isobutyl-1-1methylxanthine (IBMX) stock solution – IBMX (1 M) was 
dissolved in warm dimethyl sulfoxide (DMSO, 100%) and stored at -20°C. 
 
(xxxiii) Kodak GBX developer and replenisher solution – The reagent was diluted 1:5 
in tap H2O. 
 
(xxxiv) Kodak GBX fixer and replenisher solution – The reagent was diluted 1:5 in 
tap H2O. 
 
(xxxv) Lysogeny Broth (LB) medium - Bacto-tryptone (BD Biosciences, 10 g),  
Bacto-yeast extract (Merck, 5 g) and NaCl (10 g) were dissolved in dH2O and the pH 
was adjusted to 7 before further dilution in dH2O to 1 l. The mixture was then 
autoclaved. 
 
(xxxvi) Nitro blue tetrazolium (NBT) solution - NBT (50 µg) was dissolved in 1µl of 
DMF (100% (v/v)). 
 
(xxxvii) MACS buffer - A solution was prepared containing BSA (0.5% (w/v)) and 
EDTA (2 mM) in sterile PBS. 
 
(xxxviii) May-Grünwald - The stain, which is commercially available, was diluted 
(1:2) in PBS (see (xliii), pH 6.8) to a final concentration of 0.2% (w/v). 
 
(xxxix) Milk buffer - Fat free milk powder (5% (w/v)) was dissolved in PBS (see (xliii), 
pH 7.3). 
 
(xl) Mount for resin sections - AnalaR Normapur saccharose (VWR, 100 g), gum 
Arabic (100 g) and Thymol (1 crystal) were added to 120 ml of dH2O. The mixture 
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was dissolved in a water bath (80°C), centrifuged briefly and stored in 5 ml syringes 
at 4°C. 
 
(xli) Oil red O stock solution - Oil red O (0.5 g) was dissolved in isopropanol (Fluka) 
to a final volume of 100 ml. The solution was stored away from light at room 
temperature. 
 
(xlii) Oil red O working solution – A fresh solution was prepared every time by 
diluting Oil red O stock (see (xli)) 1:1.5 in dH2O. The solution was stirred for 15 min 
and filtered before use.  
 
(xliii) Phosphate buffered saline (PBS) - One tablet PBS (Oxoid, pH 7.3) was 
dissolved in 100 ml of dH2O. For Giemsa staining only, one tablet of PBS (Merck, 
pH 6.8) was dissolved in 100 ml of dH2O. 
 
(xliv) Refolding buffer - Triton x100 (2.5% (v/v)) was diluted in dH2O. 
 
(xlv) Resin solution - Dibuthyl phthalate (10 g), Perkadox 16 (Akzo Nobel, 1 g) and 
Novoscave (Novochem, 0.01 g) were dissolved in methyl-methaxcrylate (MMA, 89 
ml). 
 
(xlvi) Silver nitrate stock solution – Silver nitrate (15% (w/v)) was diluted in dH2O and 
stored away from light. 
 
(xlvii) Sodium dodecyl sulphate (SDS) solution – SDS (10% (w/v)) was diluted in 
dH2O. 
 
(xlviii) Sucrose solution – 50 g sucrose was added to 1 l of dH2O before being 
dissolved at 37°C for 30 min. 
 
(xlix) Tartrate Resistant Acid Phosphatase (TRAP) stain 1 – 5 ml acetate solution 
(section 2.2, (i)), 1 ml sodium tartrate (0.3 M), 100 µl naphthol AS-MX phosphate 
disodium salt (10 mg/ml) and 10 µl Triton X-100 were added to 4.39 ml dH2O. The 
buffer was incubated at 37°C for 15 min before fast red violet LB (3 mg) was added 
and kept at 37°C until used. 
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(l) TRAP stain 2 – 140 mg naphthol AS-TR phosphate (Apollo) was dissolved in 500 
µl N-N dimethyl formanide. 100 ml sodium acetate (0.2 M, pH 5.2) was added and 
230 mg sodium tartrate dehydrate. Finally, 140mg fast red salt TR were dissolved in 
the solution. 
 
(li) 3,3’5,5’ Tetramethybenzidine (TMB) solution - TMB (240 mg) was dissolved in 10 
ml DMSO-ethanol solution ( 5 ml DMSO was added to 5ml ethanol). 
 
(lii) 2-amino-2-hydroxymethyl-propane-1,3-diol buffered hydrogen chloride (Tris-HCl) 
solution – Tris-HCl (100 mM, pH 9.5), sodium chloride (NaCl, 100 mM) and 
magnesium chloride (MgCl2, 5 mM)) were prepared in dH2O. 
 
(liii) Tris-acetate-EDTA (TAE) buffer -  Tris (40 mM), Acetic acid (20 mM), EDTA (2.5 
mM), Ethidium Bromide (0.0005% (v/v)) were prepared in dH2O. 
 
(liv) Trypsin-EDTA (TE) buffer - Trypsin-EDTA, which is commercially available as 
0.5% solution (Gibco), was diluted to 1:2 or 1:10 in sterile PBS (pH 7.3). 
 
(lv) Trypan Blue solution – Trypan Blue (0.4% (w/v)) was prepared in PBS (see 
(xliii), pH 7.3) and filtered before use. 
 
(lvi) Wash buffer – Tween-20 was diluted in PBS (see (xliii)) to achieve a final 
concentration of 0.05% (v/v) at pH 7.3. 
 
(lvii) Western blot transfer buffer - Glycine (2.93 g), Tris (5.81 g), SDS (0.375 g) and 
methanol (200 ml) were made up to 1 l in dH2O. 
 
(lviii) Zymography destain – Methanol (450 ml) and glacial acetic acid (100 ml) were 
prepared in dH2O to a final volume of 1 l. 
 
(lix) Zymography digestion buffer A – DTT (2.5 mM) and EDTA (2.5 mM) were 
added to NaOAc solution (50 mM, pH 5.5). 
 
(lx) Zymography digestion buffer B – Tris-HCl (50 mM, pH 7.4), CaCl2 (5 mM), NaCl 
(120 mM) and Triton X-100 (2.5% (v/v)) were prepared in dH2O. 
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(lxi) Zymography digestion buffer C – Tris-HCl (50 mM, pH 8), NaCl (50 mM), CaCl2 
(10 mM) and Triton X-100 (2.5% (v/v)) were prepared in dH2O. 
 
(lxii) Zymography loading buffer – Tris-HCl (70 mM, pH 6.8), glyerol (10% (v/v)), 
SDS (2% (w/v)) and bromophenol blue (0.001% (w/v)) were prepared in dH2O. 
 
(lxiii) Zymography running buffer - Tris (3 g), glycine (14.4 g) and SDS (1 g) were 
dissolved in dH2O to a final volume of 1 l at pH 8.3. 
 
(lxiv) Zymography stain - Brilliant blue R Coomassie (0.25% (w/v)) was dissolved in 
zymography destain (see (lviii)). 
 
(lxv) Zymography wash buffer A - NaOAc (50 mM, pH 5.5), NaCl (100 mM), cysteine 
(10 mM) and Triton X-100 (2.5% (v/v)) were prepared in dH2O. 
 
(lxvi) Zymography wash buffer B – Tris-HCl (50 mM, pH 7.4), CaCl2 (5 mM) and 
NaCl (120 mM) were prepared in dH2O. 
 
(lxvii) Zymography wash buffer C – Tris-HCl (50 mM, pH 8), NaCl (50 mM) and 
CaCl2 (10 mM) were prepared in dH2O. 
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2.3  Determining the Role of CD59a in Osteoblast Differentiation and 
 Maturation 
The main aim of this chapter was to identify the effect of CD59a on osteoblast (OB) 
differentiation and mineralisation. Before this could be established, an in vitro 
differentiation assay was developed. Firstly a source of OBs had to be determined. 
For the purpose of these experiments and because of the availability of gene 
deficient mice, murine primary mesenchymal stem cells (MSCs) and OBs were used 
to specifically examine the function of CD59a. OBs are commonly extracted from 
explants of the calvaria and MSCs or OBs from long bones (Hu et al. 2009). In this 
study explants and bone marrow cultures were prepared from long bones and 
compared to each other. Varied culture conditions, such as cell concentrations and 
time courses, were investigated to decide on the best method to test the hypothesis 
that CD59a regulates OB differentiation and mineralisation.  
 
2.3.1  Animals and Housing 
CD59a-/- mice that were used in this thesis were bred onto a C57BL/6J background 
(more than eight generations). They were kindly supplied by Prof B Paul Morgan 
(Holt et al. 2001; Bhole and Stahl 2004). WT C57BL/6J mice were purchased from 
an in-house colony that was maintained by Dr Awen Gallimore. The colonies were 
kept in the Joint Biological Service Unit (Cardiff University). All animals were held in 
conventional housing at stable temperature and humidity on a 12 h light/dark cycle 
with food and water available ad libitum. 
 
2.3.2 Tissue Culture Materials 
The following tissue culture consumables were utilised in this thesis:- 
(i)   Nunc tissue culture plates (12 wells) and Nunc tissue culture flasks (25 
 cm2 and 75 cm2). They were purchased from VWR.  
(ii)  Petri-dishes were purchased from Fisher Scientific.  
(iii)  BD falcon tubes (15 ml and 50 ml) were purchased from SLS. 
(iv)  Universal tubes (20 ml) and Eppendorfs (0.5 ml and 1.5 ml) were bought 
 from Greiner.   
(v)   Syringes (5 ml) and 21-gauge hypodermic needles were purchased from 
 BD Pharmingen.  
All cell cultures were kept in a humidified atmosphere at constant temperature 
(37°C) with a regulated supply of CO2 that was maintained at 5% in air. 
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2.3.3 Establishment of Bone Cell Cultures and a Mineralisation Assay 
To prepare for mineralisation assays, MSCs and OBs first had to be harvested, 
expanded and finally seeded onto plates containing medium that induced 
differentiation and mineralisation. Bone marrow and explant cultures were prepared 
from male mouse bones. All animals were killed by Schedule I method. Both femora 
and humeri were dissected and stored dry in a 20 ml universal tube on ice prior to 
isolation of the bone marrow cells. 
To obtain MSCs from the bone marrow, the top of each bone was cut open 
under aseptic conditions and transferred into a sterile 0.5 ml Eppendorf with the 
open end facing down (a 2 mm2 hole was cut in the bottom of each Eppendorf). The 
0.5 ml Eppendorf was fitted into a 1.5 ml Eppendorf as shown in Fig. 2.1.  
 
 
Figure 2.1 Eppendorf assemblies for bone marrow harvesting. Diagram 
showing the protocol for bone marrow extraction. 
 
The tube assembly was centrifuged at 3,000 x g for 1 min in a conventional tabletop 
micro-centrifuge. The resultant bone marrow pellet was collected in the base of the 
1.5 ml Eppendorf. The bone marrow from each mouse was pooled (femora and 
humeri) into a single 1.5 ml Eppendorf by recurrent resuspension in 1 ml complete 
medium for murine cell cultures (section 2.2, (xxi)). A single cell suspension was 
generated by careful and repeated mixing in a 5 ml syringe fitted with a 21-gauge 
hypodermic needle. 
Once the bone marrow was removed, explants from both femora and humeri 
were used as source of OBs. For this, cartilage was discarded from subchondral 
bone and bone fragments were placed into a Petri-dish containing sterile PBS. 
Shafts were separated from all other bone components and transferred into a 
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separate Petri-dish. This was required as the growth plate containing fragments 
accommodated stem cells and chondrocytes which did not provide pure OB 
cultures. 
All bone fragments (from shaft and epiphysis/metaphysis) were cleaved into 
explants (maximum length of 3 mm) and placed in 1.5 ml Eppendorfs with sterile 
PBS. Solutions were agitated thoroughly to remove bone marrow cells still attached 
to the bone, which was visible as red staining. To remove unwanted cellular debris 
Eppendorfs were centrifuged at 3000 x g briefly. Explants were collected at the 
bottom, the solution was discarded and fresh PBS was added. This washing 
procedure was repeated until all bone fragments appeared white. 
 
2.3.3.1 Bone Cell Cultures 
Once bone marrow and explants were prepared, they were set up to test cell 
number, cell source, FCS treatment, β-Glycerophosphate (βGP, section 2.2, (xxix)) 
concentration and a time course. For this, cells were expanded in 25 cm2 or 75 cm2 
flasks containing 4 or 10 ml medium supplemented with FCS that was tested 
untreated and heat-inactivated (56°C for 30 min) (Tab. 2.1). 
 
Test condition Cell source Flask size 
in cm2 
FCS 
Cell density/ Bone marrow 2x25 Untreated 
Cell source Shaft explants    
 Epiphysis/metaphysis explants   
FCS/ βGP Bone marrow 1x75 Untreated 
supplementation   Inactivated 
Time course Bone marrow 2x75 Inactivated 
Table 2.1 Testing parameters of proliferation. 
 
If multiple flasks were used for the same condition then cells and explants were 
equally split. Explants also had to be spread evenly throughout the flask with a 
sterile pipette tip.  
Fresh complete medium for murine cell cultures was added after 3 days to 
allow MSCs to proliferate and non-adherent cells to be removed. Explant cultures 
were left undisturbed for 6 days to enable cells from the bone surface to proliferate 
onto the plastic. In both conditions, medium was then changed every 3 to 4 days 
until confluence was reached (7-14 days). MSCs and their progeny were identified 
as elongated to spindle-shaped cells that were termed confluent when all cells were 
touching as illustrated in Fig. 2.2. Once 100% confluence was reached cells were 
passaged or processed for mineralisation assays. 
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Figure 2.2 Illustration of confluent MSCs under the inverted microscope.  
 
2.3.3.2 Establishing Conditions for a Mineralisation Assay 
Expanded MSCs and OBs were plated to establish appropriate cell densities, 
supplements and time course of mineralisation (Tab.  2.2).  
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Test condition Cell source Passage FCS β-GP [mM] Cells/well 
Cell density Bone marrow Primary Untreated 10 1x104 
     2x104 
  1   3x104 
     4x104 
Cell source Bone marrow 1 Untreated 10 4x104 
 Explants (shaft and epiphysis/metaphysis)  Untreated  4x104 
FCS supplementation Bone marrow Primary Untreated 10 4x104 
   Inactivated   
β-GP concentration Bone marrow Primary Inactivated   2 4x104 
    10  
Time course Bone marrow Primary Inactivated 10 4x104 
Table 2.2 Testing parameters of to obtain mineral deposition. 
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As MSCs adhered strongly they were detached from the plastic flask using the 
following method. Medium was removed and cells were washed with 1 ml PBS. 
Trypsin-EDTA (0.25%) was utilised as dislodgement reagent by adding 300 µl or 
500 µl per (25 cm2 or 75 cm2) flask. The solution was distributed to cover the bottom 
of the flask and incubated at 37°C for 3 min before agitation at room temperature 
until the majority of cells were detached as observed microscopically. Complete 
medium for murine cell cultures (1 ml) was added to each flask to dilute out and 
block Trypsin-EDTA. The cell suspension was transferred into a universal tube and 
flasks were washed with 1 ml complete medium for murine cell cultures to collect all 
dislodged cells. The solution was transferred into the same universal tube already 
containing detached cells and centrifuged at 300 x g for 5 min to collect cells. 
Supernatant was discarded and cells were re-suspended in 1 ml complete medium 
for murine cell cultures.  
Initially an aliquot was diluted 1:2 in trypan blue solution (section 2.2, (lv)) to 
observe and quantify viable cells utilising the haemocytometer as explained in Fig. 
2.3. In this method, only dead cells are able to take up the stain and were excluded 
from the haemocytometer count. Cell concentration was determined according to 
the formula stated in Fig. 2.3. In further experiments cells were diluted 1:2 in 
complete medium for murine cell cultures to calculate cell density.  
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Figure 2.3 Demonstration of haemocytometer grid. Diagram illustrating square 
for counting procedure. The outer and centre squares were counted as indicated by 
the dashed lines. Cells touching the top and left line were included in the count, 
whereas cells touching the right or bottom line were excluded. Between 20 and 50 
cells were counted per square. If the variation between squares was greater than 
20%, the cells were re-suspended and the count repeated. Once counted, cell 
concentration was determined. Each square has an area of 1mm2 and a depth of 
0.1 mm; therefore the space holds 0.1 µl (Sigma-Aldrich 2010). The cell 
concentration was calculated according to the equation displayed. 
 
 
The cell concentration was adjusted according to the requirements of each 
mineralisation assay, as described in Tab. 2.2. Diluted cell suspension (1 ml) was 
added to each well of a 12 well plate and each condition was tested in triplicates.  
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Plated cells were left to adhere overnight before medium was discarded and 
replaced by complete medium for murine cell cultures supplemented with 
dexamethasone (DEX, stock solution described in section 2.2., (xxii), 10 nM), l-
ascorbic acid 2-phosphate sesquimagnesium salt hydrate (ASP, stock solution 
described section 2.2., (vii), 50 µg/ml) and the appropriate βGP concentration. This 
day was defined as day 0. Fresh mineralisation medium was added every 3 to 4 
days and mineralisation was observed microscopically as brown precipitate resting 
on top of cells. Cells were left to differentiate for up to 28 days. Alizarin red staining 
was used to identify the development of mature OBs within each well (section 
2.3.3.3).  
Cells that were not plated were cultured further to passage one. For this, 
bone marrow derived cells were added into 25 cm2 flasks containing complete 
medium for murine cell cultures. Explants were left in flasks after trypsin-EDTA 
digest and supplemented with fresh medium to allow for further cell expansion. 
 
2.3.3.3  Identification and Quantification of Mineralisation 
Alizarin red was used to stain for OBs, it binds to the hydroxyapatite deposited by 
OBs in culture. Alizarin red staining was performed on day 10, 14, 17, 21, 24 and 
28. Briefly, cells were washed with PBS (section 2.2, (xliii), 1 ml/well), fixed in 
buffered formalin (section 2.2, (xii), 1 ml/well) for 15 min and washed in dH2O (1 
ml/well). Alizarin red (section 2.2, (iii), 0.5 ml/well) was added to each well for 5 min, 
then non-specific unbound stain was removed by washing in 50% ethanol (5x). The 
last wash was incubated for 15 min at room temperature. Finally all stained wells 
were left to dry.  
Plates were transferred into a Hewlett-Packard (HP) scanner to obtain high 
resolution images (600 dpi). The amount of Alizarin red staining per well was 
determined by utilising Coral Paint Shop Photo ProX3 (ProX3), where a greyscale 
was applied and Image J software to quantify the total area of stain per well for each 
condition.  
 
2.3.4 Establishment of a Colony Forming Unit Assay 
The next objective was to determine the ability of bone marrow cells to establish 
colony forming units (CFU) of cells entering the OB fate. Bone marrow cells were 
harvested as described in section 2.3.3. An aliquot (10 µl) of the cell suspension 
was diluted 1:100. A high number of erythrocytes were identified which were then 
lysed by a 1:2 dilution in glacial acetic acid solution (section 2.2, (xxvi)). 
Haemocytometer counts were performed as described in section 2.3.3.2. 
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Bone marrow cells were diluted in complete medium for murine cell cultures 
to the appropriate cell concentrations (Tab. 2.3). Cells (1 ml/well) were added in 
triplicates to a 12 well plate and incubated overnight to adhere.  Medium and non-
adherent cells were discarded and replaced with the complete medium for murine 
cell cultures supplemented with DEX (10 nM) and ASP (50 µg/ml) to initiate cell 
differentiation. This day was defined as day 0. Fresh medium was added on day 3 
and 7. 
 
Test condition Cells/well  
Cell density 2x105, 4x105, 8x105 
Time point 8x105, 1.2x106 
Evaluation of the quantification procedure 1.2x106 
Table 2.3 Testing parameters of CFU.  
 
2.3.4.1 Identification and Quantification of Cells Entering CFU 
Alkaline phosphatase (ALP) staining was used to identify osteogenic lineage cells in 
cultures on day 7 and 10. For this, cells were rinsed in PBS (1 ml/well) and fixed in 
buffered formalin (1 ml/ml) for 15 min. This was followed by washing in dH2O (1 
ml/well) and cells were stained in ALP stain (see section 2.2, (ii), 1 ml/well) 
overnight; storing plates in the dark at room temperature. Cells were washed in 
dH2O (1 ml/well) and counter stained in Eosin solution (section 2.2., (xxiii), 0.5 
ml/well) for 90 s. Plates were washed with 1 ml/well dH2O twice and left to dry.  
Colonies were defined as ALP+ if a cluster of 20 or more cells contained ALP 
stained (blue) cells (Vidal et al. 2007). These were microscopically counted for each 
well in turn. Plates were processed for quantification as described in section 2.3.3.3. 
 
2.3.5 Quantification of CFU in WT and CD59a-/- Mice 
After optimisation of CFU assays, bone marrow cultures from WT and CD59a-/- mice 
were examined for their differentiation potential. Bone marrow cells were harvested 
as described in section 2.3.3 and plated at 1.2x106 cells/well. Cells were incubated 
for 10 days in complete medium supplemented with DEX (10 nM) and ASP (50 
µg/ml) and medium was replaced on day 3 and 10. ALP+ staining surface area was 
quantified as described in section 2.3.3.3. 
 
2.3.6  Testing Reproducibility of Mineralisation in WT and CD59a-/- Mice 
To evaluate the reproducibility of the established mineralisation assay, experiments 
were set up sequentially. For this, MCS from bone marrow (2 femora, 2 humeri and 
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2 tibiae) of WT and CD59-/- mice (n=7) were harvested and expanded in 2x75 cm2 
flasks per mouse as described in section 2.3.3. After confluence was reached MSCs 
were plated at 8x104 cells/well and were differentiated in complete medium for 
murine cell cultures supplemented with DEX (10 nM), ASP (50 µg/ml) and β-GP (10 
mM) for 21 days. Mineralisation by mature OBs was identified utilising Alizarin red 
(section 2.3.3.3) and ALP (section 2.3.4.1) staining.  
 
2.3.7 Comparison of CFU of Adipocytes in WT and CD59a-/- Mice 
In order to assess whether changes identified in CFU are due to differential 
regulation of MSCs, adipocyte colony (CFU-AD) generation was tested. Bone 
marrow cells were harvested (section 2.3.3), plated (sections 2.3.5) and stimulated 
with complete medium for murine cell cultures supplemented with insulin (section 
2.2, (xxxi), 5 µg/ml), indomethacin (section 2.2, (xxx), 50 µM), DEX (1 µM) and IBMX 
(section 2.2, (xxxii), 0.5 µM) for 10 days according to Ripoll et al. (Ripoll and Bunnell 
2009). Fresh medium was supplied on day 3 and 7. 
 
2.3.7.1 Identification and Quantification of Adipocytes 
Oil red O staining was utilised to identify lipid droplets of adipocytes. Cells were 
washed in PBS (1 ml/well) before fixation in buffered formalin (1 ml/well) for 10 min. 
This was followed by washing in dH2O (1 ml/well) and staining in Oil red O working 
solution (section 2.2, (xlii), 1 ml/well) for 15 min. Cells were washed in isopropanol 
(60% (v/v), 1 ml/well) and then in PBS (1 ml/well). Haematoxylin (300 µl/well) was 
utilised for counter staining before wells were washed with dH2O (1 ml/well) and 
covered with sterile PBS (1 ml/well) for storage.  
Plates were analysed immediately as lipids could not be identified once wells 
were dry. Lipids appeared as red droplets within cells and as only a small number of 
adipocytes were present, the methodology of Crisp et al. was adapted for my  study 
(Crisp et al. 2000). Adipocytes were grouped according to their proximity as 1 
adipocyte, colonies of 2-5 adipocytes or colonies containing more than 5 adipocytes. 
 
2.3.8  Statistics 
All statistical analysis was performed with Graphpad Prism software. A student T-
Test was performed when comparing 2 unpaired groups. One-way ANOVA was 
utilised when studying more than 2 unpaired groups.  Two-way ANOVAs were 
performed when assessing more than 2 groups with 2 independent variables 
respectively. Mean and standard error are stated throughout the result section. 
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2.4   Assessing the Impact of CD59a on Osteoclastogenesis 
A number of precursor cells have previously been utilised for osteoclastogenesis 
(OCG) in vitro, including primary cells (such as bone marrow preparations or blood 
monocytes) (de Vries et al. 2009) and cell lines (such as RAW 264.7 cells) (Galal et 
al. 2007). Again, as genetically modified mice were available on site, bone marrow 
preparations were selected as an appropriate precursor cell source to test the 
working hypothesis. They were grown and differentiated into osteoclasts (OCs) in 
medium containing M-CSF and RANKL on glass coverslips. Phenotypic analysis 
was performed on OC generated from WT, CD59a-/- and C6-/- bone marrow 
preparations.  
 
2.4.1  Animals and Housing 
CD59a-/- and C6-/- mice on a C57BL/6J background were kindly supplied by Prof B 
Paul Morgan and WT mice were purchased as described in section 2.3.1.  
 
2.4.2  Tissue Culture Materials 
Nunc tissue culture plates (containing 24 and 96 wells) were purchased from VWR. 
Petri-dishes were obtained from Fisher Scientific. Round glass coverslips (6 mm and 
13 mm diameter) and rectangular coverslips for microscopy (22x26 mm) were 
ordered from Knittel Gläser. The coverslips that were used for cell culture purposes 
were sterilised by soaking in ethanol (100%) and dried thoroughly before use. Other 
consumable and culture conditions are described in section 2.3.2. 
 
2.4.3 Harvesting Bone Marrow Cells 
Murine bone marrow cells were obtained from the femora of female and male 8-10 
week old mice (WT, CD59a-/- and C6-/-) as described in section 2.3.3. The bone 
marrow cell pellet was re-suspended in complete medium for murine cell cultures 
(up to 3 ml). A single cell suspension was generated by careful and repeated mixing 
in a 5 ml syringe fitted with a 21 gauge hypodermic needle. Glacial acetic acid 
solution was used at a 1:2 dilution to lyse red cells in the suspension. The cell 
suspension obtained from each femur was combined and cell concentration 
determined using a haemocytometer as depicted in Fig. 2.3. The concentration of 
the bone marrow cells was adjusted according to requirements of each OCG assay 
(section 2.4.4). 
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2.4.4 Optimisation of Murine OCG on Glass Coverslips 
The first objective was to establish a reproducible method of OCG that allowed for 
accurate evaluation of OC function. In the preliminary experiments the following 
coverslip sizes, cell densities and RANKL concentrations were tested (Tab. 2.4).  
 
Coverslip 
size (mm) 
Cells/coverslip Volume 
(µl) 
RANKL 
[ng/ml] 
Adherence 
13 3x105 or 5x105 500 2 or 5 Cell suspension added 
onto coverslip within 24 
well plate 
6 6.4x104  100 2 Cells suspension added 
onto coverslip within 96 
well plate 
6 6.4x104 10 2 Cell suspension added 
onto coverslip spread 
within Petri-dish 
Table 2.4 Parameters that were tested during optimisation of OCG assays. 
 
Bone marrow preparations were adhered at 37°C for 2 h in complete medium for 
murine cell cultures. The coverslips were then washed carefully to remove the non-
adherent cells. One 13 mm coverslip or three 6 mm coverslips were transferred into 
1 well of a 24 well plate containing complete medium for murine cell cultures 
(section 2.2, 500 µl) supplemented with M-CSF (R&D Systems, 25 ng/ml) and 
RANKL (R&D Systems, concentrations in Tab. 2.4). The OC culture supernatants 
were harvested on day 3 and stored for subsequent analysis, fresh differentiation 
medium was then added. Supernatants were also harvested on day 5 and day 7 
(end point). All supernatants were stored at -70°C until needed for subsequent 
analysis (section 2.4.7). Tartrate Leukocyte Acid Phosphatase (TRAP) staining was 
used to identify OC on the coverslips (section 2.4.5.1).  
 
2.4.5 Identification of Multinucleated OCs 
A commercially available kit (Sigma) was utilised and the methodology used was as 
described in the manufacturer’s instructions. Briefly, 0.25 ml citrate concentrate and 
1.25 ml dH2O were added to 3.75 ml acetone. Cells were fixed with 400 µl/well of 
the solution for 30 s. Cells were washed in dH2O and wells were air-dried for 15 min. 
Meanwhile 0.4 ml acetate solution, 0.4 ml tartrate solution, 0.4 ml naphthol AS-BI 
phosphoric acid solution (12.5 mg/ml) and fast garnet (3 mg) were added to 8.8 ml 
of warm dH2O. The staining solution was stirred for 60 s and filtered before use. 
Cells were stained (500 µl/well) in the dark at 37°C for 1 h and consequently 
washed in dH2O for 3 min. This was followed by counter staining with 200 µl/well 
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haematoxylin acid for 5 min and washing in dH2O twice. Glycerol gelatine was 
liquidised for mounting in a waterbath (100°C). Each coverslip was mounted onto a 
microscope slide (Menzel-Gläser).  
OC were identified microscopically (x10 object magnification utilising an 
Olympus BX41 microscope with a Camedia C-3030 digital camera attached) on 
days 3, 5 and 7. 
Finally, multinucleated TRAP+ cells (containing 2 or more nuclei) were 
counted for each condition; these were defined as OCs. The definition of OCs varies 
in the literature, but the minimum number of nuclei for an OC lies in the range of 2 to 
4 (Burgess et al. 1999; Shevde et al. 2000; Amoui et al. 2004). In accepting these 
criteria high number of OCs were counted in each field of view (FoV) and small 
changes could be monitored. The perimeters of the nuclei were defined by light 
maroon rings within the cells.  Nucleoli (dark purple) were observed after the 
coverslips were gently counter-stained with haematoxylin. 
 
2.4.5.1 Morphological Assessment of Bone Marrow Preparations on Day 0 
The phenotype of the cell population within the bone marrow preparation at assay 
initiation was assessed as an internal control for the OC assays. Bone marrow 
preparations were stained with Giemsa/May-Grünwald on day 0 and differential cell 
counts were performed.  
To obtain sufficient cell density for counting, bone marrow cells were initially 
adhered to a microscope slide using a cytospin. Briefly, bone marrow cells were 
diluted to 1x106 cells/ml. The cell suspensions (100 µl) were pipetted into the 
cytospin megafunnels that were attached to a filter card and Shandon cytoslide (all 
Thermo Scientific). The megafunnel-cytoslide assembly was centrifuged in the 
Shandon Cytospin 3 (Thermo Scientific) at 115 x g for 10 min.  
For all further experiments 6.4x103 cells were seeded onto 6 mm coverslips. 
Slides and coverslips were left to air dry prior to staining. 
 
2.4.5.2 Giemsa/May-Grünwald Staining Procedure 
Cells were fixed in methanol (300 µl/well) for 15 min before being stained in May-
Grünwald (section 2.2, (xxxviii), 300 µl/well) for 15 min. The cells were then 
counterstained in Giemsa stain (section 2.2, (xxv), 300 µl/well) for 15 min. Excess 
stain was removed by first washing in PBS pH 6.8 (section 2.2, (xliii), 300 µl/well)  
and then in dH2O (300 µl/well, 1 min in each solution). The stained cells were left to 
air-dry before they were mounted under a coverslip with a distyrene-plasticizer-
xylene mixture (DPX, Fisher Scientific). 
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The following cell types and their precursors were identified and grouped 
using this staining procedure; erythrocytes (light pink cytoplasm, no nucleus), 
lymphocytes (small cells with a round dark purple nucleus), monocytes (U-shaped 
purple nucleus), mesenchymal stem cells (large round purple nucleus with one 
nucleolus, only present 0.01-0.001% of bone marrow population (Siemionow 2006)) 
and megakaryocytes (proportionally larger than other cells with lobed purple 
nucleus). Five random areas (at x40 object magnification) were selected on each 
coverslip, cells were counted and their phenotype noted.  
 
2.4.6 Measuring CD59a Expression in OCG Assays Using Quantitative 
Polymerase Chain Reaction (qPCR) 
Initially, locally produced antibodies (Professor B Paul Morgan’s Complement 
Biology Group) were utilised to assess the level of CD59a expression on the surface 
of the bone marrow preparations. Unfortunately, and after numerous attempts, the 
antibodies failed to bind specifically to the murine cells. Antibodies were tested using 
flow cytometry and immunocytochemical methods and always provided 
unsatisfactory high background when compared against a relevant control antibody 
(data not shown). A qPCR method was therefore established as an alternative 
method to check CD59a expression in bone marrow preparations and on cells over 
the time course of the OCG assays.  
 
2.4.6.1 RNA Extraction  
WT bone marrow cells were recovered and the OCG assay initiated as described in 
sections 2.4.3 and 2.4.4. In order to assure that an adequate amount of RNA was 
recovered at each step of the OCG assay, 1.45x106 bone marrow cells were plated 
on 22x26 mm coverslips in 1.5 ml complete medium for murine cell cultures. For 
these studies, 6 well plates were utilised as carriers for the coverslips. After a 2 h 
adherence step and washing, the cells were differentiated in complete medium for 
murine cell cultures containing M-CSF (25 ng/ml) and RANKL (2 ng/ml) for 7 days. 
Cell cultures were sampled on day 0, 1, 3, 5 and 7. RNA was extracted as described 
below. 
All steps were performed in a clean room and all solutions and plastics were 
RNase free. Wells were washed with warm, sterile PBS before cells were lysed in 
ice-cold TRIzol reagent (Invitrogen, 500 µl/well). Cell lysis was supported by gentle 
agitation using a pipette. The resultant lysate was left at room temperature for 5 min 
before being transferred into 1.5 ml Eppendorfs (SLS, Safe-lock). Chloroform (230 
µl/ml of lysate) was added, the contents of the Eppendorfs mixed and then left at 
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room temperature for a further 3 min to precipitate proteins. Meanwhile, heavy-
phase lock gel Eppendorfs (SLS) were centrifuged at 12,000 x g for 30 s to pellet 
the gel.  RNA containing aqueous extract was transferred onto the gel within the 
heavy-phase lock gel Eppendorf and centrifuged at 13,000 x g for 2 min as 
illustrated in Fig. 2.4. The upper aqueous phase was added to new Eppendorfs. 
Isopropanol (same volume as extract) was mixed into each Eppendorf and RNA was 
precipitated at -20°C for 20 min. After thawing, solutions were centrifuged at 12,000 
x g at 4°C for 10 min. Supernatants were discarded and pellets washed with 750 µl 
of 75% ethanol. Pellets were dislodged by carefully mixing before centrifugation at 
7,500 x g at 4°C for 5 min. Supernatants were removed and pellets were air-dried 
before resuspension in 200 µl of RNAse free H2O (Promega). Eppendorfs containing 
RNA were heated to 65°C for 5 min (to help re-suspend the RNA pellet), vortexed 
and incubated on ice for 1 h. RNA concentration (260 nm) and purity (260/280 nm) 
was measured with the nanodrop (NanoVue, GE Healthcare). If the concentration 
was less than 100 ng/µl the following steps were performed. Total RNA was ethanol 
precipitated for storage by addition of 1 µl of Ambion glycogen (Invitrogen, 5mg/ml), 
1/10th of the total volume of sodium acetate (3 M, pH 5.2) and 2.5 volumes of 
ethanol (100%). Samples were allowed to precipitate at -80°C for at least 1 h. 
Precipitates were collected by centrifugation at 12,000 x g at 4°C for 20 min, 
washed with 80% ethanol and re-centrifuged at 12,000 x g at 4°C for 10 min. Pellets 
were air-dried and reconstituted in an appropriate volume of nuclease-free H2O.  
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Figure 2.4 Demonstration of RNA purification. 
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2.4.6.2 Reverse Transcription 
Extracted RNA was processed to generate complementary deoxyribonucleic acid 
(cDNA). cDNA was produced via a reverse transcription reaction on the Gene Amp 
PCR System 9700 (Applied Biosystems) using the Superscript II TM Reverse 
Transcriptase (Invitrogen) with the following 2-step protocol for high cDNA yield. 
Firstly 1 μl of Oligo (deoxy-thymine nucleotides (dT)) Primer (0.5 μg/μl; Promega), 1 
μl of  deoxy-nucleotide-tri-phospates (dNTPs, 10 mM; Promega) and 1-5 μg RNA 
were mixed to a final volume of 13.5 μl in RNase free dH2O. The solution was 
incubated at 65°C for 5 min to denature RNA, chilled on ice and centrifuged briefly 
at 3,000 x g to pool the contents to the bottom of the tube. Subsequently 4 μl first 
strand buffer and 2 μl DTT were added and the solution incubated at 42°C for 2 min 
to optimise conditions for the enzyme. Each reaction was started by addition of 0.5 
μl Superscript II TM Reverse Transcriptase and was incubated at 42°C for 50 min to 
generate cDNA. The temperature was raised to 95°C for 2 min to inactivate the 
enzyme. Solutions were chilled on ice again and centrifuged as before. The 
temperature was returned to 42°C for 2 min before adding fresh 0.5 μl Superscript II 
Reverse Transcriptase. Reactions were incubated at 42°C for an additional 50 min 
and Superscript II Reserve Transcriptase was heat inactivated at 70°C for 15 min. 
Finally cDNA was cooled to 4°C and stored at -20°C. 
 
2.4.6.3 Primer Design 
In order to amplify cDNA present in the sample and identify CD59a expression, 
primer sequences unique to the cDNA molecules had to be designed. A sequence 
for a probe was also required as the TaqMan method (Invitrogen) was utilised. The 
probe contains a fluorophore and a quencher. It attaches to the cDNA and is 
degraded by the polymerase during transcription. This results in a fluorescent signal 
corresponding to the number of templates during qPCR. Primers and probes were 
designed with Oligo Primer Analysis Software 4.0 and ordered from BEurofins MWG 
Operon. Murine acid ribosomal phosphoprotein P0 (H36B4) was used as 
housekeeping gene. All primers and probes are as stated in Tab. 2.5. 
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Product Sequence Concentration [nM] 
Primers for H36B4 5’ AGA TGC AGC AGA TCC 
GCA T 3’ 
5’ ATA TGA GGC AGC AGT TTC 
TCC AG 3’ 
300 
300 
Probe for H36B4 5’FAM AGG CTG TGG TGC TGA 
TGG GCA AGA AC TAMRA 3’ 
100 
Primers for murine 
CD59a 
5’ GCT ACC ACT GTT TCC AAC 
CG 3’ 
5’ GTC CAT AAT GAT CTC ACC 
ATG AC 3’ 
300 
600 
Probe for CD59 5’ FAM TCC TGT CTC TAT GCT 
GTA GCC GGA ATG C TAMRA 
3’ 
150 
Table 2.5 Primers and Probes for qPCR. 
 
2.4.6.4 Quantification of CD59a 
qPCR was performed on the Abi Prism 7000 (Applied Biosystems). CD59a primers 
were tested between 150 and 600 nM whereas probes were tested between 100 
and 200 nM. The optimised concentrations are displayed in Tab. 2.5. For the 
reaction the TaqMan PCR core reagents kit was employed. AmpliTaq Gold was 
supplied with all required buffers and dNTPs and added to obtain the final 
concentrations stated in Tab. 2.6. The AmpErase UNG, which is supplied to protect 
from RNA amplification, but caused product degradation, was not used. Reactions 
(25 µl) containing forward and reverse primer, probe, TaqMan reagents and cDNA 
(1-100 ng) were prepared in duplicates. For each primer pair the control consisted of 
qPCR reactions lacking the cDNA component. 
 
Component Final Concentrations 
x 10 TaqMan PCR Buffer x 1 
Deoxy-adenosine triphosphate (dATP) 200 µM 
Deoxy-cytosine triphosphate (dCTP) 200 µM 
Deoxy-guanine triphosphate (dGTP) 200 µM 
Deoxy-uracile triphosphate (dUTP) 200 µM 
MgCl2 2 mM 
AmpliTaq Gold DNA Polymerase 0.025 U/µL 
Table 2.6 Concentrations of TaqMan components. 
 
Solutions were pipetted into ABgene Thermo-Fast 96, semi-skirted plates (Thermo 
Scientific) and sealed with an adhesive PCR film (Thermo Scientific). The 
thermocyclic reaction to amplify cDNA products was as follows: 
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Initial denaturation:  95°C 10 min 
Denaturation:  95°C 15 s 
Annealing/extension:  60°C 1 min 
Hold:   4°C  
Reactions were analysed with ABI Prism supplied software and cycle threshold (Ct) 
of H36B4 reactions were subtracted from CD59a reactions to obtain ΔCt value. One 
time point was then determined as 1 and all others were made relative to it by a 
further subtraction (ΔΔCt). These values were then used to calculate fold changes 
(2-ΔΔCt). 
 
2.4.7  Evaluation of Supernatants Harvested from OCG Assays 
Cat K, MMP-9 and cytokine/chemokine concentrations were measured in the 
supernatants that had been harvested at each step of the OCG procedure. A 
number of techniques were adopted (enzyme-linked immunosorbent assays 
(ELISA), bioassay and zymography) to analyse the activity of the mediators. 
 
2.4.7.1 Quantification of Cat K using an ELISA 
Cat K is the major protease produced by OCs. It provides an indication of the 
functional activity of OCs as it is required to degrade the organic matrix of bone. In 
the first instance, an ELISA that was developed to quantify human Cat K 
(Biomedica) was tested. The manufacturer’s datasheet stated that there was cross 
reactivity with rodent Cat K. The kit had been successfully utilised for rat samples 
(Wada et al. 2005) and was provided free of charge to evaluate my murine 
supernatants. A human recombinant Cat K source (300 pmol/l) from Enzo Life 
Sciences was included as positive control. The ELISA was performed according to 
manufacturer’s instructions. Briefly, the assay was carried out at room temperature. 
Pre-coated microtitre strips were filled with 50µl/well of sample (neat) and standard 
(top standard = 300 pmol/l), 200 µl/well polyclonal anti-Cathepsin K-HRP was added 
and the solutions were incubated for 20 h in the dark. Strips were washed in wash 
buffer (section 2.2, (lvi), x5) by adding 300 µl/well and all solution was removed. 
Substrate (200 µl/well) was dispensed and incubated for 30 min in the dark before 
terminating the reaction with stop solution (50 µl/well). Colorimetric change in the 
assay was measured at 450 nm using a Wallac Victor2 microplate reader. 
 
2.4.7.2 Development of a Cat K Bioassay 
The objective was to develop a functional assay to assess Cat K activity in the 
supernatants harvested from the OCG. The bioassay for type I collagen (Col1) was 
x 40 
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set up on the principal that if tissue culture plates were coated with known 
concentrations of Col1, then collagenase (contained within the OCG supernatants) 
would degrade the collagen, and the changes in collagen binding would be 
measured using a collagen-specific antibody. The detection principles of an ELISA 
could then be applied to measure the changes in collagen colorimetrically. 
A 96 well ELISA plate was loaded with a solution of Col1 (section 2.2, (xvii), 
10 µg/ml, 50 µl per well). The plate was left at 4°C overnight; with gentle agitation to 
facilitate the coating process. The collagen solution was discarded and the plate 
was blocked with blocking buffer (section 2.2, (xiii), 200 μl/well) for 1 h at room 
temperature. The plate was washed 5 times in wash buffer before adding the mouse 
monoclonal anti-collagen type I (bovine) antibody. A concentration of antibody was 
not given, but recommended dilutions were included in the dilution range tested 
(1:1,000 to 1:128,000). 100 µl of each dilution was added to each well and 
incubated (with agitation) at room temperature for 1 h. The plate was washed as 
before and the secondary antibody (anti-mouse IgG peroxidase conjugated) was 
loaded onto the plate (100 μl/well). A dilution range was also suggested by the 
manufacturer and consequently a number of dilutions were examined from 1:2,000 
to 1:128,000. The plate was once more left at room temperature for 1 h. The 
colorimetric phase of the assay was triggered using streptavidin-horseradish 
peroxidase (R&D Systems). It was diluted in assay buffer (section 2.2, (viii), 1:200); 
100 μl of this solution was added to each well and left for 20 min at room 
temperature. After a final wash step, TMB solution (section 2.2, (li)) was diluted 
(1:100) in citrate buffer (section 2.2., (xv)). 100 µl of the solution was added to each 
well. After 10 min in the dark, a sufficient surface area of blue stain was achieved, 
the colorimetric reaction was then stopped by adding 12% sulphuric acid (100 
μl/well). The optical density of each well was determined at 450 nm using a Wallac 
Victor2 microplate reader. 
Bacterial Clostridiopeptidase A (mixture of enzyme purified from Clostridium 
histolyticum bacteria that contains collagenases, section 2.2., (xviii)) was used as 
the reference collagenase standard for the bioassay. It was added in triplicate (100 
μl/well) to collagen coated wells (top standard = 1,000 ng/ml) and a standard curve 
was plotted at end point to calculate absolute collagenase concentrations in each 
test sample. 
In order to test the specificity of the bioassay, other collagenases were 
examined alongside Clostridiopeptidase A : - 
(i) MMP-1 (105 µg/ml, kindly supplied by Dr Vera Knäuper, Dental School, Cardiff 
University). This enzyme is active at neutral pH, for this reason it was diluted in 
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Buffer A (section 2.2, (x), pH 7.4) for optimal function in the bioassay (top standard = 
500 ng/ml). 
(ii) Human recombinant Cat K (23 µg/ml, Enzo Life Sciences). This enzyme is 
functional at low pH, for this reason it was diluted in Buffer B (section 2.2, (xi), pH 
5.5) for optimal function in the bioassay (top standard = 5000 ng/ml).  
 
2.4.7.3 Analysis of Cat K by Col1 Zymography 
Col1 zymography was also used as an alternative method to detect active Cat K in 
OCG supernatants. 4 ml of 30% Acrylamide/bis-Acrylamide solution (Bio-Rad), 1 ml 
Col1 stock solution and 2.5 ml Tris (1.5 M, pH 8.8), 0.1 ml SDS solution (section 2.2, 
(xlvii)) were added to 2.35 ml dH2O to generate a 12% polyacrylamide gel. The 
mixture was inverted gently and supplemented with ammonium persulfate solution 
(section 2.2, (iv), 50 µl) and tetramethylethylenediamine (TEMED, Bio-Rad, 20 µl) 
immediately before pouring to induce gel setting. The gel was pipetted carefully into 
a Mini-Protean electrophoresis casting system (Biorad), the assembly of which is 
demonstrated in Fig. 2.5. The gel mixture was not added to the top of the casting 
plates in order to leave space for the comb. A 10-well Teflon comb was inserted and 
trapped air was removed. The gel was left to set for 1 h before being removed from 
the holding device and secured in an electrode construction. The gel was immersed 
in running buffer (section 2.2, (lxiii)) within a Mini Protean II (Bio-Rad) tank (Fig. 2.5). 
The comb was removed and the wells were cleaned with running buffer. 5 µl of pre-
stained SDS-polyacrylamide gel electrophoresis (PAGE) Broad Range Standards 
(Bio-Rad) or 10 µl of each sample (diluted to 80% (v/v) in loading buffer (section 2.2, 
(lxii))) were loaded into each well. The electrophoresis apparatus was connected to 
a BioRad Model 500/200 Power Supply; the gel was run at 100 V for 90 min.  
After electrophoresis the gel was removed from the tank and carefully 
transferred into a washing tray. The gel was incubated in refolding buffer (section 
2.2, (xliv), twice for 15 min) and rinsed in zymography wash buffer A or B (section 
2.2, (lxv) and (lxvi)) according to Giusti et al. ; this step re-activated the collagenases 
in the samples (Giusti et al. 2008). The enzyme was finally left to degrade the 
substrate in the gel for 20 h in digestion buffer A or B (section 2.2, (lix) and (lx)) at 
37°C.  
To visualise the degraded areas of the gel, digestion buffer was discarded 
and zymography destain (section 2.2, (lviii)) was added to the gel for 10 min. It was 
then removed, replaced by zymography stain (section 2.2, (lxiv)) and incubated (with 
agitation) at room temperature for 60 min. Zymography destain was added to the gel 
once again until the blue colour was faded sufficiently to observe clear white 
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‘digested’ bands. Gels were rinsed in water and then placed onto filter paper and 
transferred into a Hewlett-Packard (HP) scanner whilst wet to obtain a high 
resolution image. 
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Figure 2.5 Mini-Protean electrophoresis 
casting system.  
Black sealing strips (2) were sandwiched 
between 2 glass casting plates. These were 
clamped at each side to create a tight seal 
and clipped into the holding device. The gel 
was carefully poured between the casting 
plates and the comb was added on top to 
create wells before polymerisation. The 
sealed gel was carefully removed from 
holding device and transferred onto an 
electrode construction; which was placed 
into an electrophoresis tank. 
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2.4.7.4 Quantification of MMP-9 by Gelatin Zymography 
MMP-9 is a gelatinase that is secreted by OCs. MMP-9’s functional activity can be 
established in solution by using gelatin zymography, this method is routinely used in 
the literature to investigate MMP-9 bioactivity (Achilli et al. 2011). Gelatin 
zymography was performed as described in section 2.4.7.3 with the following 
changes; 7.5% polyacrylamide gel was prepared with 2% gelatin (0.2% final 
concentration) as substrate. After the refolding, gels were rinsed in zymography 
wash buffer C (section 2.2, (lxvii)) and digestion was performed with zymography 
digestion buffer C (section 2.2, (lxi)). 
 
2.4.7.5 Western Blot to Confirm MMP-9 Bio-Activity 
In order to confirm that MMP-9 was responsible for the degraded areas of the 
gelatin zymograph western blotting was performed. Proteins were blotted onto a 
Hybond-P polyvinylidene fluoride (PVDF) membrane (GE Healthcare). The 
membrane was washed in 100% methanol before use. It was then soaked in 
transfer buffer (section 2.2, (lvii)) together with several pieces of Whatman filter 
paper. The zymography gel, PVDF membrane and filter paper were arranged 
according to the schematic in Fig. 2.6.  The protein blotting was performed at 80 mA 
for 2 h. After the transfer procedure was complete, non-specific protein interactions 
were blocked by immersion of the membrane in milk buffer (section 2.2, (xxxix), for 
30 min at 4°C). The membrane was then rinsed with wash buffer for 5 min. Goat 
polyclonal MMP-9 antibody (0.4 μg/ml, Santa Cruz) was diluted in wash buffer, 
applied to the membrane and was incubated overnight at 4°C. The membrane was 
thoroughly (3 times) rinsed with wash buffer before the secondary antibody (Donkey 
anti-goat IgG-HRP diluted in wash buffer (0.4 µg/ml)) was added. The membrane 
was incubated for a further 2 h at 4°C and washed before detection of protein by 
chemiluminescence. An Amersham Detection Reagents (GE Healthcare) was used 
for this purpose. The membrane was added onto a piece of cling film and excess 
buffer was removed. Equal volumes of Detection Reagent 1 and 2 were mixed and 
pipetted onto the membrane until it was covered. After 1 min incubation excess 
solution was discarded and the membrane was turned upside down onto a fresh 
piece of cling film. The membrane was then completely wrapped in cling film and 
placed into a hypercassette. The procedure was finished in a darkroom. Here, 
Amersham Hyperfilm TM ECL (GE Healthcare) was placed on top of the membrane; 
it was exposed for 1 min in the dark. Finally the film was developed with Kodak GBX 
development reagents (Sigma). The film was placed into Kodak GBX developer and 
replenisher solution (section 2.2, (xxxiii)) until bands were visible under the red light. 
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This was followed by washing in tap water and transferring the film into the Kodak 
GBX fixer and replenisher solution (section 2.2, (xxxiv)) until it became clear. Once 
finished the film was left to dry in an upright position. 
 
Figure 2.6 Assembly of transfer components (Fermentas-International-Inc 2011). 
 
2.4.7.6  Measuring ProMMP-9 by ELISA 
ProMMP-9 concentrations were measured using an ELISA that was developed in-
house applying ProMMP-9 capture reagent, recombinant mouse MMP-9 and 
biotinylated anti-mouse ProMMP-9 antibody for detection (all purchased from R&D 
Systems). Several antibody concentrations were tested in a matrix formation; the 
following method was most sensitive. 
A 96 well ELISA plate (Nunc) was coated with 1 μg/ml capture antibody 
(diluted in sterile PBS); it was incubated at room temperature overnight. After being 
washed thoroughly, blocking buffer (300 μl/well) was added to each well. The plate 
was left at room temperature for 2 h before being washed again and the diluted 
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standard (doubling dilutions in assay buffer with a top standard of 20 ng/ml) or 
samples (diluted in the range between 1:10 and 1:100 in assay buffer) loaded in 
duplicate (100 μl per well). Samples were incubated at room temperature for a 
further 2 h, after an additional wash step the detection antibody (0.625 μg/ml in 
assay buffer) was added to each well (100 µl). After a 1 h incubation period the plate 
was washed and developed colorimetrically as described in section 2.4.7.2. 
 
2.4.7.7 Quantification of Cytokines/Chemokines 
In order to access cytokines, supernatants were firstly screened via a multiplex 
assay. The Multiplex cytokine assay kit for murine pro-inflammatory mediators 
(Mesoscale Discovery) was performed by Dr Bronwen Evans (Co-supervisor). The 
assay measured IFNγ, IL-10, IL-12 p70, IL-1β, IL-6, murine keratinocyte-derived 
cytokine (mKc) and TNFα.  
After discovering that mKc was highly expressed in OC cultures over other 
pro-inflammatory cytokines (eg. IFNγ), mKc levels were determined in all OCG 
supernatants by a specific ELISA kit (R&D Systems). The mouse CXC chemokine 
KC DuoSet was used and the ELISA was performed as described in section 2.4.7.6 
with the following changes; rat anti-mouse Kc (2 µg/ml) was utilised as capture and 
200 ng/ml biotinylated goat anti-mouse Kc as detection antibody, recombinant 
murine Kc was used as standard and samples were measured neat. 
 
2.4.8  Statistics 
All statistical analysis was performed with Graphpad Prism software. GraphPad 
QuickCal Outlier test was utilised to determine single, extreme outliers via the 
Grubbs’ test. Student T-Test was performed when comparing 2 unpaired groups. 
One-way ANOVAs were used when studying more than 2 unpaired groups and 
Two-way ANOVAs were utilised when assessing more than 2 groups with 2 
independent variables respectively. Mean and standard error (SEM) are stated 
throughout the result section. 
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2.5  Investigating the Role of Human CD59 in Bone Resorption 
In order to study the impact of CD59 insufficiency on OCG in humans it was 
necessary to establish an OCG assay in vitro. Subsequently a system to block the 
biological activity of CD59 was also developed. These steps were essential to our 
understanding of the translational value of observations from the mouse to human 
bone health and disease. CD59 deficiency in humans has only been reported in a 
single case (Yamashina et al. 1990) and therefore the study of CD59 cannot be 
supported by patient samples. CD59 blocking antibodies have been used previously 
in the Complement Biology Group (Cardiff University) (Sivasankar et al. 2009). 
Unpublished data demonstrated that antibodies were unsuitable for long term CD59 
blockade due to the rapid turnover of GPI-anchored proteins on the cell surface  
(half-life= 4 h) (Bojkowska et al. 2011).  
The predicted timeframe of the human OCG assays was in excess of 2 
weeks therefore a strategy that allowed a more complete and more stable 
suppression of CD59 production was considered most appropriate. For this reason, 
an antisense nucleic acid that induced the degradation of CD59 mRNA molecules 
was utilised. Antisense oligonucleotides, ribozymes, DNAzymes and RNA 
interference (RNAi) are commonly used to knockdown gene expression (Scherer 
and Rossi 2003). RNAi sequences against CD59 were tested in this study and a 
number of delivering strategies were examined to obtain optimal infection before 
OCG assays were commenced. 
 
2.5.1 Tissue Culture Materials 
Materials and culture conditions are described in section 2.4.2. Additionally, 30 µm 
pre-separation filters, MiniMACS columns and magnetic separator were purchased 
from Miltenyi Biotec. Ultracentrifuge tubes were obtained from Beckman and cell 
scrapers from Corning. Elephant ivory was kindly donated for research use by HM 
Customs and Excise (Heathrow, London, UK). The acquisition of the ivory was led 
by Dr Bronwen AJ Evans. Discs were cut in house (approx. 6 mm diameter) using 
an IsoMet Low Speed Saw (Buehler). 
In order to remove excess dust and obtain smooth differentiation surfaces, 
the ivory discs were immersed in tap water and sonicated for 1 min. This process 
was repeated 10 times before each disc was sterilised in 100% ethanol and dried 
before use. 
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2.5.2 Cell Line Maintenance 
Human embryonic kidney (HEK) 293T cells (kindly supplied by Dr R James 
Matthews) were grown in complete medium for HEK 293T cells (section 2.2, (xix)) 
and passaged at a dilution of 1:9 once a week. Jurkat EB.1 cells (kindly supplied by 
Dr R James Matthews) were grown in complete medium for human cultures (section 
2.2, (xx)) and passaged when 100% confluent at a dilution of 1:30 twice a week. 
Both cell lines were maintained in 75 cm2 tissue culture flasks. 
 
2.5.3  CD14+ Monocyte Purification from Human Blood 
Initially human OC precursor cells were obtained to set up resorption assays. 
Precursor cells (CD14+ monocytes) were isolated from human peripheral blood by 
adapting a published method (Nicholson et al. 2000). Blood was collected after 
approval of the project by the local ethics committee. Blood (50 ml) was obtained 
from consented healthy donors. Heparin sodium (1 unit/ml, Cardiff & Vale University 
Health Board Pharmacy, University Hospital of Wales) was used in each preparation 
to prevent clotting. Histopaque (1.077 g/ml, 5 ml) was added into 15 ml falcon tubes 
and 10ml of blood was carefully dispensed onto its surface. In order to separate cell 
populations, the tubes were centrifuged at 400 x g (without brake) for 30 min as 
shown in Fig. 2.7. Plasma was discarded and peripheral blood mononuclear cells 
(PBMCs) were transferred into clean tubes. PBMCs were diluted to 10 ml with 
Hank’s balanced salt solution (HBSS, Invitrogen) and then centrifuged at 300 x g for 
10 min. Supernatants were removed and this wash step was repeated twice. Cells 
from 50 ml of blood of the same donor were pooled, washed once more in fresh 
HBSS (10ml) and re-suspended in complete human medium (section 2.2, 5 ml). The 
cell suspension and reagents required for all subsequent steps were kept on ice. 
The cell concentration was determined utilising a haemocytometer as described in 
section 2.3.3.3. The PBMC suspension was passed through a 30 µm pre-separation 
filter to remove any aggregates. PBMCs were pelleted once again before being 
mixed with MACS buffer (section 2.2, (xxxvii), 80 µl per 1x107 cells) and CD14 
MACS beads (20 µl per 1x107 cells Miltenyi Biotec). The suspension was left for 15 
min on ice before a MiniMACS column was utilised to purify CD14+ cells according 
to manufacturer’s instructions. Briefly, a column was placed on a magnetic separator 
and rinsed with MACS buffer (500 µl) before cell-beads suspension was applied to 
the column. The MiniMACS column was washed 3 times with MACS buffer before 
elution with MACS buffer (1 ml each). The eluted cell suspension was diluted 1:2 
into complete medium for human cell cultures (section 2.2, (xx)) to keep cells viable. 
The final cell density was determined utilising the haemocytometer (section 2.3.3.3). 
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Figure 2.7 Separation of PBMCs using Histopaque.  
 
2.5.4 Resorption Assay 
To set up the resorption assay, purified human CD14+ monocytes were diluted to 
3.2x106 cells/ml and 20 µl (final 6.4x104 cells) were applied to ivory discs that were 
placed in a Petri-dish. Cells were left to adhere for 2 h at 37°C. Ivory discs were 
washed in complete human medium and transferred into 48 well plates containing 
500 µl/well complete medium for human cell cultures supplemented with 
recombinant human M-CSF (5 ng/ml), RANKL (2 ng/ml) and protein cross-linking 
antibody, murine polyHistidine (R&D Systems, 2.5 µg/ml, Clone AD.1.1.10, IgG1) to 
support RANKL signalling. Cells were grown in this differentiation medium for 14 
days. Fresh medium was added every 3 to 4 days.  
 
2.5.5 Identification of Multinucleated OCs and Resorption Pits 
TRAP staining was performed on day 14 to reveal the presence of OCs. Cells were 
washed in PBS (300 µl/well) before fixation in glutaraldehyde solution (section 2.2, 
(xxvii), 300 µl/well) for 15 min at 37°C. Excess fixative was removed by washing in 
PBS (300 µl/well) twice and air drying for 5 min. Cells were stained with TRAP stain 
1 (see section, 2.2, (xlix), 300 µl/well) for 6min at 37°C before washing in PBS and 
dH2O as before. Finally plates were left to dry. Representative images were 
obtained at x10 object magnification utilising an Olympus BX41 microscope with a 
Camedia C-3030 digital camera attached.  
 Subsequently, all cells were removed in order to assess resorption pits. 
Cells were incubated in hydrogen peroxide (1%, 300 µl/well) over night with 
agitation. Ivory discs were sonicated for 90 s and the solution was replaced by tap 
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water. Wet cotton swaps were used to gently remove cells and debris from ivory 
discs. The cleaning procedure was monitored microscopically. Once all cells were 
removed, ivory discs were stained with Toluidine blue (0.5%, 300 µl/well) for 2 min 
with agitation and rinsed in tap water. Resorption pits appeared in a darker purple 
than the ivory disc surface as more negatively charged proteoglycans are available 
for the stain to bind.  
 
2.5.6 Lentiviral Delivery System 
Once a resorption assay was established a CD59 knockdown system had to be 
developed. A lentivirus system that allowed for stable knockdown of transcripts in 
non-dividing cells had been established by Dr Sivasankar Baalasubramanian 
(Complement Biology Group, Cardiff University School of Medicine); this was tested 
in the first instance. In this system, a plasmid was utilised which produced shRNA. 
When the plasmid was transcribed, a 19-29 bp complementary RNA sequence with 
a loop was produced to create a double stranded RNA (Mittal 2004). shRNA is 
processed by various enzymes, transported into the cytoplasm where the loop is 
cleaved by the RNase III enzyme, DICER, and one strand of RNA binds to 
Argonaute. Along with other proteins the RNA molecule and Argonaute formed the 
RNA induced silencing complex (RISC). The RISC complex binds to the 
complementary CD59 mRNAs, which are then degraded by Argonaute induced 
mRNA cleavage (Rao et al. 2009). 
 
2.5.6.1 Testing Competence of CD14+ Monocytes for Lentiviral Infection 
In order to test the efficiency of the lentiviral delivery system, a recombinant 
lentivirus (kindly supplied by Dr Liam Morgan), containing a green fluorescent 
protein (GFP), but not encoding for any shRNA, was utilised. Infection was tested in 
Jurkat EB.1 cells (a positive control cell line previously utilised by Dr Sivasankar 
Baalasubramanian) and compared to CD14+ monocytes. 2x104 of confluent Jurkat 
EB.1 cells were seeded per well (96 well plates, 200 µl). GFP encoding-lentivirus 
was added to cultures at a multiplicity of infection (MOI) of 8 (Fig. 2.8).  
 
Figure 2.8 Formula to calculate dilution of virus for infection. 
 
CD14+ monocytes were purified as described in section 2.5.3. Cells were diluted in 
complete medium for human cell cultures supplemented with M-CSF (5ng/ml) to 
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obtain 3.2x104 cells in 200 µl.  Polybrene (Millipore, 6µg/ml) and GFP-encoding 
lentivirus (MOI 8) were mixed with CD14+ monocytes and transferred into a 96 well 
plate. All cells were incubated with lentivirus at 37°C for 2 days.  
 
2.5.6.2 Infection Analysis Utilising Flow Cytometry 
Flow cytometry was performed to analyse GFP expression. Initially, adherent cells 
were removed from the bottom of the well with a cell scraper. Cell solutions were 
transferred into 5 ml Falcon Polystyrene round-bottom tubes (BD Biosciences) and 
pooled from multiple wells to obtain between 1x105 to 1x106 cells/sample. Cells 
were collected by centrifugation at 800 x g for 3 min and re-suspended in FACS 
buffer (section 2.2, (xxiv), 200 µl). An equal amount of buffered formalin was added 
to fix all samples. 
Flow cytometry was performed on the FACSCalibur (BD Biosciences). 
CellQuest Pro software (BD Biosciences) was utilised. A dot plot (forward scatter 
(FSC) versus side scatter (SSC)) and a histogram, displaying FL1-H to visualise 
GFP, were created. Cell populations and autofluorescence was adjusted by altering 
the SSC voltage, FSC Amp/Gain and threshold using non-infected cells. Cells were 
applied and 10,000 events were counted for all samples.  
For the analysis, viable cells were gated and the gate was applied to the 
histogram of all samples. The autofluorescence histogram of non-infected cells was 
overlaid onto the GFP expressing cell population and the GFP positive cell 
population was determined by drawing a marker on the histogram from the tail of the 
autofluorescence in the non-infected cell population to the tail of the GFP positive 
cell population.  
 
2.5.6.3 Plasmid Replication 
Once the protocol of infection was established, the virus was generated from 
commercial available shRNA containing plasmids (Sigma). Dr Baalasubramanian 
tested a variety of CD59-shRNA targets and a non-target control in a pLKO.1-puro 
vector (Sigma) containing ampicillin (bacterial selection) and puromycin (mammalian 
selection) resistance genes. He identified CD59-shRNA target-1 as most effective in 
Jurkats EB.1 via flow cytometry and supplied the plasmid containing target-1. DNA 
sequence:  
 5’ CCG GCC GTC AAT TGT TCA TCT GAT TCT CGA GAA TCA GAT 
 GAA CAA TTG ACG GTT TTT G 3’). 
 
 83 
 
Blotting papers containing control and shRNA plasmids were obtained from 
Singapore as no virus was available in Cardiff. It was placed into Eppendorfs with 
100 µl TAE buffer (section 2.2, (liii)) to stabilise plasmids. Plasmids were 
transformed into competent DH5α (Invitrogen). Eppendorfs containing frozen DH5α 
(50 µl aliquots) were placed into a container with ice and mixed with plasmids at 
either 1:50 or 1:10 dilution. Cells were kept on ice for a further 10 min and then heat-
shocked for 20 s at 42°C. Cells were diluted to 1 ml with LB medium (section 2.2, 
(xxxv)) and Eppendorfs were incubated at 37°C and 220 rpm for 1 h. This was 
followed by centrifugation at 6,000 x g for 30 s to pellet cells.  Excess medium was 
removed leaving behind 50-100 µl solution which was used to re-suspend the pellet 
and the solution was dispersed onto ampicillin plates (section 2.2, (v)). Plates were 
incubated at 37°C overnight.  
 A colony from each agar plate was inoculated in LB medium (10 ml) 
containing ampicillin (100 µg/ml). Cultures were incubated at 37°C and 220 rpm for 
6 h. A glycerol stock was prepared by adding 0.5 ml of each culture to 0.5 ml 
glycerol buffer (section 2.2, (xxviii)) which was stored in a Styrofoam box at -80°C. 
The remaining cultures were inoculated 1:100 in LB medium (500 ml) containing 
ampicillin (100 µg/ml). Cultures were incubated at 37°C and 220 rpm for 16 h before 
harvesting bacteria by centrifugation at 11,000 x g for 10 min at 4°C.  
A PureLink HiPure Plasmid Filter Purification Kit (Invitrogen) was used to 
purify plasmid DNA (low copy number) according to manufacturer’s instructions. 
Briefly, columns were prepared by allowing equilibration buffer (30 ml; 0.1 M Sodium 
acetate, pH 5, 0.5 M NaCl, 0.15% (v/v) Triton X-100) to drain through the filter 
cartridge within the columns. Meanwhile cell pellets were re-suspended in 
resuspension buffer (20 ml; 50 mM Tris-HCl, pH 8, 10 mM EDTA) with RNase A 
(20mg/ml in resuspension buffer) before lysis buffer (10 ml; 0.2 M NaOH, 1% (w/v) 
SDS) was added and tubes were inverted gently until a homogenous solution 
formed. The cell lysate was then incubated for 5 min and precipitation buffer (10 ml, 
3.1 M potassium acetate, pH 5.5) added. This was followed by gently mixing by 
inversion. The lysate was applied to the column and the flow through discarded. The 
filter cartridge was removed and the column washed with wash buffer (50 ml; 0.1 M 
Sodium acetate, pH 5, 825 mM NaCl). The flow through was removed again and a 
fresh 50 ml falcon tube placed underneath the column. Elution buffer (15 ml; 100 
mM Tris-HCl, pH 8.5, 1.25 M NaCl) was added to the solution to precipitate the 
DNA. Isopropanol (10.5 ml) was added to the DNA and the solution mixed. DNA 
was precipitated by centrifugation at 12,000 x g for 30 min at 4°C. The DNA pellet 
was re-suspended in 70% ethanol (5 ml) before centrifugation as above. Ethanol 
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was discarded and the falcon tube air-dried for 10 min before re-suspending the 
plasmid DNA in TE Buffer (section 2.2, (liv), 200 µl). Finally, concentrations of 
plasmids were determined on the Nanodrop Spectrophotometer (260 nm) and 
plasmids stored at -20°C. 
  
2.5.6.4 Generation of Lentivirus 
Virus was generated via transfection of HEK 293T cells with the construct using the 
Effectene transfection reagent (Qiagen). Purified transfer shRNA containing vector 
plasmid target-1 (1 µg) was mixed with pΔ8.91 plasmid (encodes for capsid proteins 
and reverse transcriptase, 0.75 µg) and pMD2G plasmid (encodes for envelope 
protein, 0.5 µg). The solution was diluted to 300 µl with DNA-condensation buffer 
before Enhancer (16 µl) was added. The solution was vortexed and incubated at 
room temperature for 5 min. Effectene (60 µl) was added and mixed well with the 
pipette. The transfection complex was incubated at room temperature for 10 min 
and complete medium for HEK 293T cells (3 ml) added. HEK 293T cells were 75% 
confluent and received fresh DMEM medium (8 ml). Plasmid-lipid complexes (3.3 
ml) were slowly applied to the cells and incubated for 72 h at 37°C. 
Cell supernatant containing virus was harvested in 50 ml falcon tubes and 
cleared from the cell debris by centrifugation at 3,000 x g for 5 min. The supernatant 
was transferred into ultracentrifuge tubes and centrifuged at 80,000 x g at 4°C for 2 
h. The supernatant was removed and the virus pellet re-suspended in 900 µl serum 
free DMEM, dispensed in aliquots (60 µl) and stored at -80°C. 
 
2.5.6.5 Infection with shRNA Containing Lentivirus 
To compare viral infection efficiency to previously obtained data by Dr 
Baalasubramanian (unpublished), 2x105 Jurkat EB.1 cells were seeded per well 
(500 µl) into a 24 well plate. GFP-lentivirus was added at a MOI of 8, non-shRNA 
control virus and CD59 shRNA containing lentivirus were added at a 1:100 dilution 
(n=3). Cells were cultured with virus for 2 days before analysis.  
 
2.5.6.6 Monitoring Infection Efficiency of Lentiviruses 
Flow cytometry was performed to identify GFP and CD59 expression. Cells were 
removed from wells and re-suspended into FACS buffer as described in section 
2.5.6.2. The sample that did not contain any virus was re-suspended in 600 µl FACS 
buffer and was divided into unstained, isotype control and CD59 staining sample 
(200 µl each). Antibodies were utilised according to manufacturer’s 
recommendations and are described in Tab. 2.7. Non-labelled primary antibody 
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MEM43 (anti-CD59) and the DD7 (isotype control) were added to appropriate 
samples. All samples were incubated on ice for 30 min before centrifugation at 800 x 
g for 3 min. Buffers were then discarded and cell pellets were re-suspended in fresh 
FACS buffer (200 µl). This wash step was repeated. Secondary antibody (anti-
mouse IgG - Fluorescein isothiocyanate (FITC)) was added to appropriate samples 
and incubated on ice for 30 min. All samples were washed twice as before. Buffered 
formalin (200 µl) was added to all suspensions to fix cells and analysis was 
performed either with FACSCalibur (section 2.5.6.2) or with the Accuri C6 Cytometer 
and CFlow Plus software (BD Biosciences). 
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 Antibody/labelling proteins Supplier Raised in Concentration Dilution used 
Primary MEM43, anti-human CD59 Supplied by Dr Claire Harris Mouse 280mg/ml 1:280 
Secondary Anti-mouse IgG-FITC Vector Laboratories Horse 1mg/ml 1:100 
 F(ab’)2 fragment of anti-mouse IgG 
(H+L)- Alexa Fluor 647 
Invitrogen Goat 2mg/ml 1:100 
Directly conjugated MEM15, anti-human CD14-FITC Abcam Mouse 0.004mg/ml 1:100 
Isotype control DD7, Anti-human IgG1  Chemicon (Millipore) Mouse 0.1mg/ml 1:100 
 Anti-human IgG1-FITC BD Pharmingen Mouse Not supplied 1:100 
Table 2.7 Antibodies used in flow cytometry.
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A flow rate of 66 µl/min was chosen and 10,000 events were acquired. No further 
adjustment was needed as the Accuri has a 7 log range to capture cell parameters. 
To analyse samples gates, overlays and markers were applied as described in 
section 2.5.6.2. 
 
2.5.7 Adenovirus Delivery System 
Transient adenovirus infection was established as an alternative vector delivery 
system. Dr Daryn Michael and Tim Ashlin generated 3 viruses with different shRNA 
sequences targeting CD59. Briefly, Invitrogen BLOCK-iT RNAi Designer was utilised 
to generate sequences. miR RNAi was chosen and the accession number of mature 
CD59 from GenBank (X16447) was entered. Targets were identified for the 3’ 
untranslated region which were assessed utilising a BLAST search in Pubmed 
against the human genome. Sequences that did not match any other mRNA than 
CD59 and showed only 20% homology to non-transcribed sequences were selected 
as shRNA targets:  
1: 5’ CTA ACT GAC TAC ATC CAA GGA 3’ 
2: 5’ ACA TAT GGA ACA TTT GGC ATG 3’  
3: 5’ TTC ATG CCC TGC TAT CTG GAA 3’ 
 
The AdZ-mIR155 vector was utilised to generate shRNA and adenovirus was 
generated according to Dr Richard Stanton’s protocol (Stanton 2008). 
Oligonucleotides (oligos) were purchased from Invitrogen (Fig. 2.9).  
 
Figure 2.9 Oligo design. The forward oligo contained 40 bp vector sequence, 21 
bp anti-sense, 19 bp loop and 3 bp sense sequence whereas the reverse oligo 
started with 3 bp anti-sense, 19 bp loop and 19 bp sense sequence (forms internal 
loop) followed by 40 bp vector sequence. This created overlapping oligos that could 
be integrated into the plasmid via homologous recombination. 
 
SW102 Escherichia coli containing AdZ-mIR155 vector were utilised for 
transformation. Once SW102 cells were cultured to the appropriate density,  a 
temperature shift for activation (42°C) of the bet (single stranded DNA annealing 
protein) and exo (5’-3’ double stranded DNA exonuclease) genes was performed 
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(Murphy and Campellone 2003). These proteins enabled homologous recombination 
of oligos with the overlapping vector sequence after transformation with oligos 
utilising electroporation (2.5kV in 0.2ml cuvettes (BioRad)). SW102 cells were 
spread onto chloramphenicol plates (section 2.2, (xvi)) supplemented with sucrose, 
Isopropyl βD-1 thiogalactopyranoside (induces lacZ) and X-gal (galactose and 
indole containing compound). Colonies were grown at 32°C for 48 h. To generate 
recombinant vectors an ampicillin-lacZ (β-Galactosidase) - sacB (sensitivity to 
sucrose) cassette had to be removed. Colonies were grown on sucrose, therefore, 
cells which did not undergo recombination and still contained the sacB gene would 
not grow. SW102 cells that contained mutated sacB, but still had functional lacZ 
resulted in blue colonies as X-gal was cleaved. Colonies appearing transparent to 
white carried the vector with correctly inserted oligos.  
 The latter colonies were selected and cultured to carry out Miniprep to 
purify plasmids. After confirmation of the correct insert via restriction digestion and 
sequencing, a Maxiprep (Macherey-Nagel) was performed and adenoviruses were 
prepared in 293TREx cells (Invitrogen) utilising Polyfect kit from Qiagen. 
Supernatants were titred according to Bewig and Schmidt and number of plaques 
were counted in 3 fields of view and pfu/ml was generated (Bewig and Schmidt 
2000): 
 
 
2.5.7.1 Infection with Adenoviruses and Testing of OCG 
In order to establish infection and knockdown ability of adenoviruses, human CD14+ 
monocytes were purified as described in section 2.5.3. Monocytes were cultured in 
48 well plates (500 µl/well) in complete medium for human cell cultures 
supplemented with M-CSF (5 ng/ml). Fresh medium was added every 2 to 4 days. 
Different viruses, virus load, cell densities and incubation times were tested to 
determine CD59 knockdown as described in Tab. 2.8. 
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Testing 
Condition 
Cells seeded 
(cells/well) 
Viral source MOI Incubation 
(days) 
Infection 
efficacy 
1x105 GFP 
expressing 
50, 100, 500 5 days in M-
CSF and 2 
days with 
infection 
Virus 
selection 
1x105 shRNA1, 
shRNA2, 
shRNA3 
50, 100, 500 5 days in M-
CSF and 2 
days with 
infection 
Incubation 
time 
1x105 Empty vector, 
shRNA3, 
shRNA1+3 
100 and 200 5 days in M-
CSF and 
either 2 or 4 
with days 
infection or 7 
days with 2 
day infection 
Cell density 1x105, 3x105 Empty vector, 
shRNA3 
100, 200 1 day in M-
CSF and 2 
days infection 
Table 2.8 Parameters that were tested to obtain CD59 knockdown. 
 
2.5.7.2 Monitoring Infection Efficiency of Adenoviruses 
Flow cytometry was utilised to determine GFP, CD14 and CD59 expression as well 
as cell viability. Cells were removed from wells and re-suspended into FACS buffer 
as described in section 2.5.6.2. The sample that did not encounter any virus was 
divided into 6 to 7 samples (unstained, CD14 single staining, CD14 isotype control, 
CD59, CD59 isotype control, double staining and/or 7-amino-actinomycin D (7AAD) 
viability staining sample (200 µl each)). MEM43 (anti-CD59) and DD7 (isotype 
control) antibodies (Tab. 2.7) were added to the appropriate samples. All samples 
were incubated on ice for 30 min before centrifugation at 800 x g for 3 min. Buffer 
was discarded and FACS buffer (200µl) was utilised to re-suspend each cell pellet. 
This wash step was repeated. Alexa Fluor 647 conjugated secondary antibody (Tab. 
2.7) was added to corresponding samples and incubation followed for 30 min on ice 
before washing was performed as above. Samples utilised for double staining were 
blocked with mouse serum (in-house, 1:50). All samples were incubated for 15 min 
on ice. Directly conjugated MEM15 and the according FITC isotype control (Tab. 
2.7) was mixed into the appropriate samples. This was followed by incubation and 
washing as before. Cells were either fixed by adding an equal amount of formal 
saline or 7AAD (eBioscience, 25 µg/test) was added 10 min before the flow 
cytometry procedure to all appropriate samples. All samples were acquired by the 
Accuri as described in section 2.5.6.6. 
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2.6 Phenotypic Analysis of Bone Structure in CD59a-/- Mice 
A number of imaging techniques have been utilised in the literature to investigate 
skeletal changes in rodents including X-ray, dual energy X-ray absorptiometry 
(DXA), microcomputed tomography (MicroCT) and magnetic resonance imaging 
(MRI) (Swartz and Loevner 2008). In this study X-ray and digital caliper assessment 
was selected for prominent morphological changes and subsequent MicroCT 
allowed for high resolution analysis to identify subtle alterations in bone structure 
and BMD (van‘t Hof 2012). Finally, methylmethacrylate (MMA)-embedded bone 
sections were stained for OB and OC activity in vivo. 
 
2.6.1 Animals and Harvesting of Femora and Vertebrae 
CD59a-/- mice were kindly supplied by Prof B Paul Morgan and WT mice were 
purchased as described in section 2.3.1. Femora and vertebrae were obtained from 
female and male 8-10, 20 and 50 week old CD59a-/- and WT mice.  All animals were 
killed by the Schedule I method. Hindlimbs and vertebrae from the neck to the onset 
of the tail were dissected and fixed in 70% alcohol.  
 
2.6.2 Femoral Length and Shaft Diameter Assessment 
Hindlimbs from 8-10, 20 and 50 week old CD59a-/- and WT mice were examined for 
femoral length utilising the X-ray setting of a Kodak In-vivo Imaging System FX Pro 
(Carestream). Samples were aligned in a Petri-dish (3.5cm diameter) before being 
transferred into a plastic container (15x10 cm). This assembly was placed into the 
top pocket of the machine to allow for high resolution images. The Kodak MI SE 
software was applied to acquire images. Firstly, X-ray projections were previewed to 
adjust sample position and focus. Final settings utilised X-ray as the illumination 
source at 35 peak kV and 149 µA. The camera lens was adjusted to an f-stop 
(degree of aperture opening) of 4.96, field of view was utilised at 90.3 mm, an 
exposure time of 60 s were chosen to obtain a single image and an illumination 
correction was applied. Once images were collected, femoral length was obtained 
by changing the field of view to 49 to correct for the camera zoom. Shaft diameter 
was determined in midshaft utilising a digital caliper. 
 
2.6.3  Histomorphometric and BMD Analysis of Cortical and Trabecular 
 Bone in Femora 
MicroCT (Skyscan-1072), a 3 dimensional (3D) X-ray technique, was exploited to 
obtain BMD and morphological parameters of cortical and trabecular bone obtained 
from 8-10, 20 and 50 week old WT and CD59a-/- mice.  
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2.6.3.1 Acquisition of X-ray Projections 
The X-ray source was set to 49.6 KV and 200.8 μA and 7.952 s exposure was 
selected with a gain of 1. The stage to which the sample was attached was set to 
rotate 180°, 0.45° (rotation step) between each X-ray image. Frame averaging was 
set to 1, meaning that only one picture per angle was taken. Random movement 
was chosen at 10 to correct eventual movement of specimen. The X-ray beam went 
through a 1 mm aluminium filter and the magnification was chosen to give a 10.8 μm 
pixel size. Before samples could be tested, a flat field of the empty chamber was 
generated to subtract background noise. After the set-up of the Skyscan machine, 
hindlimbs were prepared as described in Fig. 2.10.  
 
 
Figure 2.10 Sample preparation for MicroCT scanning. Figure illustrating joint 
preparation to enter the X-ray sample chamber. Joints were straightened and 
covered in cling film to prevent drying out. Next they were inserted into a plastic tube 
(0.4cm radius) attached to a stage. The femur was facing down to allow for straight 
alignment. The sample chamber was opened and the stage was screwed tightly into 
the holder within the MicroCT scanner. 
 
Once samples were placed into the MicroCT scanner, a preview was generated and 
the sample stage was lifted to position the joint and rotated to confirm straightness 
of the femur at all angles. Finally, X-ray projections (413 vertical images/samples) 
were acquired. 
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2.6.3.2 Reconstruction and Adjustment of Acquired Projection Datasets 
X-ray projections were applied to NRecon (Skyscan) software in which a 
reconstruction algorithm generated crossectional images that enabled 3D analysis. 
To initiate reconstruction, the axial reconstruction range was set between 8 and 
1008. X-ray projections cause artefacts, such as beam hardening and ring artefacts. 
Beam hardening is caused when X-rays pass higher and lower energy photons 
creating dark streaks or skewing the shape of the object. It was corrected by 1%. 
Ring artefacts, appearing when the stage rotates, were not reduced (0). A threshold 
to remove soft-tissue noise and enhance bone structure was set to 0.005946-
0.095366. To obtain a defined, clear bone area the projections from all angles have 
to be aligned accurately by fine tuning at 3 positions within the projection before 
reconstruction created 1001 BMP files. 
BMP files were opened in CTAnalyzer (CTAn, Skyscan) and the femur was 
selected (500 images) and saved as a new dataset. Initially, femora that were not 
completely straight were corrected in the software Dataviewer (Skyscan). Datasets 
were opened (without resizing) and loaded for 3D viewing. Once straightened, 
datasets were saved as VOI TRA. 
 
2.6.3.3 Histomorphometry of Cortical Bone 
The adjusted datasets were analysed in CTAn. A reference point within the growth 
plate was determined in each femur as shown in Fig. 2.11. To measure cortical 
bone the shaft was selected 3 mm below the growth plate. Here a length of 1 mm, 
comprised of 100 images, was investigated (Fig. 2.11). A doughnut region of interest 
(ROI) was drawn around the cortical bone (Fig. 2.11). The greyscale index was set 
between 111 and 255 to highlight cortical bone. From this a 3D analysis was 
performed to obtain bone volume (BV) and crossectional thickness (CsTh).  
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Figure 2.11 MicroCT of a femur. Figure illustrates reference point and areas of 
interest selected for cortical and trabecular bone analysis. 
 
2.6.3.4 Determination of Bone Mineral Density 
To obtain bone mineral density (BMD), the Skyscan 1072 had to be calibrated. 
Mouse phantoms of 0.25 g/cm3 and 0.75 g/cm3 density were obtained from 
Skyscan. The phantoms were added on top of each other into the tube attached to 
the stage. The same settings for projection acquisition and reconstructions were 
used as described in section 2.6.3.1 and 2.6.3.2. The dataset was opened in CtAn 
and 2 mm were selected of the 0.25 g/cm3 phantom. A circular ROI was chosen of 
the core of the phantom containing minimal irregularities. From this the Attenuation 
coefficient mean was determined. This was repeated for the other phantom. BMD 
calibration was performed as described in Fig. 2.12. BMD was obtained for the 
cortical bone within the doughnut selection. 
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Figure 2.12 BMD calibration. Figure shows BMD and attenuation coefficient of 
mouse bone phantoms (A).  Equation for bone samples with unknown BMD was 
determined from calibration in A (B). 
 
2.6.3.5  Generation of 3D Representative Images 
Datasets of cortical bone selections were re-opened in CTAn and the doughnut 
shaped ROI applied to create a 3D Model. The model was saved as a STL file. 
Consequently, the Skyscan software CTVolume (CTVol) was opened and the STL 
file chosen. Zoom and orientation of the model was adjusted and screen prints were 
saved. 
 
2.6.3.6 Histomorphometry and BMD of Trabecular Bone 
Trabecular bone consists of small bone structures (trabeculae) in rod and plate 
shapes. To characterise trabeculae, parameters, such as BV/tissue volume (TV) 
trabecular number (TbN) and trabecular thickness (TbTh), trabecular separation 
(TbSp), trabecular pattern factor (TbPf) and structure model index (SMI) were 
measured. These are indicators of the amount of bone present and how it is shaped 
and distributed. Characterisation of trabecular bone according to these parameters 
allows for interpretation of bone quality (Skyscan 2009).  
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For trabecular bone analysis Dataviewer adjusted datasets were opened in 
CTAn. An area of 1 mm below the reference point was selected and 1 mm of bone 
was analysed as pictorially illustrated in Fig. 2.11. The area within the cortical ring 
was selected before choosing the greyscale index between 80 and 226. This was 
followed by a 3D analysis to obtain BV/TV, TbTh, TbN, TbSp, TbPf and SMI. Finally 
the volumetric (total) BMD was determined. It was chosen to take into account the 
space between trabeculae, not just the actual density of the bone structure. 
Generation of 3D models for Tb bone followed the methodology of section 2.6.3.5. 
To create representative images of trabecular bone, femoral datasets 
(created in section 2.6.3.2) were opened in CtAn and vertical images were 
generated by cutting the horizontal view within the reference image as shown in Fig. 
2.13. Images were saved and edited in Pro X3. 
 
Figure 2.13 Generation of vertical view of trabecular bone within femora. 
Growth plate reference point is shown and red line represents how bone was cut to 
create a vertical image. 
 
2.6.4 Histomorphometric Analysis of Trabecular Bone in Vertebrae  
In order to identify if phenotypical changes were localised to the long bones or 
extended to other areas in the body, vertebrae of 8-10 and 20 week old male WT 
and CD59a-/- specimens were analysed. Vertebrae of the lumbar spine are a major 
trabecular bone location (Turner et al. 2000) and are a recommended area for 
clinical densitometry (Lewiecki et al. 2008). MicroCT of lumbar vertebrae was 
performed in collaboration with Dr Rob van’t Hof at Edinburgh University.  
X-ray projections of vertebrae were generated utilising the Skyscan 1172. 
Parameters that changed from the previous analysis (section 2.6.3.1) were the 
following: The X-ray source was 60 kV and 167 µA with a 0.5 mm aluminium filter. 
Magnification was set to 7 µm pixel size and no random movements were corrected. 
Specimens were prepared for scanning as described in Fig. 2.10, but the tube and 
stage utilised had a larger radius (0.75 cm) to accommodate spines safely.  
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The lumbar spine of mice contain 6 vertebrae (Bab et al. 2007). The main 
body of vertebra 6 (L6) was scanned. Reconstruction was performed in NRecon as 
before (section 2.6.3.2) with the following alterations: Quality of projection datasets 
was monitored utilising the profiling function. It presents a graph plotting the pixels 
per mm of aligned images. If the 2 lines follow the same path then the scan was 
successful and the alignment has been calculated correctly by the software making 
fine-tuning redundant. Beam hardening was set to 18% and ring artefacts reduction 
to 12. An ROI was employed to reconstruct only the bone occupying area and the 
threshold ranged from 0 to 0.11. After reconstruction, Dataviewer (section 2.6.3.2) 
was used to straighten the vertebra L6 to the position illustrated in Fig. 2.14.  
 
Figure 2.14 3 orientational views of L6. 
 
Adjusted datasets were opened in CTAn and only a limited area of trabecular bone 
was analysed because of the complex shape of vertebrae. The ROI started after the 
cartilage disappeared on the distal and proximal end of L6 and the shape of the 
vertebra’s main body was followed as shown in Fig. 2.15. The greyscale index was 
set from 70 to 255 and before 3D analysis was carried out, datasets were filtered 
(median, 2D space, radius 1), a threshold (global, low 70, high 255) determined and 
datasets were despeckled (remove white speckles, 3D space, remove less than 50 
voxels, apply to image). Analysis then determined BV/TV, TbN, TbTh, TbSp, TbPf 
and SMI.  
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Figure 2.15 Selection of trabecular bone of L6. 
 
Adjusted femoral datasets were opened in CtAn and according to the illustration in 
Fig. 2.16, vertical images were created as explained in section 2.6.7. Additionally, 
3D models were prepared (section 2.6.3.5). 
 
Figure 2.16 Generation of vertical view of trabecular bone within L6. Mid-
section of vertebra is shown and the red line represents how bone was cut to create 
a vertical image. 
 
2.6.5 Investigation of OB Activity In Vivo 
Femora of 8-10 and 20 week old male WT and CD59a-/- mice were histologically 
processed after MicroCT analysis in collaboration with Dr Rob van’t Hof. All femora 
were MMA-embedded to allow for analysis of calcified bone. MMA is a hydrophobic 
resin which was used because of 1) fast infiltration of the resin, 2) polymerisation at 
low temperature, 4) morphological preservation and 5) high-quality image analysis. 
 
2.6.5.1 Tissue Processing 
In order to process femora, they were separated from the tibia at the knee joints and 
cut in half using a scalpel. Distal femora were placed into disposable baskets (small, 
4 divisions, Leica) with PBS. Baskets were added to a holder and transferred into a 
vial containing PBS. 
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The Leica Tissue processor (EM TP4C) was prepared with 100 ml reagent 
vials containing solutions described in Tab 2.9. Samples were agitated during the 
incubation for full penetration and incubated at 4°C utilising a vacuum. 
 
Step Reagent Time (h) 
Dehydration 
1 PBS 3/4 
2 50% ethanol 2 
3 70% ethanol 2 
4 80% ethanol 2 
5 96% ethanol 2 
6 100% ethanol 3 
7 100% ethanol 3 
Defatting 
8 xylene 1 
9 xylene 12 
Table 2.9 Tissue processing. 
 
After processing, excess xylene was removed from baskets and the holder was 
transferred to a vial containing a freshly prepared resin solution (section 2.2, (xlv)). 
This vial was transferred into a vacuum container which was sealed with Parafilm. 
An air-inlet on top of the container was opened to pump out all oxygen (approx. 
5min). After the air-inlet was resealed, resin infiltrated the femora during 7 day 
incubation at 4°C. Excess resin solution prepared for infiltration was stored in the 
fridge for embedding. 
 
2.6.5.2 Embedding of Femora 
Histobloc N molds (TAAB) were filled with stored resin solution and samples were 
added straight after their removal from baskets. Femora were positioned and sealed 
as illustrated in Fig. 2.17 before molds were immersed into a water bath at 29°C for 
9 h to polymerise resin. Polymerised blocks were mounted onto a universal holder 
for Histobloc N (TAAB). 1 part of cold-serving resin (Technovit) was added to 2 parts 
of HistoResin mounting medium (Leica) and the resulting solution was poured on 
top of the holder as described in Fig. 2.18. Resin hardened within 30 min and blocks 
were removed. 
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Figure 2.17 Sample preparation for polymerisation. Resin solution was added 
into molds utilising a pipette until molds were filled 90% (A). A femur was placed 
sideways into each mold with the shaft pointing towards the triangular end, but 
keeping this area free of bone (B). Molds were sealed airtight with a cover foil (C) 
and a metal holder (D). All 4 covered molds were screwed tightly into a metal 
device. 
 
 
Figure 2.18 Mounting of polymerised blocks. Raised surfaces on the holders 
were removed to prevent leakage (A) and polymerised surfaces cleaned before 
mounting. Holders were placed on top of the polymerised blocks (B) and mounting 
solution was added (C). When the mount became solid, holders were removed from 
the mold with pliers (D). This also freed polymerised blocks which were attached to 
the holder for sectioning (E). 
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2.6.5.3 Trimming of Resin Embedded Blocks 
A motorised drive microtome (Leica, RM2265) was utilised. Disposable blades 
(Leica) were applied for trimming and adjusted to the clearance angle of 5°. A block 
was clamped into the holder and to reduce the cutting force it was oriented with the 
triangular side facing the blade. A block was trimmed until a considerable amount of 
shaft was visible on the surface. 
 
2.6.5.4 Sectioning of Resin Embedded Blocks 
Once all femora were trimmed, smooth sectioning was achieved by replacing the 
blade with a D profile tungsten carbide knife 12 or 16 cm (Leica). The section 
thickness was adjusted to 5 µm. During sectioning, the block surface was moistened 
with 30% ethanol.  A section was collected using a brush wetted with 30% ethanol. 
The brush caught a section at the triangular part which appeared first. Once enough 
sections were collected from a single block, they were transferred to labelled tissue 
tack microscope slides (Polysciences, coated with saline) that were covered with 
96% ethanol. Sections were stretched with a brush and cover foils (TAAB) were 
immersed in 96% ethanol and placed on top of the sections. Excess ethanol was 
dried off and slides were sandwiched into a pressure clamp. The clamp was 
tightened and incubated at 37°C for 2 days to support drying and adhesion of 
sections. Finally the clamp was cooled for 30 min and slowly released before 
removing slides.  
 
2.6.5.5 Identification of Osteoids 
To identify osteoblast activity von Kossa/van Gieson staining procedure was 
performed to quantify osteoids. Von Kossa stained for mineralised matrix whereas 
van Gieson highlighted the OB secreted collagen-rich osteoids (Yadav et al. 2011; 
Lindhe et al. 2012). 
For this procedure sections were initially stained on slides. Before staining, 
resins had to be removed by immersion in 3 changes of methozyethyl acetate 
(MEA) for 20 min each time. Sections were transferred to xylene for 2 changes (10 
min each time) and dried for 30 s. This was followed by hydration of sections by 
rinsing them in 2 changes of 100% ethanol and then once in 96%, 80%, 70% and 
50% ethanol. Hydration was finished by immersion of slides in 2 changes of dH2O. 
Von Kossa staining was initiated by incubation of slides in 1.5% silver nitrate, 
diluted from the silver nitrate stock solution (section 2.2, (xlvi)), for 5 min in the dark. 
The excess solution was removed by brief washing in dH2O for 3 changes. To 
induce a colour change of the mineralised backbone to black, sections were 
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reduced in 0.5% hydroquinone (TAAB) for 2 min and rinsed again in dH2O for 2 
changes. Sections were counterstained in van Gieson (filtered, TAAB) for 5 min and 
washed in dH2O for 2 changes before being dried on a hot plate at 45°C. Sections 
were dehydrated in xylene for 5 min and 22x50 mm coverslips (VWR) were mounted 
onto the slides. For this DPX (Fluka) was dropped onto the coverslip and xylene 
soaked sections were carefully moved onto the coverslip with the sections facing 
down. Once the coverslip attached to the slide it was turned over again and left to 
dry over night. 
Staining on slides did not always produce sections suitable for analysis. 
Some polymerised blocks resulted in poorly attaching sections. Therefore more 
sections were removed from the corresponding blocks as described in section 
2.6.5.4. Sections were subjected to the floating method in which the resin was not 
removed to give sections support and the stain was allowed to penetrate sections 
from both sides.  For this, sections were added into ice cube trays (holding 10 ml per 
slot). One section was added to individual compartments and each section was 
washed in dH2O. Von Kossa and van Gieson staining were carried out as described 
above. Sections were dehydrated in 70% ethanol and unfolded with forceps. After 3 
sections were transferred onto slides, all sections were straightened with forceps. 
Excess resin around the bone containing area was removed utilising a scalpel. The 
mount for resin sections (section 2.2, (xl)) was melted in a water bath (65°C). 
Coverslips were mounted onto sections by dripping the resin mount next to the 
section and adding the coverslip on top. Finally slides were left to dry. 
 
2.6.5.6 Quantification of Osteoids 
Trabecular bone was chosen for osteoid analysis as its remodelling rate is higher 
than in cortical bone (see section 1.4.2.2) and small changes could be monitored. 
Slides stained with von Kossa/van Gieson were scanned with a ScanScope CS slide 
scanner (Aperio) to digitalise complete slides. A summary of the generation of high 
quality images is illustrated in Fig. 2.19. 
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Figure 2.19 ScanScope illustration. Figure demonstrates how slides were loaded 
into the rack. They were then selected to obtain a snapshot which enabled adjusting 
the area of interest (red), scan area (green), calibration point on a white background 
(blue diamond) and focus points (yellow squares) on femoral sections. 
 
ImageScope was then used to process images. As exporting images as TIF files did 
not result in the desired magnification for osteoid quantification, snapshots of the 
trabecular bone area within each femoral section were taken at x20 object 
magnification as described in Fig. 2.20. The scanned area width was utilised to 
determine the µm/pixel (0.49875) which was required for further analysis.  
 
Figure 2.20 Illustration of overlapping images. Figure demonstrates snapshots 
were taken to capture the trabecular bone in the shaft. 
 
The Fiji-Win64 image J program was used applying a Macro developed by Stephan 
Preibisch to stitch individual images together to create a single image. This was 
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supported by the Macro ‘StitchFromFile’ developed by Dr Rob van’t Hof and a 
demonstration can be viewed in Fig. 2.21.  
 
 
Figure 2.21 Stitching of high resolution images. Figure illustrates how overlaps 
of images are selected to generate a merged image. This is performed in bands to 
allow stitching in 2 dimensions. Once a band is finished, cropping allows for better 
overlap to stitch individual bands together. 
 
All sections were analysed with an additional custom designed Image J Macro also 
developed by Dr Rob van’t Hof. In the program TRAPHisto the calculated 0.49875 
µm/pixel was entered to calibrate the program (Fig. 2.22). Analysis resulted in TV, 
BV, bone surface (BS), osteoid numbers (OSN) and osteoid surface (OSS) 
quantification. 
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Figure 2.22 TRAPHisto program. A demonstration of assessment stages is shown. Initially a stitched image was opened and the program 
was calibrated (A). The TV containing the trabecular bone was selected in red (B) before the trabeculae was highlighted in blue (C). Finally 
osteoids on the bone surface were identified in red (D). 
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2.6.5.7 Calcein Labelling In Vivo 
In vivo staining with the fluorophore calcein allowed for monitoring of calcium 
deposition by OBs over time. For this an additional cohort of four 8-10 week old WT 
mice and 4 age matched CD59a-/- mice were treated by intra-peritoneal injections 
with calcein solution (section 2.2, (xiv)) 4 and 1 days before sacrifice (Home Office 
license 30/2361). Femora were histologically processed as described in section 
2.6.5.1 to 2.6.5.4. Generated sections only required counterstaining by immersion in 
Aniline blue (0.3 mg/ml, pH 7.5) for 20 min to identify position of the trabecular bone. 
Slides were washed in tap water twice, air dried, mounted with DPX as described in 
section 2.6.5.5 and dried again. 
 
2.6.5.8 Assessment of Mineral Apposition 
Images of Calcein/Aniline blue labelling slides were taken with the Leica Q5501W 
microscope. In the Leica QWinV3 software, images of trabecular bone, stained with 
Aniline blue, were taken with white light at x20 object magnification. For this the 
exposure was adjusted to 5.48 ms, the image was grey-scaled, and white balance 
and shading correction was applied. The microscope was changed to FITC (515 
nm) without moving the slide. A fluorescent image was taken at 303 ms exposure.  
A total of 4 non-overlapping images (white and fluorescent light) were generated per 
section. After all sections were processed an image was taken of the 
haemocytometer at the same magnification to calculate the pixel/mm as described 
in section 2.3.5. This was converted to µm/pixel.  
 White light and fluorescent images of the same area were stacked 
utilising Fiji-Win64 Image J program to locate trabecular BS on fluorescent images.  
All stacks were analysed with ‘CalceinHisto’ macro developed by Dr Rob van’t Hof. 
The calculation was set to 0.1407µm/pixel (Fig. 2.23) and parameters described in 
Fig. 2.23 were selected. TV, BV, BS, single label (OB mineralised at one timepoints 
only at a specific BS), double label (OB mineralised at both time points at a specific 
BS) and width of double label were quantified. From this the mineral apposition rate 
(MAR) was generated by dividing the width of the double label by the number of 
days between injections (3) in µm/day. Bone formation rate (BFR/BS) was 
calculated by multiplying the MAR by the sum of double and half of the single label. 
These were then divided by the BS (µm3/µm2/day).  
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Figure 2.23 CalceinHisto program. Stacked white light and fluorescent images were opened. White light image in grey scale was displayed 
and software was calibrated (A). As only trabecular bone was selected the total area was chosen as TV (B). Trabeculae were highlighted in 
blue (C) and BS was converted into a blue line on the fluorescent image (D). Area of parallel double labelling of calcein was selected in purple 
and single label around the bone surface was depicted as green line.
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2.6.6 Investigation of OC Localisation In Vivo 
Slides generated in section 2.6.5.4 were also assessed for OC localisation in WT 
and CD59a-/- samples utilising TRAP/Aniline blue staining. Again, sections adhered 
to slides were initially stained via the following protocol. Resin removal and 
dehydration was performed as described in section 2.6.5.5. Sections were 
transferred into the TRAP stain 2 (section 2.2, (l)) which was filtered (Whatman, 
grade 230) before use.  Sections were stained for 2 h at 37°C, but the development 
of maroon colour was monitored and the time adjusted accordingly to avoid 
background staining. Sections were rinsed in dH2O twice and counterstained in 
Aniline blue acid (section 2.2, (vi)) for 20 min. Subsequently, sections were washed 
twice in tap water, left to dry, mounted with resin mount as described in section 
2.6.5.5 and were dried again. 
Similarly, stained sections of low quality were re-stained via the floating 
section method. Sections from different blocks were added into sealable glass 
containers (50 ml). Initially all sections were washed in dH2O before 10 ml TRAP 
stain 2 was added per container and incubated on the agitator at 37°C for approx. 2 
h. Sections were washed with 3 changes of dH2O and counterstained with Aniline 
blue acid for 20 min. After another 2 changes of washing in dH2O, sections were 
mounted as described in section 2.6.5.5.  
Slides stained with TRAP/Aniline blue were scanned in ScanScope CS slide 
scanner, processed in Image Scope and stitched together in the Image J as 
described in section 2.6.5.6. The program TRAPHisto was utilised for OC 
quantification as also explained in section 2.6.5.6. When parameters were 
calculated, OC numbers (OCNr) and OC surface (OCS) was determined instead of 
osteoids. 
 
2.6.7 Statistics 
All statistical analysis was performed with Graphpad Prism software. The GraphPad 
QuickCal Outlier test was utilised to determine single, extreme outliers via the 
Grubbs’ test. A Student T-Test was performed when comparing 2 unpaired groups. 
Two-way ANOVA was utilised when assessing more than 2 groups with 2 
independent variables respectively. Mean and standard error (SEM) are stated 
throughout the result section. 
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Chapter 3 
 
 
Determining the Role of 
CD59a in Osteoblast 
Differentiation and 
Maturation 
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3.1 Introduction 
CD59 is expressed on human mesenchymal stem cells (MSCs) and osteogenic 
lineage cells (Tian et al. 2007; Hu et al. 2009; Trentz et al. 2010), therefore it is likely 
that murine MSCs express CD59a. Whether CD59a affects osteoblast (OB) 
formation or function has not been investigated previously.  
 
3.2 Aim and Objectives 
The purpose of this chapter was to evaluate the role of CD59a in OB differentiation 
and function, by measuring OB generation from precursor cells and assessing the 
capacity of the OB to form a mineralized matrix in vitro. 
To accomplish this aim the following key objectives were identified: 
1. To establish a reproducible OB mineralisation and colony forming unit (CFU) 
assay. 
2. Assess the impact of CD59a on MSC differentiation and mineralisation using 
mouse MSCs or OBs as the favoured cell source. 
 
3.3 Results 
Initially, an OB mineralisation assay was established in vitro, before the role of 
CD59a in OB differentiation and mineralisation was evaluated. Femora and humeri 
were harvested from 7 to 20 week old mice. Bone marrow and explant cultures were 
prepared as explained in section 2.3.3. Assay conditions were tested to obtain the 
optimum 1) cell density, 2) cell source, 3) foetal calf serum (FCS) supplement, 4) β-
Glycerophosphate (βGP) concentration and 5) time points for evaluation. Once 
established WT and CD59a-/- samples were compared during OB differentiation, 
mineralisation and adipocyte generation. The findings of these studies are described 
in detail below. 
 
3.3.1  Establishing a Cell Concentration Sufficient to Support OB 
 Mineralisation 
To determine the optimum cell density for the mineralisation assay, cells were 
cultured in medium supplemented with dexamethasone (DEX) and ascorbic acid 
(ASP) to induce OB differentiation and βGP (for mineralisation) for 28 days (Bellows 
et al. 1992; Peter et al. 1998; Coelho and Fernandes 2000). At end point the wells 
were stained with Alizarin red as a positive marker (Fig. 3.1) demonstrating that the 
conditions were sufficient to support OB differentiation and function in vitro. 
MSCs were seeded at various concentrations ranging from 1x104 and 4x104  
cells/well. The surface area of the Alizarin red staining was shown to gradually 
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increase with cell density, with the highest level of staining being observed at 4x104  
cells/well (Fig. 3.1D).  
Mineralised nodule formation between cells has been reported as a measure 
of functional mineralisation by OBs in the literature (Idris et al. 2008). Mineralised 
nodule size was slightly increased in those cultures seeded at 4x104 cells over the 
other cell densities (Fig. 3.2). Hence, 4x104 cells/well was chosen as the optimal cell 
density to obtain highest yield of functional OBs in subsequent assays. 
 
Figure 3.1 Mineralisation of cultures from bone marrow derived MSCs to 
determine cell density. A pool of bone marrow cells from 2 femora and 2 humeri of 
an 8 week old male mouse was obtained (n=1 mouse). MSCs were cultured until 
confluent before seeding at 1x104 (A), 2x104 (B), 3x104 (C) and 4x104 (D) cells/well 
(n=3 wells per cell density) in 12 well plates. After overnight adherence, medium 
supplemented with DEX (10 nM), ASP (50 µg/ml) and βGP (10 mM) was added to 
induce mineralisation. Cells were cultured for 28 days and Alizarin red staining was 
performed at end point to visualise mineralisation. Representative wells are shown. 
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Figure 3.2 Morphological assessment of mineralisation. Cultures seeded at 
1x104 (A), 2x104 (B), 3x104 (C) and 4x104 (D) cell/well were examined 
microscopically to determine the quality of mineralisation. Examples of mineralised 
nodules ( ), mineralisation encircling cells ( ) and diffused mineralisation (area 
denoted in green line) are indicated. 
 
3.3.2 Assessment of Cell Source for Differentiation of Functional OBs 
To test the most suitable OB precursor cell source, cells were either harvested from 
the bone marrow or grown from shaft and epiphysis/metaphysis explants before 
being expanded according to the procedure outlined in section 2.3.3. After 
expansion cells were seeded at 4x104 cells/well and left to differentiate and 
mineralise for 28 days before Alizarin red staining. Cells cultured from the bone 
marrow showed increased Alizarin red staining (Fig. 3.3) and presented with more 
medium sized mineralised nodules than cells obtained from the explants of the shaft 
or epiphysis/metaphysis (Fig. 3.4). Hence bone marrow cultures had more capacity 
to differentiate into functional OBs than explant cultures and were utilised in 
subsequent experiments. 
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Figure 3.3 Mineralisation of cultures established from bone marrow derived 
MSCs and explant cultures. A pool of bone marrow cells and bone explant derived 
cells from 2 femora and 2 humeri of an 8 week old male mouse were used (n=1 
mouse of which 3 wells were cultured per cell source). Cells were cultured and 
stained as outlined in Fig. 3.1. Representative wells from bone marrow cultures (A), 
explant cultures from the epiphysis/metaphysis (B) and shaft (C) are shown. 
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Figure 3.4 Morphological examination of mineralisation in cultures established 
with different cell sources. Bone marrow cultures (A), explant cultures from the 
epiphysis/metaphysis (B) and shaft (C) were examined microscopically at higher 
magnification to analyse the mineral deposits morphologically.  
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3.3.3 Examination of the Effect of FCS Supplements on Mineralisation of 
 OB Cultures 
FCS (as supplied by the manufacturer) was routinely used for OB mineralisation 
assays by our research group. An in vitro system without external complement was 
desired for this study to investigate the effect of CD59a on OBs. Hence FCS versus 
heat-inactivated FCS was compared in the OB assays. 
 Bone marrow cells were expanded in complete medium for murine cell 
cultures with FCS or heat-inactivated FCS (Tab. 2.1). Once plated, MSCs were left 
to differentiate in medium supplemented with the corresponding FCS and mediators 
for 21 days. Alizarin red staining was performed and mineralisation was observed 
microscopically. 
Mineralised nodules formed in cultures grown in both FCS and heat-
inactivated FCS (Fig. 3.5). Mineralised nodules were slightly smaller in heat-
inactivated FCS (Fig. 3.5B), but occurred with the same frequency as in untreated 
FCS (Fig. 3.5A). Consequently heat-inactivated FCS was adopted for all subsequent 
experiments. 
 
Figure 3.5 Morphological assessment of mineralisation utilising different 
types of FCS. A pool of bone marrow cells from 2 femora and 2 humeri of an 8 
week old male mouse were used (n=1 mouse). Bone marrow MSCs were cultured 
until confluent in medium supplemented with untreated or heat-inactivated FCS 
(10%).  MSCs (4x104 cells/well, n=3 wells per FCS type) were seeded and after 
overnight adherence, placed in medium containing DEX (10 nM), ASP (50 µg/ml), 
βGP (10 mM) and untreated (A) or heat-inactivated (B) FCS (10%) to induce 
mineralisation. On day 21 Alizarin red staining was performed to visualise 
mineralisation.  
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3.3.4 Identification of Optimal βGP Concentration for Mineralisation 
 of Bone Marrow Cell Cultures 
For OB to undergo the process of mineralisation, in vitro, βGP is required in the 
culture medium. High βGP concentration (10 mM) within the medium has been 
reported to precipitate calcium and phosphate mineral spontaneously giving an 
apparent false positive result (Khouja et al. 1990; Chang et al. 2000). To avoid this 
mineralisation assays were performed with medium containing 2 or 10 mM βGP to 
determine the concentration of βGP necessary for mineralisation (Tab. 2.2). 
Cultures were left to differentiate for 21 days and Alizarin red staining revealed 
mineralisation nodules in cultures stimulated with 10 mM βGP only (Fig. 3.6). 
Therefore βGP concentration of 10 mM was continued for subsequent assays. 
 
 
Figure 3.6 Assessment of the effect of βGP concentration on mineral nodule 
formation. Cells were harvested and seeded as described in Fig. 3.5 (n=1 mouse of 
which 3 wells were plated per βGP concentration). After overnight adherence, 
medium containing DEX (10 nM), ASP (50 µg/ml) and 2 (A) or 10 mM βGP (B) was 
added to induce mineralisation. On day 21 Alizarin red staining was performed to 
visualise mineralisation.  
 
3.3.5 Assessment of Time Course of Mineral Deposition in WT and 
 CD59a-/- Cultures 
In order to establish if cultures derived from WT and CD59a-/- bone marrow cells 
mineralise at the same rate, mineralisation was monitored on day 14, 21 and 28. 
Alizarin red staining was negligible in cultures on day 14 (Fig. 3.7). Levels of 
mineralisation significantly increased over the duration of the time course. However 
this rise was more pronounced in the CD59a-/- samples. Minimal Alizarin red staining 
was identified in WT samples which was inconsistent with data obtained in section 
3.3.3 and 3.3.4. A significant difference (p<0.001) between WT and CD59a-/- 
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samples was observed (WT=9.0±6.9 and CD59a-/-=171.7±66.3 mm2/well (results in 
this format = Mean±SEM unless stated otherwise)) on day 28 as illustrated in Fig. 
3.8. 
 
 
Figure 3.7 Assessment of mineralisation at different time points during 
culture. A pool of bone marrow cells from 2 femora and 2 humeri was obtained from 
a 7 week old WT (A, C and E) and CD59a-/- (B, D and F) mouse and cultured until 
confluence in complete medium for murine cell cultures (n=1 mouse per group). 
MSCs (4x104 cells/well, n=3 wells per condition) were seeded and after overnight 
adherence cultured in complete medium for murine cell cultures containing DEX (10 
nM), ASP (50 µg/ml) and βGP (10 mM) to induce mineralisation. Alizarin red 
staining was performed to visualise mineralisation on day 14 (A and B), 21 (C and 
D) and 28 (E and F). Representative wells are shown. 
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Figure 3.8 Quantification of mineralisation at different time points of culture. 
Cells were cultured as outlined in Fig. 3.7 (n=1 mouse per group of which 3 wells 
were analysed at each time point). Alizarin red staining was performed to visualise 
mineralisation. Surface area of Alizarin red staining was quantified utilising Image J 
on day 14, 21 and 28. Two-way ANOVA was performed (strain: p=0.0100, time: 
0.0195, interaction: p=0.0360) and Bonferroni post-tests are indicated 
(***(p<0.001)).  
 
3.3.6 Identification of Optimal Cell Seeding Density for Colony Forming 
 Units Assays 
In order to establish OB differentiation potential, murine bone marrow cultures were 
set up to evaluate CFU (more than 20 cells) (Vidal et al. 2007). Initially, cell 
concentrations were examined to generate high numbers of CFU. Bone marrow 
cells were plated at 2x105, 4x105 and 8x105 cells/well and left to adhere overnight. 
Cultures were stimulated with OB differentiation medium (complete medium for 
murine cell cultures supplemented with DEX (10 nM) and ASP (50 µg/ml)) which 
was non-mineralising. After 7 days alkaline phosphatase (ALP) staining was carried 
out to identify CFU (section 2.3.4).  
ALP staining was low in cultures at 2x105 cells/well (Fig. 3.9A). As cell 
density was increased ALP staining became more intense and more colonies were 
visible (Fig. 3.9C). When the number of colonies were quantified, values significantly 
rose (p=0.0007) from 0 to 11±2 at 8x105 cells/well (Fig. 3.10).   
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Figure 3.9 Representative images of ALP+ cells in cultures grown at different 
cell densities. Bone marrow preparations were obtained from a 9 week old WT 
mouse (n=1 mouse). Cells were seeded at 2x105 (A), 4x105 (B) and 8x105 (C) 
cells/well (n=3 wells per cell density) and grown in the presence of OB expansion 
medium. After 7 days, ALP staining (blue) was performed in order to visualise CFU. 
 
 
Figure 3.10 Quantification of CFU grown in cultures at different cell densities. 
A pool of cells from 2 femora and 2 humeri was used (n=1 mouse of which 3 wells 
were analysed per cell density). Representative image illustrating an ALP+ colony 
containing more than 20 cells (A). Number of ALP+ colonies grown at 2x105, 4x105 
and 8x105 cells/well were counted (B). A One-way ANOVA (p=0.0007) was 
performed. 
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3.3.7  Establishment of an Optimised Time Point for CFU Assays 
To determine whether a further increase in cell density would lead to a rise in CFU 
bone marrow was obtained from a 20 week old WT mouse. Cells were seeded at 
8x105 cells/well and 1.2x106 cells/well. ALP+ CFU was determined on day 7 and 10. 
When comparing CFU at 8x105 cells/well quantified after 7 days to the previous WT 
sample, CFU significantly rose (p<0.0001) from 11.3±1.8 to 82±4.4 colonies/well 
(Fig. 3.11A). Numbers of CFU demonstrated no significant difference between 8x105 
cells/well (82±4 ALP+ colonies/well) and 1.2x106 cells/well (84±3 ALP+ colonies/well) 
after 7 days in culture, but the colony size was increased in the 1.2x106 cells/well 
cultures. By day 10 colonies started to merge which may have contributed to a lower 
number of colonies in cultures of 8x105 cells/well on day 10 as illustrated in Fig. 
3.11B. Therefore 1.2x106 cells/well incubated for 7 days was chosen as the 
optimised CFU assay condition. 
 
 
Figure 3.11 CFU re-evaluation at different cell densities and 2 time points. 
Bone marrow preparations were obtained from 2 femora and 2 humeri of a 20 week 
old WT mouse (n=1 mouse). The number of ALP+ colonies grown at 8x105 and 
1.2x106 cells/well (n=3 wells per group) was determined on 7 and 10 days (A). 
Representative images are shown in B. 
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3.3.8  Development of a Quantification Procedure for CFU  
To establish if quantification of CFU could be simplified numbers of ALP+ colonies 
were compared to ALP staining surface area. At 1.2x106 cells/well the number of 
ALP+ colonies was significantly greater in WT (100±8 ALP+ colonies/well) than 
CD59a-/- (65±7 ALP+ colonies/well) cultures (Fig. 3.12). Comparable differences 
were found by computer added image analysis of each well using the Image J 
package to quantify stained surface area (section 2.3.3.3). Hence image analysis is 
a reliable measure to quantify ALP stain. ALP staining measured computationally 
was faster and was therefore adopted for studies. 
 
Figure 3.12 CFU in bone marrow cultures of WT and CD59a-/- mice on day 7. 
Bone marrow preparations were obtained from 2 femora and 2 humeri of an 8 week 
old WT and CD59a-/- mouse (n=1 mouse per group). 1.2x106 cells/well (n=3 wells 
per mouse) were grown in medium for supplemented with DEX (10 nM) and ASP 
(50 µg/ml) for 7 days. The number of ALP+ colonies (A) was determined and ALP 
staining surface area was quantified utilising Image J (B). Unpaired T-test was 
performed as indicated (*(p<0.05)). Representative images are displayed (C). 
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3.3.9 Reproducibility of Mineralisation Assays 
To determine the reproducibility of the mineralisation assays, 7 repetitions of WT 
versus CD59a-/-  samples at 8-10 weeks were performed; in some cases 2 repeats 
(samples from 2 mice) were carried out at the same time. As the mineralisation 
assay established in section 3.3.5 did not produce adequate mineralisation in WT 
samples, expanded MSCs were seeded at 8x104 cells/well.  This increase in cell 
density required the adjustment of time points to 14 and 17 days. A further alteration 
was introduced by quantifying ALP staining surface area of mineralising OBs rather 
than CFU from expanded bone marrow cultures. This was employed to monitor OB 
differentiation during mineralisation assays.  
 Although ALP staining surface area was consistent within experiments, 
between experiments as well as in WT and CD59a-/- samples, it varied greatly (Fig. 
3.13). For example, in experiment 1 staining of CD59-/- samples at 1225.5±71.1 
mm2/well was reduced compared to the WT samples at 1948.5±23.3 mm2/well (Fig. 
3.13A). In experiment 2 the CD59a-/- staining covered an area of 293.7±20.3 
mm2/well which was raised over the WT staining (236.1±24.5 mm2/well) on day 14 
(Fig. 3.13B). 
Similarly, when quantifying Alizarin red, in experiment 1 the staining surface 
area of CD59a-/- (119.5±24.1 mm2/well) was higher than in WT (42.1±25.2 mm2/well) 
samples on day 14 (Fig. 14). In contrast in experiment 6 and 7, WT and CD59a-/- 
samples stained more intensely than in experiment 1, but were comparable to each 
other with 1099.0±101.4 and 971.5±166.8 mm2/well respectively. Furthermore, ALP 
and Alizarin red surface area were strongly correlated (p=0.0004) to each other (Fig 
3.15). Therefore, in in vitro OB mineralisation assays the variation between 
mice/individual experiments was too large to reproducibly identify potential 
differences between WT and CD59a-/- mice. 
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Figure 3.13 Quantification of OB differentiation. A pool of bone marrow cells 
from 2 femora, 2 tibiae and 2 humeri was obtained from 8-10 week old WT and 
CD59a-/- mice (n=7 mice per strain). Cells were cultured and MSCs (8x104 cells/well, 
n=3 wells per group) were subsequently seeded. After overnight adherence, cells 
were cultured in medium containing DEX (10 nM), ASP (50 µg/ml) and βGP (10 
mM) to induce mineralisation. Surface area of ALP staining was quantified utilising 
Image J on day 14 and 17. Experiments 1-7 were performed over a time frame of 11 
months. After experiment 1 (A) the FCS batch was changed. Following experiment 2 
and 3 (B and C) a building move interrupted the procedure before carrying out 
experiment 4 to 7 (D and E).   
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Figure 3.14 Quantification of mineralisation. A pool of bone marrow cells from 2 
femora, 2 tibiae and 2 humeri was obtained from 8-10 week old WT and CD59a-/- 
mice (n=7 mice per strain of which 3 wells were analysed per group). Cells were 
cultured as outlined in Fig. 3.13. Surface area of Alizarin red staining was quantified 
utilising Image J on day 14 and 17. Experiments 1-7 were performed over a time 
frame of 11 months. After experiment 1 (A) the FCS batch was changed. Following 
experiment 2 and 3 (B and C) a building move interrupted the procedure before 
carrying out experiment 4 to 7 (D and E).  
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Figure 3.15 Correlation of ALP and Alizarin Red staining on day 14. Data 
displayed in Fig. 3.13 and 3.14 were plotted against each other to determine 
correlation (r2) (n=7 mice per strain). One sample T-test was performed (p=0.0004). 
 
3.3.10 Establishment of Cell Seeding Density and Time Course for 
 Assessment of CFU of Adipocytes 
Since MSCs also have the capacity to differentiate into adipocytes and in Fig. 3.12 
and some experiments in Fig. 3.13, decreases in osteogenic CFU in CD59a-/- 
cultures were noted, I questioned whether the smaller number of osteogenic CFU 
drop was accompanied by increased CFU of adipocytes (AD). In order to investigate 
this further I set up a CFU-AD in vitro assay. Bone marrow cells were plated and run 
parallel with osteogenic CFU assays as described in section 2.3.7. Unlike the 
osteogenic assays which were incubated in complete medium for murine cell 
cultures supplemented with DEX (10nM) and ASP (50µg/ml), cultures for CFU-AD 
analysis were grown in DEX (1 µM, induces differentiation via CCAAT/enhancer 
protein-β and PPARγ), insulin (5 µg/ml, induces differentiation via IGF-1), 
indomethacin (50 µM, induces differentiation via PPARγ) and IBMX (0.5 µM, 
induces production of adipogenic and lipogenic proteins) (Lehmann et al. 1997; 
Novakofski 2004). The number of adipocyte forming colonies was counted after day 
7 and 10 using Oil red O staining. 
 Fig. 3.16 illustrates that CFU-AD developed at 8x105 and 1.2x106 
cells/well on day 7 and 10. When quantifying numbers of colonies, increase in cell 
seeding density from 8x105 (14±0.3 colonies) to 1.2x106 (25±5 colonies) cells/well 
resulted in significantly more (p<0.05) colonies containing 2-5 adipocytes on day 7 
(Fig. 3.17). This pattern continued on day 10 and was also present in colonies 
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containing more than 5 adipocytes for both time points. Additionally, CFU-AD (>5 
adipocytes) significantly rose at 8x105 between day 7 and 10 with 6±1 and 17±1 
colonies respectively; this finding also applied to 1.2x106 cells/well. Consequently, 
1.2x106 cells/well were chosen as plating concentration and 10 days as the optimal 
time point for subsequent CFU-AD assays. 
 
 
Figure 3.16 Representative images of CFU-AD using different cell seeding 
densities. Bone marrow preparations were obtained from a 20 week old WT mouse. 
Cell concentrations of 8x105 (A and C) and 1.2x106 (B and D) cells/well were tested. 
Cells were cultured in complete medium for murine cell cultures containing insulin (5 
µg/ml), indomethacin (50 µM), DEX (1 µM) and IBMX (0.5 µM). Oil red O staining 
was performed after day 7 (A and B) and 10 (C and D). 
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Figure 3.17 Quantification of CFU-AD. Bone marrow preparations were obtained 
from 2 femora and 2 humeri (n=1 mouse). Number and size of Oil red O+ colonies 
(CFU-AD) grown at 8x105 and 1.2x106 cells/well (n=3 wells per group) for 7 and 10 
days was determined. A two-way ANOVA was performed (cell density over time: 
p<0.0001, colony size: p= 0.0003, interaction: p=0.1083) and significance of 
Bonferroni post-tests are indicated (*(p<0.05), ***(p<0.001)).  
 
3.3.11 Quantification of CFU-AD in WT and CD59a-/- Samples 
The adipogenesis potential of WT and CD59a-/- bone marrow cells was investigated. 
Oil red O staining on day 10 revealed, significantly reduced (p<0.001) number of 
single adipocytes in CD59a-/- (5±1) over WT (15±1) samples (Fig. 3.18). This pattern 
also emerged for colonies containing 2-5 adipocytes. A similar trend was present for 
larger colonies (>5 adipocytes) and as visualised in Fig. 3.18B and C. However, only 
a single animal was analysed for each group.  
 
 
 127 
 
 
Figure 3.18 CFU-AD formation in WT and CD59-/- samples on day 10. Bone 
marrow preparations were obtained from an 8 week old WT and CD59a-/- mouse 
(n=1 mouse per strain). 1.2x106 cells/well (n=3 wells per group) were grown in 
medium supplemented with insulin (5 µg/ml), indomethacin (50 µM), DEX (1 µM) 
and IBMX (0.5 µM) for 10 days (A). The number and size of Oil red O+ colonies was 
quantified. A two-way ANOVA was performed (strain: p<0.0001, colony size: 
p<0.0001, interaction: p=0.0063) and Bonferroni post-tests are indicated 
(***(p<0.001)). Representative images of adipocytes for WT (B) and CD59a-/- (C) 
samples are illustrated. 
 
3.4 Discussion 
The establishment of a reproducible in vitro OB mineralisation assay was necessary 
to examine OB differentiation and functionality. This chapter presents a sequential 
account of the method development. Additionally, in vitro osteogenic and adipogenic 
CFU assays were set up to evaluate the capacity of bone marrow cell populations to 
differentiate into OBs and adipocytes. These methods were then applied to analyse 
potential differences in bone marrow cells derived from WT and CD59a-/- mice. 
 
3.4.1 Establishing a Cell Concentration Sufficient to Support OB 
 Mineralisation 
Mineralisation was induced by medium containing ASP, DEX and βGP. These 
mediators are commonly utilised in mineralisation assays in the literature. Inorganic 
phosphate was reported in some studies to induce mineralisation instead of βGP. 
DEX was added less frequently to cultures and was found to be substituted with 
mediators such as BMP-2 or Vit D to enhance ALP expression. ASP 
supplementation was found most consistently, especially in combination with αMEM 
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(Fromigué et al. 2008; Hoemann et al. 2009). These data supported our choice of 
mediators, but other combinations should be investigated.  
For successful mineralisation the concentration of the mediators used has 
been shown to play an important role. In this study mediators were used at 50 µg/ml 
(ASP), 10 nM (DEX) and 10 mM (βGP). In the literature, mineralisation from mouse 
MSCs differed in their ASP concentration (14.5 µg/ml to 50mg/ml) (Choudhary et al. 
2008; Scheller et al. 2010; Zhang et al. 2011a). According to Hoemann et al. in 
mineralisation assays the concentration of DEX varied between 10 and 100nM and 
between 5 and 10mM for βGP (Hoemann et al. 2009). Therefore the concentrations 
chosen here were comparable to published research. 
In order to compare cell plating density, 1x104 to 4x104 cells were seeded 
per well (2.6x103 to 1x104 cells/cm2) and mineralisation was induced. Cells seeded 
at 1x104 cells/cm2 were observed to produce the highest level of mineralisation with 
a slightly increased size of mineralised nodules. Rajalin et al. plated 5x103 cells/cm2 
expanded MSCs to induce mineralisation via the same mediators as used in this 
study (Rajalin et al. 2010). In contrast Zhang et al. preferred 5.2x105 cells/cm2 and 
Choudhary et al. seeded 1x105 cells/cm2 (Choudhary et al. 2008; Zhang et al. 
2011a). These studies did not add DEX to their cultures. As Purpura et al. 
demonstrated, higher cell density makes DEX redundant in order to commit cells to 
the osteogenic phenotype (Purpura et al. 2004). Hence, the cell concentration in 
combination with mediators selected was in agreement with the relevant literature. 
 
3.4.2 Assessment of Cell Source for Differentiation of Functional OBs 
Bone marrow derived cultures produced more mineralised nodules than explant 
cultures. A search of current literature did not provide any examples of a murine 
study on this topic, however, a study performed by Yameen et al. in a human 
system provided results consistent with what was observed in the murine system. 
The authors compared human bone marrow derived MSC to explant cultures 
obtained from trabecular bone of tibiae and concluded that mineralised nodule 
formation was greater in bone marrow derived precursor cells (Yameen et al. 2009). 
This suggested that my study had the potential to translate to a human culture 
system. 
  
3.4.3 Examination of the Effect of FCS Supplements on Mineralisation of 
 OB Cultures 
Next a source of FCS was established. Heat-inactivated FCS produced slightly 
smaller mineralised nodules, but at the same frequency as untreated FCS. Nimura 
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et al. tested human synovial MSC differentiation in untreated and heat-inactivated 
FCS and revealed that treatment of FCS affected proliferation of cells, but 
mineralisation potential was comparable (Nimura et al. 2010). Bruinink et al. also 
examined OB differentiation (utilising ALP as a read-out) from human bone marrow 
MSCs by supplementing medium with untreated and heat-inactivated human serum. 
In this study the type of serum was critical to the outcome, heat-inactivated serum 
resulted in less ALP staining (Bruinink et al. 2004). ALP activity in cultures 
supplemented with untreated FCS led to non-physiological mineralisation according 
to Hamlin and Price (Hamlin and Price 2004). In my study heat-inactivated FCS was 
preferred as a source to rule out exogenic complement effects and these findings 
from the literature supports the choice of FCS used. 
 
3.4.4 Identification of Optimal βGP Concentration for Mineralisation 
 of Bone Marrow Cell Cultures 
When determining βGP concentration, mineralisation was found to occur at 10 mM, 
but not at 2 mM supplementation after 21 days in culture. Mineralised nodule 
formation is dependent on the presence of ALP and βGP. ALP is the enzyme that 
hydrolysis βGP to generate phosphate for hydroxyapatite production (Coelho and 
Fernandes 2000) with low levels of ALP required to convert large amounts of βGP. 
Supplementation of cell line cultures with 2 mM phosphate and 2 mM calcium was 
shown to be insufficient for induction of mineralisation (Hoemann et al. 2009). 
However, Chang et al. found that the presence of ALP and βGP in cultures causes 
mineral deposition on top of collagen fibrils in a manner that is not found in vivo 
(Chang et al. 2000). Therefore, the authors recommend reducing βGP to 2 mM. This 
concentration has been successfully used, for example, when rat calvariae derived 
precursor cells were stimulated for 21 days (Brandao-Burch et al. 2005). In my 
system only 10 mM produced distinct mineralised nodules when comparing βGP 
concentrations. 
 
3.4.5  Assessment of Time Course of Mineral Deposition in WT and 
 CD59a-/- Cultures 
To establish if mineralisation occurs at the same rate in WT and CD59a-/- samples a 
time course was generated. In Fig. 3.8 mineralisation increased between day 14 and 
28 in CD59a-/- samples whereas little staining was observed in WT samples. 
Collected data from different murine and human studies by Hoemann et al. reveals 
that mineralisation generally appeared within 2 to 3 weeks of stimulation with ASP, 
DEX and βGP (Hoemann et al. 2009). De Sauza Malaspina et al. tracked OB 
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differentiation over a 35 day time course when utilising the foetal human cell line 
hFOB 1.19. The authors observed cell proliferation within the first 7 days and 
formation of cell colonies by day 21. Matrix vesicles, which are responsible for 
initiating mineral apposition, were identified on day 21 as well. Finally, mineralisation 
appeared sporadically on day 28, but established itself by day 35 (de Souza 
Malaspina et al. 2009). Similarly, my study showed little mineralisation in WT 
samples on day 28 and might have required longer incubation in mineralisation 
medium to obtain larger mineralised nodules. 
 
3.4.6  Development of a CFU Assay 
CFU were established next in order to identify OB differentiation characteristics. 
When optimising cell concentration, CFU significantly increased between 2x105 and 
8x105 cells plated per well (5x104 and 2x105 cells/cm2). In the literature, the 
comparison of cell densities for CFU from bone marrow is not routinely reported. In 
a study by Zhang et al. bone marrow MSCs were isolated before plating 50, 200 and 
1000 cells per 60 mm diameter dishes. This was called secondary CFU as 
stimulation of other cell types of the bone marrow to obtain ALP+ colonies was 
removed. The authors identified small number of colonies at 50 cells/dish, at 1000 
cells/dish identification of individual colonies was not possible. Quantification was 
therefore performed at 200 cells/well (Zhang et al. 2011b). Scutt et al. 
recommended keeping cell seeding density low to enable individual CFU to adhere 
and proliferate to represent clonal expansion from a single precursor cell. The 
authors suggested to seed 3.6x104 cells/cm2 (Scutt et al. 2003).  Other papers utilise 
0.5 to 1.5x105 cells/cm2 which is close to the range used in my study (Isogai et al. 
1996; Chou et al. 2009). 2x105 cells/cm2 produced a small number of CFU in my 
study when quantification was performed after 7 day incubation. Published data, 
utilising these seeding densities, analysed osteogenic CFU after 10 to 18 days 
(Dimai et al. 1998; Scutt et al. 2003; Chou et al. 2009), therefore larger colonies 
would have been obtained upon longer incubation in my study. 
Consequently, 8x106 and 1.2x106 cells were seeded per well (2x105 and 
3x105 cells/cm2) and incubated for 7 and 10 days. 3x105 cells/cm2 produced the 
highest density of large, non-merging CFU after 7 days in culture. Therefore my 
study proved that a higher cell concentration allows for a shorter incubation period to 
obtain efficient colony formation. 
When comparing the number of CFU at 8x105 cells/well quantified after 7 
days between a 9 and 20 week old mouse, CFU were up-regulated in the latter. This 
could have resulted from variation between assays, but Zhang et el. studied 
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differentiation potential of C57BL/6 bone marrow cells at 3-6, 12-18 and 24 month 
old mice and data revealed that CFU increased between 3 to 18 month before 
declining at 24 month (Zhang et al. 2008). Therefore it was likely that increased CFU 
resulted from an enhanced differentiation potential in the 20 week old mice utilised 
in my study. Furthermore it highlighted the importance of comparing age matched 
mice. These were used in all subsequent experiments. 
ALP is a marker for early OB differentiation (Rosen 2008) and therefore 
ALP+ colonies containing more than 20 cells were quantified initially in this method 
as CFU. When comparing this to quantification methods in the literature, Chou et al. 
differentiated between ALP+ and total number of colonies (Chou et al. 2009). 
Similarly, Dimai et al. utilised the same methodology, but included the number of 
ALP+ cells within each colony (Dimai et al. 1998). This analysis was not performed 
here because most cells were ALP+ cells. Additionally some studies determined 
calcium+ and collagen+ colonies  (Still and Scutt 2001; Holmes et al. 2004), a 
method that should be considered for future studies as it is an efficient mean to 
identify cell differentiation and functionality within the same assay.  
As ALP+ cells were the predominant cell type in my assays, evaluation of 
ALP staining was considered. Quantification of ALP staining surface area produced 
a comparable result to the number of ALP+ colonies counted. Counting colonies is 
the predominant method of analysis in the literature, either microscopically or via 
computer software (eg. IQ software using Photoshop) (Stenderup et al. 2001; Scutt 
et al. 2003). Other groups analysed ALP activity by adding p-nitrophenylphosphate 
to cultures and measuring the absorbance of formed p-nitrophenyl at 405 nm (Evans 
et al. 2000; Baksh et al. 2007). Kamalia et al. demonstrated quantification of 
endogenous ALP by flow cytometry after trypsin-EDTA digestion of OBs and 
staining with fast violet lb salt or fast red tr salt (fluorescent) (Kamalia et al. 1992). 
Hence the literature either focused on the number of colonies or the quantification of 
ALP. The methodology applied in this study allowed for ALP quantification while 
retaining colony and cell morphology. 
 
3.4.7  Quantification of CFU in WT and CD59a-/- Bone Marrow 
 Cultures 
When applying the optimised methodology to samples, ALP staining surface area 
was raised in WT over CD59a-/- samples, but this experiment needs to be repeated. 
Human CD59 is expressed on MSCs and used as the surrogate marker in many 
studies to identify MSCs from primary cell sources and long term cultures 
(Izadpanah et al. 2006; Lange et al. 2007; Watson et al. 2010). Javazon et al. 
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monitored and compared CD59 expression on human and rat expanded MSCs in 
colony forming assays without stimulation by DEX and ASP. CD59 was expressed 
on all mature MSC colonies in human and rat cultures (Javazon et al. 2001).  
Consistent expression of CD59 on mature MSCs suggests that CD59 might be 
involved in MSC differentiation. If the down-regulation of ALP+ colonies in CD59a-/- 
mice can be repeated, the effects of the complement system need to be considered. 
Moll et al. studied the interaction of MSCs and the complement system. MSCs were 
shown to suppress acute immune response when activated and recruited to the site 
of injury by C3a and C5a. When MSCs were injected into blood, deposition of iC3b 
and C3dg, but not C1q was noted. Additionally, MSCs were shown to express CD59 
as the sole complement regulator that efficiently prevented complement mediated 
lysis (Moll et al. 2011). The effect of MAC on MSCs has not been identified yet, but 
from the collated research it can be predicted that CD59 signalling and protection 
from complement mediated lysis may be involved in OB differentiation. 
 
3.4.8 Reproducibility of Mineralisation Assays 
When quantifying ALP and Alizarin red staining surface area of the mineralisation 
assays, experiments were internally consistent, but assays showed a large degree 
of variation between animals or individual experiments. During the study numerous 
environmental factors were altered. Initially a batch change in FCS had to be 
performed. Anselme et al. performed a batch test with 6 different FCS to choose the 
one which produced most ALP+ colonies, demonstrating the variability caused by 
this supplement (Anselme et al. 1999). Here only 3 batches were tested to obtain 
comparable mineralisation to the present batch. Additionally, our laboratories moved 
building after experiment 3 and an incubator change was performed. Successful 
bone marrow cell cultures depend on temperature, pH and humidity  (Till and 
McCulloch 1961) which should be regulated by the incubator, but might have been 
affected by the new environmental conditions. 
Further variables arose as these were primary cultures derived from mice. 
The mice encountered infections (pinworm, protozoa, Novovirus, Helicobacter 
species) within the Joint Biomedical Service Unit. Helicobacter species, for example, 
are gram-negative bacteria that infect the gastrointestinal tract. These bacteria can 
cause gastritis, inflammatory bowel diseases as well as hepatitis and liver lesions 
(Laboratory 1997). The resulting inflammatory response might have led to activation 
and release of numerous leukocytes from the bone marrow (Hermesh et al. 2010) 
possibly affecting starting cell populations.  
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On some occasions, these infections were treated with antibiotics in the 
drinking water. Bruckner et al. highlighted that treatment of mice with antibiotics can 
alter gastrointestinal bacteria leading to antibiotic resistance (Bruckner 1976). 
Alterations in gastrointestinal flora might have also induced inflammation. 
Additionally, antibiotics could have caused toxicity to murine cells. Hu et al. identified 
that when porcine heart valves were stored in RPMI with Streptomycin it caused a 
reduction of cell viability by 60% within 12 h (HU et al. 1989). Consequently, 
reduced viability might have altered the bone marrow environment. Various 
exogenous factors contributed to assay variability and should be kept constant in 
future experiments to obtain more consistent results. 
 
3.4.9 Establishment of Cell Density and Time Course for CFU-AD 
To investigate MSCs’ capacity of WT and CD59a-/- samples to differentiate into 
adipocytes, a CFU-AD assay was established. 1.2x106 cells were plated per well 
(3x105 cell/cm2) and incubated for 10 days in presence of DEX (1 µM), Insulin (5 
µg/ml), Indomethacin (50 µM) and IBMX (0.5 µM) to obtain the highest possible yield 
of CFU-AD. Stimulation with these mediators is most common in the literature, but is 
also performed by other mediators such as hydrocortisone, rosiglitazone and 
netolgitazone. Furthermore, the cell density of 3x105 cell/cm2  used in this chapter is 
in agreement with published data (Moerman et al. 2004; Novakofski 2004; 
Lazarenko et al. 2006).  
 
3.4.10 Quantification of CFU-AD in WT and CD59a-/- Samples 
CFU-AD were reduced in one CD59a-/- over WT samples and also requires 
repeating. However, Festy et al. identified expression of CD59 on mature adipocytes 
and linked CD59 to obesity (Festy et al. 2005). Misso et al. studied aromatase 
knockout mice which developed obesity featured by hypertrophy of adipocytes. 
When these mice were fed with cholesterol weight loss was induced and, amongst 
the mediators monitored, CD59 expression levels were altered (Misso et al. 2005). 
This evidence highlights not only the continued expression of CD59 once 
differentiated, but also its diverse involvement in different tissue mechanisms. As 
OB and adipocyte differentiation could be reduced in CD59a-/- mice, MSCs 
differentiation capacities should be investigated.  
 
3.5 Conclusion 
To conclude, in vitro investigation of the effect of CD59a on OB differentiation 
revealed the subsequent findings: 
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 Internally consistent mineralisation and CFU assay were successful 
established. 
 The impact of CD59a on mineralisation was not revealed due to assay 
variability.  
 However, CD59a may be involved in regulation of CFU. 
With regard to the effect of CD59a upon mineral apposition, my data was 
inconclusive. Since the function of OBs is dynamically related to the functions of 
OCs in bone I next investigated the impact of CD59a upon OC differentiation and 
function. 
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Chapter 4 
 
 
Assessing the Impact 
of CD59a on 
Osteoclastogenesis 
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4.1 Introduction 
The possible changes seen in osteoblast (OB) differentiation in the absence of 
CD59 in chapter 3 add further weight to the hypothesis that CD59a could exert an 
important function in bone in mice. Evidence for this notion comes from observations 
in experimental models of arthritis. In a murine model of rheumatoid arthritis (RA) 
CD59a insufficiency caused an increase in erosive bone pathology (Williams et al. 
2004). Unpublished preliminary data of Dr Anwen Williams revealed that 19 month 
old CD59a-/- mice presented with a spontaneous bone disease characterised by 
excessive osteoclast (OC) expression in joint tissues, which was not seen in WT 
mice. At the same time the synovial joint was clear of inflammatory cells. This data 
led us to my hypothesis that this effect might be independent of inflammation. This 
also led to the question: is CD59a’s functionality in bone uncoupled from or 
dependent upon MAC? To address this question C6-/- mice were included in this 
study. C6 is an essential component of the MAC complex. C6-/- mice cannot 
therefore assemble the MAC complex and all functions performed by CD59a should 
be uncoupled from the complement system in these mice. If C6-/- mice behave like 
WT mice, than the signalling of CD59a in bone would be complement independent. 
If C6-/- act like CD59a-/- mice than both components (MAC and CD59) are required 
for signalling and disruption of either component would prevent regulation of OCs. 
Complement independent function of CD59a has been reported previously in T-cells 
and other areas of biology, these are described in detail in section 1.3.1. The 
mechanisms that might explain the protective effect of CD59a on bone in mice (with 
or without arthritis) have not been evaluated previously.  
 
4.2 Aim and Objectives 
The aim of this chapter was to study the impact of CD59a and MAC upon OCG from 
mouse bone marrow preparations. In order to achieve this aim I identified 3 key 
objectives; they were: 
1. To develop a reproducible OCG assay. 
2. To perform phenotypic analysis of bone marrow cells in WT, CD59a-/- and 
C6-/- mice, in order to determine whether any differences in OCG might be 
attributed to variability in the starting cell population. 
3. To measure OCG under controlled conditions in vitro in WT, CD59a-/- and 
C6-/- mice. 
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4.3  Results 
In the first instance, a reproducible system for monitoring OC differentiation in vitro 
had to be established in the laboratory. Only then could the role of MAC and CD59a 
be determined during OCG. Murine bone marrow cells were obtained from WT, C6-/- 
and CD59a-/- mice. All mice were aged between 8 and 10 weeks at time of sacrifice. 
Bone marrow cells were harvested as described in section 2.4.3. Initially, OCG was 
established using WT bone marrow cell cultures. Assay conditions were optimised 
to obtain 1) uniform OC coverage on glass coverslips, 2) reproducible OC titres 
between assays, and 3) sufficient OC yields for counting and mechanistic studies. 
OCG assays were then established in C6-/- and CD59a-/- and all outcome measures 
(Cat K, MMP-9, mKc) compared against WT data. The results of these studies are 
reported herein. 
 
4.3.1  Morphological Assessment of Bone Marrow Preparations 
When bone marrow preparations were adhered to glass coverslips, they were 
densely populated (Fig. 4.1A). Hence cytospins of bone marrow samples were 
prepared in order to conduct differential cell counts on the bone marrow cell 
populations (Fig. 4.1B and C). The Giemsa/May-Grünwald stain was used to 
differentiate between leukocyte cell populations (section 2.4.5.2). From the initial 
investigations, the following groups were identified: erythrocytes, lymphocytes, 
monocytes, megakaryocytes and others (including small numbers of MSCs). All 
leukocyte subsets were of an equivalent number in WT and CD59a-/- cell 
populations on day 0. Samples contained monocytes (50-60%), megakaryocytes 
(20%) and lymphocytes (8-10%). Erythrocyte counts varied somewhat between WT 
(18%) and CD59a-/- (6%) samples (Fig. 4.1B and C). 
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Figure 4.1 Characterisation of bone marrow preparation at day 0. Cell 
preparations obtained from the bone marrow of 8-10 week old female WT and 
CD59a-/- mice were cultured on 6 mm glass coverslips (n=1 mouse per strain of 
which 3 coverslips were set up). Cells were seeded at a density of 6.4x104 cells/10 
µl and stained for Giemsa/May-Grünwald after 2 h adherence (A). Bone marrow 
cells prepared using cytospin (6.4x104/100 µl) and stained with Giemsa/May-
Grünwald for differential cell counts (n=5 random FoV per coverslip). Graph 
illustrating percentage of total cell number of grouped populations (B). 
Representative images of cytospin are shown and arrows point to examples of 
monocytes (C). 
 
4.3.2 Differentiation of WT Mouse Bone Marrow Preparations into OCs 
WT bone marrow cells (3x105 and 5x105 per well) were adhered to 13 mm glass 
coverslips that were cultured in M-CSF (25 ng/ml) alone or in combination with 
RANKL (2 and 5 ng/ml) for 7 days. Pre-OCs and OCs stained maroon with TRAP 
and were counted using light microscopy (section 2.4.5).  
No TRAP+ cells were observed in cultures grown in M-CSF alone (Fig. 4.2 A 
and B). The addition of RANKL was required to generate TRAP+ cells (Fig. 4.2 C to 
E). For each test condition studied, 1) the average number of cells, 2) average 
number of TRAP+ cells and 3) average number of TRAP+ multinucleated cells per 
FoV (n=5 per coverslip) was determined. 
Total cell numbers were higher in cultures containing M-CSF over those 
containing M-CSF and RANKL (Fig. 4.3A). There was no significant difference in the 
number of TRAP+ cells at RANKL concentrations of 2 ng/ml compared to 5 ng/ml 
(Fig. 4.3B and D).  
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In the literature, OC differentiation was shown to be dependent on starting 
cell number (Ishida et al. 2002), hence OC yield were compared at initial bone 
marrow cell densities of 3x105 cells/well and 5x105 cells/well. Multinucleated TRAP+ 
cells (OCs) were counted for each condition as defined in section 2.4.5 (Fig. 4.3C). 
OCs (expressed as a percentage of total cells) were significant higher (p<0.01 and 
p<0.001) when cells were seeded at 3x105 cells/well (42.8±2.1% and 44.2±2.8% 
(results in this format = Mean±SEM unless stated otherwise)) compared to 
5x105cells/well (32.5±2.4% and 29.8±2.4%) with RANKL at 2ng/ml and 5ng/ml 
respectively (Fig. 4.3D). There was no significant difference in the percentage of 
multinucleated TRAP+ cells in cultures containing RANKL at 2ng/ml versus 5ng/ml 
seeded at the same initial cell density. Therefore, in succeeding experiments 
3x105cells/well was selected as the optimal starting cell density with M-CSF 
(25ng/ml) and RANKL (2ng/ml) chosen as optimal conditions to achieve the highest 
OC yields.  
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Figure 4.2 Representative images of OCs grown on 13 mm glass coverslips. 
Bone marrow preparations were obtained from an 8 week old male WT mouse. Cell 
concentrations 3x105 (A, C, E) and 5x105 (B, D, F) were tested. Cells were cultured 
in presence of M-CSF (25ng/ml) with and without RANKL on 13 mm glass 
coverslips. After 7 days, TRAP staining was performed. Cells were stimulated with 
M-CSF only (A and B), M-CSF and 2ng/ml RANKL (C and D), M-CSF and 5ng/ml 
RANKL (E and F).  
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Figure 4.3 Quantification of OC on 13 mm glass coverslips. A pool of cells from 2 femora for each mouse was used (n=1 mouse of which 3 
coverslips were prepared). Cells grown in M-CSF only (●), M-CSF and 2ng/ml RANKL (□) and M-CSF and 5ng/ml RANKL (♦) were quantified. 
Total cells (A), TRAP+ (B) (maroon stained) cells and multinucleated TRAP+ (D) cells were counted. Multinucleated cells were defined as 2 or 
more nuclei containing cells (C). Data are shown as total cells counted in 5 FoV (a) and % TRAP+ cells (b, c) determined at end point (5-15 
FoV). Two-way ANOVAs (and Bonferroni post-tests (see in text) were performed for A (cell density: p<0.3703, RANKL concentration: 
p<0.0001, interaction: p=0.3231), B (cell density: p<0.0021, RANKL concentration: p<0.0001, interaction: p=0.0002) and D (cell density: 
p<0.0001, RANKL concentration: p<0.0001, interaction: p=0.0016).  
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4.3.3 Improving OC Coverage on Coverslips 
Although OC yields were adequate using 13 mm coverslips, I frequently observed 
inconsistency in cell coverage and a patchy appearance to the cells at end point. In 
order to overcome this problem, 6 mm coverslips were trialled as shown in Tab. 2.4. 
The cell density was adjusted accordingly from 3x105 cells/coverslip to 6.4x104 
cells/coverslip. These smaller coverslips also allowed for capture of more than 80% 
of the total surface area of the coverslip in 5 FoV at x10 object magnification under 
the microscope. The total cell number and TRAP+ multinucleated cells were 
determined in order to calculate OC differentiation (%) on each coverslip. Cells were 
distributed evenly over the coverslips; average cell numbers ranged from 310 to 385 
cells/FoV as summarised in Fig. 4.4A. Multinucleated TRAP+ cells were compared in 
3 separate wells, the values were comparable at 15.8±1.1%, 16.0±1.4% and 
15.3±1.1% (Fig. 4.4B). 
 
Figure 4.4 OC coverage on coverslips. 6.4x104 bone marrow cells from an 8 week 
old female mouse were plated onto 6 mm glass coverslips (n=1 mouse). After 
adherence 3 coverslips were added into single wells (n=3 wells) of a 24 well plate 
containing differentiation medium (M-CSF and RANKL). One coverslip/well was 
removed on day 3, 5 and 7. After 7 days, TRAP staining was performed on one 
coverslip/well. Total cells (A) and multinucleated TRAP+ cells were counted for a 5 
FoV/coverslip to determine variation between wells. Percentage multinucleated 
TRAP+ cells was calculated (B).  
 
 143 
 
4.3.4 Assessing the OCG Assay over a Seven Day Time Course  
OCG assays were initiated using WT and CD59a-/- bone marrow preparations as 
described in section 2.4.4. Cells were incubated in M-CSF (25 ng/ml) alone or M-
CSF and RANKL (2 ng/ml). OC differentiation was monitored on day 3, 5 and 7 of 
the assay using TRAP staining. 
On day 3 (Fig. 4.5A), total cells per FoV in samples grown in M-CSF were 
higher in CD59a-/- (156±77 cells/FoV) than WT (42±12 cells/FoV). The trend was 
unchanged on day 5; the total cell number rose in CD59a-/- to 499±92 cells/FoV and 
in WT to 117±33 cells/FoV. By day 7 the total cells per FoV were significantly 
different in CD59a-/- (1975±483 cells/FoV) versus WT (381±70 cells/FoV) cultures 
(p<0.001). Proliferation between day 3 and 7 was comparable in WT and CD59a-/- 
samples. Representative images of the changes in TRAP- cell number are shown in 
Fig. 4.5B. 
Counts of cells (WT and CD59a-/-) grown in M-CSF and RANKL were 
comparable to samples cultured in M-CSF alone at day 3 (Fig. 4.6A). By day 7 the 
total cell per FoV in CD59a-/- was 401±63 cells/FoV which was significantly higher 
(p<0.001) than day 3 counts. In contrast, WT cell expansion was stagnated giving 
total cell counts of 100±41 cells/FoV. Cell counts were therefore significantly higher 
in CD59a-/- than WT cultures on day 5 (p<0.05) and on day 7 (p<0.001).  
Multinucleated TRAP+ cells or OCs (expressed as percentage of total cells) 
increased significantly in both WT (p<0.01) and CD59a-/- (p<0.001) cultures over 
time (Fig. 4.6B). On day 3 only a small number of OCs were observed in WT 
(0.1±0.1%) and CD59a-/- (0.4±0.3%) samples (Fig. 4.6C). By day 5, OCG had 
increased slightly to 3.3±0.1% in CD59a-/- and 1.8±0.5% in WT samples. By day 7 
the majority of cells stained positive for TRAP. OCs were significantly increased 
(versus day 3) in both CD59a-/- (17.3±1.6%) and WT (5.2±0.5%) samples (p<0.001, 
p<0.01), however, OC numbers were significantly greater for CD59a-/- versus WT 
cells (p<0.001).  
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Figure 4.5 Time course testing to evaluate cell proliferation. 6.4x104 bone marrow cells from an 8 week old female WT (●) and CD59a-/- (□) 
were plated onto 6 mm glass coverslips. A pool of cells from 1 femur for each mouse was used (n=1 mouse per strain). All coverslips were 
placed in triplicates into wells (n=4 wells per condition) of a 24 well plate containing medium supplemented with M-CSF.  TRAP staining was 
performed after 3, 5 and 7 days. Total cells per FoV was determined for 5 FoV per coverslip (A). A two-way ANOVA was performed (strain: 
p=0.0018, time: p=0.0004, interaction: p=0.0098) and Bonferroni post-tests were indicated (*** (p<0.001) significantly different to all other 
groups). Representative images of cultures grown in M-CSF alone on day 3, 5 and 7 are shown (B). 
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Figure 4.6 Time course testing to evaluate OC assay. Cells were harvested and plated as outlined in Fig. 4.5 (n=1 mouse per strain of which 
4 wells containing 3 coverslips each were cultured). Cells were cultured in medium supplemented with M-CSF and RANKL. TRAP staining was 
performed after 3, 5 and 7 days. Total cells per FoV (A) and % multinucleated TRAP+ cells (B) were determined for 5 FoV per coverslip. Two-
way ANOVAs were performed for A (strain: p=0.0002, time: p=0.0013, interaction: p=0.0154) and B (strain: p<0.0001, time: p<0.0001, 
interaction: p<0.0001) and Bonferroni post-tests are indicated ((*p<0.05), ***(p<0.001). Representative images of cultures on day 3, 5 and 7 are 
shown (C). 
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4.3.4.1 Increasing Yield of OCs by Improving Efficacy of Adherence at 
 Baseline 
In the results described in section 4.3.3, 100 µl of bone marrow cells were 
dispensed onto each coverslip by flooding the well on day 0, the bone marrow cells 
looked broadly spread across the coverslip and only diminutive cell/cell contact was 
observed. At endpoint on day 7, the resultant patchy OCs were widely spread over 
the coverslip surface and OC yield was low. In order to improve the initial adherence 
of bone marrow cells and thereby improve OC yield, the bone marrow preparations 
were seeded at 6.4x104 cells in 10 µl of culture medium per coverslip. This covered 
the surface area of the coverslip. The bone marrow preparations were cultured in 
differentiating medium containing M-CSF and RANKL. On day 3 the modified culture 
conditions revealed elevated cell counts in both CD59a-/- (266±113 cells/FoV) and 
WT (208±16 cells/FoV) samples (Fig. 4.7A). This was higher than the cell counts 
previously obtained with 100 µl seeded cells cultured under the same conditions; 
CD59a-/- (96±28 cells/FoV) and WT (62±6 cells/FoV). A reciprocal increase in OCG 
was also observed in CD59a-/- (28±0%) and WT (21±4%) samples. OC density was 
also higher at end point than in the previous method that used 100 µl of bone 
marrow cells (Fig. 4.7C). Assay optimisation was successful, and this was the final 
method employed for subsequent experiments. 
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Figure 4.7 OC time course re-evaluation. Bone marrow cells obtained from 8-10 
week old female WT (●) and CD59a-/- (□) were cultured on 6 mm glass coverslips. A 
pool of cells from 1 femur for each mouse was used (n=1 mouse per strain of which 
1-3 coverslips were cultured per group at 5 FoV per time point). TRAP staining was 
performed on day 3, 5 and 7. Total cells counts were performed for samples 
stimulated with M-CSF and RANKL (A) and OCG was quantified as % 
multinucleated TRAP+ cells (B) on day 3, 5 and 7. Representative pictures at 
endpoint are shown (C). 
 
4.3.5 Measuring CD59a Expression during OCG 
CD59a expression was determined over the time course of the OCG assay in WT 
cells using qPCR (methodology in section 2.4.6). qPCR was performed using 
primers designed for CD59a and the housekeeping gene acid ribosomal 
phosphoprotein P0 (H36B4). 
Primers were designed for CD59a and CD59b; both sets were tested for 
expression levels in murine testis and bone marrow. CD59a primers were found to 
be specific. qPCR data revealed expression of CD59a in adhered bone marrow 
samples on day 0. CD59a expression followed 5.6 cycles (CT=31.1) after the house 
keeping gene that emerged at Ct=25.5 (Fig. 4.8A). CD59a expression in this sample 
was set as 1; it was used as the reference baseline value for all other samples (Fig. 
4.8B).  
On day 1, CD59a expression decreased in samples stimulated with M-CSF 
and RANKL (relative transcript level of 0.07) or M-CSF alone (relative transcript 
level of 0.08). However, from day 3 onwards expression increased to 0.32 for M-
CSF and 0.26 for M-CSF plus RANKL. Transcription levels were further increased 
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on day 5 (M-CSF=0.71; M-CSF +RANKL=0.99). These levels did not increase any 
further to day 7 (relative transcript level = 0.73 for both conditions). This suggested 
that CD59a was expressed on the bone marrow preparation and the cell populations 
on day 3, day 5 and day 7, however it was unclear whether OCs specifically 
expressed CD59a.  
 
Figure 4.8 Determination of CD59a expression in OCG. Total RNA was isolated 
from cultures and analysed by qPCR for murine CD59a and H36B4 (n=1 mouse). At 
day 0 transcript levels for CD59a of adherent bone marrow cells was normalised to 
house keeping gene expression (A). This was utilised as baseline to monitor 
changes in mRNA expression of CD59a over time in cultures stimulated with M-CSF 
or M-CSF and RANKL (B).  
 
4.3.6  Quantification of OCG from WT, CD59a-/- and C6-/- Bone 
 Marrow Preparations 
After the key set-up experiments described thus far were completed (section 2.4.4) 
and CD59a expression was confirmed (section 2.4.6); OC assays were performed 
using bone marrow preparations from male and female WT, CD59a-/- and C6-/- mice. 
6.4x104 cells were plated onto 6 mm coverslips, they were left to adhere for 2 h and 
morphological assessments were performed. The remaining coverslips were run 
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through the optimised OCG assay described in section 4.3.4.1. Coverslips were 
sampled on day 3, 5 and 7 of the OCG assay, cells were stained with TRAP and 
differential cell counts were performed using a light microscope. 
Morphological assessment of starting cell populations revealed no 
differences in cell number in female mice studied (Fig. 4.9A). In males, the cell 
number was significantly reduced (p<0.05) between WT and C6-/- mice but was 
comparable between all other groups (Fig. 4.9B). The majority of cells adhering to 
glass coverslips were identified as monocytes for WT, CD59a-/- and C6-/- in both 
female (36.0±3.2%, 44.1±4.1% and 48.9±3.8% respectively) and male (39.2±3.1%, 
36.6±2.3% and 52.2±5.1% respectively) mice (Fig. 4.10A-D). Monocyte adherence 
was significantly higher in male C6-/- versus CD59a-/- cells (p<0.05).  
Erythrocyte and lymphocyte numbers were comparable in cells from female 
and male mice (Fig. 4.10 E-H). Megakaryocyte numbers did not change in cells from 
female mice (Fig. 4.10I).  Megakaryocyte numbers in male mice were 29.4±5.7% 
(WT), 36.8±3.1% (CD59a-/-) and 16.8±2.4% (C6-/-) respectively. C6-/- megakaryocyte 
numbers were significantly (p<0.05) lower than CD59a-/- samples (Fig. 4.10J).  
On day 3, OC differentiation (percentage of total cells) in females was not 
significantly different in WT (1.65±0.7%), CD59a-/- (2.9±1.9%) and C6-/- (4.9±5.2%) 
samples (Fig. 4.11A). A similar observation was made in males where OCG was 
1.8±1.1%, 4.28±2.2% and 0.82±0.3% in WT, CD59a-/- and C6-/- cells (Fig. 4.11B). A 
mixture of TRAP+ and TRAP- cells was observed in WT, CD59a-/- and C6-/- as shown 
in Fig. 4.11C. On day 5, OC numbers in female and male samples were also not 
significantly different (Fig. 12A and B). The majority of cells were TRAP+ (Fig. 
4.12C). OCG significantly increased in both female (p<0.001) and male (p<0.001) 
WT, CD59a-/- and C6-/- mice cultures between day 3 and 7. After 7 days, OCG in 
females was 27±1.3% in WT, 29.8±2.4% in CD59a-/- and 28.1±3.4% in C6-/- samples 
(Fig. 4.13A). These values were not significantly different from one another. In male 
CD59a-/- samples (Fig. 4.13B) OCs were significantly raised to 34.2±1.9% in 
comparison to 26.6±1.7% in WT (p<0.05) and 24.6±1.5% in C6-/- samples (p<0.01).  
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Figure 4.9 Evaluation of adherence ability of bone marrow preparations at day 0. 6.4x103 bone marrow cells from 8-10 week old WT (●), 
CD59a-/- (□) and C6-/- (♦) mice were plated onto 6 mm glass coverslips. A pool of cells from 1 femur for each mouse was used (n=5-7 mice per 
strain of which 3 coverslips were cultured per group). Cells were left to adhere for 2 h and washed before samples were taken for Giemsa/May-
Grünwald staining. Average cell number per FoV was determined for female (A) and male (B) samples from 1:10 dilution by counting 5 FoV at 
x10 object magnification for 3 coverslips. One-way ANOVAs were performed for A (p=0.8873) and B (p=0.0150) and Bonferroni post-tests are 
indicated (*(p<0.05)).  
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Figure 4.10 Morphological assessment of bone marrow preparations at day 0. 
A pool of cells from 1 femur for each mouse was used at 6.4x104 seeding density 
(n=5-7 mice per strain of which 3 coverslips were analysed at 5 random FoV). To 
determine differential cell counts coverslips at x40 object magnification were 
examined. Data is shown as percentage cell type of total cell counts for female (A) 
and male (B) samples. Two-way ANOVAs were performed for A (strain: p=0.9988, 
cell type: p<0.0001, interaction: p=0.0888) and B (strain: p=0.9925, cell type: 
p<0.0001, interaction: p=0.0058). A breakdown of this data is shown for monocytes 
(C and D), erythrocytes (E and F), lymphocytes (G and H) and megakaryocytes (I 
and J). Results of Bonferroni post-tests are indicated (*(p<0.05). A representative 
image illustrating the classification of cell types is presented (K).  
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Figure 4.11 Cell differentiation at day 3. 6.4x104 bone marrow cells from 8-10 week old WT (●), CD59a-/- (□ ) and C6-/- (♦) mice were plated 
and adhered onto 6 mm glass coverslips. A pool of cells from 1 femur for each mouse was used (n=5-7 mice per strain of which 3 coverslips 
were prepared). Cells were cultured in M-CSF (25 ng/ml) and RANKL (2 ng/ml) for 3 days before TRAP staining was performed. Total cells and 
multinucleated TRAP+ cells were counted on 15 FoVs. Data is displayed as percentage multinucleated TRAP+ cells for females (A) and males 
(B). One-way ANOVAs were performed for A (p=0.4250) and B (p=0.2500). Representative images of OC cultures from male mice are 
displayed and arrows indicate examples of OCs (C). 
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Figure 4.12 Cell differentiation at day 5. Bone marrow cells were seeded, cultured and stained as explained in Figure 4.11. A pool of cells 
from 1 femur for each mouse was used (n=5-7 mice per strain of which 3 coverslips were analysed at 5 FoV). Data is displayed as percentage 
multinucleated TRAP+ cells for females (A) and males (B) on day 5. One-way ANOVAs were performed for A (p=0.1291) and B (p=0.1761). 
Representative images of OC cultures from male mice are displayed and arrows indicate examples of OCs (C). 
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Figure 4.13 Cell differentiation at day 7. Bone marrow cells were plated as outlined in Fig. 4.13. A pool of cells from 1 femur for each mouse 
was used (n=5-7 mice per strain of which 3 coverslips were prepared). Cells were cultured in M-CSF (25 ng/ml) alone or in combination with 
RANKL (2 ng/ml) for 7 days before TRAP staining was performed. Total cells and multinucleated TRAP+ cells were counted on 15 FoVs. Data 
is displayed as percentage multinucleated TRAP + cells for females (A) and males (B). One-way ANOVAs were performed for A (p=0.8015) and 
B (p=0.0052) and Bonferroni post-tests are indicated (*(p<0.05), **(p<0.01)). Representative images of OC cultures in M-CSF (C-E) and M-CSF 
plus RANKL (F-H) from male mice are shown. 
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4.3.7  Quantification of Cathepsin K 
Cathepsin K (Cat K) is the major cysteine protease generated by OCs, and is 
essential for resorption of the organic bone matrix (Corisdeo et al. 2001). Cat K is 
produced as a zymogen. It means that Cat K contains an inactivating pro-domain 
when produced in the endoplasmic reticulum. After synthesis, Cat K is transported 
into lysosomal vesicles. Resorbing OCs release lysosomal vesicles at the ruffled 
border before Cat K is activated by other cathepsins, or by auto-activation at low pH 
(which may be dependent on presence of glycosaminoglycans). Once activated it 
cleaves fibrillar Col1 at numerous sites (Lecaille et al. 2008). ELISA, Col1 bioassay 
and zymography methodology were performed to confirm the activity of Cat K in 
OCs.  
 
4.3.7.1 ELISA for Cat K Secretion 
The only ELISA kit to measure protein levels available on the European market was 
a kit for human Cat K from Biomedica. However, the product advertised cross-
species reactivity (Wada et al. 2005). The assay was carried out as described in 
section 2.4.7.1. 
The data revealed that the positive Cat K control provided in the kit gave a 
strong signal for Cat K equivalent to 113.1±3.8 pmol/l (Fig. 4.14). The negative 
control used for the assay (medium containing 10% FCS) gave an average of 
14.2±1.4 pmol/l (OD of 0.26 at 450 nm) and was significantly different (p<0.001) to 
the positive control. When WT and CD59a-/- supernatants were tested, the 
detectable signal was lower than the negative control. A commercially available 
source of human recombinant Cat K (Enzo Life Sciences) was tested as an 
additional positive control for the ELISA. Once again no signal was detected, and 
the assay was deemed not fit for purpose. 
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Figure 4.14 Cat K ELISA. Concentration of positive Cat K control (not further 
specified) was calculated from standard curve. Medium (containing 10% FCS) was 
used as negative control. WT and CD59a-/- samples were taken from OCG assays 
at day 5 and loaded neat (n=2 supernatants from 1 OCG assay per strain that were 
analysed in duplicates). Human recombinant (hr) Cat K was diluted to 300pmol/l (top 
standard concentration) with assay buffer (provided with kit). A One-way ANOVA 
was performed (p<0.0001) and Bonferroni post-tests are indicated (***(p<0.001) 
significantly different to all other groups).  
 
4.3.7.2 Cat K Bioassay 
In order to examine functional activity of Cat K a type I collagen (Col1) bioassay was 
developed (section 2.4.7.2). Col1 was coated to a 96 well ELISA plate, the collagen 
was degraded using commercially available collagenase (Clostridiopeptidase A) as 
standards and collagenases within OCG assay supernatants. After washing, the 
remaining collagen bound to the plate was detected utilising a collagen-specific 
primary antibody and a biotinylated secondary antibody. The principles of ELISA 
were applied to measure the changes colorimetrically. 
Antibodies bind the antigen of interest (specific binding), but when these 
binding sites are saturated, other antigens with lower affinity (non-specific binding) 
are targeted. The concentration range of primary and secondary antibodies was 
tested to detect Col1. The secondary antibody reached optimum concentration at 
1:10,000 dilution (Fig. 4.15A). A dilution range of 1:1,000 to 1:16,000 of primary 
antibody was not sufficient to obtain specific binding and a further dilution to 
1:128,000 did not show improvement (Fig. 4.15B). When comparing collagen 
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degradation curves, OD values drastically dropped from 2.0 to 0.3 within a 1:5 
dilution of Clostridiopeptidase A. To avoid inaccuracy by over diluting, a 1:15,000 
dilution of primary antibody was selected. Consequently a standard curve utilising 
Clostridiopeptidase A revealed a limited assay sensitivity of 3.2 to 400 ng 
collagenase per ml (Fig. 4.15C).  
A blank consisting of buffer only (expressed as 100% collagen binding) was 
compared to recombinant human Cat K (active conformation) and matrix 
metalloproteinase 1 (MMP-1). These collagenases exhibited pH specificity; in buffer 
A (pH 7.4) MMP-1 significantly reduced (p<0.001) collagen binding to 12.3±0.3% at 
5,000 ng/ml. Cat K only demonstrated 65±1.2% binding at 500 ng/ml which was 
significantly reduced (p<0.001) over the blank, but was less active (p<0.001) in 
comparison to MMP-1 at the same concentration (Fig. 4.15D). In buffer B (pH5.5) 
Cat K significantly degraded (p<0.001) collagen to a 15.0±0.6% binding capacity at 
500 ng/ml which stayed constant when diluted further, demonstrating high enzyme 
activity (Fig. 4.15E). In comparison MMP-1 only slightly reduced collagen binding to 
91±2.6% at 5,000 ng/ml. Therefore in succeeding experiments Cat K (diluted in 
buffer B) and MMP-1 (diluted in buffer A) were chosen as positive control at 500 
ng/ml each to determine unknown collagenase specificity. 
Supernatants of WT and CD59a-/- cultures diluted 1:2.5 in buffer A were 
compared to blank (buffer A) and MMP-1. 500ng/ml MMP-1 revealed 68.1±10.2% 
collagen binding relative to control, a significant reduction (p<0.01) and hence 
confirmed the assay’s functionality (Fig. 4.16A). WT and CD59a-/- supernatants 
containing M-CSF did not show any collagenase activity at day 3 (WT=118.0±0.4%, 
CD59a-/-=114.1±3.6%), 5 (WT=113.5±2.4%, CD59a-/-=120±0.5%) or 7 
(WT=113.7±4.7%, CD59a-/-=116.3±0.1% binding). Instead, values were slightly 
raised in comparison to the blank. Interference from the FCS within the medium 
might have caused the recovery to exceeded 100%. In cultures supplemented with 
M-CSF and RANKL, collagen binding was significantly reduced (p<0.001) to 
56±1.6% in WT and to 38.8±0.8% in CD59a-/- supernatants on day 5. The CD59-/- 
sample was also significantly reduced in comparison to the MMP-1 standard. On 
day 7 collagen digestion potential of WT (81.4±3.6%) and CD59a-/- (79.5±8.3%) 
supernatants was comparable; showing slight collagenase activity. Collagenase 
activity was highest on day 5 of OCG assays, but considering that FCS could have 
influenced the binding capacity; levels quantified may not be accurate. 
At low pH (buffer B) Cat K degradation of Col1 resulted in 10.9±1.8% 
collagen binding in comparison to the blank (buffer B), again confirming the assays 
functionality (Fig. 4.16B). All WT and CD59a-/- samples diluted with buffer B showed 
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binding above 200%. The enhanced binding was probably caused by protein 
denaturation from the FCS. Hence the bioassays were terminated as accurate 
analyses were not possible and Cat K was not detectable.  
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Figure 4.15 Testing of Cat K bioassay. 96 well plates were coated with Col1 (10 µg/ml). Initially different primary [mouse monoclonal anti-
collagen type I] and secondary [anti-mouse IgG peroxidase conjugated] antibody concentrations were tested (A) to identify a gross dilution 
range. Clostridiopeptidase A was added at various concentrations to digest Col1 and primary antibody concentration (B) was further defined. A 
standard curve was generated with Clostridiopeptidase A (C). Further collagenase standards were tested on optimised protocol at pH 7.4 (D) 
and pH 5.5 (E). A two-way ANOVA of combined data (D and E, collagenase: p<0.0001, buffer: p=0.0416, interaction: p<0.0001) was 
performed.  
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Figure 4.16 Quantification of Cat K on bioassay. Buffer A and buffer B are shown as blank. Samples (n=3 supernatants per group from 1 
OCG assay per strain that were analysed in triplicates) were diluted 1:2.5 in buffer A (pH 7.4) and MMP-1 was applied as positive control at 500 
ng/ml (A). Samples were diluted 1:2.5 in buffer B (pH 5.5) and Cat K was applied as positive control at 500 ng/ml (B). One-way ANOVAs were 
performed for A (p<0.0001) and B (p<0.0001). Bonferroni post-tests are stated in the text.  
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4.3.7.3 Type I Collagen Zymography 
Zymography was utilised as an alternative method to identify functional Cat K and 
other potential collagenases according to their size (methodology in section 2.4.7.3). 
The SDS-PAGE gels were prepared with Col1 (0.2 mg/ml) as collagenase substrate. 
Once electrophoresis was performed, gels were incubated with zymography wash, 
refolding and digestion buffers to initiate collagen degradation (staining with 
Coomassie blue R leaves areas where collagen was digested as white bands). 
Zymograms incubated in wash and digestion buffer A (section 2.2., low pH) did not 
show any proteolytic activity (Fig. 4.17A). Instead dark bands were observed at 
115kDa, 94kDa and 70kDa. As Cat K is functionally active at low pH I concluded it 
was not detectable. 
When zymograms were treated with wash and digestion buffer B (neutral 
pH), bands of Col1 digestion emerged at the molecular weight (MW) of 115kDa, 
54kDa and 29kDa indicating MMP-9, MMP-2 and MMP-1 activity according to Chau 
et al. (Chau et al. 2005) (Fig. 4.17B).  No differences were observed between WT 
and CD59a-/- OCG samples. Additionally a white mark was visible at 70kDa in all 
samples which matched with a dark band in Fig. 4.18A. This is likely due to large 
amounts of bovine serum albumin (BSA) being present in the samples. BSA was 
pushing Col1 out of solution, therefore reducing the Coomassie blue stain at the 
70kDa in Fig. 4.17B. As proteases were visible at neutral pH succeeding 
experiments focused on their optimised detection. 
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Figure 4.17 Col1 zymography. 12% non-reducing SDS-PAGE gels containing Col1 (0.2mg/ml) were prepared. Ladder (L), medium (C), day 7 
OCG samples (n=1 OCG assay per strain) of WT 1:2 (1), 1:5 dilution (2) and CD59a-/- 1:5 dilution (3) were loaded. After electrophoresis gels 
were washed with either zymography wash buffer A (A) or zymography wash buffer B (B). Afterwards gels were incubated in zymography 
digestion buffer A (A) or zymography digestion buffer B (B) for 20 h. Gels were then stained with Coomassie blue R.  
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4.3.8 Quantification of MMP-9 
MMP-9 is an extracellular matrix degrading protease. Amongst other cells it is highly 
expressed by OCs. It is also produced as zymogen and released in a similar manner 
to Cat K from lysosomal compartments. MMP-9 digests denatured collagen, such as 
gelatin, at different binding sites to Cat K (Lecaille et al. 2008). Herein its secretion 
was investigated via gelatin zymography and ELISA. 
 
4.3.8.1 Gelatin Zymography  
MMP-9 can be readily detected by the established method of gelatin zymography 
(Kleiner and Stetlerstevenson 1994). SDS-PAGE gels were prepared containing 
gelatin (0.2 mg/ml) as substrate for MMP-9 digestion (section 2.4.7.4). WT, CD59a-/- 
and C6-/- supernatants, obtained from cultures grown in M-CSF and RANKL for 7 
days, were tested for proteolytic activity. 
In Fig. 4.18A, a human neutrophil control sample demonstrated protease 
activity at 120kDa and 94kDa as well as 70kDa. These bands were known to be 
MMP-9 bound to NGAL (125kDa), ProMMP-9 (92kDa) as well as Pro-MMP-2 
(72kDa) as described by Gupta et al (Gupta et al. 2007). OCG samples revealed a 
broad band around 115kDa followed by a thin band underneath. Murine ProMMP-9 
is a larger protein than its human equivalent with a MW of 105kDa (Zeng et al. 1999; 
Hahn-Dantona et al. 2001). Once activated MMP-9 retains a MW of 92kDa. In OCG 
supernatants MMP-9 was predominantly present in its zymogen conformation. 
Another band was identified around 70kDa corresponding to ProMMP-2 which has a 
similar MW to the human protein. It demonstrated that OC precursor cells and OCs 
produce proteases that are functionally active. Expression of ProMMP-9, MMP-9 
and ProMMP-2 was comparable between WT, CD59a-/- and C6-/- samples. 
To confirm the identity of MMP-9, a zymograph was prepared with different 
dilutions of supernatant (Fig. 4.18B). An identical gelatin containing gel was blotted 
with polyclonal anti-MMP-9 antibody (section 2.4.7.5). The Western Blot revealed 
antibody binding at 105kDa in WT and CD59a-/- samples at 1:5 dilution as well as in 
medium containing heat-inactivated FCS (Fig. 4.18C). Additional bands appeared at 
higher MWs, likely representing inactive MMP-9 bound to other proteins.  
 165 
 
Figure 4.18 Gelatin zymography. 7.5% non-reducing SDS-PAGE gels containing gelatine (0.2 mg/ml) were prepared. Ladder (L), medium 
(C), supernatant of human neutrophils (1) and OCG samples from day 7 were loaded at 1:5 dilution (1-9, 13) for WT (2,4,6), CD59a-/- (3,5,7) 
(n=3 OGC assays per strain) and C6-/- (8, n=1 OGC assays per strain) samples. Serial 1:5 dilutions of WT (9) and CD59a-/- (13) samples were 
loaded (10-12 and 14-16). After electrophoresis gels were washed in zymography wash buffer C and incubated in zymography digestion buffer 
C (A and B) or blotted to detect MMP-9 (C).    
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4.3.8.2 ProMMP-9 ELISA  
In order to determine specific ProMMP-9 concentrations in OCG supernatants an in-
house ELISA was developed. Different buffers and incubation times were examined 
to obtain maximal specificity, while reducing background signal. The optimised 
protocol can be found in section 2.4.7.6. ProMMP-9 was detectable in samples 
cultured in M-CSF at day 3; concentrations averaged between 6 and 10 ng/ml 
ProMMP-9. The level of ProMMP-9 diminished below detection limit of the assay by 
day 5 and 7 (data not shown).  
Samples grown in M-CSF and RANKL demonstrated comparable ProMMP-9 
concentration in females (WT=24.8±4.6 ng/ml, CD59a-/-=33.0±5.9 ng/ml, C6-/-
=43.4±9.3 ng/ml) and males (WT=35.8±9.5 ng/ml, CD59a-/-=50.9±18.9 ng/ml, C6-/-
=26.8±5.1 ng/ml) on day 3 (Fig. 4.19A and B). By day 5 ProMMP-9 level increased, 
but this observation was not statistically significant as the variability between 
samples was high. On day 5, ProMMP-9 level was similar between WT, CD59a-/- 
and C6-/- in females and males (Fig. 4.19C and D). ProMMP-9 level remained 
constant between day 5 and day 7. On day 7 ProMMP-9 concentration in female 
samples; WT, CD59a-/- and C6-/- were not significantly different (Fig. 3.19E). 
Similarly, in males all data was comparable in WT, CD59a-/- and C6-/- samples. No 
correlation was identified between ProMMP-9 expression and OC or total cell 
number. 
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Figure 4.19 ProMMP-9 ELISA. ProMMP-9 concentrations were measured via 
ELISA and results for samples grown in M-CSF and RANKL are illustrated (n=5-7 
OCG assays per strain of which 3 supernatants were analysed in duplicates). 
Concentrations were measured at day 3 (A and B), day 5 (C and D) and day 7 (E 
and F) for female (A, C, E) and male (B, D, F) WT (●), CD59a-/- (□) and C6-/- (♦) 
samples (n=5-7 mice per group). One-way ANOVAs were performed for A 
(p=0.1937), B (p=0.4265), C (p=0.3557), D (p=0.4119), E (p=0.5256) and F 
(p=0.5350). 
 
4.3.9 Quantification of Cytokines/Chemokines 
OC precursor cells rely heavily on cytokine and chemokine stimulation for 
differentiation and activity of OCs. RANKL is the most important cytokine and can be 
induced by various pro-inflammatory cytokines such as IL-1β, TNFα, IL-6. These 
cytokines support OCG via additional mechanisms; IL-1, for example, has been 
shown to enhance OC precursor cell interactions with bone matrix whereas TNFα 
stimulates pre-OCs to express c-Fms (Lorenzo et al. 2010). Chemokines, such as 
macrophage inflammatory protein-1α (MIP-1α) and IL8/mKc, also favour resorption 
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by inducing OC migration via chemotaxis (Fuller et al. 1995). Cytokines inhibiting 
OCG (IL-10, IL-12 and IFNγ) were found to prevent NFATc1 expression and nuclear 
translocation (Lorenzo et al. 2010). Many of these interactions have been shown to 
be aberrantly regulated leading to increased OCG in bone disease; these 
cytokines/chemokines were investigated here to uncover the mechanism of CD59a’s 
involvement in OC up-regulation.  
 
4.3.9.1 Murine Pro-Inflammatory Multiplex Assay 
The multiplex assay, measuring IFNγ, IL-10, IL-12 p70, IL-1β, IL-6, mKc and TNFα 
in male WT and CD59a-/- samples at day 7, was utilised as described in section 
2.4.7.7. The largest differences between WT and CD59a-/- samples were observed 
for IL-10 and mKc (Fig. 4.20). In cultures grown in M-CSF, IL-10 was 63.0pg/ml in 
WT samples which was slightly decreased to 35.8 pg/ml in CD59a-/- samples. IL-10 
level was significantly reduced (p<0.001) to 17.5 pg/ml in WT and slightly diminished 
to 15.6 pg/ml in CD59a-/- samples when RANKL was added. No significant difference 
was observed between WT and CD59a-/- samples. mKc level was raised 
significantly (p<0.05) in CD59a-/- (47.9 pg/ml) over WT (9.9 pg/ml) samples when 
supplemented with M-CSF. In cultures grown in M-CSF and RANKL mKc level was 
slightly reduced to 4.7 pg/ml in WT and significantly reduced to 20.7 pg/ml in CD59a-
/- samples over cultures grown in M-CSF. Hence a 4.5 fold difference was present in 
mKc level between WT and CD59-/- in absence and presence of RANKL in medium. 
Other cytokines (IL-12 p70, IL-6, TNFα, IFNγ and IL-1β) did not show 
significantly different levels between CD59a-/- and WT samples. This data suggest 
that mKc is the most important target to investigate further as it was found to be up-
regulated in CD59a-/- when compared to WT samples. 
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Figure 4.20 Pro-inflammatory multiplex assay. Mesoscale Multiplex assay kit for 
murine pro-inflammatory mediators was performed by Dr Bronwen Evans. Cytokine 
(IL-10, mKc, IL-12 p70, IL-6, TNFα, IFNγ and IL-1β) concentrations were determined 
in WT and CD59a-/- OCG supernatants grown in M-CSF and M-CSF plus RANKL on 
day 7 (n=1 OCG assay per strain of which 1-3 supernatants were analysed per 
sample in duplicates). A two-way ANOVA (condition: p=0.0368, cytokine: p<0.0001, 
interaction: p=0.0051) and Bonferroni post-tests were performed (see in text).  
 
4.3.9.2 Quantification of mKc 
To evaluate mKc concentration in all OCG supernatants, ELISAs were performed 
according to section 2.4.7.7. On day 3 baseline level of mKc was 6.3±1.4 pg/ml in 
female WT samples cultured in M-CSF alone (Fig.  4.21A). mKc level in CD59a-/- 
(7.0±1.1 pg/ml) and C6-/- (6.3±1.4 pg/ml) were significantly higher (p<0.05) than in 
WT samples. A similar trend was noted in males (Fig. 4.21B). This pattern continued 
on day 5 for both genders (Fig. 4.21C and D). By day 7 mKc level in female CD59a-/- 
(42.7±3.6 pg/ml (p<0.001)) samples was significantly increased over WT (10.2±2.6 
pg/ml) (Fig. 4.21E). mKc level in C6-/- samples (26.5±6.6) was not significantly 
different from WT or CD59a-/- samples. In males mKc level of WT samples was 
significantly lower in comparison to CD59a-/- (p<0.01) and C6-/- samples (p<0.01) 
(Fig. 4.21F). Here, levels of CD59a-/- and C6-/- were comparable.  
Upon the addition of RANKL to the medium the same pattern emerges for 
female WT, CD59a-/- and C6-/- samples on day 3 (Fig. 4.22A and B). By day 5 mKc 
level was comparable between WT (3.8±1.0 pg/ml), CD59a-/- (10.4±1.9 pg/ml) and 
C6-/- (11.6±3.7 pg/ml) samples (Fig. 4.22C). In contrast to day 5, mKc level in 
CD59a-/- was significantly increased (p<0.01) over WT samples on day 7 (Fig. 
4.22E), C6-/- level was not different from WT and CD59a-/- samples. In males a 
constant pattern was observed. mKc levels in CD59a-/-  and C6-/-  were significantly 
raised over WT samples on day 3, 5 and 7 (Fig. 4.22B, D and F). 
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mKc (expressed by monocyte/macrophages) levels were normalised for total 
cell number to account for different proliferation rates. Interestingly, datasets differed 
upon this normalisation. In females, mKc level were not significantly different in WT, 
CD59a-/- and C6-/- samples on day 3 (WT=0.4±0.1, CD59a-/-=1.2±0.1, C6-/-= C6-/-
=1.0±0.4 pg/ml/1000 cells) and 5 (Fig. 4.23A and C). mKc level in CD59a-/- was 
significantly (p<0.01) enhanced over WT samples on day 7 only. In males, mKc 
level of C6-/- was significantly raised compared to WT on day 3 (C6-/-=1.6±0.3, 
WT=0.6±0.2 pg/ml/1000 cells), 5 and 7 (Fig. 4.23B, D and F). Additionally, mKc 
level of CD59a-/- was significantly different compared to WT (p<0.05) and C6-/- 
(p<0.05) samples on day 5. 
 
Figure 4.21 mKc ELISA of samples cultured in medium supplemented with M-
CSF only. Concentrations were measured at day 3 (A and B), day 5 (C and D) and 
day 7 (E and F) for female (A, C, E) and male (B, D, F) WT (●), CD59a-/- (□) and C6-
/- (♦) samples (n=5-7 OCG assays per strain of which 3 supernatants were analysed 
in duplicates). One-way ANOVAs were performed for A (p=0.0123) B (p=0.0002), C 
(p=0.0041), D (p<0.0001), E (p=0.0007) and F (p=0.0011) and Bonferroni post-tests 
are indicated (*(p<0.05), **(p<0.01), ***(p<0.001)). 
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Figure 4.22 mKc ELISA of samples cultured in medium supplemented with M-
CSF and RANKL. Concentrations were measured at day 3 (A and B), day 5 (C and 
D) and day 7 (E and F) for female (A, C, E) and male (B, D, F) WT (●), CD59a-/- (□) 
and C6-/- (♦) samples (n=5-7 OCG assays per strain of which 3 supernatants were 
analysed in duplicates). One-way ANOVAs were performed for A (p=0.0143) B 
(p=0.0003), C (p=0.1028), D (p<0.0001), E (p=0.0057) and F (p=0.0038) and 
Bonferroni post-tests are indicated (*(p<0.05), **(p<0.01), ***(p<0.001)). 
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Figure 4.23 mKc ELISA of samples cultured in medium supplemented with M-
CSF plus RANKL and normalised for total cell number. Concentrations were 
measured at day 3 (A and B), day 5 (C and D) and day 7 (E and F) for female (A, C, 
E) and male (B, D, F) WT (●), CD59a-/- (□) and C6-/- (♦) samples (n=5-7 OCG 
assays per strain of which 3 supernatants were analysed in duplicates). One-way 
ANOVAs were performed for A (p=0.0779) B (p=0.0183), C (p=0.0584), D 
(p<0.0002), E (p=0.0030) and F (p=0.0117) and Bonferroni post-tests are indicated 
(**(p<0.01), **(p<0.01),  ***(p<0.001)). 
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4.4  Discussion 
The development of a reliable OCG assay was essential in order to monitor cell 
differentiation from the stage of bone marrow precursor through to mature OC. This 
chapter provides a chronological description of the procedures employed to 
characterise and validate this OCG assay.  Later in the chapter, the assay was 
adopted to study the impact of MAC and CD59a upon osteoclast function in vitro.  
 
4.4.1  Morphological Assessment of Bone Marrow Preparations on Day 0 
In the first instance differential cell counts were performed on WT bone marrow cell 
isolates; these were compared against cell data obtained from CD59a-/- and C6-/- 
mice. Surprisingly, phenotypic analysis of the starting bone marrow cell population is 
not routinely reported in the literature for OCG assays. A small number of studies 
applied a differential stain either to further define OC precursor cells (Arai et al. 
1999) or identify OCs in starting cell populations (Ariffin et al. 2010). The nature of 
the bone marrow cell population at baseline was considered to be important for 
accurately delineating gene-dependent osteoclast responses in this study. 
Realistically, differences in the proportion of each individual cell type on day 0 
(baseline) could affect the number and function of the osteoclasts generated in each 
assay at endpoint.  
Consequently cell populations were positively selected according to their 
frequency. These were monocytes (OC precursor cells), lymphocytes (producer of 
RANKL) (Rodan and Martin 2000), erythrocytes and megakaryocytes (secrete OPG) 
(Kacena et al. 2006) whereas MSCs, stromal cells and granulocytes were grouped 
as other due to their low numbers. In the literature different monocytic cell 
populations determined as OC precursors were quantified after cell sorting as total 
of 0.2 to 1.99% of bone marrow mononuclear cells (Arai et al. 1999). Many studies 
do not quantify monocytes specifically.  Craft et al. studied female dogs and found 
that 3.8% of bone marrow cells were premyelocytes and 4.7% were 
haemocytoblasts (Crafts 1948). However, when examining adherent human blood 
mononuclear cells, Takahashi et al. identified more than 95% as monocytes after 
incubation on plastic overnight (Takahashi et al. 1995). Therefore the concentration 
of monocytes and their precursor cells can vary. In my hands, about 40% of 
adherent cells isolated on glass constituted monocytes.  
 When comparing adhered cell populations, WT and CD59a-/- samples 
presented a similar pattern. This suggests that differences identified at a later stage 
did not result from variations in adherence ability so expression of molecules such 
as N-cadherin, β-catenin and VCAM which are important for the HSC homing and 
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OC precursor recruitment are likely to be regulated normally (Shin et al. 2005; Yin 
and Li 2006). Interestingly, when examining male CD59a-/- to C6-/- bone marrow 
cells a significant increase in monocyte numbers was observed in C6-/- samples. 
This suggested that more monocytes were present in the bone marrow or had 
adhered more readily. In the literature, the effects of MAC components on bone 
marrow monocytes had not been investigated. Kim et al. revealed that in bone 
marrow transplantation, deficiency in C5 resulted in impaired HSC engraftment 
probably because of less signalling through CR3 and CXCL12/stromal derived 
factor-1 (SDF-1) secretion (Kim et al. 2011). This demonstrated that complement 
and haematopoiesis are closely linked and a down-regulation of monocyte 
differentiation by background levels of MAC activation might be a possible 
mechanism.  
 
4.4.2 Optimisation of OCG Assay 
After bone marrow cell adherence, cells were cultured in M-CSF supplemented with 
and without RANKL; only cultures containing both mediators generated OCs. 
According to the literature, M-CSF stimulation is initially required to induce RANK 
expression and then provides for additional proliferation, differentiation and survival 
signals. RANKL is essential to induce OC generation and also guarantees 
resorption activity (Rosen 2008) as described in section 1.4.3.1.  
There are ways of growing OCs using alternative supplementation without 
the addition of RANKL or M-CSF. When no recombinant M-CSF was added 
differentiation was supported by Flt3-ligand, IL-3, GM-CSF, VEGF or other growth 
factors (Galal et al. 2007; Karieb and Fox 2011; Kawamoto et al. 2011) whereas a 
lack of external recombinant RANKL was substituted by light stimulation, TNFα, IL-6 
or other cytokines. OCs grown through these alternative routes have less nuclei and 
hence resorb bone less efficiently (Filgueira 2009; Knowles and Athanasou 2009) 
than with M-CSF and RANKL supplementation. 
In addition to mediator supplementation, cell seeding concentrations were 
tested and 3x105 cells/well resulted in an increased yield of OCG over 5x105 
cells/well.  Ishida et al. identified that cells plated sparsely were not in optimal 
proximity to merge and therefore differentiation time was elongated; whereas cells 
that were plated too densely had a reduced ability for full differentiation (Ishida et al. 
2002). Therefore this research confirms that initial cell density is crucial for 
successful generation of OCs. 
OCs were plated onto glass coverslips in this study. In the literature OCs are 
commonly cultured directly onto tissue culture plates (Idris et al. 2010). Visualisation 
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of OCs by microscopy was challenging in the laboratory when the cells were 
adhered directly to plastic plates (data not reported). Glass coverslips have also 
been used extensively in the literature (Komarova et al. 2003; Calle et al. 2004) as 
myeloid cells have been reported to adhere to glass (Trinchieri et al. 1986). They 
provide an excellent support that enables cells to be observed microscopically at 
high magnification as illustrated by Chen et al. (Chen et al. 2008).  
When culturing bone marrow cells on 13 mm glass coverslips, cells formed 
distinct colonies which left a large area of the coverslip untouched.  Macrophages 
stimulated with M-CSF have been shown to form colonies in vitro (Hamilton 2008). 
Additionally, OCs grown sparsely on surfaces develop into colonies as illustrated by 
Barsony et al (Barsony et al. 2011). In order to achieve even distribution, the 
coverslip size was reduced to 6 mm giving cells less surface area for more contact 
between colonies. 
On 6 mm glass coverslips, the differentiation was still a challenge. Initially 
bone marrow cells were plated in a volume of 100 µl as recommended by Flanagan 
and Massey (Flanagan and Massey 2003) . As known from the literature, monocytes 
readily adhere to plastic and are also able to migrate (Czepluch et al. 2007). 
Therefore adherence in 100 µl resulted in adherence to plastic as well as the glass 
coverslip. Cell migration of the glass coverslip towards the plastic might have been 
caused by cytokines produced in monocytes that induced chemotactic gradients 
(Gein et al. 2011). In order to increase the yield, cells were adhered for a short 
period of time to the glass coverslip in a minimal volume (10 µl). To selectively 
enrich myeloid cells, the cells were only in contact with the glass coverslip during 
adherence which might have reduced migration and finally resulted in increased OC 
density. 
In order to track OC development, coverslips were stained with TRAP on day 
3, 5 and 7. It revealed that cells grown in M-CSF were TRAP- throughout the assay 
and proliferated exponentially. Cells cultured in M-CSF and RANKL proliferated less 
readily, but became TRAP+ and large OCs started to appear by day 5. Biskobing et 
al monitored the effect of M-CSF induced proliferation on OCs. For this cells were 
treated with anti-M-CSF antibody from day 3 to 7 of OCG. The authors identified that 
M-CSF stimulation is most effective on day 3 of a 7 day culture and RANKL induced 
cell fusion is more dominant from day 4 onwards (Biskobing et al. 1995), reducing 
further proliferation.  Furthermore, Chen et al. confirmed that when analysing 
differentiation over time, mature OCs appeared on day 5 (Chen et al. 2008). 
Therefore my data is consistent with published research. 
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When quantifying OCs, the percentage of TRAP+ multinucleated cells was 
reported in this thesis. The manner in which OC differentiation data is presented 
varies tremendously between research groups. OC data is commonly presented as 
the absolute number of TRAP+ multinucleated cells in a particular culture condition 
(Chen et al. 2008; Kukita et al. 2011).  Variations in total cell number can also 
influence the capacity of cells to differentiate into OCs, therefore OC numbers were 
normalised according to total cell counts. This format has already been published by 
our group (Bull et al. 2008). 
 
4.4.3 Measuring CD59a Expression during OCG 
After optimisation of the OCG assay, CD59a expression was investigated over the 
time course utilising qPCR. CD59a was identified in adhered bone marrow cultures 
on day 0 (Fig. 4.8A). Within the next 24 h expression levels of CD59a decreased in 
samples stimulated with M-CSF alone or M-CSF and RANKL (Fig. 4.8B). 
Additionally, by day 1 the cell density was reduced as only cells reacting to the 
stimulation with M-CSF survived (Takahashi et al. 2003). This indicates that CD59 
expression levels on OC precursor cells, probably mixed with HSCs, was low and 
other cell types within the bone marrow population were the primary source of 
synthesis. Davies et al. identified CD59 expression using immunofluorescence from 
human blood cells (Davies et al. 1989). The authors revealed strong staining of 
lymphocytes and granulocytes whereas erythrocytes and platelets showed weak 
staining, but monocyte expression was not revealed. In mice, only total bone 
marrow expression of CD59a had been evaluated by Baalasubramanian et al. 
(Baalasubramanian et al. 2004). My data showed that lymphocytes adhered to 
coverslips (section 4.3.1) and presented 8-10% of the differential cell counts. Hence, 
if lymphocytes also have a strong expression profile in mice, they could have 
caused the expression levels seen on day 0.  
Transcription levels started to recover on day 3 and further increased by day 
5 in cultures grown in M-CSF plus RANKL and M-CSF alone. Takahashi et al. 
identified an M-CSF-dependent bone marrow macrophage phenotype after 3 days 
of M-CSF stimulation (100 ng/ml). The phenotype was acquired by most cells 
expressing macrophage specific antigens such as F4/80 (Takahashi et al. 2003). As 
M-CSF concentration in OCG assays was lower, the macrophage phenotype might 
have required 5 days to develop. Therefore qPCR data suggests that differentiation 
into macrophages could account for increased expression of CD59a.  
On day 7 expression of CD59a was comparable to day 5. As OC assays 
produced a mixture of precursor cells and OCs, it implies that OCs did not up-
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regulate CD59a expression. Expression levels were not different between M-CSF 
and M-CSF plus RANKL stimulated cultures, but as OCs result from merging 
precursor cells which express CD59a, it is likely that OCs express low levels of 
CD59a. This is supported by a recent study which demonstrated weak human CD59 
expression using immunofluorescent staining on human OCs (Ignatius et al. 2011). 
 
4.4.4  Quantification of OCG from WT, CD59a-/- and C6-/- Bone 
 Marrow Preparations  
When quantifying OC differentiation over time, male CD59a-/- samples showed 
significantly increased OCG over WT and C6-/- samples at day 7. This supported the 
findings of preliminary in vivo data by Dr Anwen Williams in which increased TRAP+ 
staining was observed in the epiphysis of femur and tibia at the knee joint in aging 
CD59a-/- mice. Additionally it was in agreement with findings of a human study in 
which CD59 and DAF deficiency was correlated to increased bone resorption 
markers found in plasma samples (Terpos et al. 2003). Taken together, it suggests 
that CD59a might down-regulate OCG directly via an unknown mechanism.  
Increased OCG was not seen in female CD59a-/- mice. This gender specific 
effect is not restricted to OCs. PNH phenotype in CD59a-/- mice was also exclusively 
present in male mice which was caused by higher haemolytic complement activity 
as explained in section 1.3.3 (Holt et al. 2001). Many complement studies are 
performed in male mice as additional factors have been shown to be involved in 
gender specific effects (Bora et al. 2007; Mamane et al. 2009; Lewis et al. 2011).  
Baba et al., for example, identified a C5 dimorphism in male mice which were 
functionally identical, but the additional protein was controlled by testosterone (Baba 
et al. 1984). Furthermore sex-limited protein, a homologue of C4 with partial C4a 
functions, was also identified to be specific to males (DIJK 1999). Moreover, 
hormonal fluctuations were thought to be involved in gender specific effects of 
CD59a regulation in the brain during focal cerebral ischemia. In that study, 
progesterone was mentioned to exhibit protective effects in females (Harhausen et 
al. 2010). Another sex hormone, oestrogen had been found to influence the 
complement pathway in numerous ways. C3 expression was shown to be altered at 
the transcriptional level by oestrogen (Fan et al. 1996) and C5a-mediated calcium 
influx in neurones is modulated by estradiol (Farkas et al. 2012). Interestingly 
oestrogen was found to increase susceptibility of female mice to CIA by enhancing 
CR1 expression on B-cells and therefore linking the complement system to the 
hormonal response (Nilsson et al. 2009). Furthermore, bone diseases present 
different gender prevalence. Osteoporosis for example, results in fractures in 1:2 
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women and 1:5 men over the age of 50 years. Post-menopausal women are 
especially affected as oestrogen levels diminish dramatically (Rosen 2008). A large 
variety of studies have investigated the role of oestrogen in bone health and disease 
(Hughes et al. 1996; Bilezikian et al. 1998; Schiessl et al. 1998; Bone et al. 2000). 
Oestrogen acts directly on bone cells to favour OB formation over OCG as 
described in Tab. 1.10. Here it seems that the effect of sex hormones is stronger 
than the effect of CD59a, therefore sex hormones are likely to cause protection from 
increased OCG in female mice. 
Finally, C6-/- had been included in the study to enable distinguishing between 
complement dependent or independent function. As initial cell populations from C6-/- 
behaved differently from CD59a-/- cultures a direct comparison was not possible and 
this should be investigated via an alternative method. 
 
4.4.5 Quantification of Cathepsin K 
Cat K is the major protease, produced by OCs, which degrades the organic 
component of the bone matrix (Corisdeo et al. 2001). In order to identify if OCs 
generated in vitro are functionally active, Cat K expression was investigated in OC 
assay supernatants. 
A human Cat K ELISA kit was initially tested. Supernatants did not reveal 
Cat K levels above background readings of the medium. In a rat study by Wada et 
al., plasma Cat K levels of 2.5 to 10 pmol/l were quantified utilising the same kit. 
This illustrates the sensitivity of the assay (Wada et al. 2005). Sequence 
composition showed 85% amino acid identity between the human and mouse Cat K 
protein (Gelb et al. 1996). However, it is possible that the mouse isoform is not 
recognised by the antibodies raised against human Cat K.  
Consequently, a bioassay was developed to evaluate Cat K activity. The 
bioassay had a limited sensitivity in the low ng/ml range for collagenase utilised. 
Many assays and ELISA kits commercially available can detect proteins in the 
picogram range. Zee et al., for example, developed a bioassay that allowed for 
sensitive collagenase activity detection. Radiolabelled [C14] collagen was added to 
culture supernatants and left for digestion. Collagen that was not digested was 
centrifuged and radioactivity left in the supernatant was measured (Zee et al. 1998). 
My bioassay was unsuitable for measuring small quantities of Cat K and alternative 
techniques were considered. 
A collagen type I zymography was set up to identify Cat K activity at low pH, 
but no proteolytic activity was revealed. Recently, Li et al. optimised a zymography 
methodology to quantify Cat K. Instead of using supernatants, cells were lysed and 
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protein extraction was concentrated before being subjected to zymography (Li et al. 
2010). This suggests the possibility that small amounts of Cat K could be present 
within OCs which would not have been detected by my method.  
In my bioassay and Col1 zymography collagenase activity was not identified 
at low pH. Cathepsin K is mainly present in its proform, but once activated by low pH 
is susceptible to denaturation which might have caused problems during my assays 
(Zhao et al. 2009).  
Furthermore, bioassay and zymography were inhibited by FCS components 
at low pH. Kitami et al. cultured all OCG assays in serum free medium for the last 24 
h to avoid interference (Kitami et al. 2010). This would have been a possibility to 
enhance signals of collagenase activity in this project. 
Both methods confirmed collagenase activity at pH7.4 and MMP-1 was 
identified. MMP-1 is produced by OCs to initiate collagen degradation before the 
resorption pit has been established (Derenne et al. 1999), but it is not specific to this 
cell type (Kähäri and Saarialho-Kere 1997) and might have been secreted by 
monocytes/macrophages or stromal cells (Riikonen et al. 1995) that might have 
been present in the culture system. 
After identifying that none of the methods were suitable to detect Cat K in 
OCG supernatants, there is a strong possibility that Cat K was not expressed in OCs 
on glass coverslips. Corisdeo et al. revealed that Cat K is only secreted by actively 
resorbing OCs. Therefore, it is likely that the absence of bone matrix was 
responsible for the lack of Cat K. The same study suggested that OPG is required to 
stimulate Cat K expression and as cultures in this study did not favour OBs, the 
microenvironment for resorption was not given (Corisdeo et al. 2001).  
Furthermore, Wilson et al. showed that Cat K is essential for the initiation of 
resorption by uncovering Arginine-Glycine-Aspartic acid motifs for VNR to attach to 
(Wilson et al. 2009). RANKL induces Cat K expression in the early stages of 
resorption. The enzyme is then stored in lysosomal vesicles and should be released 
into the resorption pit (Zhao et al. 2009), again suggesting that the bone surface is 
required to induce Cat K.   
In contrast to this, a study by Fuller et al. proved that a bone environment is 
not essential for resorption. In this study OC were grown in serum free medium and 
activity was tested on glass coverslips coated with vitronectin. Sole binding of the 
VNR induced a sealing zone and resorption like trail formation. When fibronectin 
coating was used instead of vitronectin, OC activity was not observed suggesting 
that VNR attachment to a substrate is required (Fuller et al. 2010). As VNR was not 
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used in my study, OCs did not anchor to the surface and therefore might not have 
received the correct signals to express or secrete Cat K. 
A single paper described Cat K detection in culture supernatant by western 
blotting when growing Raw 264.7 on plastic  (Kitami et al. 2010). This lack of studies 
looking at secreted protein suggests that Cat K release requires a trigger whether it 
is the bone surface or VNR.  
 
4.4.6 Quantification of MMP-9 
MMP-9 is another protease highly expressed by OCs (Ishibashi et al. 2006). After 
identification of MMP activity in Cathepsin K studies, the activity of MMPs was 
further investigated. A large band of ProMMP-9 as well as smaller bands of active 
MMP-9 and Pro-MMP-2 were identified by gelatin zymography. The literature 
confirms that multiple MMPs, such as MMP-2, -3, -7, -9, -10, 12 and -13, are 
expressed by OCs and MMP-9 is produced in the largest quantity (Ishibashi et al. 
2006; Lynch 2011). Hence zymography proved that proteases are secreted by OCs 
and their precursor cells.  
When comparing gelatin zymography results to zymography studies of other 
OCG assays, rat samples confirmed the presence of ProMMP-9 and ProMMP-2 
(Oka et al. 2012). OC differentiation of Raw 264.7 cells and murine bone marrow 
precursor cells cultured on plastic produced a band for active MMP-9 at 92kDa, but 
no ProMMP-9 or MMP-2 (Sundaram et al. 2007; Franco et al. 2011; Ghayor et al. 
2011). Interestingly, Samanna et al. reported Pro-MMP-9, active MMP-9 and MMP-
14 secretion in WT OCG samples (Samanna et al. 2007). These findings revealed 
that the type of culture conditions and precursor cells used alters the MMP profile 
visible on gelatin zymography.  
The high level of ProMMP-9 identified in my study suggested that ProMMP-9 
activation is not triggered efficiently in the culture system in this study. ProMMP-9 is 
activated by MMP-1,-2, -3 and -7. MMP-2 in turn is activated by MMP-14 and 
plasmin (Baramova et al. 1997). Therefore, inactivity may result from a missing 
activation cascade. 
Western blotting was utilised to confirm identity of MMP-9 on zymographs. 
Interestingly, the anti-MMP9 antibody did not only bind active MMP-9 and ProMMP-
9, but it was identified in an inactive conformation in medium containing FCS. 
Clinical studies in humans have shown that serum from healthy participants 
contained 200 to 600µg/ml MMP-9 (Jung et al. 2001). Therefore it is likely high 
concentrations of ProMMP-9 were also present in FCS, but as these are inactive, 
they did not interfere with the detection of mouse ProMMP-9.   
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MMP-9 was also identified at higher MW in WT and CD59a-/- samples at 1:5 
dilution. Tissue inhibitors of metalloproteases (TIMPs) have a molecular weight of 21 
to 29kDa and are produced by MMP secreting cells to balance MMP activity. They 
can bind a wide range of MMPs (Reynolds 1996; Visse and Nagase 2003). As 
zymography is performed without reducing disulphide bonds, proteins bound 
together due to disulfide exchange can be identified at their combined MW. As 
TIMPs have a low MW it is likely that the additional bands identified are MMP-9 - 
TIMP complexes. 
As ProMMP-9 was the major protease identified, concentrations were 
measured via ELISA. Cells stimulated with M-CSF alone, produced 6-10ng/ml 
ProMMP-9 on day 3 and levels diminished. Xie et al. identified that peripheral blood 
monocytes that did not receive any stimulation produced little ProMMP-9 whereas 
stimulation with M-CSF resulted in a 5 to 7-fold increase. ProMMP-9 levels were 
thought to be supporting cell adhesion, spreading and macrophage differentiation 
(Xie et al. 1998). Therefore if macrophage phenotype was reached by day 5 in 
cultures in this study as discussed in section 4.4.2, MMP-9 stimulation may have not 
been required anymore and therefore could have returned to basal levels.  
Supplementation of cultures with RANKL resulted in a 5 fold increase in 
ProMMP-9 on day 3 which slightly increased by day 5 and then remained constant. 
The literature confirms that in OC precursor cells RANKL stimulation leads to MMP-
9 up-regulation which in turn drives differentiation (Sundaram et al. 2007). Franco et 
al revealed that when inhibiting MMP-9 with doxycycline, cells were not able to 
express TRAP or Cat K (Franco et al. 2011).  Additionally, Ishibashi  et al. had 
discovered that MMP-9 is essential for pit formation, made possible by allowing OCs 
to migrate though matrixes containing proteoglycans (Ishibashi et al. 2006). This 
suggested that ProMMP-9 secretion in cultures of this study was likely related to 
OCG.  
ProMMP-9 levels were comparable between WT, CD59a-/- and C6-/- 
suggesting that its concentration is not related to OCs specifically. Other markers of 
OCs, such as CTR, should be explored. This marker is also shared by macrophage 
precursor cells and OCs (Granholm et al. 2008). Therefore subtle differences 
between WT and CD59a-/- OC expression pattern might not be readily detectable. 
 
4.4.7 Quantification of Cytokines/Chemokines 
Cytokine screening revealed mKc up-regulation in CD59a-/- over WT samples in 
cultures containing M-CSF and RANKL (Fig. 4.20). mKc is the murine ortholog of 
human Groα and IL-8, and it signals through CXCR2 (Hol et al. 2010). mKc was 
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identified as one of the two major neutrophil chemoattractants expressed by resident 
tissue macrophages (De Filippo et al. 2008). Onan et al. identified mKc up-
regulation in OB lineage cells after PTH or PTHrP stimulation. OB utilised mKc to 
attract OC precursor cells which possess CXCR2. It was demonstrated that CXCR2 
knockout mice presented an underdeveloped phenotype with fragile jaw bones 
supporting the finding that mKc signalling might be involved in bone development. 
Therefore mKc was thought to play a role in OCG in this study.  
When mKc levels were compared in WT, CD59a-/- and C6-/- samples utilising 
ELISAs, levels in CD59a-/- and C6-/- samples were significantly enhanced over WT 
samples, but when normalised to cell number the difference between WT and 
CD59a-/- samples in male samples disappeared on day 3 and 7. Onan et al. 
supplemented OCG assays with mKc and did not discover a difference in OC 
formation or function (Onan et al. 2009). This suggests that enhanced mKc 
expression was solely due to proliferation and not contributing to OCG. Proliferation 
rates should be investigated further to understand the function of CD59a in OCG. 
More recently it has been shown that mKc is expressed by megakaryocytes 
in the bone marrow to induce neutrophil mobilisation into the blood stream (Köhler et 
al. 2011). As megakaryocytes were elevated in male CD59a-/- over C6-/- mice, mKc 
secretion by megakaryocytes might have stimulated bone marrow precursor cells, 
but this has not been investigated yet. Megakaryocytes and OC precursor cells 
originated from the common myeloid progenitor (Akashi et al. 2000) and it should be 
examined if numbers of these progenitors are up-regulated which could result in 
enhanced differentiation and maybe take forward the search for a mechanism of 
increased OCG in CD59a-/- mice. 
In order to take forward this search, other chemokines should be analysed. 
CXCL12/SDF-1 has been shown to recruit OC precursor cells as well as support OC 
formation and activity. Moreover, MIP-γ is the main chemokine of OCs. It is up-
regulated by RANKL directly and also responds to M-CSF in order to enhance OC 
formation. Finally, CCL2/monocyte chemotactic protein 1 (MCP-1) and CCL3/MIP-α 
are involved in precursor recruitment and OCG (Onan et al. 2009). Additionally, 
receptor expression on OCs, such as RANK, might be affected. Any of these might 
be a potential target of CD59a and should be investigated. 
 
4.5 Conclusion 
In summary, in vitro assessment of CD59a on OCG resulted in the following 
findings: 
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 An OCG assay was successfully developed with optimal yield of TRAP+ 
multinucleated cells.  
 Initial plating showed no difference in CD59a-/- and C6-/- in comparison to 
WT. However, male CD59a-/- samples showed increased formation of OCs 
after 7 days of culture.  
 Mediator analysis (Cat K, ProMMP-9, mKc) did not reveal a mechanism for 
increased OCG in male CD59a-/- samples. 
The main finding of significantly raised OCG in CD59a-/- in comparison to WT 
samples highlighted a role of CD59a in bone homeostasis and the investigation of 
CD59’s effect in human OCG was performed subsequentially. 
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Chapter 5 
 
 
Investigating the Role 
of Human CD59 in Bone 
Resorption 
 
  
 185 
 
5.1 Introduction 
The up-regulation of OCG in CD59a-/- mice revealed in chapter 4 provides a 
potential mechanism not only for increased bone pathology identified in murine 
inflammatory arthritis models, but also in human diseases. CD59 down-regulation 
has been shown in diseases with bone pathology, such as RA and PsA, as 
described in Tab.1.6. Additionally, a study in multiple myeloma patients revealed a 
correlation of CD59 and DAF deficiency with elevation of OC resorption (Terpos et 
al. 2003). In this chapter, the functional significance of the effect of CD59 on bone in 
humans was investigated, as this has not been addressed in previous studies. 
 
5.2 Aim and Objectives 
The aim of this chapter was to determine the effect of CD59 depletion on OCG in 
humans. In order to achieve this aim, three specific objectives were formulated, 
namely: - 
1. To establish a human OC resorption assay from peripheral blood CD14+ 
monocytes from healthy donors. 
2. To develop a stable knockdown system for CD59 in human CD14+ 
monocytes/macrophages. 
3. To determine the effect of CD59 on human OCG and resorption from 
peripheral blood CD14+ monocytes from healthy donors. 
 
5.3  Results 
A resorption assay was set up to confirm CD59 induced down-regulation of OCG in 
humans. Peripheral blood CD14+ monocytes were used in these assays, as they are 
known to express CD59. To establish the efficacy of CD59 knockdown using 
shRNA, several specific issues needed to be addressed. Firstly, to achieve CD59 
knockdown a suitable delivering system for the shRNA had to be tested. The next 
step was to identify the most effective shRNA sequence for the silencing of CD59. In 
addition the kinetics of achieving maximal knockdown of CD59 protein after infection 
were investigated. Finally, the viability of CD14+ monocytes after viral infection was 
examined. Data collected during these experiments are described below. 
 
5.3.1 Establishment of a Resorption Assay for Human Cells 
To reveal the involvement of CD59 in human OCG and OC function, a resorption 
assay was set up. Human CD14+ monocytes (6.4x104 per ivory disc) were left to 
adhere to 6 mm ivory discs. Cells were cultured in M-CSF (5 ng/ml) alone or in 
combination with RANKL (2 ng/ml) for 14 days. TRAP staining was used to identify 
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OCs in the mixed cell population at endpoint, whilst subsequent staining of the disk 
with Toluidine blue revealed the OC-induced resorption pits (section 2.5.3 to 2.5.5).  
TRAP+ cells or resorption pits were rare in cultures grown in M-CSF alone 
(Fig. 5.1A and C). The addition of RANKL resulted in a higher density of 
mononucleated TRAP+ and induced multinucleated TRAP+ cells (Fig 5.1B). Cultures 
stimulated with M-CSF and RANKL generated a high density of resorption pits (Fig. 
5.1D), confirming the functionality of the assay. These data validated the assay for 
subsequent tests. 
 
 
Figure 5.1 Testing of human OC for resorption activity. CD14+ monocytes 
purified from peripheral blood were adhered to ivory discs and cultured in the 
presence of M-CSF (5 ng/ml) alone (A and C) or in combination with RANKL (2 
ng/ml) (B and D) (n=1 donor of which 3 ivory discs were analysed at 5 FoV). After 
14 days TRAP staining was performed to identify OCs (A and B) and cells were 
removed to stain for resorption pits utilising Toluidine blue (C and D). Examples of 
resorption pits are indicated ( ). 
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5.3.2 Assessment of a Lentiviral Delivery System 
Once the resorption assay was established, CD59 knockdown systems were tested 
in order to expose the role of CD59 in human OCG. Firstly the infection efficiency of 
a GFP-tagged lentivirus was investigated in Jurkat EB.1 cells (used as a positive 
control due to high levels of infectivity (Lombardo et al. 2007; Zhang et al. 2007; 
Yang et al. 2009)) and CD14+ monocytes. Cells were cultured with the lentivirus for 
2 days and then analysed by flow cytometry for GFP expression. Finally, CD59 
shRNA containing virus was produced and its efficacy tested in Jurkat EB.1 cells 
(section 2.5.6). 
Flow cytometry analysis of GFP-lentivirus infected Jurkat EB.1 cells 
demonstrated that 96% of the cells expressed GFP and the median fluorescent 
intensity shifted from 4 to 195, confirming that the virus had a high infection rate and 
the assay set up was correct (Fig. 5.2B). When infecting CD14+ monocytes the 
median fluorescence of the population changed only slightly (from 3 to 5), indicating 
that either 1) the infection efficiency was low, 2) cells changed morphology causing 
autofluorescence to shift, 3) the cell viability was compromised or 4) the GFP 
expression and folding had slowed down (Fig. 5.3B). Jurkat EB.1 cells were 
therefore used to test the efficiency of the CD59 shRNA. 
CD59 was consistently found to be expressed on the surface of Jurkat EB.1 
as identified by antibody labelling and flow cytometry analysis (Fig. 5.4B). However, 
addition of control or indeed CD59 shRNA-containing lentivirus did not alter the 
expression level of CD59, indicating a poor knockdown, though other possible 
reasons for this are indicated below (Fig. 5.4C and D). In order to establish whether 
the lentivirus was able to infect cells, positive selection of the antibiotic puromycin 
was utilised. Only cells successfully infected with the lentivirus could grow in the 
presence of puromycin; therefore this would allow for the expansion of infected cells. 
Unfortunately, no infected cells could be enriched using this method. 
 
 
 
 
 188 
 
 
Figure 5.2 Flow Cytometry of GFP-lentivirus infected Jurkat EB.1 cells. 2x104 
Jurkat EB.1 cells were seeded and infected with GFP-lentivirus (MOI 8) for 2 days 
before analysis via flow cytometry (n=1 assay). The dot plot of cell size (FSC) 
versus granularity (SSC) identified a relatively homogenous population of cells 
which was gated (A). GFP was detected using FL1 (emission 525 nm). Cells without 
virus infection (green curve) were compared to infected cells (filled blue) and the 
percentage GFP positive cells (M1) as well as the median was determined (B). 
 
 
Figure 5.3 Flow cytometry of GFP-lentivirus infected human CD14+ monocytes. 
3.2x104 monocytes were mixed with GFP-lentivirus (MOI 8) and Polybrene (6µg/ml), 
seeded and left to infect for 2 days before analysis via flow cytometry (n=1 assay 
from one donor). The dot plot of cell size (FSC) versus granularity (SSC) identified a 
relatively homogenous population of cells which was gated (A). GFP was detected 
in FL1 (emission 525 nm). Cells without virus infection (green curve) were compared 
to infected cells (filled blue) and the median was determined (B). 
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Figure 5.4 Flow cytometry of shRNA-lentivirus infected Jurkat EB.1 cells. 
2x105 cells were seeded and infected with virus (1:100 dilution) for 2 days (n=1 
assay). Cells were stained for CD59 surface expression using an FITC conjugated 
secondary antibody. The dot plot of cell size (FSC) versus granularity (SSC) 
identified a relatively homogenous population of cells which was gated (A). FITC 
was detected in FL1 (emission 525nm). Isotype control (green curve) were 
compared to CD59 expression (filled blue) in cells that did not encounter viruses (B), 
cells infected with control virus without shRNA (C) and cells infected with CD59 
shRNA expressing virus (D). 
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5.3.3  Development of an Adenoviral Delivery System  
Adenoviruses only allow for a transient infection, but have the advantage of infecting 
monocytes readily (Mittal 2004; McLaren et al. 2010). Adenoviruses were therefore 
tested as an alternative delivery strategy for shRNA. GFP tagged, non-silencing 
shRNA control adenovirus and shRNA expressing adenoviruses were utilised to test 
infection efficiency and establish CD59 knockdown in CD14+ 
monocytes/macrophages. Flow cytometry was performed to monitor cellular CD59 
expression levels (section 2.5.7). 
Initially, cells were transduced at different MOIs to test efficiency of infection. 
For this, viable cells were gated (Fig. 5.5A) and cell aggregates excluded (Fig. 
5.5B). GFP expression at an MOI of 50 caused a clear shift in the histogram 
(median: 1,311,603) (Fig. 5.5C). Rising MOI resulted in higher median (MOI 
500=7,167,817), even though the percentage of infected cells did not alter (Fig. 
5.5D and E).  
The knockdown potential of 3 different shRNA expressing adenoviruses was 
investigated. To select a virus, cells were gated as before and CD59 expression was 
confirmed in non-infected cells (Fig. 5.6A). All viruses tested knocked down CD59 
expression (Fig. 5.6B). When comparing viruses, shRNA3 containing adenovirus 
down-regulated CD59 expression by 32% (median: 1,037,601) at an MOI of 50. 
With increasing MOI, the knockdown also improved; shRNA3 expressing adenovirus 
at an MOI of 500 caused the highest CD59 down-regulation by 56% (median: 
674,944). TRAP staining of cultured CD14+ monocytes/macrophages revealed 
declining cell density with increasing MOI (Fig. 5.7). Therefore higher MOIs were 
avoided in subsequent experiments. 
As shRNA targets CD59 mRNA molecules, the translation into proteins and 
renewal of existing CD59 could be delayed. Therefore, protein expression was 
utilised as an indicator of knockdown efficiency. Cultures were incubated with virus 
for 2 or 4 days. Cell gating, CD14 and CD59 expression was carried out as before 
(Fig. 5.8A). Knockdown capacity was determined by comparing CD59 shRNA 
adenovirus to a control adenovirus at the same MOI. shRNA1 expressing 
adenovirus showed a 15% knockdown (median: 772,856) at an MOI of 200 in 
comparison to control virus, when cells were infected for 2 days after 5 day culturing 
in M-CSF (Fig. 5.8B). Similarly, when a combination of shRNA1 and 3 containing 
adenoviruses (an MOI of 100 each) were tested, a 12% reduction (median: 801,039) 
in CD59 expression was achieved at the same time point. When incubating cells 
with shRNA adenovirus for 4 days after 5 day culturing in M-CSF, a 48% knockdown 
(median: 679,767) of CD59 was achieved in cultures infected with shRNA1 
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expressing adenovirus at an MOI of 100. An MOI of 200 or combination of 2 viruses 
did not reach the same level of knockdown (42% and 35% respectively). After 7 
days of pre-culturing in M-CSF, 7% knockdown was achieved when infecting CD14+ 
monocytes with either shRNA1 containing adenovirus alone or a combination of 
shRNA1 and 3 expressing adenoviruses (total MOI of 200). shRNA1 containing 
adenovirus at an MOI of 100 therefore produced the most effective knockdown and 
was utilised in subsequent experiments.  
To improve the cell viability, monocytes at different cell densities were 
infected after 1 day in culture. This time 7AAD was utilised to gate dead cells after 
aggregate exclusion (Fig. 5.9A-C). Viable cells were negative for 7AAD. CD59 
expression was confirmed on uninfected cells (Fig. 5.9D), 20% knockdown (median: 
358,278) was achieved when transducing 1x105 cells with shRNA containing virus at 
an MOI of 100 whereas a 40% knockdown was obtained when 3x105 cells were 
infected (Fig. 5.9E and F). TRAP staining uncovered a comparable cell density in 
both conditions after infection (Fig. 5.10). When cultured, these cells died instead of 
proliferating and therefore experiments were terminated. Unfortunately the limited 
time frame of the project did not allow further experimentation in this area. 
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Figure 5.5 Flow cytometry to establish infection efficiency. 1x105 CD14+ 
monocytes were seeded and cultured in medium supplemented with 5 ng/ml M-CSF 
for 5 days (n=1 assay from 1 donor). Cells were infected with GFP expressing 
adenovirus at MOI 50, 100 and 500 for 2 days. The dot plot of cell size (FSC) versus 
granularity (SSC) identified a relatively homogenous population of cells which was 
gated. To remove cell aggregates FCS-H (height) was plotted against FCS-A (area) 
and cells that did not follow the linear correlation were excluded (A). GFP was 
detected in FL1 (emission 530 nm). Unstained cells were compared to GFP 
expression and the percentage GFP positive cells (M1) as well as the median were 
determined (B).  
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Figure 5.6 Flow cytometry to select the best CD59 shRNA containing 
adenovirus. 1x105 CD14+ monocytes were seeded and cultured in medium 
supplemented with 5 ng/ml M-CSF for 5 days (n=1 assay from 1 donor). Cells were 
infected with shRNA1, 2 and 3 expressing adenovirus at MOI 50, 100 and 500 for 2 
days. CD14 and CD59 staining was compared to isotype staining. FITC and Alexa 
Fluor 647 were detected in FL1 and FL4 respectively (emission 530 nm and 675/25 
nm) (A). CD59 expression of cells that did not encounter virus was compared to 
shRNA containing viruses and the median was determined (B).  
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Figure 5.7 Representative images of cultured CD14+ monocytes/macrophages. 
Cells were cultured and infected as outlined in Fig. 5.6. TRAP staining was 
performed to monitor cell phenotype of non-infected cells to cells with different virus 
load. Cells infected with shRNA 1 expression adenovirus are shown. 
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Figure 5.8 Flow cytometry to establish efficiency of knockdown at different 
time points of infection. 1x105 monocytes were seeded and cultured in medium 
supplemented with 5 ng/ml M-CSF for 5 or 7 days (n=1 assay from 1 donor). Cells 
were infected with shRNA1 alone or in combination with shRNA3 expressing 
adenovirus at MOI 100 and 200 for 2 to 4 days. Dot plot and aggregate exclusion 
was performed as described in Fig. 5.5A. CD59 staining was compared to isotype 
staining. Alexa Fluor 647 was detected in FL4 (emission 675/25 nm) (A). CD59 
expression of cells that did not encounter virus and control virus were compared to 
shRNA viruses and the median was determined (B).  
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Figure 5.9 Flow cytometry to determine cell density. 1x105 or 3x105 CD14+ 
monocytes were seeded and cultured in medium supplemented with 5 ng/ml M-CSF 
overnight (n=1 assay from 1 donor). Cells were infected with shRNA1 expressing 
adenovirus at MOI 100 for 2 days. To remove cell aggregates FCS-H (height) was 
plotted against FCS-A (area) and cells that did not follow the linear correlation were 
excluded (A). 7AAD was detected in FL-3 (580/40 nm) in unstained cells and were 
plotted against FSC (size) (B). A gate was determined for low FL-3 expressing cells 
and to also exclude cell debris. This gate was applied to stained cells to exclude 
non-viable cells utilising 7AAD staining (C). CD59 staining was compared to isotype 
staining. Alexa Fluor 647 was detected at FL4 (emission 675/25 nm) (D). CD59 
expression of cells that did not encounter virus, transfected with control virus or with 
shRNA1 containing virus, were compared (E and F) and the median was 
determined. 
 
 
Figure 5.10 Representative images CD14+ monocytes infected at different cell 
densities. Cells were cultured and infected as described in Fig. 5.9. TRAP staining 
was performed to monitor monocytic cell phenotype. 
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5.4 Discussion 
A human OCG and resorption assay was set up to build a basis for introducing a 
CD59 knockdown system. The latter was crucial to depict the involvement of CD59 
in OCG. In this 5th chapter, a number of viral delivery systems were developed and 
explored, with the eventual aim of achieving successful CD59 knockdown in target 
cells. 
 
5.4.1 Establishment of a Resorption Assay for Human Cells 
A resorption assay of human OCs was initiated on ivory discs. In the literature it was 
determined that these are the better source of bone supplement compared to 
calcium phosphate-coated plates (also called Osteologic discs). Beeton et al. 
confirmed functionality of both methods, but identified greater reproducibility when 
using Osteologic discs. In contrast, Contractor et al. highlighted that Osteologic 
discs were missing essential bone proteins, including collagen which builds a 
network that contains minerals (Contractor et al. 2005). As the structure of bone was 
mimicked closely by the ivory discs, they represented the best substrate for the 
assessment of the function of CD59 in the regulation of bone resorption. 
Once monocytes were cultured on ivory, differentiation into TRAP+ cells and 
some multinucleated TRAP+ cells were observed in cultures supplemented with 5 
ng/ml M-CSF and 2 ng/ml RANKL. These cells were functionally active and able to 
resorb bone, evidenced by pitting on the ivory discs. In the literature OCG and 
resorption on ivory discs were commonly induced by 25 ng/ml M-CSF and 20-50 
ng/ml RANKL and stimulation was supplemented by other mediators (Kudo et al. 
2002; Kim et al. 2005; Beeton et al. 2006). Here resorption was achieved with a 
lower concentration of M-CSF and RANKL compared to published data. As 
recombinant proteins from different suppliers might have varying activity, this 
suggested that R&D Systems reagents are suitable for supplementation at low 
concentrations. 
  
5.4.2 Assessment of a Lentiviral Delivery System 
Lentiviral infection of mammalian cells for research use and gene therapy were 
initially developed by Naldini et al. (Naldini et al. 1996). These recombinant 
lentiviruses were derived from human immunodeficiency virus type I (HIV-1) and 
other lenti- or retroviruses such as Venezuelan equine encephalitis to allow infection 
of non-dividing cells and genome integration (Paessler et al. 2003; Schambach et al. 
2006; Picanço-C et al. 2012). To obtain a stable down-regulation of CD59 on human 
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CD14+ monocytes/macrophages, a lentiviral knockdown system was desired for this 
project. 
When infecting CD14+ monocytes/macrophages with lentivirus, substantially 
less GFP signal was detected than in Jurkat EB.1 cells, suggesting higher infectivity 
in the latter (Lombardo et al. 2007; Zhang et al. 2007; Yang et al. 2009)). In 
monocytes the shift of fluorescent intensity was small but the fluorescent signature 
of the whole cell population was altered.  Therefore cells might have been GFP 
positive but level of expression of the vector was low as not only transfection 
efficiency but also expression can differ between cell types (Zhang et al. 2004), but 
this was not confirmed here. 
Studies utilising lentiviral infection of CD14+ monocytes are mainly 
concerned with dendritic cell generation, achieved by stimulation with granulocyte 
colony stimulating factor (Rouas et al. 2002; Koya et al. 2003; Breckpot et al. 2004; 
Schmid et al. 2007). Only a small number of studies have infected monocytes with 
lentivirus for the purpose of OCG. Hamaza et al. generated a lentivirus containing 
shRNA against P2X7 the pLKO.1-puro vector. This virus was successfully 
introduced into human CD14+ monocytes and caused significant down-regulation of 
P2X7 (Hazama et al. 2009). Additionally, Park-Min et al. reported a 90% infection 
efficiency in pre-OCs utilising a lentivirus (Park-Min et al. 2009). These previous 
reports showed that it is possible to infect CD14+ monocytes with lentivirus under 
certain conditions; unfortunately this success could not be replicated in this study.  
Furthermore, the findings of this chapter showed that addition of CD59 
shRNA-lentivirus did not alter the cell surface expression level of CD59 on Jurkat 
EB.1 cells. This indicated that no knockdown of CD59 was achieved. The principle 
aim of this study was to prepare viral titres from the degree of knockdown at 
different lentiviral concentrations tested and the Poisson distribution, which was 
inconclusive. To further examine if the infection rate was disturbed by a viral defect 
or concentration problem, viral titres could also be established with the use of an 
ELISA to detect the HIV p24 gag antigen (Marr et al. 2003). Additionally genomic 
viral RNA qPCR could have been used to scan for integrated virus and quantify 
infection rate (Perez et al. 2010).  
Further reasons for malfunction of virus production need to be considered. 
Plasmid transfection to generate recombinant lentivirus was performed with 
Effectene transfection reagents. The lipid formation relies on a optimal ratio of 
plasmids and Effectene, incubation time and vector size (Qiagen 2002). 
Unfortunately due to time and cost constraints this optimisation could not be 
performed.  
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When considering the density of lentivirus, it has to be noted that the virus 
was concentrated by ultracentrifugation. However, as the MOI was unknown, the 
virus concentration could have still been low, which could have resulted in a low 
infectivity. Interestingly, Rouas et al. reported that upon infection with 2 lentivirus 
solutions of the same virus and MOI, of which one was diluted 1:2, the more 
concentrated virus infected cells at a higher rate (Rouas et al. 2002). Therefore, 
highly concentrated lentivirus would have been desirable in this study. 
Finally, not only are optimised viral preparation and high concentration 
essential for a high infection rate, but the surface interaction of the cell of interest 
with the viral envelope is also thought to be critical. In this study, the vesicular 
stomatitis virus glycoprotein (VSV-g) was utilised. VSV-g associates with 
phospholipids rather than by specific receptor interaction and therefore viruses 
expressing VSV-g should potentially be able to infect any cell type. Due to this lack 
of specificity, certain cell types such as airway epithelial cells have proven difficult to 
infect with VSV-g. A range of pseudotyped envelope vectors have been developed 
to overcome this problem (Burns et al. 1993; Engelke and Rossi 2005; Schambach 
et al. 2006). In a recent study the Aura virus derived pseudotyped Aura-G, which 
uses lectins to enter dendritic cells, was engineered (Froelich et al. 2011) and hence 
provides a more effective mechanism of cell entry for myeloid lineage cells. 
 Each of the factors outlined might have influenced the infection efficiency. 
Better checkpoints in virus development such as the p24 ELISA should be 
considered in the future to improve the quality of virus preparations before 
attempting infection.  
 
5.4.3 Development of an Adenoviral Delivery System  
Adenoviruses are an effective transient RNAi delivering system, producing large 
quantities of double-stranded RNA that is cleaved into miRNA within the cell 
allowing for effective knockdown. High infection efficiency was obtained when 
infecting human CD14+ monocytes with GFP-tagged adenovirus. CD59 knockdown 
(up to 56%) was observed when cells were treated with shRNA containing 
adenovirus. McLaren et al., who also utilised this adenovirus system, achieved 
successful knockdown of death receptor 3 in human monocytic leukaemia THP-1 
cells and human primary macrophages (McLaren et al. 2010). Adenoviruses do not 
naturally target human monocytes/macrophages, but have been found to be easily 
adaptable (Foxwell et al. 1998) and are generally known to infect at a high rate 
(Leyva et al. 2011).  Hence the adenoviral system was more suitable for this study, 
as the infection efficiency of human monocyte/macrophages was already 
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established. Interestingly, adenoviruses have been shown to infect terminally 
differentiated cells including OCs (Tanaka et al. 1998). Therefore to study 
resorption, differentiated OCs could have been infected in this study, instead of 
CD14+ monocytes/macrophages. 
The knockdown system was not only dependent on the infection efficiency of 
the viral delivery, but also on a shRNA that was able to mediate the degradation of a 
substantial amount of CD59 mRNA. shRNA1 adenovirus showed the highest level of 
knockdown at MOI of 50 and 500. In the literature, MOI of 1 to 1,000 have been 
utilised for sufficient infection (Craig 2009; Borniquel et al. 2010; Minamitani et al. 
2011). This suggests a wide range of potential viral load on the cells; however when 
TRAP staining on cultured CD14+ monocytes was performed declining cell densities 
were observed with increasing MOI. The literature shows that adenoviruses can 
induce cell lysis via autophagy (Jiang et al. 2011). Therefore, in the current study, it 
is possible that cell death may have occurred via this mechanism. 
To avoid this, a moderate MOI of 100 was selected for shRNA1 infection. 
shRNA1 reduced CD59 expression by 48% when incubated for 4 days with virus 
before analysis. Knockdown efficiency depends on the half-life of the target protein. 
Kolodekic et al. analysed vascular ATPase knockdown with siRNA after 2.5 h 
(Kolodecik et al. 2009). In contrast, CD59 is a GPI-anchored protein which, turns 
over at the cell surface within 4 h (Bojkowska et al. 2011); suggesting a different 
mechanism involved. As part of membrane traffic some proteins internalised from 
the cell membrane can be recycled. Cell surface proteins are captured in early 
endosomes which merge with trans-Golgi network vesicles. Here undamaged 
proteins are selected to be transported back to the cell membranes (Peer 2011). 
CD59 is likely to be a protein that was selected for recycling as it is essential for cell 
viability. Therefore mRNA levels might not be reflected in surface CD59 expression 
after a short time period. Alternatively, the down-regulation of CD59 expression 
identified using flow cytometry could have resulted from cell apoptosis. Cell death 
was shown to result in decreased expression of CD59 (Jones and Morgan 1995) 
and viability should be monitored more closely. Before any of these theories can be 
tested, knockdown of total CD59 expression should be visualised by qPCR/RT-PCR 
or western blotting of lysed cells (Szulc et al. 2006; Perez et al. 2010) to confirm and 
validate data obtained by flow cytometry. 
Viral delivering systems were desirable in this study to obtain sustained 
knockdown of CD59, but siRNA or anti-sense mediated silencing can be achieved 
by direct delivery or utilising cyclodextrin-containing polycations, lipids or polymers 
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as coating molecules (Bartlett and Davis 2006). These systems could be tested to 
improve infectivity with reduced toxicity. 
 
5.5 Conclusion 
In attempting to determine the role of CD59 in human precursor cell differentiation 
and subsequent OC function in vitro, the following key results were obtained: 
 Human CD14+ monocytes generated functional OCs in the presence of M-
CSF and RANKL.  
 The lentiviral delivery of CD59 shRNA was unable to knockdown CD59 
expression, however, adenoviral delivery of CD59 shRNA showed up to 48% 
CD59 knockdown, but cell viability was compromised. 
 The role of CD59 in human OCG and OC function could not be determined 
within the given time scale, but this builds the basis for future investigations. 
To further investigate findings from chapter 4, morphologic and mechanistic 
studies of CD59a’s effect in vivo were carried out in WT and CD59a-/- mice. 
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Chapter 6 
 
 
Phenotypic Analysis of 
Bone Structure in 
CD59a
-/-
 Mice 
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6.1 Introduction 
Murine OB and OC cultures in vitro highlighted CD59a’s regulatory function of cell 
differentiation in vitro. In vivo their differentiation and function is influenced by 
numerous cell types, such as OTs, stromal cells, bone lining cells and OBs, OCs, 
monocytes and other haematopoietic progeny (section 1.5) (Rosen 2008). These 
function through membrane bound and secreted mediators, such as RANKL, OPG, 
cytokines, M-CSF and other growth factors. Furthermore hormones (eg. PTH), and 
environmental factors are able to direct bone homeostasis as summarised in Tab 
1.10 (Rosen 2008). The role of CD59a in this regulatory environment in vivo has not 
been established.  
 
6.2  Aim and Objectives 
The aim of this chapter was to compare histomorphometry of bone in WT and 
CD59a-/- mice over a 50 week time course. To address this aim the subsequent key 
objectives were derived: 
 To identify architectural changes in femora of WT and CD59a-/- mice at 8-10, 
20 and 50 weeks. 
 To measure bone mineral density (BMD) in cortical and trabecular bone of 
WT and CD59a-/- mice at 8-10, 20 and 50 weeks. 
 To determine if CD59’s function is gender specific. 
 To establish if bone phenotype in CD59a-/- mice is localised to long bones or 
extends to other areas of the body. 
 To quantify in vivo OB function by measuring osteoids and mineral 
apposition rate (MAR) in trabecular bone of WT and CD59a-/- mice. 
 To measure OCs via TRAP staining in trabecular bone of WT and CD59a-/- 
mice. 
 
6.3 Results 
Femoral length and shaft diameter were determined for 8-10, 20 and 50 week old 
female and male WT and CD59a-/- mice to reveal morphological changes in CD59a-/- 
mice. These were determined utilising X-ray projections and a digital caliper. Once 
differences were identified, architectural parameters of cortical and trabecular bone 
were determined in specific areas of femora and spines using MicroCT. Femoral 
samples of 8-10 and 20 week old male WT and CD59a-/- samples were then 
processed for histological quantification of osteoids and OC. To further evaluate 
bone formation calcein was injected into a new cohort of 8-10 week old WT and 
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CD59a-/- mice to determine bone mineral apposition rate histologically. The results 
obtained from these studies are explained in detail below. 
 
6.3.1 Quantification of Femoral Length and Shaft Diameter 
Hindlimbs fixed in 70% ethanol were subjected to X-ray scanning in order to 
accurately measure femoral length as described in section 2.6.2. In females, values 
were comparable at 17.6±0.2 mm and 17.7±0.1 mm (results in this format: 
Mean±SEM unless stated otherwise) for CD59a-/- and WT samples respectively at 8-
10 weeks of age (Fig. 6.1A and 6.2A). Femoral length rose significantly (p<0.0001) 
over time and was still comparable at 50 weeks (CD59a -/-=19.8±0.5, WT= 19.7±0.2 
mm). 
In males, femoral length was significantly increased in CD59a-/- over WT 
mice at 8-10 (CD59a-/-=18.4±0.1, WT=17.7±0.2 mm, p<0.01), 20 (CD59a-/-
=19.2±0.2, WT=18.8±0.1 mm, p<0.01) and 50 weeks (CD59a-/-=20.0±0.2, 
WT=19.3±0.2 mm, p<0.05) of age (Fig. 6.1B and 6.2B). Femoral length significantly 
increased (p<0.0001) over time in male CD59a-/- and WT samples. 
When determining mid-shaft diameter, there was no difference in posterior-
anterior direction in females at 8-10 (CD59a-/-=1.29±0.01, WT=1.28±0.01 mm), 20 
(CD59a-/-=1.30±0.01, WT=1.32±0.01 mm) or 50 weeks (CD59a-/-=1.53±0.05, 
WT=1.49±0.02 mm) (Fig. 6.3A). However in males, posterior-anterior diameter was 
significantly raised (p<0.001) in CD59a-/- (1.39±0.03 mm) over WT (1.22±0.02 mm) 
samples at 8-10 weeks (Fig. 6.3B). By 20 (p<0.05) and 50 weeks (p<0.001), 
diameter in WT samples were significantly increased in comparison to 8-10 weeks. 
In CD59a-/- samples the diameter did not change over time. This resulted in 
comparable diameters in WT and CD59a-/- samples at 20 and 50 weeks of age. 
Similarly, female CD59a-/- and WT samples had a comparable medial-lateral 
diameter at 8-10, 20 and 50 weeks of age (Fig. 6.3C). However in males, the 
diameter in CD59a-/- was significantly enhanced (p<0.01) over WT samples at 8-10 
weeks (Fig.6.3D). Again, the diameter only significantly increased in WT sample 
over time (p<0.001), resulting in no difference between CD59a-/- and WT samples at 
20 and 50 weeks of age. 
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Figure 6.1 Representative X-ray projections of femora. Hindlimbs from female 
(A) and male (B) WT and CD59a-/- mice were submitted to X-rayed imaging at 8-10, 
20 and 50 week of age utilising the Kodak In-vivo Imaging System FX Pro and 
representative images are shown. 
 
Figure 6.2 Quantification of femoral length. X-ray projections of female (A) and 
male (B) WT and CD59a-/- femora at 8-10, 20 and 50 weeks of age were assessed 
(n=6 mice per group). Femoral length was quantified utilising the Kodak MI SE 
software. Two-way ANOVAs were performed for A (strain: p=0.8983, age: 
p<0.0001, interaction: p=0.9643) and B (strain: p<0.0001, age: p<0.0001, 
interaction: p=0.9922). Bonferroni post-tests are indicated (*(p<0.05), **(p<0.01)).  
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Figure 6.3 Measurement of shaft diameter. Diameter was determined with a digital caliper for female (A and C) and male (B and D) WT and 
CD59a-/- femora at 8-10, 20 and 50 weeks of age (n=6 mice per group). Measurements were performed for anterior-posterior (A and B) and 
medial-lateral (C and D) direction. Two-way ANOVAs were performed for A (strain: p=0.5712, age: p<0.0001, interaction: p=0.6050), B (strain: 
p=0.0052, age: p<0.0001, interaction: p=0.0167), C (strain: p=0.5154, age: p<0.0001, interaction: p=0.2373) and D (strain: p=0.0057, age: 
p<0.0001, interaction: p=0.0326). Bonferroni post-tests are indicated (**(p<0.01), ***(p<0.001)). 
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6.3.2 3D Assessment of Cortical Bone in Femora 
After identification of differences in bone length and diameter between CD59a-/- and 
WT samples (section 6.3.1), phenotypical analysis of structural parameters was 
performed utilising MicroCT (methodology in section 2.6.3.3). Initially cortical bone in 
the femoral shaft was evaluated.  
In females, cortical bone volume (cBV) was comparable in CD59a-/- and WT 
samples at 8-10 and 20 weeks (Fig. 6.4A). Interestingly at 50 weeks, cBV is 
significantly reduced (p<0.05) in CD59a-/- (0.89±0.05 mm3) over WT (0.98±0.01 
mm3) samples. cBV significantly grew (p<0.001) between 8-10 and 20 weeks for 
CD59a-/- and WT samples, but no significant difference was identified between 20 
and 50 weeks for either sample group. 
In males, significantly more cBV was present in CD59a-/- than in WT samples 
at 8-10 (CD59a-/-=0.86±0.03, WT=0.68±0.03 mm3, p<0.001) and 20 (CD59a-/-
=0.93±0.03, WT=0.83±0.02 mm3, p<0.05) weeks (Fig. 6.4B). At 50 weeks, cBV was 
slightly decreased in CD59a-/- over WT samples. This was due to a significant 
increase (p<0.001) in cBV in WT, but constant cBV in CD59a-/- samples between 8-
10 and 50 weeks.  
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Figure 6.4 cBV evaluation in the femoral shaft. Femora of 8-10, 20 and 50 week 
old WT and CD59a-/- mice were analysed utilising MicroCT. A (1 mm) segment of 
bone shaft was analysed in female (n=6 mice per group) (A) and males (n=6 mice 
per group) (B). cBV was determined and shown. Two-way ANOVAs were performed 
for A (strain: p=0.0118, age: p<0.0001, interaction: p=0.3863) and B (strain: 
p=0.0177, age: p<0.0001, interaction: p=0.0001).  Bonferroni post-tests are 
indicated (*(p<0.05), ***(p<0.001)). 
 
6.3.2.1 Examination of Crossectional Thickness 
Crossectional Thickness (CsTh) is a measure of cortical bone thickness and was 
determined to reveal if size and cBV differences translate to a stronger cortical 
structure. In females, CsTh was comparable between CD59a-/- (0.128±0.002 mm) 
and WT (0.132±0.002 mm) samples at 8-10 weeks (Fig. 6.5A). CsTh significantly 
increases (p<0.001) in CD59a-/- (0.172±0.002 mm) and WT (0.177±0.002 mm) 
samples between 8-10 and 20 weeks and samples groups were still comparable at 
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20 weeks. By 50 weeks CsTh did not change in WT samples, but showed a trend of 
reduced CsTh in CD59a-/- samples.  
 In males, no significant differences were identified between CD59a-/- and 
WT samples at 8-10, 20 or 50 weeks (Fig. 6.5B), but a trend to enhanced CsTh was 
visible in CD59a-/- over WT samples at 8-10 weeks. By week 20, CsTh had 
significantly increased (p<0.001) in CD59a-/- and WT samples in comparison to 8-10 
weeks as also seen in female samples. At 50 weeks again, a trend to reduced CsTh 
was present in CD59a-/- over WT samples. 
 To relate changes in cBV and CsTh to each other, crossections of all 
samples were compared. These crossectional views confirm that cBV was 
comparable in females at week 8-10 and 20 (Fig. 6.6A, B, D and E). At 50 weeks 
CD59a-/- samples exhibit slightly thinner cortical rings (cBV) than in WT samples 
confirming the trend seen in CsTh (Fig. 6.6C and F). In males, CD59a-/- samples 
revealed larger and thicker rings of cortical bone than WT samples at 8-10 weeks 
which was also seen as a trend in the CsTh (Fig. 6.6G, H, J and K). At 50 weeks 
CD59a-/- samples present smaller and slightly thinner cortical bone rings than WT 
samples (Fig 6.6I and L). 
 210 
 
 
Figure 6.5 Assessment of CsTh. Column scatter plots showing a comparison of 
CsTh in WT and CD59a-/- mice. A (1 mm) segment of bone shaft was analysed in 
female (n=6 mice per group) (A) and males (n=6-9 mice per group) (B). Two-way 
ANOVAs were performed for A (strain: p=0.0313, age: p<0.0001, interaction: 
p=0.3396) and B (strain: p=0.4715, age: p<0.0001, interaction: p=0.0544). 
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Figure 6.6 Representative images of cortical bone. Crossectional view is 
displayed of cortical bone within the femoral shaft. Images were obtained from the 
mid slice (0.5 mm) of quantified 1 mm area for female (A to F) and male (G to L) WT 
(A to C and G to I) and CD59a-/- (D to F and J to L) samples at 8-10 (A, D, G, J), 20 
(B, E, H, K) and 50 (C, F, I, L) week of age (n=6-9 per group). 
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6.3.2.2 Quantification of BMD of Cortical Bone in Femora 
Additionally to the shape of bone, the BMD is a characteristic parameter of bone and 
was measured in cortical bone as described in section 2.6.3.4. In females, BMD was 
significantly lower (p<0.05) in CD59a-/- samples at 1.23±0.02 g/cm3 in comparison to 
WT samples at 1.29±0.01 g/cm3 at 8-10 weeks (Fig. 6.7A). Between 8-10 and 20 
weeks BMD significantly rose (p<0.001) to 1.38±0.01 g/cm3 and 1.37±0.01 g/cm3 in 
CD59-/- and WT samples resulting in comparable values between strains. Between 
20 and 50 weeks a further significant increase (p<0.001) in CD59a-/- and WT 
samples was identified. At 50 weeks BMD was significantly raised (p<0.05) in 
CD59a-/- samples over WT samples. Therefore the genotypes showed a different 
effect over time.  
In males, BMD was significantly lower in CD59a-/- in comparison to WT 
samples at 8-10 and 20 weeks (Fig. 6.7B). Between 20 and 50 weeks BMD in 
CD59a-/- samples (1.48±0.02 g/cm3) rose significantly (p<0.001) whereas BMD in 
WT samples (1.40±0.02 g/cm3) did not change, again the different strains changed 
their phenotype over time. This caused a significantly increased (p<0.05) BMD in 
CD59a-/- over WT samples at 50 weeks. When comparing 3D images of 8-10 week 
old male samples, CD59a-/- shafts presented a more porous bone structure than WT 
shafts as illustrated in Figure 6.7C.  
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Figure 6.7 Cortical BMD assessment in the femoral shaft. Column scatter plots showing a comparison of mean BMD in WT and CD59a-/- 
mice. A (1 mm) segment of bone shaft was analysed in female (n=6 mice per group) (A) and males (n=6-9 mice per group) (B).  Two-way 
ANOVAs were performed for A (strain: p=0.7530, age: p<0.0001, interaction: p=0.0002) and B (strain: p=0.1032, age: p<0.0001, interaction: 
p=0.0005). Bonferroni post-tests are indicated (*(p<0.05), **(p<0.01)). Representative 3D images of cortical bone from 8-10 week old male 
mice are shown and porosity is highlighted by red arrows (C). 
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6.3.2.3 Cortical Bone at a Glance 
When summarising analysed parameters, alterations of cortical bone between 
CD59a-/- and WT were compared between genders and over time (Tab. 6.1). 
Whereas cBV did not change in femora from 8-10 and 20 week old female mice, it 
was increased in males. Interestingly at 50 weeks, cBV significantly decreased in 
females whereas no significant difference was identified in males. CsTh did not 
significantly alter in any group at 8-10, 20 or 50 weeks. Similarly in crossections, 
alterations did not present before the age of 50 weeks in females, whereas slightly 
larger cortical rings were present at 8-10 and 20 weeks in males. Thinner cortical 
rings were present in both genders at the age of 50 weeks. Finally, BMD alterations 
were comparable between females and males at 8-10 weeks, where a decreased 
BMD was monitored, and 50 weeks, where an increase was shown. Therefore, 
cortical bone from CD59a-/- femora differed between genders.  
 
Parameter Age in 
weeks 
♀ ♂ 
cBV 8-10 - ↑ 
 20 - ↑ 
 50 ↓ - 
CsTh 8-10 - - 
 20 - - 
 50 - - 
Cross-
section 
8-10 - Larger, 
thicker 
cortical ring 
 20 - Larger, 
thicker 
cortical ring 
 50 Thinner 
cortical ring 
Smaller, 
thinner 
cortical ring 
BMD 8-10 ↓ ↓ 
 20 - ↓ 
 50 ↑ ↑ 
Table 6.1 Summary of cortical bone parameters. Alterations in CD59a-/- 
compared to WT samples are presented for cBV, CsTh, crossections and BMD. 
Significant increase (↑), decrease (↓) and no significant changes (-) are indicated for 
female and male samples at 8-10, 20 and 50 weeks of age. 
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6.3.3 3D Assessment of Trabecular Bone in Femora 
Datasets obtained for cortical bone assessment utilising MicroCT were also 
analysed for trabecular bone (methodology in section 2.6.3.6) which is 
predominantly present in the metaphysis. As trabecular bone consists of a 
meshwork of thin rod and plate structures (trabeculae) different parameters had to 
be considered than in the analysis of cortical bone. 
Initially percentage bone volume over tissue volume (BV/TV) was 
determined. In females, BV/TV was comparable in CD59a-/- and WT samples at 8-
10 (CD59a-/-=12.5±0.7, WT=13.0±0.6%), 20 and 50 weeks of age (Fig. 6.8A). BV/TV 
significantly decreased (p<0.0001) in CD59a-/- and WT samples over time. 
This contrasted in males, BV/TV was significantly higher (p<0.01) in CD59a-/- 
(22.0±1.6%) in comparison to WT (11.6±0.3%) samples at 8-10 weeks and a similar 
trend was present at 20 weeks (Fig. 6.8B). Whereas BV/TV in WT samples did not 
alter over the timecourse, it significantly decreased (p<0.001) in CD59a-/- samples; 
this resulted in comparable values at 50 weeks.  
 
Figure 6.8 BV/TV examination of trabecular bone in the metaphysis. Column 
scatter plots showing a comparison of BV/TV in WT and CD59a-/- mice. A (1 mm) 
segment of the metaphysis was analysed in female (n=6 mice per group) (A) and 
males (n=6-9 mice per group) (B). Two-way ANOVAs were performed for A (strain: 
p=0.6708, age: p<0.0001, interaction: p=0.4196) and B (strain: p=0.0015, age: 
p=0.0117, interaction: p=0.0199). Bonferroni post-tests are indicated (**(p<0.01)).  
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6.3.3.1 Examination of Trabecular Number in the Metaphysis of Femora 
When examining trabecular number (TbN) the result was similar to BV/TV. In 
females, there was no significant difference between CD59a-/- and WT at 8-10 
(CD59a-/-=2.1±0.1, WT=2.1±0.1 mm-1), 20 (CD59a-/-=1.5±0.1, WT=1.3±0.1 mm-1) or 
50 (CD59a-/-=0.8±0.1, WT=0.7±0.1 mm-1) weeks and the TbN decreased 
significantly (p<0.0001) in both strains over time (Fig 6.9A).  
In males, TbN in CD59a-/- samples was 3.2±0.2 mm-1, this was significantly 
higher (p<0.01) than WT samples, which was 2.0±0.04 mm-1 at 8-10 weeks of age 
(Fig. 6.9B). This was followed by a trend of increased TbN in CD59a-/- over WT at 20 
weeks. CD59a-/- and WT samples were comparable at 50 weeks.  
 
Figure 6.9 TbN evaluation in the metaphysis. Column scatter plots showing a 
comparison of TbN in WT and CD59a-/- mice. A (1 mm) segment of the metaphysis 
was analysed in female (n=6 mice per group) (A) and males (n=6-9 mice per group) 
(B). Two-way ANOVAs were performed for A (strain: p=0.1992, age: p<0.0001, 
interaction: p=0.4391) and B (strain: p=0.0024, age: p=0.0005, interaction: 
p=0.0627). Bonferroni post-tests are indicated (**(p<0.01)).  
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6.3.3.2 Evaluation of Trabecular Thickness in the Metaphysis of Femora 
Additionally, trabecular thickness (TbTh), another important parameter of trabecular 
architecture, was analysed. In females, values were comparable between CD59a-/- 
and WT at 8-10 (CD59a-/-=0.059±0.001, WT=0.061±0.001 mm), 20 (CD59a-/-
=0.070±0.002, WT=0.070±0.002 mm) and 50 (CD59a-/-=0.068±0.002, 
WT=0.069±0.002 mm) weeks as seen for all other trabecular parameters so far (Fig. 
6.10A). In comparison to TbN, TbTh significantly increased (p<0.0001) over time in 
CD59a-/- and WT samples.  
In males, TbTh was also significantly higher (p<0.01) at 8-10 weeks and 
slightly increased at 20 weeks in CD59a-/- over WT samples (Fig. 6.10B). Between 
8-10 and 50 weeks TbTh in WT (0.069±0.003 mm) samples significantly rose 
(p<0.01) whereas in CD59a-/- samples (0.065±0.002 mm) no significant difference 
was observed. Hence, at 50 weeks TbTh was comparable in WT and CD59a-/- 
samples.  
 
Figure 6.10 TbTh assessment in the metaphysis. Column scatter plots showing a 
comparison of TbTh in WT and CD59a-/- mice. A (1 mm) segment of the metaphysis 
was analysed in female (n=6 mice per group) (A) and males (n=6-9 mice per group) 
(B). Two-way ANOVAs were performed for A (strain: p=0.3294, age: p<0.0001, 
interaction: p=0.9463) and B (strain: p=0.0126, age: p= 0.3618, interaction: 
p=0.0042). Bonferroni post-tests are indicated (**(p<0.01)).  
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6.3.3.3 Investigation of Trabecular Separation in the Metaphysis of Femora 
Trabecular separation (TbSp) is the width of the spaces between bone structures in 
the metaphysis (Skyscan 2009). In females, TbSp was comparable between CD59a-
/- and WT samples at 8-10 and 20 weeks (Fig. 6.11A). Over the timecourse, TbSp 
significantly increased (p<0.001) in different strains (CD59a-/-=0.65±0.05 mm and 
WT=0.47±0.04 mm). This increase was elevated in CD59a-/- samples and resulted in 
a significant difference (p<0.001) between CD59a-/- and WT samples at 50 weeks. 
In males, TbSp did not change between CD59a-/- and WT samples at 8-10 (CD59a-/-
=0.19±0.01, WT=0.22±0.01 mm), 20 or 50 weeks (Fig. 6.11B). TbSp significantly 
rose (p<0.001) in CD59a-/- and WT samples between 8-10 and 50 weeks, but was 
significantly less (CD59a-/-=p<0.001, WT=p<0.05) than in females at end point.  
 
Figure 6.11 Examination of TbSp in the metaphysis. Column scatter plots 
showing a comparison of TbSp in WT and CD59a-/- mice. A (1 mm) segment of the 
metaphysis was analysed in female (n=6 mice per group) (A) and males (n=6-9 
mice per group) (B). Two-way ANOVAs were performed for A (strain: p=0.0558, 
age: p<0.0001, interaction: p=0.0009) and B (strain: p=0.1511, age: p<0.0001, 
interaction: p=0.6895). Bonferroni post-tests are indicated (***(p<0.001)).  
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6.3.3.4 Assessment of Trabecular Pattern Factor in the Metaphysis of 
Femora 
When examining trabecular pattern factor (TbPf), which is a measure of how well 
the trabeculae are connected. Lower TbPf resulted from better connected 
trabeculae (Skyscan 2009). In females, TbPf of CD59a-/- and WT samples did not 
differ at 8-10 and 20 weeks (Fig. 6.12A). In WT samples connectivity was 
significantly reduced (higher TbPf) (p<0.001) by 50 weeks causing a significant 
difference between CD59a-/- (20.3±1.3 mm-1) and WT (26.9±1.25 mm-1) samples. 
Interestingly in males, CD59a-/- samples presented with significantly reduced 
(p<0.05) TbPf and hence better connectivity at 8-10 and 20 weeks and no difference 
was observed at 50 weeks (Fig. 6.12B). 
 
Figure 6.12 Evaluation of TbPf in the metaphysis. Column scatter plots showing 
a comparison of TbPf in WT and CD59a-/- mice. A (1 mm) segment of the 
metaphysis was analysed in female (n=6 mice per group) (A) and males (n=6-9 
mice per group) (B). Two-way ANOVAs were performed for A (strain: p=0.0030, 
age: p=0.0217, interaction: p=0.0042) and B (strain: p=0.0019, age: p=0.6982, 
interaction: p=0.1146). Bonferroni post-tests are indicated (*(p<0.05), ***(p<0.001)).  
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6.3.3.5 Examination of Structure Model Index in the Metaphysis of Femora 
SMI is a measure of rod (0) or plate (3) like shape of trabeculae. The lower the SMI 
the better is the quality of the trabeculae structure (Skyscan 2009). SMI changed in 
a similar pattern as TbPf (Fig. 6.13A and B). In females, only WT samples 
developed a more rod-like structure over time. However, SMI was significantly 
different (p<0.001) at 50 weeks between CD59a-/- (2.1±0.04) and WT (2.5±0.03) 
samples. In males, there was a trend to more plate-like structure in CD59a-/- over 
WT samples at 8-10 weeks. By 20 weeks this trend was significant (p<0.05). At 50 
weeks SMI was comparable between CD59a-/- and WT samples. 
 
Figure 6.13 Assessment of SMI in the metaphysis. Column scatter plots showing 
a comparison of SMI in WT and CD59a-/- mice. A (1 mm) segment of the metaphysis 
was analysed in female (n=6 mice per group) (A) and males (n=6-9 mice per group) 
(B). Two-way ANOVAs were performed for A (strain: p<0.0001, age: p=0.0061, 
interaction: p<0.0001) and B (strain: p=0.0041, age: p=0.2429, interaction: 
p=0.1642). Bonferroni post-tests are indicated (***(p<0.001)).  
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6.3.3.6 Evaluation of Vertical Crossections in the Metaphysis of Femora 
When comparing trabecular bone meshwork of the metaphysis (cut vertically), 
female and male WT and CD59a-/- samples showed diminished trabecular 
meshwork over time (Fig. 6.14). Additionally, more trabecular bone was present in 
male than female samples. Females had comparable amounts of trabecular bone in 
WT and CD59a-/- samples at 8-10, 20 and 50 week of age (Fig. 6.14A-F). In males, 
the difference of trabecular bone between WT and CD59a-/- samples at 8-10 weeks 
was striking (Fig. 6.14G and J); an increased amount of TbN and connectivity was 
present and the increased TbTh was also clearly visible in CD59a-/- samples. At 20 
weeks the denser trabecular meshwork was still identifiable in CD59a-/- samples, but 
less pronounced than at 8-10 weeks of age (Fig. 14H and K). By 50 weeks 
trabecular bone was comparable between WT and CD59a-/- samples (Fig. 14I and 
L). 
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Figure 6.14 Representative images of trabecular bone in the metaphysis. The 
vertical view of distal femora is displayed. The area of metaphysis analysed is 
marked in a rectangular shape. Images were obtained by cutting across growth 
plate rings within the reference slice. Representative images of female (A to F) and 
male (G to L) WT (A to C and G to I) and CD59a-/- (D to F and J to L) samples at 8-
10 (A, D, G, J), 20 (B, E, H, K) and 50 (C, F, I, L) week of age (n=6-9 per group) are 
illustrated. 
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6.3.3.7 Quantification of BMD within the Metaphysis of Femora 
Finally, total BMD was quantified to determine the mineral content within the TV of 
the metaphysis. In females, the total BMD showed no significant differences 
between WT and CD59a-/- samples at 8-10 (WT=0.21±0.01, CD59a-/-=0.20±0.01 
g/cm3), 20 (WT=0.16±0.01, CD59a-/-=0.18±0.01 g/cm3) or 50 (WT=0.07±0.01, 
CD59a-/-=0.06±0.02 g/cm3) weeks of age (Fig. 15A) which was comparable to other 
trabecular parameters established. Over the timecourse total BMD significantly 
decreased (p<0.0001) in WT and CD59a-/- samples.   
In males, total BMD was significantly higher (p<0.05) in CD59a-/- over WT 
samples at 8-10 and 20 weeks (Fig. 15B), again mirroring BV/TV, TbN and TbTh 
data, but contrasting with the reduced total BMD identified in CD59a-/- samples of 
cortical bone at earlier time points. Between 8-10 and 50 weeks, total BMD of 
CD59a-/- samples (0.15±0.02 g/cm3) significantly decreased (p<0.001) whereas WT 
samples (0.18±0.03 g/cm3) only showed a slight reduction in total BMD. 
Consequently, a slightly lower total BMD was observed in CD59a-/- over WT 
samples at 50 weeks. 3D models of 8-10 week old samples (displayed in Fig. 15C) 
demonstrated a complex meshwork of trabeculae in CD59a-/- samples, which was 
denser than in WT samples. 
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Figure 6.15 BMD evaluation of trabecular bone in the metaphysis. Column scatter plots showing a comparison of total BMD (including TV 
that is occupied by trabeculae) in WT and CD59a-/- mice. A (1 mm) segment of the metaphysis was analysed in female (n=6 mice per group) 
(A) and males (n=6-9 mice per group) (B). Two-way ANOVAs were performed for A (strain: p=0.8442, age: p<0.0001, interaction: p=0.3179) 
and B (strain: p=0.0169, age: p<0.0001, interaction: p=0.0240). Bonferroni post-tests are indicated (*(p<0.05)). Representative 3D images of 
trabecular bone from 8-10 week old male mice are shown (C). 
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6.3.3.8 Trabecular Bone in the Metaphysis at a Glance 
Once data of trabecular architecture was collected, alterations of trabecular bone 
between WT and CD59a-/- were compared between genders and over time (Tab. 
6.2). In females trabecular bone was comparable between WT and CD59a-/- 
samples in BV/TV, TbN and TbTh. TbSp and connectivity was increased and 
trabeculae were more plate-like in CD59a-/- over WT samples at 50 weeks 
respectively. In males, architectural changes were present in young adult mice only. 
BV/TV, TbN and TbTh were up-regulated at 8-10 weeks. The connectivity of these 
structures was increased at 8-10 and 20 weeks and also more plate-like at 20 
weeks in CD59a-/- over WT samples.  Meshwork and total BMD were increased at 8-
10 and 20 weeks of age. These data again present a gender specific phenotype. 
 
Parameter Age in 
weeks 
♀ ♂ 
BV/TV 8-10 - ↑ 
 20 - - 
 50 - - 
TbN 8-10 - ↑ 
 20 - - 
 50 - - 
TbTh 8-10 - ↑ 
 20 - - 
 50 - - 
TbSp 8-10 - - 
 20 - - 
 50 ↑ - 
TbPf 8-10 - ↓ 
 20 - ↓ 
 50 ↓ - 
SMI 8-10 - - 
 20 - ↓ 
 50 ↓ - 
Cross-
section 
8-10 - Denser 
meshwork 
 20 - Denser 
meshwork 
 50 - - 
Total BMD 8-10 - ↑ 
 20 - ↑ 
 50 - - 
Table 6.2 Summary of trabecular bone parameters. Alterations in CD59a-/- over 
WT samples are presented for BV/TV, TbN, TbTh, TbSp, TbPf, SMI, crossections 
and total BMD. Significant increase (↑) and no significant changes (-) are indicated. 
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6.3.4 3D Evaluation of Trabecular Bone in Vertebra L6 
As all previous analysis was carried out in a femur from each mouse, it was crucial 
to identify if changes applied to other bones. Due to the consistent phenotype 
identified in young male mice, vertebra L6 of male mice at 8-10 and 20 weeks of age 
were scanned using MicroCT and trabecular parameters were determined as 
described in section 2.6.4. 
When BV/TV was determined, CD59a-/- samples were significantly higher 
than WT samples at 8-10 (CD59a-/-=27.8±0.7, WT=23.1±0.9%, p<0.01) and 20 
(p<0.001) weeks (Fig. 6.16A). Similarly, TbN was increased significantly in CD59a-/- 
over WT samples at 8-10 (CD59a-/-=4.8±0.1, WT=4.4±0.1 mm-1, p<0.05) and 20 
(p<0.001) weeks (Fig. 16B). TbN of WT samples significantly decreased (p<0.05) 
between 8-10 and 20 weeks of age, whereas TbN of CD59a-/- stayed constant. 
Furthermore, TbTh in CD59a-/- (0.058±0.001 mm) significantly differed (p<0.05) from 
WT samples (0.053±0.001 mm) at 8-10 weeks (Fig. 16C). By 20 weeks, this 
significant increase (p<0.05) was retained. TbSp and TbPf were significantly 
reduced in CD59a-/- over WT samples at 8-10 (TbSp=p<0.05, TbPf=p<0.01) and 20 
(TbSp=p<0.001, TbPf=p<0.001) weeks, again revealing increased connectivity and 
more plate-like structure (Fig. 16D and E). Similar to trabecular bone in the 
metaphysis, SMI revealed a significantly more (p<0.001) plate-like structure in 
CD59a-/- samples over WT samples at 20 weeks of age (Fig. 16F). 
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Figure 6.16 Trabecular bone parameters were determined in the vertebra L6. 
Vertebra L6 of 8-10 and 20 week old male WT and CD59a-/- mice were analysed 
with MicroCT. Trabecular bone was selected in the main body of the vertebrae 
between the cartilage surfaces on either side (n=6-9 mice per group). Percentage 
BV/TV (A), TbN (B), TbTh (C), TbSp (D), TbPf (E) and SMI (F) were determined. 
Two-way ANOVAs were performed A (strain: p<0.0001, age: p=0.0312, interaction: 
p=0.7241), B (strain: p<0.0001, age: p=0.0081, interaction: p=0.2170), C (strain: 
p=0.0007, age: p=0.6506, interaction: p=0.4500), D (strain: p<0.0001, age: 
p=0.0048, interaction: p=0.4407), E (strain: p<0.0001, age: p=0.4721, interaction: 
p=0.3695) and F (strain: p=0.0002, age: p=0.9647, interaction: p=0.0923). 
Bonferroni post-tests are indicated (*(p<0.05), **(p<0.01), ***(p<0.001)). 
 
6.3.4.1 Evaluation of Vertical Crossections in Vertebra L6 
When examining crossections of vertebra L6, a size difference was observed 
between 8-10 and 20 weeks in WT and CD59a-/- samples (Fig. 17). Additionally, the 
vertebra L6 was larger in CD59a-/- than in WT samples at 8-10 and 20 weeks. 
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Furthermore, the trabecular meshwork was more complex and trabeculae were 
thicker in CD59a-/- over WT samples at 8-10 and 20 weeks. 
 
 
Figure 6.17 Representative images of trabecular bone in the vertebra L6. The 
vertical view of the main body of L6 is displayed. Images were obtained by selecting 
the mid-section within the dataset and cutting across the man body of the vertebra. 
Representative images of male WT (A and B) and CD59a-/- (C and D) samples at 8-
10 (A and C) and 20 (B and D) weeks of age are illustrated. 
 
 
6.3.4.2 Quantification of BMD within the Vertebra L6 
Finally, total BMD was determined at 8-10 and 20 weeks (Fig. 18A). Again, total 
BMD in CD59a-/- samples (8-10 weeks=0.27±0.01, 20 weeks=0.25±0.01 g/cm3) was 
significantly raised over WT samples (8-10 weeks=0.23±0.01, 20 weeks=0.20±0.01 
g/cm3). 3D models of trabecular bone at 8-10 weeks confirmed the size difference of 
the vertebrae and highlighted the more tightly connected meshwork of trabeculae in 
CD59a-/- over WT samples (Fig. 18B). The data obtained from the vertebra L6 were 
comparable to findings acquired for the same trabecular parameters in the femur. 
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Figure 6.18 BMD evaluation of trabecular bone in the vertebra L6. Trabecular 
bone was selected in the main body of the vertebrae between the cartilage surfaces 
on either side (n=6-9 mice per group) (A). Total BMD was determined. A two-way 
ANOVA was performed (strain: p<0.0001, age: p=0.0346, interaction: p=0.5680) and 
Bonferroni post-tests are indicated (*(p<0.05), ***(p<0.001)). Representative 3D 
images of trabecular bone from 8-10 week old mice are shown (B). 
 
 
6.3.5 In Vivo OB Activity in the Trabecular Bone of Femora 
After the MicroCT assessment, femora of 8-10 and 20 week old male WT and 
CD59a-/- samples were methylmethacrylate (MMA)-embedded and von Kossa/van 
Gieson staining was performed on bone sections as described in section 2.6.5.  
Firstly, the osteoid surface was normalised for the trabecular bone surface 
(OSS/BS) (Fig. 6.19A). Interestingly, the OSS/BS was significantly reduced 
(p<0.001) in CD59a-/- (8.5±1.6%) over WT (22.9±1.4%) samples at 8-10 weeks. By 
20 weeks, the OSS/BS in WT samples was significantly reduced (p<0.001) 
compared to 8-10 weeks, and therefore was comparable to the stagnated OSS/BS 
in CD59a-/- samples.  
 When normalising the osteoid surface for TV (OSS/TV) the results were 
comparable (Fig. 6.19B). OSS/TV in CD59a-/- samples (0.15±0.03%) was 
significantly lower (p<0.001) than in WT samples (0.37±0.04%) at 8-10 weeks, as 
illustrated in Fig. 6.19C. Over time OSS/TV in WT samples was significantly reduced 
(p<0.001); hence OSS/TV was slightly lower in WT over CD59a-/- samples at 20 
weeks of age. 
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As this did not account for the increased bone length and BV observed 
utilising X-ray and MicroCT, a new cohort of 8-10 week old mice was treated with 
calcein to measure mineral apposition by OBs (methodology in section 2.6.5.7).  
 CD59a-/- samples (2.2±0.1 µm) showed a significantly higher (p<0.05) 
MAR than WT samples (1.7±0.1 µm) (Fig. 20A). Bone formation rate (BFR/BS) 
showed the same pattern (Fig. 20B), opposing the results obtained utilising von 
Kossa/van Gieson staining.  
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Figure 6.19 Osteoid quantification of trabecular bone in the metaphysis of femora. Femora of 8-10 and 20 week old male WT and 
CD59a-/- mice were analysed utilising von Kossa/van Gieson staining on sections. TV, Trabecular bone (black) and collagen-rich osteoids (pink) 
were quantified (n=6-9 mice per group). OSS was calculated and normalised for BS (A) and TV (B). Two-way ANOVAs were performed for A 
(strain: p=0.0006, age: p=0.0026, interaction: p<0.0001) and B (strain: p=0.0163, age: p=0.0004, interaction: p<0.0001). Bonferroni post-tests 
are indicated (***(p<0.001)). Representative images of trabecular bone from 8-10 week old mice are shown (C). 
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Figure 6.20 Calcein assessment of trabecular bone in the metaphysis of 
femora. 8-10 week old male WT and CD59a-/- mice (n=4 mice per group) were 
injected with calcein 4 and 1 day before sacrifice. Femoral sections were 
counterstained with Aniline blue to identify bone surfaces. Calcein was captured at 
515 nm and analysed for double (calcein deposition at both time points) and single 
(calcein deposition on a single time point) staining. MAR (A) and BFR/BS (B) were 
calculated. Unpaired student T-tests were performed and indicated (*(p<0.05)). 
Representative images are shown (C). 
 
6.3.6 Resorption Area in the Trabecular Bone of Femora 
Femoral sections obtained in methodology section 2.6.5 were also stained for TRAP 
(OCs) to reveal active resorption surfaces (2.6.6). The OC surface normalised for 
BS (OCS/BS) was significantly higher in CD59a-/- over WT samples at 8-10 (CD59a-
/-=18.3±2.4, WT=10.7±1.0%) and 20 (CD59a-/-=23.0±2.0, WT=13.7±2.0%) weeks 
(Fig. 6.21A).  
When normalising OC number for BS (OCNr/BS), CD59a-/- samples were 
significantly raised over WT samples at 8-10 (CD59a-/-=1.16±0.16, WT=0.65±0.05%, 
p<0.05) and 20 (CD59a-/-=1.5±0.13, WT=0.92±0.14%, p<0.01) weeks (Fig. 21B).  
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Figure 6.21 OC analysis of trabecular bone in the metaphysis of femora. Femora of 8-10 and 20 week old male WT and CD59a-/- mice 
were analysed utilising TRAP/Aniline blue staining on sections. Trabecular bone (blue) and OC (maroon) were quantified (n=6-9 mice per 
group). OCS (A) and OCNr (B) were calculated and normalised for BS. Two-way ANOVAs were performed for A (strain: p=0.0003, age: 
p=0.0668, interaction: p=0.6882) and B (strain: p=0.0003, age: p=0.0236, interaction: p=0.7082). Bonferroni post-tests are indicated (*(p<0.05), 
**(p<0.01)). Representative images of trabecular bone from 8-10 week old mice are shown (C). 
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6.4 Discussion 
This study utilised a variety of imaging techniques to characterise the bone 
phenotype of CD59a-/- mice. The main focus was on weight-bearing bones such as 
femora, but vertebrae L6 were also analysed (Högler et al. 2003). 
 
6.4.1 Quantification of Femoral Length and Shaft Diameter 
Morphological assessment of femora was carried out utilising X-ray projections 
(radiographs). Zhang et al. demonstrated that radiographs are a valuable method to 
determine bone changes. The authors studied a BMP receptor type IA mutant 
mouse that had abnormal trabecular bone like structures which developed within the 
femoral shaft. These structures were clearly visible on X-ray projections. Zhang et 
al. were therefore able to localise aberrant features to direct histological analysis 
(Zhang et al. 2003) which was aimed for in this study also. 
When evaluating the femoral length of WT samples on C57/BL6J 
background, the length in male mice was recorded between 17.7 mm at 8-10 weeks 
and 19.3 mm at 50 weeks of age. Other studies reported shorter bone length 
(Rowling et al. 2007; Philip et al. 2010; Yao et al. 2010). Rowling et al. for example, 
identified 16.5 mm long femora in 12 week old male mice with C57/BL6 background 
(Rowling et al. 2007). These measurements were mostly acquired via a digital 
calliper and not from X-ray projections which might account for some of the 
variation. Variability may have also arisen from diet and other housing conditions 
(Graham 1972; Borer et al. 1988; Sarma 2009). These mice were an established 
colony and were healthy (monthly screening by Debora Adams), therefore this 
increased femoral length in WT mice was not viewed as an adverse effect.  
In this study, radiographs revealed comparable morphology in female WT 
and CD59a-/- mice at 8-10, 20 and 50 weeks. In males only, significantly increased 
(2-4%) femoral length was observed in CD59a-/- mice over WT mice at 8-10, 20 and 
50 week of age. Larsson et al. for example, identified a 24% reduction in femoral 
length in the human FGF-23 transgenic mice on CBA X C57/BL6 background 
(Larsson et al. 2004) whereas Mohan et al. revealed a 40% reduction in femoral 
length when IGF-1 was deleted (Mohan et al. 2003). In contrast oestrogen receptor 
knockout mice showed a 4-14% change in femoral length in comparison to WT mice 
(Lindberg et al. 2001).  Small differences obtained here were significant due to low 
variability between samples and suggested a subtle effect of CD59a. Studies 
characterising long bones, reported that enhanced femoral or tibial length was not 
accompanied by an increased cortical area. Additionally, the BMD was increased in 
these long bones, but the 4 point bending test revealed that femora and tibiae were 
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more brittle (Tommasini et al. 2005; Miller et al. 2007). This suggested a possible 
reduction in bone quality in the femora of male CD59a-/- mice. 
This interpretation was further supported by the shaft diameter 
measurements. In males, CD59a-/- had significantly higher anterior-posterior and 
medial-lateral diameter compared to WT samples at 8-10 weeks, but were not 
significantly different at 20 and 50 weeks of age. Tommasini et al. also revealed a 
reduced shaft diameter when characterising more fragile tibiae (Tommasini et al. 
2005). Therefore at 20 and 50 weeks in my study femora were slender and therefore 
more likely to be brittle. 
When studying the X-rays further no other gross architectural changes were 
observed, but evaluation for clinical bone pathology such as: osteophytes, 
subchondral sclerosis or joint space narrowing; features that are characteristic for 
OA (Gale et al. 1999; Abramson and Attur 2009) was not performed. Furthermore, 
for identification of an osteopenic phenotype (murine model of osteoporosis) DXA 
analysis is commonly carried out to obtain BMD. This method has proved useful for 
whole animal studies, but accuracy is lost upon selection of a region of interest on 
particular bone areas (Rosen 2008) and was not available for this study. As 
radiographs were limited to 2D assessment (Rosen 2008) and did not allow for 
establishment of BMD,  3D evaluation was conducted. 
 
6.4.2 3D Assessment of Cortical Bone in Femora 
MicroCT was utilised for characterising bone pathology in CD59a-/- mice. MicroCT is 
the preferred method of many researchers when studying micro-architecture of 
murine bone samples. High resolution (6-10 µm) analysis of small trabeculae is 
possible by utilising images taken from bone acquisition obtained from multiple 
projections at different angles (3D). MicroCT enables evaluation of specific regions 
of interest, but at the same time allows for analysis of a larger volume of bone than 
is possible by histology (Rosen 2008).  
Initially, cortical bone in the femoral shaft was analysed. cBV was 
comparable in females at 8-10 (WT=0.73±0.01, CD59a-/-= 0.71±0.02 mm3) and 20 
weeks. cBV in the shaft (1 mm) was also analysed by Zhang et al. At 6 weeks of 
age, female WT mice on FVB-N background had a cBV of 0.537±0.025 mm3 (Zhang 
et al. 2002). These values were comparable to data obtained in this study if the 
growth phase is considered (Efstratiadis 1998). Lloyd et al. determined a cBV of 5.5-
6.5 mm3 per 3 mm shaft area measured in female C57/BL6J mice at 10 weeks of 
age (Lloyd et al. 2008). When correcting for the ROI as measured here, 1.8-2.1 mm3 
cBV were calculated which is hugely raised over the values obtained in this study. 
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Interestingly femora were air-dried and MicroCT was performed with different 
equipment (µCT20 scanner, SCANCO Medical AG, Switzerland) (Lloyd et al. 2008) 
which might have caused higher readings. Hoenderop et al. also measured cBV in 
mm3, but did not provide a size for the ROI (Hoenderop et al. 2003), therefore not 
allowing for comparison. Consequently, to avoid these problems cBV in the literature 
is often normalised for TV, but alterations in cBV/TV were not identified in this study. 
cBV was presented here, because male CD59a-/- mice demonstrated an increased 
cBV over WT at 8-10 (21%) and 20 (11%) weeks. When comparing these data to 
changes obtained in the literature, for example in ovariectomy or RANKL 
supplementation (0.4 mg/kg/day) of mice, a 6-11% alteration in cBV was observed 
(Potts et al. 2004; Lloyd et al. 2008); whereas knockout models that affected Ca2+ 
channels or were related to IGF-1 produced a 14-36% alteration. Hence changes 
revealed within the CD59a-/- model was comparable to published data and revealed 
that more cortical bone was formed in young male CD59a-/- mice. 
Over time cBV significantly increased in female (WT and CD59a-/-) samples 
and male WT samples whereas cBV stagnated in male CD59a-/- samples. At 50 
weeks a significantly lower (9%) cBV in female CD59a-/- over WT mice was seen. A 
similar trend (not significant) was present in male mice. In the literature cortical area 
in femora of C57/BL6 mice was identified to increase until the age of 52 weeks 
(Price et al. 2005), but Halloran et al. revealed that in male C57/BL6J mice cortical 
thickness only grew for the first 24 weeks of age and then decreased continuously 
with aging (Halloran et al. 2002). This suggested that bone growth slowed in CD59a-
/- mice before WT mice and that bone loss was initiated earlier.  
 
6.4.2.1 Examination of Crossectional Thickness 
An additional parameter that reveals the bone quality is cortical thickness. This was 
measured by CsTh and did not differ between WT and CD59a-/- at 8-10, 20 or 50 
weeks. In 8-10 week old, male WT mice CsTh was 0.12±0.006 mm. Zhong et al. 
reported a CsTh of 0.125 mm in 7 week old WT mice (Zhong et al. 2012). Hence my 
data is in agreement with published work. Thicker cortical bone should accompany 
an increase in cortical diameter/area to retain bone quality as discussed by Watkins 
et al. (Watkins et al. 2012). In my study cortical thickness was unchanged, but shaft 
diameter was increased at 8-10 weeks as well as tissue area at 8-10 and 20 weeks 
(data not shown), suggesting that bone strength was compromised in young adult 
mice. Watkins et al. further reported that mice lacking the gap junction protein 
annexin 43, present with increased cortical tissue area and slender cortical 
thickness. This was due to increased resorption at the endosteum as well as up-
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regulated periosteal formation of bone (Watkins et al. 2012). To identify whether 
cortical bone changes were caused by alterations in remodelling at endo- and 
periosteum in my study, OB and OC should be quantified on cortical bone. 
  
6.4.2.2 Quantification of BMD of Cortical Bone in Femora 
Another indicator of bone quality is BMD. At 8-10 weeks CD59-/- samples were 
shown to have decreased BMD (female (4%) and male (7%)) over WT samples in 
my study. Uveges et al. identified 3-4% cortical BMD change between Brtl 
(osteogenesis imperfecta mouse model) and WT mice. Cortical BMD (1.5-1.6 g/cm3) 
was measured in SV129/CD-1/C57BL/6S mice at 6 and 12 weeks of age (Uveges et 
al. 2009). In my study BMD values between 1.2 and 1.3 g/cm3 were identified which 
is lower than published data. When comparing changes in cortical BMD, Högler et 
al. identified a rise in cortical BMD between puberty and young adulthood. BMD 
alterations were comparable between sexes (Högler et al. 2003), suggesting that 
BMD during growth is less dependent on sex hormones than other cortical bone 
parameters.  When examining the effect of calcium supplementation on BMD in a 
human study in 6-14 year old children, Slemenda et al. revealed that the treatment 
resulted in enhanced BMD and a 15% decrease in osteocalcein. The authors 
concluded that the rise in BMD was accompanied by a reduced rate in bone 
remodelling (Slemenda et al. 1997). Therefore the reduced BMD, identified in my 
study at 8-10 weeks, could have resulted from increased bone remodelling. By 50 
weeks BMD was enhanced in female and male CD59a-/- over WT samples in my 
study. This suggested that the rate of remodelling was reduced and resorption 
markers should be analysed in serum samples of CD59a-/- and WT mice to 
investigate this theory. 
Bone stiffness and flexibility are not only determined by BMD, but other 
component of the bone matrix. The analysis of Col1 or it’s cross-linking was not 
considered in this project and might have helped to predict bone quality and fracture 
risks (Seeman 2007). Structural changes seen in the skeleton of CD59a-/- mice may 
have resulted from adaptations to different loads caused by the deficiency. In 
disease models such as the brittle IV mouse (another model of osteogenesis 
imperfecta) an altered ratio of collagen and minerals to counteract the collagen 
mutations was observed (Seeman and Delmas 2006). Therefore longer bones in 
CD59a-/- mice might have been sufficiently supported by their BMD if other matrix 
components were up-regulated. Structure and flexibility of bone is also controlled by 
trabecular bone, which was also investigated.  
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6.4.3 3D Assessment of Trabecular Bone in Femora 
Trabecular bone is most commonly analysed in the metaphysis of femora or tibiae. 
Bone diseases, such as OA, usually affect the epiphysis which contains complex 
trabecular architecture known as the subchondral bone. Imaging techniques, such 
as MicroCT, do not always support analysis of joint damage as similarities are 
quantified and pathological features that differ are difficult to measure. Therefore 
joint analysis was not included in this study and trabecular bone of the metaphysis 
was a major focus.  
 In females, BV/TV, TbN, TbTh and total BMD were comparable at 8-10, 
20 and 50 weeks. TbSp and trabeculae connectivity were increased with a more 
plate-like structure at 50 weeks. Whereas TbSp points toward reduced bone quality, 
the more plate-like structure of trabeculae suggested a stronger trabecular bone 
architecture (Recker et al. 2009; Skyscan 2009). As the cortical bone volume was 
also reduced in CD59a-/- mice at 50 weeks, more plate-like structure might have 
developed to counteract weaknesses in bone strength. 
 In males, BV/TV, TbN, TbTh, trabecular connectivity and total BMD were 
significantly raised in CD59a-/- over WT samples at 8-10 weeks of age. By 20 weeks, 
trabeculae were still better connected and had an increased total BMD in CD59a-/- 
over WT mice. Additionally, trabeculae presented a more plate-like structure in 
CD59a-/- samples. At 50 weeks, trabecular bone was comparable in all parameters 
between CD59a-/- and WT mice. 
 Male WT samples had a BV/TV of 11.6±0.3%, TbN of 2.0±0.04 mm-1, 
TbTh of 0.059±0.001 mm, TbSp of 0.2±0.01 mm, SMI of 2.2±0.05 and total BMD of 
0.23±0.02 g/cm3 at 8-10 weeks. Halloran et al. characterised the trabecular 
parameters of male WT C57/BL6 tibiae over time. At 8 weeks, the BV/TV was 14%, 
TbN 5.5 mm-1, TbTh 0.043 mm, TbSp 0.26 mm and SMI 2.8 (Halloran et al. 2002). 
Similar data were published for trabecular bone in the femur by Gowen et al. 
(Gowen et al. 2003). Therefore values in my study were slightly lower than in 
published data which again might be due to different equipment or sample 
preparation. A total BMD of 0.29±0.03 g/cm3 of WT femora was obtained by Larsson 
et al. (Larsson et al. 2004) and this was also in agreement with data of this study.  
To reveal the effect of CD59a, differences between CD59a-/- and WT 
samples need to be interpreted. All parameters pointed towards increased 
trabecular bone that is thicker, denser and more connected meshwork in young 
adult male mice. In humans it was shown that people from different ethnicities have 
different structural features. African Americans were reported to have shorter 
vertebrae with higher trabecular volume which was suggested to have protective 
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affects for age related bone loss (Seeman and Delmas 2006). Hence, alterations of 
trabecular bone in CD59a-/- mice might have been required to counteract reduced 
BMD in cortical bone at 8-10 and 20 weeks.  
Interestingly, micro-architectural variations between inbred strains have been 
shown to be significant (Beamer et al. 1996). As WT and CD59a-/- mice were not 
obtained from a heterozygous colony, variations might have arisen from genetic 
alterations of these in-house colonies, therefore experiments should be performed 
with WT control animals from different sources to confirm these findings.  
 
6.4.4 3D Evaluation of Trabecular Bone in Vertebra L6 
It was essential to perform trabecular analysis on several parts of the skeleton to 
determine if the effect of CD59a was localised to the femur or not. Hildebrand et al. 
examined CT parameters in human spine, femur, iliac crest and calcaneus biopsies. 
The authors identified the largest amount of bone in femora and the lowest in the 
lumbar spine. Additionally, lumbar spines consisted of thin rod-like structures 
whereas femoral trabeculae were thick and appeared plate-like (Hildebrand et al. 
1999). Interestingly, my data presented comparable trabecular architecture in femur 
and spine at 8-10 weeks of age whereas at 20 weeks the modifications in CD59a-/- 
samples were more pronounced in spine samples. This implied not only that femora 
and vertebrae are differentially regulated, but that control of CD59a is not restricted 
to femora. 
 
6.4.5 In Vivo OB Activity in the Trabecular Bone of Femora 
As MicroCT does not support analysis of cellular composition, histology was carried 
out (Rosen 2008). This 2D analysis is an established method that allows for in situ 
hybridization, RT-PCR, immunohistochemistry, bone histomorphometry and electron 
microscopy (Helfrich and Ralston 2003). To distinguish between osteoids and 
mineralised bone, von Kossa/van Gieson staining was utilised in my study. The 
quantification of osteoids can be difficult, because they appear as thin structures 
which require strong staining and high magnification analysis to be identified 
correctly. Vedi and Compston suggested to exclude structures of less than 3 µm for 
precise determination of osteoid surfaces (Helfrich and Ralston 2003). Von Kossa 
staining was consistent in this study and no readjustment was required. 
An alternative method for monitoring OB activity is the application of near 
infrared imaging reagents which allow for in vivo monitoring of bone apposition. 
Examples are reagents such as Osteosense (Perkins Elmer) and BoneTag (Licor). 
Imaging with these reagents can be performed on live animals and therefore can be 
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repeated over time. The resolution is limited to 50 µm when utilising, for example the 
Ivis system (Caliper Life Sciences 2009). These methods should be considered as a 
less time consuming technique in future studies. 
Von Kossa staining of trabecular bone within the metaphysis revealed, 
decreased OSS/BS in CD59a-/- mice at 8-10 weeks of age in this study. By 20 
weeks, OSS/BS in WT samples decreased to the level (approx. 10%) of the 
unchanged CD59a-/- sample. Luo et al. identified 20% OSS/BS at the first two days 
after birth (Luo et al. 2009) whereas Potts et al. quantified OSS/BS at 3 month of 
age with 10.186±3.17% (Potts et al. 2004). This was in agreement with my theory 
that the osteoid levels were higher during initial growth and that the number reduced 
once the growth rate had slowed down. As CD59a-/- mice contained larger bones, 
the growth rate had reached the peak of osteoid formation earlier than WT mice. 
 To obtain readout for OB activity, MAR was determined at 8-10 weeks of 
age. MAR was significantly up-regulated in CD59a-/- (2.2±0.1 µm/day) over WT 
samples (1.7±0.1 µm/day). This pattern also emerged for BFR/BS. MAR rate was 
relatively low compared to published data which averaged around 2.5-2.9 µm/day 
(Ferguson et al. 2003; Rubin et al. 2007; Luo et al. 2009); this variability was likely 
dependent on the type of analysis performed. Microscope, camera and software 
packages utilised would have influenced the outcome. Increased MAR in CD59a-/- 
samples confirmed that OB activity was increased and therefore resulted in faster 
bone growth (Erlebacher et al. 1998) and turnover (Shih and Norrdin 1986) as 
observed during X-ray and MicroCT analysis. 
 
6.4.6 Resorption Area in the Trabecular Bone of Femora 
TRAP staining was used to highlight OC activity histologically. This method should 
be complemented by investigation of resorption cavities which can be performed by 
polarised light microscopy to highlight the structure of lamellae. When lamellae are 
disturbed at an angle, resorption pits are formed. Additionally, lamellae filled with an 
osteoid can be noted as a complete resorption cavity (Helfrich and Ralston 2003), 
therefore allowing for an accurate account of remodelling surfaces. This was not 
performed in this study. 
When evaluating OCs in vivo, TRAP staining was performed to determine 
OCS/BS. This surface was significantly raised in CD59a-/- over WT (18.3±2.4% vs 
10.7±1.0%) samples at 8-10 weeks of age. Hoenderop et al. obtained a similar 
OSC/BS (10.5±1.37%) for WT controls samples (Hoenderop et al. 2003). As data is 
in agreement, it is most likely that enhanced OC, stimulate increased bone 
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remodelling and therefore growth, but this has to be further investigated because 
bone development is dependent on chondrocyte action (Rauch 2005). 
To complete the characterisation of bone pathology, mechanical loading 
should have been tested. Bone gives strength to the body and guards organs, so it 
should be rigid and withstand impact at the same time. In rodents the most 
commonly used tests are 3 and 4 point bending. In the 3 point test, force is applied 
to the middle of the bone shaft whereas in the 4 point method the force is distributed 
evenly over the shaft (Helfrich and Ralston 2003). Breaking or bending of bone, 
aberrant from WT controls would have supported characterisation of bone 
phenotypes. Mechanical testing could have therefore helped in estimating bone 
quality of CD59a-/- samples.  
 
6.5 Conclusion  
In vivo examination of the effect of CD59a on bone architecture uncovered the 
following points: 
 Femoral architecture was altered in CD59a-/- when compared to WT mice at 
8-10, 20 and 50 weeks. This was apparent from increased femoral length, 
and increased bone volume in cortical and trabecular bone. 
 The balance of BMD was shifted from cortical to trabecular bone in young 
CD59a-/- mice. 
 Male CD59a-/- mice showed a defect over more parameters of bone growth 
and remodelling than females, indicating gender specificity. 
 The trabecular bone phenotype in male CD59a-/- mice was also present in 
vertebra L6 and hence not restricted to the femur. 
 OC numbers and OB function were enhanced in young CD59a-/- male mice 
indicating an accelerated rate of bone remodelling. 
Therefore CD59a influences bone growth and homeostasis in vivo. This was the first 
time that the detailed histomorphometry was performed on, not only CD59a-/- mice, 
but also complement deficient mice, as arthritis studies were restricted to scoring 
systems of bone erosion (section 1.3.3.1.3).  
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The role of CD59a in inflammatory arthritis models has been previously established 
in the literature. During an experimental model of RA enhanced bone erosion was 
identified, whereas during a trauma induced osteoarthritis model osteophyte 
formation was revealed in CD59a-/- mice in comparison to WT mice (Williams et al. 
2004; Wang et al. 2011). Opposing bone pathologies were reportedly due to 
inflammatory response by two independent disease triggers (immune complex and 
injury). In the immune complex-driven antigen-induced arthritis model a 
degenerative bone phenotype was revealed, whilst in the medial meniscectomy 
model excess bone formation was observed in the knee joint. As inflammatory 
arthritis and bone were shown to be regulated through shared myeloid progenitors 
and cytokines (such as RANKL, IL-1, TNF and IL-6), the complexity of signalling did 
not allow for the extraction of CD59a function in bone homeostasis (Lorenzo et al. 
2010). Hence CD59a was studied in a non-inflammatory context here. This 
homeostatic effect of CD59a on bone was not investigated and had not been 
reported in the literature in advance of the initiation of this project.  
 Revealing a role of CD59a in bone homeostasis could support research 
of bone pathology upon aging. The aging population was shown to develop 
alterations in extracellular matrix proteins, cell apoptosis and regeneration, joint 
loading and capacity to resolve inflammation which often results in osteoarthritis 
(Geurts and Valderrabano 2012). A study of 90 year olds in Leiden, Netherlands, 
identified that only 16% of participants did not present with osteoarthritic symptoms 
on radiographs when scored for sclerosis, osteophytes, ossicles, pseudocystic 
areas, joint space narrowing and shape of bone ends. This highlighted the 
association between age and osteoarthritis (Kellgren and Lawrence 1957; Goekoop 
et al. 2011; Loeser 2011). As the aging population was predicted to rise to 25% of 
over 65 year old by 2033 in the UK and the increased burden on the health system 
as well as contradictory evidence for current pharmaceutical interventions was 
reported, new therapeutic approaches are needed (Birrell and Felson 2009; Box et 
al. 2010). These can only be taken forward by understanding bone homeostasis in 
detail. 
 During the course of the research that embodies this thesis; the role of 
CD59a in regulating bone homeostasis was examined. Key findings emerged with 
regard to CD59a’s contribution to osteoblast-driven mineralisation, 
osteoclastogenesis and defining the micro-architecture of bone in vivo. These are 
discussed in relation to the current literature below.  
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7.1 Determining the Role of CD59a in Osteoblast Differentiation and 
 Maturation 
In chapter 3, the effect of CD59a upon osteoblast differentiation (measured by 
alkaline phosphatase staining) and osteoblast function (measured in mineralisation 
assays) was reported. In vitro bone marrow cultures were established with precursor 
cells derived from age matched (7 to 20 weeks) wild-type and CD59a-deficient mice. 
In the absence of CD59a, the surface area of alkaline phosphatase positive colony 
forming units showed reduced staining when compared against wild-type cultures in 
a single experiment. This experiment needs to be repeated before drawing 
conclusion and the investigation could also be advanced by studying Runx2, β-
catenin and osterix, the main transcription factors that regulate osteoblast 
differentiation. qPCR could to be utilised to observe their expression levels to 
determine if cells from CD59a-/- samples are aberrantly regulated (Otto et al. 1997; 
Nakashima et al. 2002; Haÿ et al. 2009; Cawthorn et al. 2011).   
 Although CD59a insufficiency reduced colony forming units (n=1 only) 
there was no significant effect upon osteoblast function assessed by mineralisation 
assays.  In order to demonstrate formation of osteoblasts in mineralisation cultures, 
secondary markers such as osteocalcin, osteopontin, bone sialic protein and type I 
collagen should be analysed utilising qPCR (Haÿ et al. 2009; Teplyuk et al. 2009; 
Cawthorn et al. 2011; Zhang et al. 2011a) (Fig. 7.1). To confirm protein levels of 
these markers, culture supernatants should also be examined. Ferron et al. for 
example, developed an ELISA method to detect osteocalcin allowing for 
distinguishing between active (undercarboxylated) and total osteocalcein (Ferron et 
al. 2010). Alternatively, flow cytometry of markers such as RANKL or 
immunohistochemistry of osteopontin, should be performed to identify osteoblasts in 
culture (Atkins et al. 2003; Uaesoontrachoon et al. 2008). 
Published literature revealed an inverse association between osteoblast 
differentiation and adipogenesis (Duque 2008). This was identified during in vitro 
and in vivo  studies with Runx2 and PPARγ which are controlled by the common 
transcriptional co-activator with PDZ binding motif (TAZ) (Hong et al. 2005). 
Therefore the same bone marrow cell population was stimulated towards adipocytes 
in this study and an increase in adipocyte numbers (measured by Oil red O) was 
expected. Interestingly, data analysis pointed once again towards less adipocyte 
maturation in CD59a-/- over WT bone marrow (n=1) which was an unexpected 
finding. Other differentiation pathways of mesenchymal stem cells were not 
investigated here, but the literature describes that mesenchymal stem cell activity 
can be altered. During aging, for example, mesenchymal stem cells were shown to 
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undergo less cell division and be prone to oxidative stress resulting in declining cell 
density (Stolzing et al. 2008). A sensitivity or damage to mesenchymal stem cells in 
a CD59a-/- environment could possibly have caused a decreased differentiation.  
 CD59 expression has been revealed on mesenchymal stem cells and 
used as a surrogate marker in many studies to identify mesenchymal stem cells 
from primary cell sources and long term cultures (Izadpanah et al. 2006; Lange et al. 
2007; Watson et al. 2010). Furthermore, Moll et al. reported that mesenchymal stem 
cells within the blood express CD59 as the sole complement regulator (Moll et al. 
2011). The effect of the membrane attack complex on mesenchymal stem cells has 
not yet been identified, but lack of CD59 might affect mesenchymal stem cell 
survival and subsequently differentiation potential. Furthermore, Ignatius et al. 
revealed its presence on human osteoblasts and Festy et al. identified expression of 
CD59 on mature adipocytes (Festy et al. 2005; Ignatius et al. 2011). This evidence 
highlighted not only the continued expression of CD59 once differentiated, but also 
possible involvement in different tissue mechanisms.  
 In order to assess the impact of CD59a upon OB function one must look 
in vivo where all mediators and cells that regulate the bone balance are present. 
The in vitro study did not take into account environmental changes encountered by 
the mice during the ageing process. The in vivo effect of CD59a-/- in OB is reported 
in chapter 6 and discussed further in section 7.4 of the general discussion. 
 
 
Figure 7.1 Schematic illustrating potential experimental plans to identify a 
mechanism for CD59a regulation of osteoblast differentiation. Mesenchymal 
stem cells should be characterised from WT and CD59a-/- bone marrow. Upon 
differentiation of mesenchymal stem cells towards osteoblast or adipocytes, 
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transcription factor and protein expression (examples given) should be monitored to 
identify regulatory role of CD59a and reveal its potential ligand (Tropel et al. 2004; 
Kumar et al. 2005). 
 
7.2 Assessing the Impact of CD59a on Osteoclastogenesis  
The impact of CD59a on osteoclastogenesis was assessed in chapter 4. Mouse 
bone marrow preparations from 8-10 week old mice were utilised; 
osteoclastogenesis assays were performed in C6-/- and CD59a-/- and all outcome 
measures (Cathepsin K, MMP-9, mKc) compared against WT data.  
 Once bone marrow cells were plated, the majority of cells adhering to 
glass coverslips were identified as monocytes for WT, CD59a-/- and C6-/- in both 
female and male mice. This revealed an enrichment of precursor cells, but 
populations should be further characterised by flow cytometry to obtain an accurate 
breakdown of cell populations and identify small differences. Qui et al. for example, 
developed software called spanning-tree progression analysis of density normalised 
events which allowed for distinguishing between different cell types according to 
their levels of marker expression. These markers should include ckit/Sca1 for 
haematopoietic, CD11b for myeloid, B220 for B-cells and TCR-β/CD4/CD8 for T-cell 
populations (Qiu et al. 2011) and should be considered for further characterisation of 
adherent cells, which were not readily distinguishable during differential cell counts. 
 CD59a expression was gauged by qPCR in adhered murine bone 
marrow cells. Although CD59a expression was detected the assay did not 
discriminate which cells expressed this regulator of the terminal complement 
pathway. In order to overcome this problem flow cytometry analysis was employed. 
Flow cytometry using the murine antibodies such as MEL-4 or anti-mCD59a.1 have 
been reported (Harris et al. 2003; Lin et al. 2004), a number of in-house antibodies 
were tested, but a specific antibody having satisfactory background staining was not 
identified. Therefore, phenotypic analysis of the cell localisation of CD59a in mouse 
was not pursued further. To reveal CD59a expression on different cell types qPCR 
analysis should be performed on the individual time points to identify markers 
essential for myeloid cells and their progeny such as bone marrow precursor 
(CD11b+/Gro-/low), macrophage precursor (F4/80) and osteoclast (Cathepsin K, CTR, 
integrin receptors) (Takahashi et al. 2003; Yao et al. 2006; Otero et al. 2010). 
Although the current research did not definitively show CD59a expression on murine 
osteoclasts, a study identified CD59 on human osteoclasts (Ignatius et al. 2011). It 
is therefore likely that mouse OC also express CD59a; however this was not 
conclusively demonstrated.  
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 Once assays were performed, data demonstrated that insufficiency of 
CD59a in vitro resulted in enhanced osteoclastogenesis in male mice (Fig. 7.2). This 
anti-osteoclastogenic functionality of CD59a has not been reported previously in 
mice. However, in a human study where both CD59 and DAF deficiency was 
recorded on erythrocytes. Researchers found an inverse correlation between these 
complement regulatory proteins and plasma levels of bone resorption markers: 
tartrate resistant acid phosphatase, RANKL, IL-6 and N-terminal cross-linking 
telopeptide of type-I collagen (Terpos et al. 2003). This study did not identify 
whether one or both mediators were involved, nor did conclusively explore the effect 
of each regulator on osteoclastogenesis. In my study increased differentiation was 
identified at the late stage of osteoclast formation. This might have resulted from 
variations in precursor cell merging or because of increased proliferation in CD59a-/- 
samples. Hence, proliferation assays and expression of fusion proteins (MITF, DC-
STAMP and CD47) should be performed to demonstrate if mediators or receptors of 
these pathways are affected by CD59a (Battaglino et al. 2004; Lorenzo et al. 2010). 
In the literature, conditional knockouts of NOTCH1-3 have shown to enhance bone 
marrow macrophage proliferation by increased sensitisation of the M-CSF receptor 
c-Fms (Bai et al. 2008). Moreover, PU.1 which induces c-Fms expression as well as 
down-stream targets of M-CSF, such as MITF and Bcl-2, have been associated with 
proliferation (Negishi‐Koga and Takayanagi 2009). These proliferation and fusion 
factors should be analysed via qPCR to uncover a possible mechanism of enhanced 
osteoclastogenesis.   
 From collected osteoclastogenesis supernatants, quantification of 
Cathepsin K was attempted utilising a Cat K ELISA kit, a developed bioassay and 
type I collagen zymography, but it could not be detected. A single paper described 
Cathepsin K detection in culture supernatant by western blotting when growing the 
murine macrophage cell line Raw 264.7 cells on plastic dishes  (Kitami et al. 2010). 
However this Cathepsin K is difficult to detect from primary cell cultures. The 
expression of mRNA or internal Cathepsin K has been reported frequently and 
should be utilised in future to confirm osteoclast formation (Chen et al. 2008; Song 
et al. 2009; Li et al. 2010).  
 After Cathepsin K, other proteases were analysed. Gelatin zymography 
presented ProMMP-9, MMP-9 and ProMMP-2 activity and quantification of ProMMP-
9 by ELISA revealed comparable levels in WT and CD59a-/- samples. This 
suggested that either protease secretion was not altered by CD59a or that 
differences in osteoclasts cannot be identified by measuring secreted ProMMP-9 as 
it is not a functional output. Therefore mRNA expression or concentrations in cell 
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extracts of total MMP-9 in osteoclast should be determined instead to identify 
potential aberrant MMP-9 expression (Chen et al. 2011; de Vrieze et al. 2011). If 
differences could be identified in MMP-9 expression, then pathways including AP-1, 
STAT3 and Runx2, which regulate MMP-9 expression, might be included in the 
search for a CD59a signalling pathway in bone homeostasis (Fanjul-Fernández et 
al. 2010).   
 Not only proteases, but cytokines and chemokines are important for 
osteoclastogenesis and osteoclast resorption. The level of the chemokine mKc 
(measured by ELISA) was not significantly different between male WT and CD59a-/- 
samples when normalised for cell density. In order to identify a mechanism for 
CD59a’s regulation of osteoclastogenesis, other chemokines should also be 
considered. CXCL12/SDF-1 has been shown to recruit osteoclast precursor cells as 
well as support osteoclast formation and activity. Moreover, MIP-γ was identified as 
the main chemokine produced by osteoclasts and has been shown to be up-
regulated by RANKL directly; it also responded to M-CSF in order to enhance 
osteoclast formation. Finally, MCP-1 and CCL3/MIP-α were reported to be involved 
in precursor recruitment and osteoclastogenesis (Onan et al. 2009). Any of these 
might be a potential target of CD59a and should be measured utilising qPCR or 
ELISA (Zhang et al. 2011c; Schüler et al. 2012).  
In vitro findings of osteoclastogenesis should also be considered in relation 
to the in vivo environment to examine the function of CD59a as described and 
discussed in chapter 6 and section 7.4. 
 
7.3  Investigating the Role of Human CD59 in Resorption 
To investigate the role of human CD59 in resorption assays, peripheral blood CD14+ 
monocytes were utilised to grow functional osteoclasts on ivory discs in the 
presence of M-CSF and RANKL (chapter 5). To improve the characterisation of 
human osteoclasts, qPCR and immunohistochemistry should be performed to 
identify markers such as Cat K as suggested in section 7.2 (Cenni et al. 2010; 
Grigoriadis et al. 2010).  
 As CD14+ monocytes also express CD59, a CD59 knockdown system 
using shRNA was established. The lentiviral CD59-containing shRNA was unable to 
knockdown CD59 expression. A small number of studies have infected monocytes 
with lentivirus for the purpose of osteoclastogenesis. Hamaza et al. generated a 
lentivirus containing shRNA against P2X7 in the pLKO.1-puro vector which was also 
used in my study. This virus generated by Hamza et al. was successfully introduced 
into human CD14+ monocytes and caused significant down-regulation of P2X7 
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(Hazama et al. 2009). Additionally, Park-Min et al. mentioned a 90% infection 
efficiency in human osteoclast precursor cells utilising a lentivirus against TREM-2 
cDNA followed by enhanced green fluorescent protein (Park-Min et al. 2009). In my 
project, infectivity should be enhanced by monitoring viral titres via ELISA to detect 
the HIV p24 gag antigen (Marr et al. 2003) or genomic viral RNA qPCR (Perez et al. 
2010). Additionally, a different viral envelope should be tested to improve infectivity. 
In a recent study the Aura virus derived pseudotyped Aura-G which uses lectins to 
enter dendritic cells, was engineered (Froelich et al. 2011). Different coating proteins 
should be utilised to enhance transfection efficiency of CD14+ 
monocytes/macrophages here. 
 In my study an adenoviral CD59 shRNA delivery system was 
consequently developed and showed up to 48% CD59 knockdown, but unfortunately 
cell viability was low. McLaren et al., who also utilised the adenovirus type 5 vector 
developed by Dr Stanton, achieved successful knockdown of death receptor 3 in 
THP-1 cells and human monocyte-derived macrophages obtained from peripheral 
blood (McLaren et al. 2010). Therefore experimental design required further 
optimisation in my study. Interestingly, adenoviruses have been shown to infect 
terminally differentiated cells including osteoclasts (Tanaka et al. 1998). Therefore to 
examine resorption, differentiated osteoclasts should be infected in subsequent 
experiments of my study, instead of CD14+ monocytes/macrophages; this might 
supply functional data before apoptosis is triggered. The literature shows that 
adenoviruses induce cell lysis via autophagy, a mechanism utilised in cancer 
therapy (Jiang et al. 2011). It was likely that this pathway caused cell death within 
my study. Viral delivery systems were desirable in this study to obtain stable 
knockdown of CD59, but siRNA or anti-sense mediated silencing could be achieved 
by direct delivery or utilising cyclodextrin-containing polycations, lipids or polymers 
as coating molecules (Bartlett and Davis 2006). These systems should be tested to 
improve infectivity with the reduced toxicity and therefore allow osteoclastogenesis 
after infection. 
 
7.4 Phenotypic Analysis of Bone Structure in CD59a-/- Mice 
In chapter 6, phenotypic analysis of bone structure was studied in CD59a-/- mice at 
8-10, 20 and 50 weeks of age. Femoral length was determined via X-ray and 
femoral diameters established utilising a digital caliper. Micro-architectural 
parameters of cortical and trabecular bone were examined in specific areas of 
femora and spines utilising microcomputed tomography. Femoral samples of young 
adult male WT and CD59a-/- samples were then processed for histological 
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quantification of osteoids (von Kossa/van Gieson staining), mineral apposition rate 
(calcein labelling) and osteoclasts (tartrate resistant acid phosphatase staining).  
 Femoral architecture was studied first and found to be altered in male 
CD59a-/- over WT mice at 8-10, 20 and 50 weeks. This was apparent from increased 
femoral length, diameter and increased bone volume in cortical and trabecular bone 
(Fig. 7.2). In the literature increased length was correlated with reduced cortical area  
of tibiae of male human donors (17-46 years of age). Furthermore, femora of 
C57BL/6J mice treated with a low dose of xenoestrogen (10-23 weeks of age) 
showed the same phenomenon. Murine bone samples also revealed enhanced 
bone mineral density suggesting that this increase compensated for lost bone 
strength upon architectural changes. When performing the 4 point bending test on 
human tibia and murine femora, long and slender bones were more brittle than 
shorter/untreated bones, suggesting that increased stiffness reduced overall bone 
quality (Tommasini et al. 2005; Pelch et al. 2011). This could be translated to the 
CD59a-/- mice model where cortical bone volume and cortical thickness was 
comparable to WT samples at 50 weeks of age, whereas femoral length was 
increased and therefore lower bone quality was likely and mechanical studies 
should be performed. According to the literature, to retain bone strength, variations 
in length also have to be accompanied by changes in shaft diameters (Rauch 2005), 
which was the case in this study at 8-10 weeks only; this again suggested reduced 
bone quality. Trabecular bone was reported to be an additional indicator of bone 
structure and flexibility. It was shown that people from different ethnicities have 
different structural features. African Americans were reported to have shorter 
vertebrae with higher trabecular volume which was suggested to have protective 
effects for age related bone loss (Seeman and Delmas 2006). Hence, increased 
trabecular bone in CD59a-/- mice was maybe increasing bone quality, possibly to 
compensate for the reduced cortical thickness. In order to draw conclusions, 
structural and micro-architectural variations between inbred strains should be 
considered as they have been shown to be significant (Beamer et al. 1996). As WT 
and CD59a-/- mice were not obtained from a het/het colony, variations might have 
partly arisen from genetic alterations of these in-house colonies and experiments 
should be performed with WT control animals from different sources to confirm 
obtained findings.  
 Not only bone volume, but also bone mineral density is an essential 
parameter of bone quality. Bone mineral density was down-regulated in cortical and 
up-regulated in trabecular bone of CD59a-/- over WT mice at 8-10 weeks. By 50 
weeks of age, cortical bone mineral density was enhanced in CD59a-/- mice, but no 
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significant difference was identified in trabecular bone. Fritton et al. reported site 
specific bone mineral content alterations after 2-6 weeks of mechanical loading of 
10 week old, male C57BL/6 mice. The authors identified 14% change in the 
metaphysis (mainly trabecular bone) and only 4% change in the cortical bone of the 
shaft (Fritton et al. 2005). Additionally, Hamann et al. reported that 6 week old 
female Sprague-Dawley rats subjected to downhill running for 1 week presented 
significantly enhanced trabecular bone mineral density, whereas no difference was 
identified in cortical bone mineral density. They concluded that changes were visible 
earlier in trabecular bone because of its higher bone remodelling rate (Hamann et al. 
2012). Hence a phenotype of enhanced bone mineral density which was visible at 
an earlier stage in trabecular bone than cortical bone was present in CD59a-/- 
samples in this study. Alternatively, trabecular bone mineral density in CD59a-/- 
samples might have compensated for the reduced bone mineral density in cortical 
bone to enhance bone strength at a young age, which was not required at an older 
age due to the increased cortical thickness, but no published research was identified 
to support this notion. Additionally, bone quality is determined by a balance of 
stiffness and flexibility, which relies not only on the mineralisation, but on the type I 
collagen structure and cross-linking (Seeman and Delmas 2006). The analysis of 
type I collagen should be performed by scanning and transmission electron 
microscopy to support bone mineral density findings in predicting bone quality 
(Seeman and Delmas 2006; Seeman 2007).  
 All parameters so far were generated from femora. When looking at the 
vertebra L6, the trabecular bone phenotype of enhanced bone volume, trabecular 
thickness and bone mineral density, seen in femora of CD59a-/- mice, was also 
present here. Hildebrand et al. analysed trabecular bone architecture in the femora, 
spine and other sites in the human body and identified site specific variations in 
trabecular bone volume as well as in the structure of trabeculae (Hildebrand et al. 
1999). In my study trabecular architecture in femur and spine at 8-10 weeks of age 
were comparable whereas at 20 weeks the modifications in CD59a-/- samples were 
more pronounced in spine samples indicating that the effect of CD59a is not 
restricted to long bones. 
 When evaluating histological samples, in vivo quantification of osteoblast 
function in trabecular bone revealed less osteoids and an enhanced mineral 
apposition rate in CD59a-/- over WT mice at 8-10 weeks. Luo et al. identified 20% 
osteoid surface over bone surface in mice 1 or 2 days after birth (Luo et al. 2009) 
whereas Potts et al. quantified a 10% osteoid surface over bone surface in mice at 3 
month of age (Potts et al. 2004). This indicates that the osteoid levels are higher 
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during initial growth and the number reduces once the growth rate slows down. As 
CD59a-/- mice contain larger bones, the growth rate might have reached the peak of 
osteoid formation earlier than WT mice. In contrast increased mineral apposition 
rate in CD59a-/- samples revealed enhanced OB activity and therefore could have 
resulted in faster bone growth (Erlebacher et al. 1998) and turnover (Shih and 
Norrdin 1986). 
 When examining osteoclast density in this study, tartrate resistant-acid 
phosphatase staining demonstrated increased osteoclast surface over bone surface 
in trabecular bone of CD59a-/- over WT mice at 8-10 and 20 weeks of age. As the 
data is in agreement with preliminary data by Dr Anwen Williams and in vitro 
findings, it is most likely that enhanced osteoclasts stimulated increased bone 
remodelling and therefore growth. In osteomalacia, where mineralisation is 
malfunctioning, it was discovered that enhanced bone remodelling resulted in 
thinner and more porous cortical bone and increased unmineralised osteoids that 
caused a drop in bone mineral density (Bhambri et al. 2006). Hence reduced cortical 
bone mineral density in this study could have resulted from a fast bone turnover that 
left osteoids partly unmineralised in growing mice. Once growth was finished 
accelerated osteoclastogenesis was followed by efficient bone formation. Bone 
growth has to be further investigated because bone development is dependent on 
chondrocyte actions which have not been considered here (Rauch 2005). 
From in vitro data it was expected that increased osteoclastogenesis and 
possible decreased colony forming units would result in an osteoporotic phenotype. 
When bone phenotypes in CD59a-/- mice were analysed increased 
osteoclastogenesis was confirmed but osteoblast activity was also found up-
regulated and more bone volume was demonstrated in trabecular and cortical bone 
in young male mice. Therefore osteoclastogenesis seems to be tightly coupled to 
osteoblast formation in CD59a-/- mice, suggesting that a potential mechanism for 
CD59 signalling could be found either in osteoclastogenesis itself or in a coupling 
mechanism, for example through TGFβ or BMPs (Matsuo and Irie 2008).  
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Figure 7.2 Schematic to summarise the role of CD59a in bone homeostasis in 
young adult male mice. CD59a deficiency increased osteoclast (OC) differentiation 
which is likely to enhance the bone remodelling unit (BRU) as seen by the mineral 
apposition (MAR). This results in a longer bone with more trabecular and cortical 
bone. The effect on mesenchymal stem cells (MSCs) and osteoblast (OB) formation 
needs to be further investigated. 
 
7.5 Does Gender Have an Effect on Phenotypic Changes? 
The effect of CD59a on osteoclastogenesis and most changes in bone architecture 
was restricted to male samples in young adult mice. The paroxysmal nocturnal  
haemoglobinuria phenotype in CD59a-/- mice was also exclusively present in male 
mice which was caused by higher haemolytic complement activity as explained in 
section 1.3.3 (Holt et al. 2001). Moreover, hormonal fluctuations were thought to be 
involved in gender specific effects of CD59a regulation in the brain during focal 
cerebral ischemia. Progesterone, for example, was mentioned to exhibit disease 
preventing effects in females (Harhausen et al. 2010).  
 Some architectural parameters such as bone mineral density was 
observed in female mice too, this effect in females could have been delayed or 
down-regulated by hormones such as oestrogen. Gender specific bone alterations 
were found in other murine knockout models. Leptin deficient mice, for example, 
presented a gender specific bone loss (effect in males only). This was due to 5 
times higher free testosterone which resulted in modified androgen signalling 
(Cirmanova et al. 2008). Certainly, the gender specific effect of CD59a should be 
investigated to identify the interplay between oestrogen and CD59a signalling. Rat 
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models of ovariectomy and castration were reported to result in osteoporosis (Wink 
and Felts 1980; Gürkan et al. 1986; Wronski et al. 1989) and might be a model to 
determine alterations in androgen, oestrogen and testosterone levels in relation to 
CD59a. Additionally, oestrogen receptor knockouts have been generated (Dupont et 
al. 2000) and oestrogen treatment, for example 17b-estradiol as reported by Ito et 
al., are available and should be utilised to study the gender specific effect of CD59a 
in bone (Ito et al. 2001).  
 
7.6 Is the Effect of CD59a Complement Dependent? 
In vitro cultures of WT and CD59a-/- bone marrow preparations were performed in 
heat-inactivated foetal calf serum. Therefore, CD59a should not have been affected 
by complement within the serum suggesting that CD59a might have signalled 
through a complement independent pathway (Fig. 7.1). A ligand for CD59a is 
currently unknown, but proposed molecules include T-cell ligands such as CD2, 
natural killer cell proteins such as NKp46 or NKp30 and calreticulin (Kimberley et al. 
2007). Mesenchymal stem cells have been shown to interact with CD2 on T-cells via 
leukocyte functional antigen 3 to inhibit their proliferation (Rasmusson et al. 2005). 
Moreover, calreticulin was found to regulate glucocorticoid receptor to decrease Wnt 
signalling by preventing nuclear concentration of β-catenin in osteoblasts (Olkku and 
Mahonen 2009). These findings suggest a link between mesenchymal stem cell 
regulation and CD59a which should be studied to widen mechanistic understandings 
of CD59 signalling.  
 Attempts to study this complement dependency were performed in C6-/- 
mice in this study. The data obtained was not sufficient to make definite conclusions 
and in vivo as well as in vitro changes should be monitored in single and double 
knockouts of C6 and CD59a in future studies. If C6-/- mice would present with the 
bone phenotype of WT mice and double knockouts were comparable to CD59a-/-, 
this effect would be complement independent. 
Alternatively in vivo imaging techniques should be used to dissect out 
complement dependency. Reagents to regulate membrane attack complex have 
been developed. BB5.1, for example, an anti-C5 antibody reduces complement 
mediated lysis by 80% (Peng et al. 2005). Recently a RNA antisense oligo against 
C6 was developed by Frank Baas’s group to enhance membrane attack complex 
down-regulation (Fluiter et al. 2011). These should be tested in WT and CD59a-/- 
mice to determine mineral apposition utilising reagents such as Bone Tag (Licor), 
which can be monitored over time by in vivo fluorescent equipment, such as the Ivis 
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200 (Caliper Life Sciences 2009), that is available within the School of Medicine, 
Cardiff University. 
Additionally, elevated or induced CD59a expression should be tested in WT 
and knockout models in vitro or in vivo. Many attempts to develop CD59a 
therapeutics have been made. The CD59-APT542 is a recombinant protein with a 
membrane associated tag developed in rats which was identified to be a 100 fold 
more active than soluble forms of CD59 in preventing complement mediated lysis in 
vitro. Intra-articular injection into Lewis rats prevented initiation of antigen induced 
arthritis (Fraser et al. 2003). More recently gene therapy has been utilised to 
enhance CD59a expression by injecting an adenovirus or adeno-associated virus, 
containing genetic information for sCD59a, into mice. This was tested in different 
disease models and was shown to also down-regulate complement lysis (Gandhi et 
al. 2011). These reagents should be utilised to determine complement dependency 
as well as therapeutic potential of CD59/CD59a on rodent bone homeostasis. 
 
7.7 Role of CD59a in Osteoarthritis 
Osteoarthritis treatment is somewhat limited to reducing disease progression and 
symptoms. The NHS supports patients by the mean of encouraging them to 
exercise and lose weight and supplying them with pain killers (paracetamol, 
NSAIDs, opioids, capsaicin cream) and intra-articular injection of corticosteroids 
(NHS-Choices 2010b). A treatment to prevent onset of osteoarthritis is not available 
yet (Wang et al. 2011). A recent paper observed for the first time that aging CD59a-/- 
mice developed spontaneous osteoarthritis. Deficiency in CD59a resulted in mild 
pathology characterised by diminished cartilage compared to WT mice at 18 month 
of age. Complement activation was shown in early osteoarthritis and deficiency in 
terminal pathway components protected from disease. Hence, the effect of CD59a 
was believed to be complement mediated (Wang et al. 2011). These changes 
suggested that CD59a protects from cell lysis in osteoarthritis. As cartilage 
degradation is a feature of osteoarthritis which is preceded by changes in bone 
structure, CD59a could have also functioned via a different mechanism. Early 
osteoarthritis was reported to be caused by accumulation of osteoclasts and 
cytokine production that resulted in a reduction in bone mass (Hayami et al. 2004). 
Up-regulation of osteoclastogenesis in CD59a-/- might be more readily amplified by 
pro-inflammatory cytokines than in WT mice and therefore cause more severe 
disease. If the effect of CD59a can be driven by the immune system it could have 
been influenced by macrophages. Induction of different subsets of macrophages M1 
(T helper 1 cell activated) and M2b (immune complex and LPS activated) have been 
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shown to down-regulate CD59a expression (Luo et al. 2012). CD59a has also been 
shown to decelerate T-helper cell proliferation by interacting with the lipid raft 
associated kinases (section 1.3.1.1). Therefore, a deficiency in CD59a might have 
altered the interplay of T-cells and macrophages leading to inflammation as seen in 
osteoarthritis. 
Furthermore, other parameters of osteoarthritis, such as cartilage, should be 
investigated. Tissue for this analysis was harvested and cartilage quality should be 
analysed utilising Safranin O staining (Kuroda et al. 2007). Furthermore joint space 
narrowing and pathology in the epiphysis, for example osteophytes, should be 
determined from microcomputed tomography images obtained here which include 
the knee joint (Abramson and Attur 2009). These would support the characterisation 
of CD59a-/- mice and consequently the aging induced osteoarthritis model.  
 
7.8 Future Work 
The characterisation of the bone phenotype of CD59a-/- mice should be finished by 
performing mechanical strength tests on femora to determine if changes 
demonstrated here reduce or enhance bone quality. Secondly, characterisation of 
mesenchymal stem cell differentiation in vitro should be repeated and resorption 
assays performed to determine functional potential of osteoclasts lacking CD59a. 
Thirdly, expression of transcription factors, hormones, mediators and receptors such 
as TAZ, BMPs for osteoblasts and CCL2/MCP-1, RANK for osteoclasts should be 
investigated to identify a mechanism for CD59a signalling. Moreover, it should be 
determined if CD59a acts complement dependent or independent by mechanisms 
described in section 7.6. Finally, the characteristics of osteoarthritis should be 
investigated to determine the possibility of CD59a as a therapeutic. 
 
7.9 Conclusion 
The complement regulator CD59a has been well classified in models of 
inflammatory diseases. I set out to investigate if CD59a-/- mice presented an 
osteoarthritic bone phenotype. The hypothesis was proved as osteoclastogenesis, a 
hallmark of early osteoarthritis, was up-regulated in young adult male CD59a-/- mice 
in vitro and in vivo. Furthermore, increased bone volume in cortical and trabecular 
bone was revealed as well as enhanced mineral apposition rate in vivo in absence 
of CD59a. These were an important finding as features of enhanced bone formation 
are also evident in osteoarthritis. Consequently, these studies highlight CD59a as a 
potential target for osteoarthritis treatment but more research needs to be performed 
to determine its mechanism of action.  
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Caltag Laboratories Inc, Burlingame, US 
Carestream Health, Inc., Rochester, US 
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Daido Sango Co. Ltd, Tokio, Japan 
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Jackson ImmuneResearch Europe Ltd, Suffolk, England 
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